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Summary 
Inhibition of enzymes from mycobacteria using fragment-based approaches 
The work described in this thesis is focused on the application of fragment-based approaches for two 
essential mycobacterial target proteins, fumarate hydratase (fumarase) from Mycobacterium 
tuberculosis (Mtb) and tRNA (m1G37) methyltransferase (TrmD) from Mycobacterium abscessus (Mab). 
With Mtb fumarase a high-throughput screening (HTS) hit was used to design a small library of fragments 
in a deconstruction-reconstruction approach. These fragments were screened using a range of both 
biochemical and biophysical methods. The resultant fragments showed evidence of weak protein binding. 
As an alternative strategy, derivatives of the HTS hit were synthesised and screened by a biochemical 
assay, which identified nanomolar inhibitors of this enzyme. In addition, X-ray crystallography was also 
carried out with a range of these compounds.  Selected compounds were subsequently screened by 
collaborators at the NIH against Mtb. 
With the enzyme TrmD from Mab, the fragment hits identified were used as the basis of a fragment-
merging approach to develop potent inhibitors, guided by structural biology. In the implementation of 
this approach, synthesis and biophysical techniques were extensively utilised, including both differential 
scanning fluorimetry and isothermal titration calorimetry. This approach led to the development of novel 
inhibitors with low nanomolar affinity. Select compounds were screened by collaborators against 
both Mab and Mtb in vitro. In light of encouraging activity against Mtb, the TrmD homolog in Mtb was 
expressed and screened against select compounds to demonstrate the broader applicability of the lead 
series. 
Andrew John Whitehouse 
June 2019 
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1: Introduction 
1.1: Mycobacterial Infection 
1.1.1: Background 
The genus Mycobacterium comprises a large number of diverse bacterial species, ranging from the well 
characterised slowly-growing pathogens Mycobacterium tuberculosis (Mtb) and Mycobacterium leprae, 
to the non-tuberculous mycobacteria (NTM) that are the focus of increasing scientific study . 1 
Mycobacteria are characterised by a complex cell envelope, with hydrophobic mycolic acids attached to 
the underlying peptidoglycan layer through a branched arabinogalactan polysaccharide network. 2 These 
long chain fatty acids intercalate with other lipids to form an outer membrane that provides a permeability 
barrier for mycobacteria. 3,   4 If compounds do traverse the mycobacterial cell envelope, efflux pumps are 
extensively utilised to actively transport toxic molecules out of the cell, 5,    6  making the targeting of 
mycobacteria a challenging task. 
 
1.1.2: Mycobacterium tuberculosis 
Mtb is the causative agent of the disease tuberculosis (TB), which maintains a significant global impact in 
the 21st century with 10 million new cases diagnosed annually, 9% of which are in combination with HIV. 
With 1.3 million directly attributed deaths in 2017, in addition to 300,000 associated deaths in HIV-positive 
individuals, TB remains the leading worldwide cause of death due to a single infectious agent. 7 
TB infection begins with the inhalation of Mtb-containing aerosol into the alveoli of the lungs where 
resident macrophages internalise the bacteria through phagocytosis, however Mtb is capable of 
interfering with the fusion of the phagosome with the lysosome and avoiding degradation. Disruption of 
the enclosing phagosomal membrane enables the release of material into the cytosol, with subsequent 
spread of the infection beyond the alveoli to the lung parenchyma initiating the recruitment of immune 
cells. 8 These cells aggregate to form granulomas, organised and compact structures that surround the 
infected cells in a necrotic centre, in which Mtb can persist in a contained state. 9 The possession of these 
structures is a hallmark of asymptomatic and non-transmissible latent TB infection, 10 a condition that is 
exhibited by 1.7 billion people worldwide. 11 In the event that granuloma-mediated containment fails, 
active TB disease can disseminate throughout the body with the symptoms of fatigue, fever, weight loss 
and coughing, which can transmit infectious material to new hosts, commonly observed. 8 In the absence 
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of chemotherapy, active TB disease is associated with high mortality rates in patients even without the 
additional complication of HIV, 12 underlining the essentiality of effective anti-TB treatments. 
The standard recommended treatment regimen for TB includes an initial intensive phase of isoniazid, 
rifampicin, ethambutol and pyrazinamide over 2 months, followed by 4 months of continuation therapy 
with isoniazid and rifampicin (Figure 1). 13 
 
Figure 1: First-line drugs recommended for the treatment of drug-susceptible TB infection. 13 
Worryingly, the effectiveness of antibiotics against TB is in decline with increasing worldwide prevalence 
of rifampicin-resistant (RR) and multidrug-resistant (MDR) TB, the latter possessing resistance to both 
rifampicin and isoniazid, with 558,000 cases and 230,000 deaths reported in 2017 due to RR- and MDR-
TB. 7 The treatment of these drug-resistant strains requires longer regimens with additional second-line 
anti-TB drugs, with conditional recommendation provided for the use of pyrazinamide in combination 
with a fluoroquinolone, an injectable agent and two alternative antibiotics. 14 However, as with the first-
line anti-TB drugs, extensively drug-resistant (XDR) TB strains are now also emerging that display 
additional resistance to the second-line drugs. 7 In light of the worsening issue of drug-resistant strains of 
TB, the development of novel antibiotics with orthogonal mechanisms of action to current anti-TB drugs 
is urgently required. 15 
 
1.1.3: Mycobacterium abscessus 
Mycobacterium abscessus (Mab) is an NTM that derived its name by its discovery from a knee abscess in 
1952. This infection had persisted for 48 years in a semi-dormant state after the initial trauma in a 
farmyard, with surgical intervention in the patient leading to reactivation and dissemination to other parts 
of the body. 16 Mab, which is characterised by rapid growth and a rod-like profile of 1.0 to 2.5 µm in length 
by 0.5 µm in width, was considered a subspecies of Mycobacterium chelonae before being reclassified as 
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an independent NTM species in 1992. 17 The species can itself be divided into the subspecies abscessus, 
bolletii and massiliense, 18 which have been shown to exhibit similar clinical behaviour albeit with some 
difference in antibiotic susceptibility . 19  This behaviour is reflected in the Mab genome, with a bias 
towards genes involved in intracellular parasitism and survival in soil and water, in addition to displaying 
evidence of horizontal gene transfer from pathogens associated with cystic fibrosis (CF) including 
Pseudomonas aeruginosa and Burkholderia cepacia. 20 
Mab is an opportunistic pathogen that can cause a variety of disease types in humans, including infection 
of the eyes, bloodstream and central nervous system. It is however most commonly associated with skin 
and soft tissue infections, induced either directly through the contact of wounds with contaminated 
material or indirectly by disseminated disease, in addition to infection of the respiratory tract in patients 
with preexisting pulmonary disease. 21 In general, Mab pulmonary disease results in the observance of 
chronic coughing and a susceptibility to fatigue in patients , 22  with imaging of the lungs revealing 
bronchiectasis and the development of nodules. 23  When present in patients with underlying CF, this 
infection is correlated with an accelerated decline in lung function over time and therefore an impaired 
quality of life. 24,   25 This phenomenon is of increasing concern in light of indirect transmission of Mab 
infection occurring between CF patients in hospitals despite the enforcement of segregation, potentially 
through the ability of Mab to persist both on surfaces (fomite) and within aerosols . 26,   27  These 
transmitted infections, which are more virulent than those acquired from the environment due to prior 
genetic adaptation within hosts, worryingly constitute the majority of Mab infections in CF patients. 27 
Mab possesses high intrinsic resistance to chemotherapy, including anti-Mtb drugs, making the treatment 
of infection particularly challenging relative to other mycobacteria. This intrinsic resistance is caused by 
the confluence of a variety of features in the species, including the impermeable mycobacterial cell 
envelope, efflux mechanisms, antibiotic- and target-modifying enzymes and the genetic polymorphism of 
target genes, in addition to Mab’s ability to acquire resistance through the spontaneous mutation and 
modification of these genes. 28  As a result, treatment of Mab infection requires the sustained use of 
combination therapy with multiple antibiotics taken in parallel over long periods of time . 22  This is 
reflected in the current recommended treatment regimen for Mab infection in CF patients, which 
supports prolonged implementation with the aim of improving symptoms and inducing regression of the 
disease. This regimen begins with an initial intensive phase lasting up to 3 months, depending on patient 
tolerance, that includes the oral macrolide azithromycin in combination with intravenous application of 
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the aminoglycoside amikacin and at least one of the antibiotics cefoxitin, imipenem or tigecycline (Figure 
2). 29 
 
Figure 2: Drugs recommended for inclusion in combination therapy for the treatment of Mab infection in CF patients. 29 
The intensive phase of treatment of Mab infection in CF patients is followed by a continuation phase over 
the long term, with further azithromycin in combination with inhaled amikacin and 2 to 3 of the oral 
antibiotics minocycline, moxifloxacin, clofazimine or linezolid (Figure 2). In the event that success in 
disease eradication is suggested, continued application of antibiotic therapy is still recommended for a 
year . 29  This outcome though is not guaranteed and numerous side effects are associated with the 
antibiotics in this therapy, 29 which can result in the modification or cessation of treatment. 30 Hence, 
there is a need for the development of novel antibiotics with improved efficacy against Mab infection, 
particularly for the treatment of afflicted CF patients. 
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1.2: New Targets of Interest 
1.2.1: Fumarate hydratase 
Fumarate hydratase (fumarase) is an enzyme in the citric acid cycle, a system that is utilised in energy 
generation and the connection of numerous biosynthetic pathways in aerobic organisms including 
mycobacteria, where it catalyses the reversible interconversion of L-malate and fumarate (Figure 
3a). 31,   32 
 
 
Figure 3: Proposed operation of the citric acid cycle in Mtb with involvement of Mtb fumarase during (a) aerobic conditions, 32 
and (b) anaerobic conditions. 33 
The citric acid cycle has also received attention for its role in facilitating Mtb survival in a non-replicating 
state under hypoxic conditions through operating in the reverse direction. Reduced cofactors accumulate 
within Mtb cells in the absence of oxygen as a terminal electron acceptor, with relief provided through 
the excretion of succinate produced by reductive derivatives of the citric acid cycle (Figure 3b). 33,   34 
Under these conditions, which closely mimic the hypoxic conditions of granulomata in latent TB infection, 
expression of Mtb fumarase is upregulated, 33 making it a potential target of interest for treatment of 
latent infection. 
Mtb fumarase is a vulnerable target as it is the only protein that Mtb expresses to carry out its function in 
direct contrast to other sections of the citric acid cycle , 31,   33  a situation that is not guaranteed in 
bacteria, 35 and has been shown to be essential for Mtb survival. 36 This essentiality was determined in a 
conditional knockdown mutant of Mtb to be linked to intracellular accumulation of fumarate, which can 
(a)
 
  
(b)
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react as an electrophile with cysteine thiols of proteins and metabolites. The inactivation of antioxidants 
catalase and mycothiol by covalent modification with fumarate induces hypersensitivity to oxidative stress 
in Mtb (Figure 4), leading to impaired growth and cell death in vitro and in mouse infection models. 37 
 
Figure 4: Covalent modification of mycothiol by fumarate. 37 
Bacteria have been observed to express fumarases from structurally distinct protein families, with 
homodimeric Class I fumarases exhibiting thermolability and iron-dependence in contrast to those 
belonging to Class II that are homotetrameric and thermostable. 35 Mtb fumarase belongs to Class II, 38 
with a structure consistent with previously characterised bacterial fumarases of this class (Figure 5a). 39 
The N-terminal domain (NTD) of the subunits in the Mtb fumarase homotetramer begins with a 2-
stranded antiparallel beta sheet, followed by a compact collection of 5 alpha helices up to residue 137. 
This is succeeded by a central domain from residues 138 to 393, including 5 alpha helices oriented parallel 
to each other over ~40 Å, and a conformationally flexible assembly of 6 short alpha helices in the C-
terminal domain (CTD) from residue 394 onwards (Figure 5b). 38 
The homotetramer of Mtb fumarase can be considered to be assembled from two dimers, each consisting 
of two subunits in a ‘head-to-head’ orientation joined by contacts at the top of the central domain with 
the central and C-terminal domains of the other subunit (Figure 5c). The arrangement of these dimers in 
a ‘head to tail’ orientation then completes the homotetramer, which is held together by extensive 
interactions between the alpha helices of the central domains in an elongated 20-helix bundle (Figure 
5d) . 38,   39  The complex quaternary structure is essential for catalytic activity, with Mtb fumarase 
possessing 4 symmetry-related active sites located in clefts each with contributions from 3 subunits 
(Figure 5a and Figure 6a). 38,   40  
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Figure 5: X-ray crystal structure of Mtb fumarase bound to formate (PDB code 5F92, 1.86 Å), illustrating (a) the four subunits of 
the homotetramer (subunit A = white, subunit B = green, subunit C = cyan, subunit D = yellow), (b) one of the subunits further 
subdivided into three domains (NTD = orange, central domain = blue, CTD = red), (c) the head-to-head arrangement of two subunits 
(subunit A = white, subunit C = cyan), and (d) the head to tail arrangement of subunit pairs in the homotetramer (dimer 1 = pink, 
dimer 2 = purple). 41 
(a) (b) 
(c) (d) 
Active 
Site 
Active 
Site 
Active 
Site 
Active 
Site 
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Figure 6: X-ray crystal structures of Mtb fumarase (subunit A = white, subunit B = green, subunit C = cyan, subunit D not visible), 
with the apo form (PDB code 4APA, 2.04 Å) illustrating (a) the active site in the open conformation, and the L-malate bound form 
(PDB code 4ADL, 2.20 Å, L-malate = lilac) illustrating (b) the active site in the closed conformation, and (c) the residues surrounding 
L-malate; 38 (d) a proposed mechanism of catalysis for Mtb fumarase. 38 
(a) (b) 
Ser318 
His187 
SS Loop 
SS Loop 
(d) (c) 
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The active sites of Mtb fumarase share sequence identity and a similar mechanism of action with other 
members of the wider aspartase/fumarase superfamily that release fumarate as a product. 38,   42 In the 
event of substrate binding the loop from residues 316 to 325, the ‘SS’ loop, undergoes movement from 
an ‘open’ state, where the active site is exposed and accessible (Figure 6a), to a ‘closed’ state that covers 
the site and brings several residues in contact with the substrate (Figure 6b). When this state is reached 
the conversion of substrate is suggested to proceed through a two-step acid-base process with the 
generation of an enediolate intermediate 1, utilising the conserved residues Ser318 and His187 that are 
in close proximity to the Cα and Cβ atoms of the substrate (Figure 6c and d) . 38,   42  Further, in Mtb 
fumarase the movement of the ‘SS’ loop, which is disordered in the open state, has been shown to be 
dependent on the flexibility of the CTD, which exhibits significant rotation on substrate binding (Figure 6a 
and b). 38 
Inhibitors of fumarase have previously been found that demonstrated dose-dependent effects on cell 
growth, 43 underlining its vulnerability, however a key concern in its use as a target for the development 
of antibacterial compounds is selectivity against the human homolog. Human and Mtb fumarase share 
the same quaternary structure and around 52% sequence identity, which increases to complete 
conservation of residues in the active site. 38,   44 This issue was recently circumvented with the discovery 
of an inhibitor 2 (Figure 7a) of Mtb fumarase that binds twice in an allosteric site at the subunit head-to-
head interface (Figure 7b and c) (Monica Kasbekar, Department of Chemistry, University of Cambridge), 
locking the neighbouring CTDs in place and preventing SS loop movement on substrate binding (Figure 
7c). 41 
The residues to which 2 binds in Mtb fumarase are not conserved with the human homolog, conferring 
demonstrable selectivity. Unfortunately 2 was not able to induce a measurable minimum inhibitory 
concentration (MIC) against Mtb growth in vitro, however its selectivity against human fumarase, 41 in 
conjunction with the essentiality of fumarase to Mtb, 36,   37 supports further study. 
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Figure 7: (a) Inhibitor 2, identified by HTS of fumarase from Mtb; 41 X-ray crystal structure of Mtb fumarase bound to 2 (PDB code 
5F91, 2.00 Å, subunit A = white, subunit B = green, subunit C = cyan, subunit D = yellow, 2 = lilac), illustrating (b) the dual binding 
mode of 2 in the allosteric site and (c) the location of the allosteric site and the open conformation of the adjacent active site. 41 
(a) (b) 
(c) 
SS Loop 
Disorganised 
Allosteric Site 
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1.2.2: tRNA (m1G37) methyltransferase 
tRNA (m1G37) methyltransferase (TrmD) is a bacterial protein that belongs to the SpoU-TrmD (SPOUT) 
superfamily of RNA methylases . 45  TrmD is responsible for post-transcriptional modification of tRNA 
molecules containing the sequence G36 – G37, 46 catalysing the addition of a methyl group from the 
cofactor S-adenosyl-L-methionine (SAM) to the N1 atom of G37 (m1G37) (Figure 8). 
 
Figure 8: Transfer of the methyl group of SAM by TrmD to G37, forming S-adenosyl-L-homocysteine (SAH) and m1G37. 
The nucleotide G37 lies immediately 3’ to the anticodon in these tRNA molecules, and its methylation 
increases the efficiency of protein translation through a reduction in the frequency of +1 frameshifting 
errors on the ribosome that result in inactive peptides . 47  This has been shown to occur through 
suppression of two mechanisms depending on both the identity of the tRNA molecule and the position of 
the codon in the open reading frame. These involve a +1 frameshift of tRNA during translocation between 
the A and P sites of the ribosome, and whilst stalled on the P site during a delay in occupation of the A 
site by a new molecule. 48 The molecular basis of the effect of m1G37 on these mechanisms has been 
suggested by X-ray crystal structures of the ribosome in complex with the anticodon stem loop (ASL) of 
tRNAPro. When m1G37 is present an intramolecular base pairing between U32 and A38 is observed in the 
ASL, however this is not visible in its absence due to poor density at nucleotides 30 to 32. 49 Hence, the 
m1G37 modification could be reducing the risk of frameshifting through the promotion of preorganisation 
within the tRNA ASL, which could lead to improved intermolecular interactions on the ribosome. 48,   49 
Importantly, the presence of a functional TrmD gene has been demonstrated to be essential for normal 
cellular function in mycobacteria, including Mtb and Mab, 24,   50 making TrmD an attractive target protein 
for further study. 51 52 53 
Members of the SPOUT superfamily are dimeric in nature, with significant buried surface area, and share 
conserved structural features. These include a ‘common core’ in each subunit consisting of a 5-stranded 
parallel beta sheet flanked by two layers of alpha helices, in addition to deep active sites defined by a 
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complex arrangement of loops termed a ‘trefoil knot’. 51 These are represented in the TrmD homodimer, 
with SPOUT common cores in the NTDs oriented antiparallel to each other around a 2-fold rotation axis 
(Figure 9a). 52   −   54 
 
 
Figure 9: X-ray crystal structure of Mab TrmD bound to SAM (PDB code 6NW6, 1.67 Å, subunit A = white, subunit B = green, SAM 
= lilac), illustrating (a) the whole homodimer and (b) one of the active sites. 50 
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Within each monomer a flexible interdomain linker connects the NTD to a smaller CTD, however these 
domains are held away from each other with no contact, instead interacting with domains of the other 
subunit (Figure 9a). 52   −   54 TrmD possesses two symmetry-related active sites with trefoil knots, formed 
by loops connecting the beta strands and alpha helices of the common core from one NTD, holding SAM 
in a bent ‘L-shaped’ orientation. Each site is located at a subunit interface, with the other subunit making 
a direct contribution through its CTD and interdomain linker in addition to indirectly stabilising the trefoil 
knot structure through interactions with its NTD (Figure 9b). 52,   53 
The trefoil knot facilitates communication between the active sites through the subunit interface, with 
subunit asymmetry and differences in conformational freedom evident on substrate binding . 55  As a 
result, whilst the active sites in TrmD can both bind SAM simultaneously, only one of the sites can be 
catalytically active at any time and bind tRNA. 56 A notable manifestation of this asymmetry between the 
active sites is the organisation of the interdomain linker, which is ordinarily not visible in X-ray crystal 
structures (Figure 9b), into an alpha helix at the tRNA-bound active site (Figure 10a). 57 
In the tRNA - Haemophilus influenzae (H. influenzae) TrmD complex the guanine base of G37 is ‘flipped 
out’ towards the cofactor, leaving space at the tRNA anticodon for G36 to adopt a syn conformation and 
form π-stacking interactions with the bases of nucleotides 35 and 38. The base of G36 also hydrogen 
bonds to the side chain of the conserved residue Asp50, which smaller pyrimidine bases would not be 
able to achieve, providing selectivity for tRNA molecules with a G36 – G37 sequence (Figure 10a). 57 In the 
active site the flipped out base of G37 interacts with Arg154 and Asp169 (Figure 10b), 57 which have been 
shown to be essential for TrmD catalytic activity in site-directed mutagenesis studies. 53 Asp169 engages 
the N1 atom of G37, and could function as a general catalytic base to abstract its proton and facilitate 
nucleophilic attack on the methyl group of SAM, with Arg154 stabilising any developing negative charge 
through its interaction with the carbonyl oxygen of G37 (Figure 10b). 57 A magnesium(II) cation has also 
been shown to be essential for catalysis, with evidence suggesting a role in coordination to the oxygen of 
G37 alongside Arg154 in addition to aiding the orientation of Asp169. 58 A full catalytic cycle for TrmD has 
been proposed that begins with ‘loosening’ of the trefoil knot, allowing SAM to move into the active site, 
followed by ‘tightening’ to a state that can bind tRNA through interactions of the phosphates with surface 
residues before active site insertion of G37. In this model organisation of the interdomain linker, which 
contains the catalytic residue Asp169, occurs following recognition of G36 by TrmD, allowing methyl 
transfer and release of the reaction products. 57 
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Figure 10: X-ray crystal structure of H. influenzae TrmD bound to tRNA and the SAM-analogue sinefungin (PDB code 4YVI, 3.01 Å, 
subunit A = white, subunit B = green, sinefungin = lilac, tRNA = cyan), illustrating (a) the anticodon region of the bound tRNA and 
(b) the interaction of G37 with catalytic residues near sinefungin with the alpha helix of the organised interdomain linker removed 
for clarity. 57 
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The m1G37 tRNA modification has been shown to be essential for normal cellular function in organisms 
spanning all three domains of life, including archaea and eukarya in addition to bacteria . 59  Hence, a 
potential concern could be the interference of a bacterial TrmD inhibitor with the human equivalent. The 
protein responsible for m1G37 modification in archaea and eukarya is Trm5, and whilst structural 
information is not currently available for human Trm5 the archaeal ortholog from Methanocaldococcus 
jannaschii (Mj) has been characterised. 60 Mj Trm5 is considered to provide a useful replacement model 
for the human ortholog, 61 and is structurally distinct from bacterial TrmD with an alternative SAM binding 
mode. 60 This was illustrated in the screening of nucleoside and amino acid fragments against Escherichia 
coli (E. coli) TrmD and Mj Trm5, including adenosine and methionine, which afforded different results for 
each protein. 62 Further, H. influenzae TrmD was recently used as the target of a fragment-based study 
based on the development of thienopyrimidone 3 (Figure 11). Whilst the compounds in this study 
demonstrated weak antibacterial activity, with 4 only possessing an MIC of 3.1 µM against a recombinant 
H. influenzae strain with debilitated AcrAB TolC efflux pumps in vitro, the compounds showed selectivity 
for TrmD when screened against a Trm5 surrogate. 63 As a result, selectivity for bacterial TrmD against 
human Trm5 would probably not be an issue in inhibitor development. 
 
 
Figure 11: The application of a fragment-based study against H. influenzae TrmD. 63 
The demonstrated essentiality of TrmD in mycobacteria, 36,   50 the existence of structural data for the 
Mab ortholog, 54 and low risk of selectivity issues with the human equivalent, 60   −   63 supports the use 
of a fragment-based approach against Mab TrmD to develop compounds with antimycobacterial 
properties. To this end, the Abell research group fragment library was recently screened against Mab 
TrmD by Dr Sherine Thomas (Department of Biochemistry, University of Cambridge), affording 27 
fragment hits for subsequent elaboration. 50 
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1.3: Fragment-based Drug Discovery 
1.3.1: Background 
Over the past 30 years, high-throughput screening (HTS) has been the primary method used by 
pharmaceutical companies to identify leads for drug discovery programmes. The HTS approach requires 
the automated screening of large libraries of compounds, typically 300-500 Da in size, against biological 
targets with the most attractive hits subsequently optimised for potency and ‘drug-like’ physicochemical 
properties. Whilst these libraries often contain millions of compounds they can at best sample an 
insignificant proportion of the over 1063 molecules of this size that are estimated to comprise ‘lead-like’ 
chemical space . 64  Since its first successful utilisation by Fesik et al. in 1996 , 65  fragment-based drug 
discovery (FBDD) has been gaining traction as both an alternative and complementary approach to HTS. 66 
The increasing use of FBDD is exemplified by the FDA approval in recent years of the FBDD-developed 
drugs Vemurafenib and Venetoclax as treatments for late stage melanoma and chronic lymphocytic 
leukaemia respectively. 67,   68  These were joined in 2017 by the cyclin-dependent kinase 4/6 inhibitor 
Ribociclib as a first-line drug for the treatment of breast cancer (Figure 12). 69,   70 
 
Figure 12: FDA-approved drugs developed using a fragment-based approach. 67,   70,  71 
In FBDD weakly binding small molecules, fragments with affinity in the 10 mM to 100 µM range, are 
identified and subsequently elaborated into potent small-molecule ligands. 72 Fragments typically comply 
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with ‘Rule of Three’ guidelines , 73  analogous to Lipinski’s ‘Rule of Five’ for orally bioavailable drug 
candidates, 74 with molecular weights below 300 Da, limits of 3 hydrogen bond donors and 3 hydrogen 
bond acceptors, and a maximum partition coefficient (cLogP) of 3. 75 Computational chemistry analysis 
has placed the total number of lead-like molecules at up to 17 carbon, nitrogen, oxygen, sulfur or halogen 
atoms in size at 1011 in magnitude, 76 therefore a library of only 1000 fragments can sample a higher 
proportion of chemical space than a larger HTS library. However, careful consideration of fragment library 
composition is essential to effectively sample chemical space with focus on molecular complexity, 
diversity and stability in addition to synthetic tractability and the availability of commercial 
analogues. 77,   78 
In addition to their improved sampling of chemical space, fragments are more capable than fragment-
sized moieties in HTS hits of probing ligand-binding sites without interference from unfavourable steric or 
electronic matches, forming high-quality interactions due to their reduced molecular complexity. 79 The 
presence of these high-quality interactions is essential for a fragment’s intrinsic affinity for a protein to 
overcome the loss of its rigid body translational and rotational entropy on binding, 15-20 kJ mol-1 or 3 
orders of magnitude of binding affinity at 298 K as for a larger HTS hit. 80 The elaboration of a high-quality 
fragment can present less challenge than the optimisation of an HTS hit with multiple sub-optimally 
aligned moieties, and ligands derived by FBDD have been shown to display improved physicochemical 
properties in relation to HTS-derived leads. 81 
 
1.3.2: Biophysical Techniques 
In contrast to HTS, the weak binding affinities of fragments necessitate the use of sensitive biophysical 
techniques. Each technique presents a unique mixture of strengths and challenges, and the use of several 
in combination is frequently required. 82 Flexibility in the utilisation of biophysical methods in a FBDD 
project is desirable, and it has been demonstrated that the use of multiple screening techniques in parallel 
can minimize the proportion of false negatives , 83  however throughput and time constraints are 
important considerations and the prioritisation of fragment hits is generally of more concern than their 
availability. Hence, the use of a biophysical screening cascade can be useful, with an initial preliminary 
screen followed by validation with lower-throughput techniques. After validation, characterisation of the 
structural features, thermodynamic parameters and stoichiometry of the ligand-protein interaction is 
essential. 84,   85 
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Differential scanning fluorimetry (DSF) is a high-throughput technique that allows rapid testing of a 
fragment library, providing enrichment of hits and allowing assessment of target ligandability in the 
absence of structural information. 86 The technique is dependent upon analysis of a protein’s thermal 
melting temperature (Tm), the temperature at which its Gibbs free energy of unfolding (ΔGu) is zero and 
the concentrations of folded and unfolded states equal in a reversible two-state equilibrium. 87 This is 
carried out through the monitoring of the fluorescence of an environmentally sensitive dye with affinity 
for the hydrophobic interior of proteins, which are typically exposed upon protein unfolding. Sypro 
Orange® is commonly used due to its favourable signal-to-noise ratio in addition to possessing a high 
wavelength of excitation, minimising the risk of interference by tested ligands in the dye’s optical 
behaviour. 87 The binding of the dye to the protein results in an increase in the fluorescence signal with 
Tm corresponding to the inflection point of the sigmoidal curve. The binding of a fragment to a protein is 
typically associated with stabilisation of the folded protein state, resulting in an increase of the Tm with a 
reproducible ΔTm of two to three standard deviations often classified as a hit. 87 Whilst the ΔTm values of 
similar compounds within a series can be utilised to an extent in affinity ranking, their dependence on the 
relative contributions of entropy and enthalpy to the thermodynamics of binding limits this application, 
with entropically driven binding affording higher ΔTm values whilst also providing interference through 
binding to the unfolded protein state. 88  Preferential binding of ligands to the unfolded protein state 
results in the common observance of negative ΔTm values that are usually discounted in hit selection, but 
have shown some use in the development of tool compounds against certain targets. 89,   90 
Several ligand-observed 1H NMR techniques are available for validation of fragment-protein interactions 
as part of a screening cascade with saturation transfer difference (STD), water-ligand observed via 
gradient spectroscopy (waterLOGSY) and Carr-Purcell-Meiboom-Gill (CPMG) NMR utilised in the Abell 
research group. 84 In comparison to protein-observed NMR alternatives, ligand-observed NMR techniques 
are faster, require no protein isotopic labelling or resonance assignment, tolerate lower protein 
concentrations, impose no restraints on protein size and allow direct ligand quality control. 91 STD NMR 
involves the selective saturation of protein resonances that rapidly diffuse throughout the protein. In the 
event of fragment binding, intermolecular magnetisation transfer through the nuclear Overhauser effect 
(NOE) results in the appearance of a difference spectrum for the fragment. 92 WaterLOGSY NMR utilises 
NOE transfer of magnetisation from water molecules to the fragment, with transfer from waters at the 
protein binding site of opposite sign to that from bulk water due to the different tumbling regime. As a 
result, non-binding fragments show no change in signal upon addition of protein whilst binding fragments 
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exhibit dominance of the negative signals. 93 In contrast to STD and waterLOGSY, CPMG NMR utilises an 
acquisition delay to filter out signals from rapidly relaxing molecules. Fragments bound to proteins exhibit 
increased relaxation rates, hence the signals from fragments hits are reduced in intensity in the presence 
of protein. 94 
Structural information on the protein-ligand complex is crucial for the development of FBDD projects, and 
is commonly provided by X-ray crystallography through high concentration soaking of protein crystals with 
ligand solution and the processing of diffraction data through molecular replacement . 84  X-ray 
crystallography is a time-consuming technique, and compromises are often required in the selection and 
prioritisation of ligands for the acquisition of structural information. Despite the relatively low-throughput 
of X-ray crystallography, it is also utilised in FBDD as a screening technique in its own right. 95 
Full determination of the thermodynamic parameters of ligand binding can be obtained by isothermal 
titration calorimetry (ITC) through injection of ligand into a sample cell containing protein within an 
adiabatic enclosure. The operation of a differential cell feedback system between the sample and 
reference cells during injections allows the direct measurement of the enthalpy of binding (ΔHB) and 
estimation of the equilibrium dissociation constant (Kd) and stoichiometry of the interaction, from which 
the Gibbs free energy (ΔGB) and entropy (ΔSB) of binding can be calculated. 96 Whilst ITC suffers from low-
throughput and high protein requirements, it is utilised for its sensitivity in ligand affinity 
determination. 72 The thermodynamic parameters of enthalpy and entropy of binding are attributed in 
general to specific binding interactions and non-specific hydrophobic effects respectively, hence the 
selection of starting points with enthalpically-dominated binding and minimisation of entropic increases 
during a project could be beneficial. 97 However, due to the nature of these values as the net sums of 
many competing aspects of ligand-protein interactions that can be challenging to control, as reflected in 
the commonly observed phenomenon of enthalpy-entropy compensation, over interpretation and their 
use as endpoints in and of themselves is discouraged. 98 The high-quality interactions of fragment hits 
though are reflected in favourable enthalpic profiles, and the use of thermodynamic data in combination 
with structural information can lead to the development of ligands with desirable physicochemical 
properties. 99 
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1.3.3: Fragment Elaboration 
Following screening and characterisation, fragment hits are elaborated into ligands with improved 
potency through an iterative cycle of synthesis and testing, guided by the strategies of linking, growing 
and merging . 72  Fragment-linking, the connection of fragments with non-overlapping binding poses 
through a linker that allows the resultant ligand to recapitulate the original fragment binding modes 
without hindrance, can result in large gains in affinity (Figure 13). 100 
 
 
 
  
Figure 13: (a) The application of a fragment-linking strategy against Mycobacterium thermoresistible (Mth) inosine-5′-
monophosphate dehydrogenase (IMPDH) to a fragment 5 bound twice in the active site to achieve a ~1300x potency improvement 
in 6, illustrated in X-ray crystal structures of Mth IMPDH (Mth IMPDH = white, ligand = lilac) bound to (b) 5 (PDB code 5OU2, 
1.45 Å), and (c) 6 (PDB code 5OU3, 1.60 Å). 100 
The affinity gains that are achievable in a fragment-linking strategy are due to the effective independence 
of ligand molecular weight and the rigid body entropic penalty of binding, which allows the combination 
of two fragments to afford a greater increase in the free energy of binding than would be suggested by 
simple addition of their individual energies. 101 However, despite its conceptual appeal, this approach is 
not commonly used due to the inherent difficulty of developing an ideal linker with appropriate flexibility 
and geometry in addition to providing favourable interactions with the protein . 102  In contrast to 
(b) (c) 
(a) 
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fragment-linking, when fragments exhibit overlapping binding poses a fragment-merging strategy can be 
beneficial where portions of the fragments, particularly those with the highest contribution to binding, 
are incorporated into one ligand with improved affinity (Figure 14). 103  
 
 
 
  
Figure 14: (a) The application of a fragment-merging strategy against human lipoprotein-associated phospholipase A2 (Lp-PLA2) 
to fragments 7 and 8 bound in the active site to achieve a ~400x potency improvement in 9, illustrated in (b) an overlay of X-ray 
crystal structures of human Lp-PLA2  bound to 7 or 8 (overlay of PDB code 5JAO and PDB code 5JAL, human Lp-PLA2 = white, 7 = 
lilac, 8 = pink) and (c) an X-ray crystal structure of human Lp-PLA2 bound to 9 (PDB code 5JAP, 2.46 Å, human Lp-PLA2 = white, 9 = 
lilac). 103 
The modification of fragment scaffolds based on a fragment-merging approach can provide new 
possibilities for elaboration however, as in fragment-linking, conceptually appealing changes can be 
challenging to apply in practice . 104,   105  In the event of success in carrying out a fragment-linking or 
merging exercise, new functionality can be added to the scaffold based on structural information. Due to 
the challenges presented by fragment-linking and merging, the direct addition of new functionality to a 
fragment hit with the goal of increasing affinity, the fragment-growth approach, is the most common 
route taken in FBDD projects. 72 Based on analysis of published X-ray crystallographic data the addition of 
(a) 
(b) (c) 
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new functionality to a fragment generally does not significantly change its binding mode , 106  and 
significant increases in affinity are frequently published. 107  
During the elaboration of fragment hits it is essential that efficiency metrics are utilised in the decision-
making process, maximising the benefits of the high-quality fragment starting points and increasing the 
probability of obtaining potent ligands with ‘drug-like’ physicochemical properties. 108  A key efficiency 
metric in FBDD is ligand efficiency (LE), the Gibbs free energy of binding per non-hydrogen or ‘heavy’ atom 
(HA) (Equation 1), which allows the assessment of ligand affinity with respect to molecular weight. 109 
LE =
−RT. InKd
𝐻𝐴
=
−∆𝐺𝐵
𝐻𝐴
 
Equation 1 : Ligand efficiency. 109 
The maintenance of LE during fragment elaboration prevents excessive increases in molecular mass in the 
goal of improved affinity. A value of at least 0.3 kcal mol-1 HA-1 is recommended, corresponding to a Kd of 
10 nM  in a ligand with a molecular weight below 500 Da. 109 Further, LE is often utilised in conjunction 
with the more sensitive metric of group efficiency (GE), the change in the Gibbs free energy of binding per 
added HA (Equation 2). 110 
GE =
−∆∆G𝐵
∆HA
 
Equation 2: Group efficiency. 110 
The use of GE analysis in FBDD allows assessment of the contributions of individual moieties to the ligand’s 
free energy of binding, facilitating the development of potent and ligand-efficient compounds. 111,   112 
Finally, if ‘lead-like’ ligands are already reported for the target in question, the trial of a deconstruction-
reconstruction approach could be beneficial rather than starting a new fragment screening exercise. 113  
This approach would involve defragmentation of the ligand scaffold, breaking it down conceptually into 
smaller fragments, with derivatives that show evidence of binding elaborated to new ligands with 
improved properties (Figure 15). 114 However, such a strategy may not succeed as the individual moieties 
of lead-like ligands are not guaranteed to be able to either exhibit detectable binding on their own as 
fragments or bind with the same pose as the parent ligand. 115 
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Figure 15: The application of a deconstruction-reconstruction approach against human phosphoinositide-3-kinase (PI3K) for 
selectivity between the α and δ isoforms using the unselective ligand 10, with the fragment-like ligand 11 still exhibiting PI3K 
inhibition and the resultant ligand 12 affording selective inhibition of the δ isoform. 114 
 
1.4: Project Aims 
The aim of this project is to utilise fragment-based methods to develop ligands with high affinity against 
Mtb fumarase and Mab TrmD. These could then be utilised as tool compounds to evaluate the potential 
of these enzymes as drug targets for the development of novel antimycobacterial treatments. 
With regards to Mtb fumarase, an HTS hit 2 was previously discovered, and a deconstruction-
reconstruction approach will be explored to develop fragments with high quality interactions with the 
enzyme that could be elaborated into ligands with improved affinity. Facilities and expertise in structural 
biology will be provided by the Hyvӧnen research group at the Department of Biochemistry, to aid in the 
performance of X-ray crystallography with Mtb fumarase. 
With regards to Mab TrmD, the use of a fragment screening cascade has identified 27 fragments with 
associated structural information on the protein-ligand interaction. The aim will be to obtain affinity data 
for these fragments and use the most promising hits as starting points for multiple elaboration 
programmes, taking advantage of the large diversity of binding modes to identify novel compounds for 
the treatment of Mab infection. The work will be performed in collaboration with the Blundell research 
group at the Department of Biochemistry, with Dr Sherine Thomas providing structural information on 
ligand binding modes with Mab TrmD by X-ray crystallography, and the Floto research group at the 
Department of Medicine with Dr Karen Brown screening compounds against Mab in vitro. 
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Compounds synthesised against both protein targets will be sent to the group of Dr Helena Boshoff at the 
Tuberculosis Research Section, National Institutes of Health, for screening against Mtb in vitro by Dr Daben 
Libardo. 
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2: Fumarate Hydratase 
2.1: Project Setup 
The application of a deconstruction-reconstruction approach to the allosteric inhibitor 2 of Mtb fumarase 
required the ranking of compounds. The use of a biochemical assay to achieve this was dependent on 
both the acquisition of Mtb fumarase, whose activity would be monitored, and the synthesis of 2 to 
determine a reference IC50 value for comparison to subsequent derivatives. 
 
2.1.1: Synthesis and Screening of High-throughput Screening Hit 2 
Synthesis of the allosteric inhibitor 2 was based on a convergent route requiring the synthesis of carboxylic 
acid 16 (previously developed by Monica Kasbekar, University of Cambridge) (Scheme 1). 41 The synthesis 
of 16 involved the Wittig reaction of phthalic anhydride 13 and ethyl (triphenylphosphoranylidene)acetate 
to afford the unsaturated intermediate 14 (67% yield). Heating under reflux with hydrazine in ethanol 
converted 14 to the phthalazinone ester 15 (99% yield), with subsequent hydrolysis providing 16 (44% 
yield) (Scheme 1a).  
The route also focused on the synthesis of aniline 20, 41 starting with the addition of a trifluoroacetyl 
protecting group to o-anisidine 17 (99% yield). The protected amide 18 was then treated with 
chlorosulfonic acid to introduce a sulfonyl chloride group on its phenyl ring through electrophilic aromatic 
substitution, affording 19 (78% yield) (Scheme 1b). The addition of this electrophilic functional group 
allowed the synthesis of a sulfonamide, which in the case of 20 was carried out with azepane and NaH, 
followed by heating under reflux under acidic conditions to remove the trifluoroacetyl protecting group 
(83% yield). This was achieved in the original synthesis with the isolation of the trifluoroacetyl-protected 
sulfonamide intermediate, 41 however for expediency this was combined into a two-step reaction with 
the dropwise addition of acid under cooled conditions to the basic reaction mixture, which also resulted 
in an improvement in yield (Scheme 1b).  
With 20 and 16 successfully obtained, attention could shift to the synthesis of 2, which was previously 
achieved through COMU-mediated amide coupling. 41  This was attempted, however this gave a poor 
yield, therefore an alternative amide coupling reagent propylphosphonic anhydride (T3P®) was utilised 
(60% yield) (Scheme 1b). T3P®, a water-soluble reagent originally developed for the coupling of peptides 
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under mild conditions without racemisation, 116 was utilised throughout the remainder of the project for 
the synthesis of most amides.  
 
 
 
 
Reagents and Conditions: (a) (Carbethoxymethylene)triphenylphosphorane, CHCl3, reflux, 3 h; (b) N2H4·H2O, EtOH, 50 °C, 2 h; (c) NaOH (10% 
w/v), THF, reflux, 1 h; (d) TFAA, pyridine, DCM, 0 °C to rt, 3 d; (e) HSO3Cl, DCM, 0 °C to rt, 16 h; (f) (i) hexamethyleneimine, NaH, DMF, 0 °C to 
rt, 3 h (ii) EtOH, H2O, HCl (37.5% w/v), reflux, 20 h; (g) 16, T3P® (50 wt. % in DMF), DIPEA, DMF, 70 °C, 1 h. 
Scheme 1: Synthesis of (a) 16 in three steps from 13, and (b) 2 in four steps from 17, including 16. 
Following the synthesis of 2, the determination of its IC50 against Mtb fumarase was carried out using a 
biochemical assay based on the oxidative citric acid cycle (previously optimised by Monica Kasbekar, 
University of Cambridge) (Figure 16a), which monitors the production of reduced nicotinamide adenine 
dinucleotide (NADH) (Figure 16b). 117 
(b) 
(a) 
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Figure 16: The biochemical assay utilised for the monitoring of Mtb fumarase activity, (a) illustrating the relevant portion (red) of 
the oxidative citric acid cycle and (b) illustrating the reactions of the assay and required materials (red); 41 (c) dose-response curve 
for 2 obtained from the biochemical assay, with data points representing an average of replicates (n = 6) and error bars indicating 
standard errors of the mean. 
 
(c) 
(b) (a) 
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The components of the biochemical assay were obtained from commercial sources, except for Mtb 
fumarase itself. The target protein was expressed and purified with a yield of 24 mg L-1 by the 
transformation of E. coli BL21(DE3) strain (plasmid provided by Monica Kasbekar, University of 
Cambridge). The screening of 2 against Mtb fumarase afforded a mean IC50 of 2.0 ± 0.1 µM (Figure 16c), 
which is consistent with the previously determined value of 2.5 ± 1.1 µM. 41 
 
2.1.2: X-ray Crystallography 
In addition to the quantification of inhibition through biochemical assays, the acquisition of structural 
information on protein-ligand interactions is considered essential for subsequent elaboration, with X-ray 
crystallography the most widely used technique for this purpose. A successful crystallisation protocol was 
previously described for Mtb fumarase, utilising sitting drop vapour diffusion with the combination of 2 µL 
protein solution (14 mg mL-1 Mtb fumarase, 0.15 M NaCl, 10 mM Tris pH 8.0 and 0.5 mM TCEP) and 1 µL 
reservoir solution (17% w/v PEG3350, 5% DMSO and 0.20 M magnesium formate). 41 This protocol was 
used as a starting point for the acquisition of new Mtb fumarase crystals.  
A sitting drop plate was set up with concentration gradients in PEG3350 (12 – 19% w/v) and magnesium 
formate (0 – 0.28 M) to account for differences in laboratory technique that could have a significant 
influence on crystallisation outcome. Crystal quality in this plate was higher at lower levels of PEG3350 
and the highest concentration of magnesium formate, therefore a new sitting drop plate was established 
with a reduced PEG3350 concentration gradient (10 – 17% w/v) and an increased single concentration of 
magnesium formate (0.30 M). Whilst the crystals were of improved quality, they were generally too small 
and numerous for practical use, therefore the well with the highest quality crystals was removed (Figure 
17a), diluted and sonicated to produce seed stock, which was further diluted (17% w/v PEG3350, 5% 
DMSO and 0.30 M magnesium formate) to afford 100, 1,000, 5,000 and 10,000x solutions. 
The seed stock solutions were applied to a new plate (10 – 12.8% w/v PEG3350, 5% DMSO and 0.30 M 
magnesium formate) with three ratios of protein, reservoir and seed stock solution. The wells arising from 
the combination of protein, reservoir and seed stock solution in a 3 : 1 : 0.5 ratio by volume afforded the 
best quality Mtb fumarase crystals (Figure 17b) and were taken forward for soaking trials. 
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Figure 17: Images of wells from sitting drop plates, with (a) 2 µL protein solution (14 mg mL-1 Mtb fumarase, 0.15 M NaCl, 10 mM 
Tris pH 8.0 and 0.5 mM TCEP) + 1 µL reservoir solution (10% w/v PEG3350, 5% DMSO, 0.30 M magnesium formate), 2 w, and (b) 
3 µL protein solution (14 mg mL-1 Mtb fumarase, 0.15 M NaCl, 10 mM Tris pH 8.0 and 0.5 mM TCEP) + 1 µL reservoir solution (10% 
w/v PEG3350, 5% DMSO, 0.30 M magnesium formate) + 0.5 µL seed stock solution (10,000x dilution), 5 d. 
Three solutions of 2 (1 mM) with the same concentration of DMSO (7.5%) and magnesium formate 
(0.20 M) but differing PEG3350 and glycerol contents (19% w/v PEG3350 and 0% glycerol, 19% w/v 
PEG3350 and 14.5% glycerol, or 26.25% w/v PEG3350 and 0% glycerol) were applied to crystal-containing 
drops from the seeding trial (2 µL), representing alternative cryoprotectant strategies. The application of 
these solutions to crystals with overnight incubation induced a degree of cracking, however crystals were 
successfully mounted into loops and flash frozen in liquid nitrogen. 
X-ray data were collected at a wavelength of 0.9795 Å at the Diamond Light Source synchrotron 
(Oxfordshire, United Kingdom). Diffraction was best observed with a drop representing the 26.25% w/v 
PEG3350 cryoprotectant strategy, which was used in all subsequent protocols. Molecular replacement 
was carried out on this dataset of spacegroup C121 and 1.59 Å resolution using PHASER, 118  accessed 
through the Collaborative Computational Project Number 4 (CCP4) software suite, 119 with the previously 
published 2-bound Mtb fumarase structure used as a search model after removal of ligand and water 
molecules (PDB code 5F91) . 41  The dataset was compatible with this model, with clear density 
corresponding to dual-bound 2 visible at one of the head-to-head subunit interfaces of Mtb fumarase. 
Molecules of 2 were fitted to this density using the COOT molecular graphics software package, 120 and 
the new model (Figure 18) refined with REFMAC5, 121  accessed through CCP4. 119 
(a) (b) 
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Figure 18: X-ray crystal structure of Mtb fumarase bound to 2 (1.59 Å, subunit A = white, subunit B = green, subunit C = cyan, 
subunit D = yellow, 2 = lilac) after molecular replacement and refinement of a dataset obtained from a crystal of Mtb fumarase 
soaked with 2, with a 2Fo-Fc mesh at 2.0 Å of resolution surrounding 2. 
 
2.2: Defragmentation of High-throughput Screening Hit 2 
With the inhibition of Mtb fumarase by 2 successfully reproduced, the deconstruction-reconstruction 
strategy was initiated. This would entail the design and synthesis of a focused library of ‘fragment-like’ 
molecules based on the structure of 2, and their screening against Mtb fumarase. 
 
2.2.1: Library Design 
The structure of 2 was used to design a focused library of 10 ‘fragment-like’ molecules of varying 
molecular weights, including compounds both with and without inclusion of the phthalazinone ring 
system (Figure 19). Fragments 16 and 20 represent cleavage of the amide bond of 2 into a carboxylic acid 
and amine, with additional functionality provided by 21 and 22 respectively in case these fragments were 
unable to bind at a detectable level. This eventuality was suspected to be possible with 16 due to the 
absence of the central phenyl ring associated with the π-stacking interaction that facilitates the dual 
binding mode of 2. 
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Figure 19: Focused library of fragment-like molecules produced from defragmentation of 2. 
The ester 15 was included in the focused library to insure against the carboxylic acid of 16 not being 
tolerated in the allosteric site, with similar reasoning behind 23 for the aniline functionality of 20 (Figure 
19). The truncation of 22 to the N-methyl sulfonamide 24 was to allow investigation of alternatives to the 
7-membered azepane ring with retention of the sulfonamide, which is absent in 21, whilst also providing 
a new hydrogen bond donor at the nitrogen atom. In contrast, fragments 25, 26 and 27, with modification 
or removal of the methoxy group of 20, were intended to provide variety in substitution of the phenyl ring 
(Figure 19). 
 
2.2.2: Library Synthesis 
Whilst fragments 15, 16 and 20 were accessible by the synthetic route for 2, further synthesis was required 
for the other members of the focused library. Fragment 21 was produced in one step by the T3P®-
mediated coupling of 16 with 17 (82% yield) (Scheme 2a). Synthesis of 23 began with the reaction of 
anisole 28 with chlorosulfonic acid (64% yield), followed by the application of the conditions for the first 
step of the conversion of 19 to 20 to sulfonyl chloride 29 (79% yield) (Scheme 2b). 
32 
 
 
 
 
 
 
 
Reagents and Conditions: (a) T3P® (50 wt. % in DMF), DIPEA, DMF, 40 °C, 2 h; (b) HSO3Cl, CHCl3, 0 °C to rt, 30 min; (c) hexamethyleneimine, 
NaH, DMF, 0 °C to rt, 1 h; (d) HSO3Cl, CHCl3, 0 °C to reflux, 90 min; (e) hexamethyleneimine, DIPEA, DCM, 15 h; (f) NaBH4, NiCl2·6H2O, MeOH, 0 
°C to rt, 2 h.  
Scheme 2: Synthesis of (a) 21 in one step from 16 and 17, (b) 23 in two steps from 28, and (c) 25 in three steps from 30. 
In contrast to 29, sulfonyl chloride 31, itself produced by treatment of 30 with chlorosulfonic acid (78% 
yield), was reacted with azepane under milder conditions due to its acidic phenol functionality (64% yield). 
The nitro group of the resultant 32 was then reduced to the aniline 25 using a mixture of NaBH4 and NiCl2 
(62% yield) (Scheme 2c). A third method for the conversion of a sulfonyl chloride to a sulfonamide was 
applied in the synthesis of N-methyl sulfonamide 33a, with the heating under reflux of 19 with 
methylamine in THF prior to acidic trifluoroacetyl deprotection (82% yield). The free aniline of 33a was 
then acetylated with acetic anhydride and pyridine to give 24 (56% yield) (Scheme 3a). 
(c) 
(b) 
(a) 
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Reagents and Conditions: (a) (i) Methylamine (2 M in THF), THF, reflux, 90 min (ii) EtOH, HCl (37.5% w/v), H2O, reflux, 3 h 30 min; (b) Ac2O, 
pyridine, DCM, 2 d; (c) hexamethyleneimine, NaH, DMF, 0 °C to rt, 90 min; (d) NaBH4, NiCl2, MeOH, 0 °C to rt, 45 min; (e) Ac2O, pyridine, DCM, 
90 min to 5 h. 
Scheme 3: Synthesis of (a) 24 in two steps from 19, (b) 26 in two steps from 34, and (c) 22 and 27 in one step from 20 or 26. 
Aniline 26 was synthesised by the initial treatment of sulfonyl chloride 34 with azepane and NaH (42% 
yield), followed by reduction of the nitro group of 35 in the same manner as 32 with NaBH4 and NiCl2 (82% 
yield) (Scheme 3b). As with 33a, 20 and 26 were reacted with acetic anhydride to give the acetylated 
derivatives (79-86% yield) (Scheme 3c).  
 
(b) 
(c) 
(a) 
34 
 
2.2.3: Library Screening 
With the synthesis of the focused library completed, the majority of the fragments were screened using 
the biochemical assay, with negligible inhibition values afforded at 1 mM concentration (Table 1). 
Compound 
Inhibition (%) 
at 1 mM 
ΔTm (°C) at 
5 mM 
 Compound 
Inhibition (%) 
at 1 mM 
ΔTm (°C) at 
5 mM 
15 < 10 -0.6  23 ND +0.1 
16 < 10 -0.4  24 < 10 -0.4 
20 < 10 -0.7  25 ND -1.6 
21 13 -0.4  26 < 10 -1.2 
22 12 -0.6  27 < 10 -0.4 
Table 1: The results from the screening of the focused library from defragmentation of 2 against Mtb fumarase using both the 
biochemical assay and DSF. 
Due to the lack of measurable inhibition from screening of the fragments with the biochemical assay, the 
use of sensitive biophysical techniques was explored. A protocol for the application of DSF against Mtb 
fumarase (previously optimised by Monica Kasbekar) was subsequently utilised for the screening of the 
focused library (Table 1). 117 In contrast to 2, which gave a ΔTm of +3.9 °C at a ligand concentration of 
0.63 mM, DSF screening of the focused library against Mtb fumarase at 5 mM afforded negative ΔTm 
values for the majority of fragments, with a ΔTm of -1.6 °C induced by 25 (Table 1). Whilst negative values, 
which are associated with preferential binding to the unfolded state of the protein , 88  are usually 
discounted, the investigation of fragments that afford these values has yielded useful information in 
previous studies. 89,   90 Hence, further characterisation was sought. 
Ligand-observed NMR is a technique in FBDD that can provide validation of fragment-protein 
interactions, 91 and was previously applied against Mtb fumarase. 117 The same conditions were adopted 
for use with selected fragments of the focused library, 22 and 26, the largest and smallest molecules by 
molecular weight possessing the central phenyl ring (Figure 20). 
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Figure 20: Ligand-observed NMR experiments (fragment-only = blue, fragment + protein = red) for 22 and 26, including STD (a), 
waterLOGSY (b) and CPMG (c) experiments, with a focus on peaks from aromatic protons. 
Comparison of the fragment-only ligand-observed NMR experiments with those in the presence of Mtb 
fumarase was supportive of fragment-protein interaction for both 22 and 26, with the addition of protein 
resulting in the appearance of fragment peaks by STD (Figure 20a), the replacement of negative peaks 
with positive peaks by waterLOGSY (Figure 20b), and a clear attenuation of peak intensity by CPMG (Figure 
20c). 2 was also added as a competitor ligand in the CPMG experiments, however this did not result in a 
(a) 
(c) 
(b) 
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difference in peak intensity for either 22 or 26 (Figure 21), suggesting that the fragments did not possess 
the same binding mode as 2 with the protein. As a result, the acquisition of structural information on the 
fragment-protein interactions was sought. 
 
 
 
 
 
 
  
Figure 21: Ligand-observed CPMG experiments (fragment-only = blue, fragment + protein = red, fragment + protein + 2 = green) 
for 22 and 26, with a focus on peaks from the highlighted protons (red). 
Based on the prior work of recreating the X-ray crystal structure of 2-bound Mtb fumarase, crystals of Mtb 
fumarase were produced by the application of 10,000x seed stock solution to a sitting drop plate with a 
3 : 1 : 0.5 ratio by volume of protein (14 mg mL-1 Mtb fumarase, 0.15 M NaCl, 10 mM Tris pH 8.0 and 
0.5 mM TCEP), reservoir (10% w/v PEG3350, 5% DMSO and 0.30 M magnesium formate) and seed stock 
solution. Fragments 15, 20 and 22 were soaked overnight into wells with the highest quality crystals, with 
the application of high concentration ligand solutions (50 mM ligand, 7.5% DMSO, 26.25% w/v PEG3350 
and 0.20 M magnesium formate), with subsequent mounting and flash freezing, and the collection of X-
ray data at the Diamond Light Source synchrotron or European Synchrotron Radiation Facility (Grenoble, 
France). Crystals soaked with 22 failed to diffract sufficiently for full data collection, however data were 
collected for crystals soaked with 15 or 20. Molecular replacement with these datasets, using PHASER, 118 
was best performed with formate-bound Mtb fumarase (PDB code 5F92) as a search model. 41 Analysis of 
the resultant electron density contour map failed to reveal evidence of a bound fragment. In the absence 
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of structural information from X-ray crystallography, the pursuit of a deconstruction-reconstruction 
approach with 2 and Mtb fumarase was not further prioritised. 
 
2.3: Structure-activity Relationship Study of 2 
Following the defragmentation strategy with 2, a structure-activity relationship (SAR) study was explored 
to develop inhibitors of Mtb fumarase more potent than 2. This SAR study focused on modification of the 
phthalazinone and azepane rings of 2 in addition to the methoxy and sulfonyl groups on the central phenyl 
ring (Figure 22). 
 
Figure 22: Areas of focus for the SAR study on 2, the phthalazinone and azepane rings and the methoxy and sulfonyl substituents 
on the central phenyl ring, with initial ideas for modification. 
 
2.3.1: Analogue Synthesis 
The synthesis of the analogues of 2 with alternative substituents to the methoxy group required the 
coupling of the corresponding anilines 26 and 38 with 16 by T3P® (45-50% yield) (Scheme 4b). Aniline 26 
was available as a member of the focused library, however 38 required synthesis, which was achieved 
through the application of the synthetic route for 26 to sulfonyl chloride 36 (Scheme 4a). The amide 
analogue of 2, 45, was synthesised in four steps with the initial coupling of carboxylic acid 41 to azepane 
with T3P® to afford 42 (24% yield), whose phenolic functionality was methylated by dimethyl sulfate (77% 
yield). The product, 43, was reduced by NaBH4 and NiCl2 to give aniline 44 (64% yield), which was coupled 
to 16 with T3P® (45% yield) (Scheme 4c). 
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Reagents and Conditions: (a) hexamethyleneimine, NaH, DMF, 0 °C to rt, 1 h; (b) NaBH4, NiCl2, MeOH, 0 °C to rt, 45 min; (c) T3P® (50 wt. % in 
EtOAc), DIPEA, DMF, 70 °C, 2 h; (d) hexamethyleneimine, T3P® (50 wt. % in DMF), DIPEA, DMF, 1 d; (e) Me2SO4, K2CO3, acetone, reflux, 2 h; (f) 
NaBH4, NiCl2·6H2O, MeOH, 0 °C to rt, 90 min; (g) 16, T3P® (50 wt. % in EtOAc), DIPEA, DMF, 70 °C, 2 h. 
Scheme 4: Synthesis of (a) 38 in two steps from 36, (b) 39 and 40 in one step from 16 and 26 or 38, and (c) 45 in four steps from 
41, including 16. 
(a) 
(c) 
(b) 
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In contrast to 45, the synthesis of 2 analogues 46a-f and 46h required only one reaction with the T3P®-
mediated coupling of 20 to various carboxylic acids (21-67% yield) (Scheme 5a). The application of T3P® 
in coupling 20 and 4-pyridylacetic acid to synthesise 46i was unsuccessful, however the use of an EDC-
mediated reaction did afford the desired product (64% yield). 
 
 
 
Reagents and Conditions: (a) RCH2CO2H, T3P® (50 wt. % in EtOAc), DIPEA, DMF, 70 °C, 1 to 4 h; (b) 4-pyridylacetic acid HCl, EDC.HCl, DIPEA, 
DMAP, DCM, 90 min; (c) CO2 (s), LDA (2 M in THF/ heptane/ ethylbenzene), THF, -78 °C to rt, 1 h; (d) 20, T3P® (50 wt. % in EtOAc), DIPEA, DMF, 
70 °C, 40 min. 
Scheme 5: Synthesis of (a) 46a-f and 46h-i in one step from 20, and (b) 46g in two steps from 47, including 20. 
In the synthesis of 46g, 4-methylquinoline 47 was deprotonated with LDA and treated with solid carbon 
dioxide to yield carboxylic acid 48. However, due to difficulties in extracting this compound from the 
aqueous phase during workup, the solution was concentrated and the resultant solid taken forward crude 
with inorganic impurities for T3P®-mediated amide coupling with 20 (5% yield overall) (Scheme 5b).  
(a) 
(b) 
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Reagents and Conditions: (a) (i) RH, NaH, DMF, 0 °C to rt, 30 min to 20 h (ii) EtOH, HCl (37.5% w/v), H2O, reflux, 4 h to 1 d; (b) (i) RH, NEt3, 
DMAP, DCM, 30 min to 1 h (ii) EtOH, HCl (37.5% w/v), H2O, reflux, 3 to 16 h; (c) T3P® (50 wt. % in EtOAc), DIPEA, DMF, 70 °C, 45 min to 5 h. 
Scheme 6: Synthesis of (a) 33b-n in one step from 19, and (b) 49a-n in one step from 16 and 33a-n. 
In the case of analogues 49a-n of 2 with alternative amine substituents attached to the sulfonamide, a 
two step synthetic route was utilised. The second step for all analogues involved the T3P®-mediated 
coupling of the corresponding aniline with 16 (10-43% yield) (Scheme 6b). Anilines 33b-f and 33h-l were 
made from 19 using the same procedure as 20 with commercially available amines and NaH, followed by 
acidic trifluoroacetyl deprotection (37-73% yield) (Scheme 6a). However, milder reaction conditions were 
employed in the synthesis of 33g due to concern about deprotonation adjacent to the sulfone group of 
thiomorpholine 1,1-dioxide by NaH, and these were subsequently applied to the last synthesised anilines 
33m-n due to greater ease of use (65-80% yield). 
 
(b) 
(a) 
41 
 
2.3.2: Screening against Target Protein 
The synthesised analogues in the SAR study were initially screened at a single concentration of 50 µM 
using the Mtb fumarase biochemical assay (Figure 16b), with full dose-response curves also obtained to 
determine IC50 values, when allowed by solubility and potency. Structural information on ligand 
interactions with the target protein was also sought, with seventeen of the described analogues soaked 
into crystals of Mtb fumarase. Soaking was performed as described with fragments 15, 20 and 22, albeit 
with solutions including a lower concentration of ligand (0.5 – 5 mM).  
X-ray data were collected at the Diamond Light Source synchrotron or European Synchrotron Radiation 
Facility, with datasets obtained for all soaked analogues. Molecular replacement was initially carried out 
with a dataset from the soaking of 49b into Mtb fumarase, due to its high resolution of 1.42 Å, using the 
previously published 2-bound Mtb fumarase structure as a search model (PDB code 5F91) with 
PHASER . 41,   118  Cycles of model building and refinement were then performed, using COOT and 
REFMAC5 respectively, 120,   121 until improvements in model quality were judged to be unforthcoming. 
This model, with ligands and water molecules removed, was then used for molecular replacement with 
datasets obtained from the soaking of other 2 analogues into Mtb fumarase. Whilst an initial cycle of 
model building and refinement was performed for all analogues, full model building was only carried out 
with six further compounds of interest due to time constraints from the size of Mtb fumarase. 
Beginning with modification of the substituents on the central phenyl ring of 2 (> 90% Inhibition at 50 µM), 
the SAR study showed that removal of the methoxy group in 39 (16% inhibition at 50 µM) was not 
tolerated. The potency of 39 was not restored with the addition of a methyl group at the same position 
of the phenyl ring in 40 (< 10% inhibition at 50 µM) (Figure 23a). It is possible that the replacement of the 
methoxy group of 2 reflects a negative impact on the π-stacking interaction between the central phenyl 
rings of the two binding molecules in the allosteric site of Mtb fumarase. However, 39 and 40 would also 
have not been able to recapitulate the complex water-mediated hydrogen-bonding network of 2 with the 
imidazole side chain of His397 and the backbone carbonyls of residues Leu303, Gly305 and Leu306 (Figure 
23b). 
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Compound Inhibition (%) at 50 µM 
2 
 
> 90 
39 
 
16 ± 1 
40 
 
< 10 
45 
 
14 ± 1 
  
 
  
 
    
Figure 23: (a) Inhibition at 50 µM concentration afforded by compounds 39, 40 and 45 in contrast to 2; X-ray crystal structure of 
Mtb fumarase bound to 2 (PDB code 5F91, 2.00 Å, subunit A = white, subunit C = cyan, 2 = lilac, subunits B and D not visible), 
illustrating through rotation and the inclusion of interacting residues the interactions of (b) the methoxy group of one of the 
molecules of 2 and (c) the sulfonamide group of one of the molecules of 2. 41 
His397 
Leu306 Gly305 
Leu303 
Arg400 
Arg432 
(b) (c) 
(a) 
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The sulfonamide of 2 was shown to be sensitive to replacement, with the amide analogue 45 (14% 
inhibition at 50 µM) affording significantly reduced inhibition of Mtb fumarase (Figure 23a). As with the 
methoxy group, this result is likely to be due to disruption of hydrogen bonds with adjacent residues, 
including the water-mediated interaction with Arg400 and the hydrogen bond with the guanidyl 
functional group of Arg432. This would have consequences for the dual binding mode of 2 in the allosteric 
site of Mtb fumarase, with the side chain of Arg432 interacting with the second molecule through both a 
hydrogen bond with the amide carbonyl and a cation-π interaction with the phthalazinone ring system 
(Figure 23c). The replacement of the sulfonamide of 2 with an amide would also introduce additional 
rigidification of the scaffold and could orientate the azepanyl ring in an unfavourable conformation in the 
allosteric site. With these key findings obtained the central phenyl ring of 2 was left unmodified 
throughout the rest of the study, with focus shifted to other regions including the phthalazinone ring 
(Figure 24). 
 
Figure 24: X-ray crystal structure of Mtb fumarase bound to 2 (PDB code 5F91, 2.00 Å, subunit A = white, subunit B = green, subunit 
C = cyan, subunit D = yellow, 2 = lilac), illustrating the interactions of the phthalazinone ring of 2. 41 
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Whilst fragment 22 showed that the absence of the phthalazinone ring had a detrimental impact on Mtb 
fumarase inhibition, it was unknown whether it could be replaced with alternative ring systems. In the 2-
bound Mtb fumarase X-ray crystal structure, the phthalazinone ring is surrounded by networks of 
hydrogen-bonded water molecules and interacts with residues from both subunits at the head-to-head 
interface, including the backbone carbonyl of Leu429 as a hydrogen bond donor. As previously mentioned, 
the phthalazinone ring of 2 also participates in a cation-π interaction with Arg432, with which it 
additionally interacts through a hydrogen-bonded water molecule (Figure 24). 41 
 
 
 
Compound R 
Inhibition (%) 
at 50 µM 
 Compound R 
Inhibition (%) 
at 50 µM 
2 
 
> 90  46e 
 
< 10 
46a 
 
27 ± 6  46f 
 
< 10 
46b 
 
38 ± 5  46ga 
 
86 ± 2 
46c 
 
12 ± 9  46h 
 
21 ± 17 
46d 
 
< 10  46i 
 
< 10 
 
a IC50 determined to be 4.1 ± 0.3 µM. 
Table 2: Inhibition at 50 µM concentration afforded by derivatives of 2 with alternative aromatic substituents attached to the 
amide, compounds 46a-i, in contrast to 2. 
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A 3-substituted indole ring was initially explored as a replacement for the phthalazinone ring of 2, based 
on a consideration of the available space in the binding pocket, however 46a (27% inhibition at 50 µM) 
did not inhibit Mtb fumarase significantly at the screened concentration (Table 2). The soaking of Mtb 
fumarase crystals with 46a afforded visible electron density corresponding to ligand in the allosteric site 
(Figure 25). The water networks and conformations of residues surrounding the indole ring of 46a were 
not significantly changed relative to the 2-bound Mtb fumarase structure, with the indole nitrogen also 
acting as a hydrogen bond donor to the backbone carbonyl of Leu429. In addition to the altered electronic 
profile of the indole relative to a phthalazinone ring system and its impact on the interaction with Arg432, 
it is possible that the loss of inhibitory capability was linked to the movement of the phenyl portion of the 
indole ring away from His397 relative to the phthalazinone of 2, and its impact on a potential π-π stacking 
interaction (Figure 24 and Figure 25). 
 
Figure 25: X-ray crystal structure of Mtb fumarase bound to 46a (PDB code 6S7U, 1.48 Å, subunit A = white, subunit B = green, 
subunit C = cyan, subunit D = yellow, 46a = lilac), illustrating the interactions of the indole ring of 46a. 
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Several derivatives of 46a were synthesised to explore further SAR on this series, this includes the 
modification of the electronic properties of the indole ring through the substitution of a methoxy group 
in 46b (38% inhibition at 50 µM), and the addition of another methylene unit between the indole and 
amide functional groups of 46a to provide further flexibility in 46c (12% inhibition at 50 µM) (Table 2). 
Analogues 46d-f, possessing alternative 5-6 fused rings including benzofuran, benzisoxazole and 
benzimidazole, were also trialed however none of these offered observable inhibition in the biochemical 
assay (< 10% inhibition at 50 µM). Therefore, 6-6 fused rings were explored due to their shape similarity 
to the phthalazinone ring. The use of a quinoline ring in 46g (86% inhibition at 50 µM) inhibited Mtb 
fumarase sufficiently at the tested concentration that a full dose-response curve was determinable (IC50 
4.1 µM), and in addition an X-ray crystal structure of this compound was solved (Figure 26). 
 
Figure 26: X-ray crystal structure of Mtb fumarase bound to 46g (PDB code 6S7W, 1.44 Å, subunit A = white, subunit B = green, 
subunit C = cyan, subunit D = yellow, 46g = lilac), illustrating the interactions of the quinoline ring of 46g. 
The X-ray crystal structure of 46g-bound Mtb fumarase did not show significant movement in the 
conformations of the residues of the allosteric site relative to 2, as with 46a. However, due to the 
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improved overlap of the quinoline ring with the phthalazinone of 2, it also exhibited the same relative 
orientation with His397 (Figure 24 and Figure 26). Whilst the quinoline ring of 46g did not interact with 
the carbonyl of Leu429, it did hydrogen bond to two water molecules in an extensive hydrogen-bonded 
network (Figure 26). The loss of this nitrogen atom in 46h (21% inhibition at 50 µM), which possessed a 
naphthalene ring instead of a quinoline, resulted in a loss of inhibitory capability that prevented the 
measurement of an IC50 value (Table 2). Further, the introduction of a smaller pyridine ring in 46i (< 10% 
inhibition at 50 µM), which retained the hydrogen-bonding capability of the quinoline 46g, illustrated the 
importance of full occupation of this portion of the allosteric site and the interaction with His397. 
In addition to the phthalazinone ring of 2, its azepanyl ring, occupying an ‘azepane binding pocket’ defined 
by His397, Arg400, Leu401 and Arg432 (Figure 27), was the focus of the majority of the SAR study. As this 
portion of the molecule made no hydrogen-bonding interactions with Mtb fumarase, it was judged that 
replacement of this ring with alternative moieties would be tolerated better than the phthalazinone ring 
system.  
 
Figure 27: X-ray crystal structure of Mtb fumarase bound to 2 (PDB code 5F91, 2.00 Å, subunit A = white, subunit B = green, subunit 
C = cyan, subunit D = yellow, 2 = lilac), illustrating the azepane binding pocket of the allosteric site. 41 
The first modification was to produce a truncated derivative of 2, 49a (IC50 57 µM), with an N-methyl 
sulfonamide. In comparison to 21, which lacked the sulfonamide of 2, 49a gave a measurable IC50 value 
that was only one order of magnitude higher than 2 (IC50 2.0 µM) (Table 3). 
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Compound R IC50  Compound R IC50 
2 
 
2.0 ± 0.1  49h 
 
17 ± 3 
49a  57 ± 3  
49i 
 
NDa 
49b 
 
4.0 ± 0.1  49j 
 
2.2 ± 0.2 
49c 
 
4.4 ± 0.1  49k 
 
3.4 ± 0.2 
49d 
 
38 ± 2  49l 
 
0.67 ± 0.03 
49e 
 
12 ± 1  49m 
 
0.67 ± 0.01 
49f 
 
4.7 ± 0.2  49n 
 
NDb 
49g 
 
13 ± 1     
 
a 53 ± 3% inhibition at 50 µM concentration. 
b 44 ± 5% inhibition at 50 µM concentration. 
Table 3: Half-maximal inhibitory concentrations (IC50) afforded by derivatives of 2 with alternative amine substituents attached to 
the sulfonamide, compounds 49a-n, in contrast to 2. 
An X-ray crystal structure of 49a-bound Mtb fumarase was obtained, illustrating a 5 Å movement of the 
side chain of Arg400 (at Cε) relative to the structure with 2 to engage Glu396 in a salt bridge and form a 
hydrogen-bonded water network with Arg432, His397 and the amide carbonyl of 49a, shrinking the 
apparent volume for elaboration in the azepane binding pocket (Figure 27 and Figure 28a). 
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Figure 28: X-ray crystal structures of Mtb fumarase (subunit A = white, subunit B = green, subunit C = cyan, subunit D = yellow, 
ligand = lilac) bound to (a) 49a (PDB code 6S7K, 1.55 Å), and (b) 49b (PDB code 6S43, 1.42 Å), illustrating the azepane binding 
pocket of the allosteric site. 
X-ray crystallography also shows the N-methyl sulfonamide of 49a acting as a hydrogen bond donor, 
interacting with a water molecule hydrogen-bonded to Arg400 (Figure 28a). Following 49a, derivatives of 
2 were synthesised with alternative saturated heterocyclic rings attached to the sulfonamide to probe the 
azepane binding pocket. The larger 8-membered azocanyl analogue 49b (IC50 4.0 µM) possessed a slightly 
attenuated IC50 value relative to 2 (IC50 2.0 µM) (Table 3), showing that whilst larger ring sizes were 
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tolerated to an extent in the azepane binding pocket, they might not afford improvements in inhibition of 
Mtb fumarase. The X-ray crystal structure of 49b-bound Mtb fumarase showed a similar binding pose for 
49b relative to 2 (Figure 27 and Figure 28b). A difference was seen with residue Arg400, adjacent to the 
azocanyl ring, which displayed greater uncertainty in its orientation, possibly due to a steric impact from 
the larger size of the ring system. The screening of the smaller 6-membered piperidinyl derivative 49c (IC50 
4.4 µM) afforded a similar IC50 value to 49b (IC50 4.0 µM) (Table 3), supporting the status of the 7-
membered azepanyl ring system as the ideal size for occupation of this pocket. The inhibition was 
sufficiently low to justify the exploration of further 6-membered heterocyclic analogues. The 
thiomorpholino derivative 49f (IC50 4.7 µM) afforded the best inhibition out of these analogues, however 
it was not an improvement on 49c (IC50 4.4 µM). In comparison, the N-methyl piperazinyl derivative 49d 
(IC50 38 µM) was worse than 49c (IC50 4.4 µM), possibly due to the insertion of a basic nitrogen atom 
between the two positively charged residues Arg400 and Arg432. Surprisingly, the morpholino and 
thiomorpholine dioxide analogues 49e (IC50 12 µM) and 49g (IC50 13 µM), which were expected to 
successfully engage these residues with their oxygen atoms acting as hydrogen bond acceptors, afforded 
inhibition intermediate between 49d (IC50 38 µM) and 49c (IC50 4.4 µM). 
With several saturated heterocyclic ring systems explored, the tolerance of the azepane binding pocket 
to aromatic rings was examined, with the goal of engagement of residues Arg400 and Arg432 in cation-π 
interactions, beginning with 49h (Figure 29).  
 
Figure 29: X-ray crystal structure of Mtb fumarase bound to 49h (PDB code 6S7S, 1.70 Å, subunit A = white, subunit B = green, 
subunit C = cyan, subunit D = yellow, 49h = lilac), illustrating the interactions of the N-phenyl substituent of 49h. 
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The attachment of a phenyl ring to the sulfonamide in 49h (IC50 17 µM) did not lead to an improvement 
in inhibition (Table 3), despite the X-ray crystal structure of 49h-bound Mtb fumarase revealing a coplanar 
arrangement of the guanidyl functional group of Arg400, 4Å above the phenyl ring (Figure 29). Notably, 
the sulfonamide nitrogen atoms of the two 49h molecules in the allosteric site were found sharing a water 
molecule in an indirect hydrogen-bonded interaction (Figure 29), which was not observed in 49a (Figure 
28a). The drop in inhibition of 49h (IC50 17 µM) may be due to a combination of insufficient extension into 
the azepane binding pocket and a lack of flexibility, however the benzyl derivative with a methylene linker 
between the sulfonamide and phenyl ring, 49i (53% inhibition at 50 µM), performed worse in the 
biochemical assay (Table 3).  
Rigidification of 49i through the incorporation of the benzyl group into a tetrahydroisoquinolyl ring system 
in 49j (IC50 2.2 µM) improved inhibition, with a comparable IC50 to 2 (IC50 2.0 µM) (Table 3). The X-ray 
crystal structure showed a 3 Å movement of the phenyl portion of the tetrahydroisoquinolyl ring system 
of 49j relative to the phenyl ring of 49h (Figure 29 and Figure 30a), reaching further into the azepane 
binding pocket and lying between the guanidyl functional groups of Arg400 and Arg432 (Figure 30a). The 
movement of the phenyl portion of the tetrahydroisoquinolyl ring system of 49j through ring expansion 
to the tetrahydrobenzoazepane analogue 49l (IC50 0.67 µM) (Table 3 and Figure 30b), afforded the first 
sub-micromolar inhibitor with an improved IC50 value against Mtb fumarase relative to 2 (IC50 2.0 µM). 
This was hypothesised to be the result of more efficient coverage of the azepane binding pocket and 
better tolerated interactions with Arg400 and Arg432. 
Modifications were made to 49j and 49l to afford further improvements in binding, with the addition of 
methoxy substituents in 49k (IC50 3.4 µM) and 49m (IC50 0.67 µM), however this did not significantly alter 
the values obtained from the biochemical assay (Table 3). A methylene bridge was also added to the 
tetrahydrobenzoazepane ring system of 49l in 49n (44% inhibition at 50 µM), however this was not 
tolerated, presumably due to steric effects in the azepane binding pocket and the movement of the phenyl 
portion of the ring system. 
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Figure 30: X-ray crystal structures of Mtb fumarase (subunit A = white, subunit B = green, subunit C = cyan, subunit D = yellow, 
ligand = lilac) bound to (a) 49j (PDB code 6S7Z, 1.85 Å), and (b) 49l (PDB code 6S88, 1.59 Å), illustrating the azepane binding pocket 
of the allosteric site. 
 
2.3.3: Screening against Mycobacterium tuberculosis 
With a significant amount of SAR explored with this series, twenty of the 2 analogues were sent to 
collaborators Dr Daben Libardo and Dr Helena Boshoff (Tuberculosis Research Section, National Institutes 
of Health) for testing against Mtb in liquid culture (Table 4).  
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Compound 
H37Rv Mtb MIC (µM)  
GAST-Fe 7H9/BSA 7H9/glucose 7H9/DPPC 
2 
 
> 100 > 100 > 100 > 100 
46a 
 
> 100 > 100 100 9.4 
46b 
 
> 100 > 100 > 100 12.5 
46c 
 
> 100 > 100 25 9.4 
46d 
 
> 100 > 100 9.4 6.3 
49b 
 
> 100 > 100 25 18.8 
 
Table 4: MIC values afforded by compounds 46a-d and 49b in contrast to 2 against H37Rv Mtb, performed by Dr. Daben Libardo. 
The compounds were tested against Mtb in four different growth media (Table 4), which included low-
iron glycerol-alanine-salts (GAST-Fe) and Middlebrook 7H9 broth (7H9). GAST-Fe is a minimal medium that 
is used to test compound efficacy when the majority of the de novo biosynthetic pathways in Mtb are 
active, whereas 7H9 is a commercially available medium that supports mycobacterial growth when 
supplemented with other nutrients. In this study three 7H9-based media were tested, supplemented with 
mixtures defined by inclusion of either bovine serum albumin (BSA), glucose or 
dipalmitoylphosphatidylcholine (DPPC). 7H9/BSA is used to investigate plasma protein binding, whereas 
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7H9/glucose and 7H9/DPPC test compound efficacy with Mtb utilising either glucose or a fatty acid as a 
carbon source, which are both predicted to be relevant during in vivo pathogenesis. 122 
To enable direct comparisons with 2, the compound was also sent with its analogues for in vitro tests but 
did not afford an MIC value in any media at the tested concentrations (Table 4), consistent with the 
previous study. 41 Whilst no compounds afforded MIC values with GAST-Fe or 7H9/BSA media, values 
were obtained for 5 compounds in 7H9/glucose and 7H9/DPPC media (Table 4). Three compounds 
afforded MIC values against Mtb with glucose as a carbon source, however the best results were seen 
with 7H9/DPCC. In this medium, the testing of 49b gave an MIC value of 18.8 µM, whilst the values from 
2 analogues with 5-6 fused rings ranged from 9.4 to 12.5 µM. As negative results were obtained at the 
screened concentrations with 7H9/BSA as a medium, it is possible that plasma protein binding could be 
an issue for this series. 
Out of the compounds with observable MIC values against Mtb (Table 4), 49b is the only 2 analogue for 
which an IC50 value was also determinable (IC50 4.0 µM) and possesses the greatest structural similarity to 
2, differing only by its possession of a larger ring attached to the sulfonamide (8- vs 7-membered). It is 
possible that the difference in behavior of 49b relative to 2 in the Mtb in vitro growth assay is related to 
differing physicochemical properties, such as its increased lipophilicity (cLogP 3.1 vs 2.7), however it is not 
guaranteed that this result is from on-target engagement. Further study on this series is required to 
optimise the physicochemical properties of these molecules to develop potent compounds to kill Mtb. 
 
2.4: Summary and Future Work 
The exploration of a deconstruction-reconstruction approach with Mtb fumarase and 2 proved 
challenging, with fragments affording negative ΔTm values by DSF and their soaking into crystals failing to 
afford ligand density by X-ray crystallography. This is likely due to the multiple interactions that 2 makes 
across the allosteric site with two subunits from the protein, in addition to itself through its dual binding 
mode. The subsequent application of a SAR study on 2 was fruitful, with the development of a sub-
micromolar inhibitor of Mtb fumarase with an IC50 three-fold lower than the original HTS hit. Multiple X-
ray crystal structures were obtained of ligand-bound Mtb fumarase that could be utilised in the further 
improvement of ligand-target interactions. Further, the screening of a range of analogues of 2 against Mtb 
in vitro identified several compounds that afford measurable MIC values, in contrast to the original HTS 
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hit. These results represent a significant improvement on the starting point and encourage further work 
on Mtb fumarase as a target for the development of bactericidal compounds. 
With the reassuring results from the screening of 2 analogues in the Mtb in vitro growth assay, it would 
be useful to determine whether the MIC values are the result of successful target engagement or off-
target effects. This could be achieved through the screening of compounds against Mtb strains with 
modified fumarase expression, which have already been developed in the recent study on fumarase 
deficiency in Mtb. 37 In the event that in vitro effects are the result of successful target engagement, a 
physicochemical study on the compounds could be initiated to improve the bactericidal activity of this 
series of Mtb fumarase inhibitors. 
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3: tRNA (m1G37) methyltransferase 
3.1: Fragment Hits and Initial Elaboration Approaches 
The screening of the Abell research group fragment library against Mab TrmD was performed by Dr 
Sherine Thomas (Department of Biochemistry, University of Cambridge) using a two-stage biophysical 
screening cascade. 50 This consisted of the initial use of DSF as a first-line screen, where 53 fragment hits 
(5.6% hit rate) were identified affording ΔTm values greater than the cut-off of 3 standard deviations. 
These hits were then validated by X-ray crystallography on soaking into crystals of Mab TrmD, of which 
27 showed evidence of binding to the active site. These fragments, representing a variety of scaffolds, 
possessed binding modes that occupied different regions of the active site defined by the X-ray crystal 
structure of Mab TrmD with SAM bound (Figure 9b). 50 
The adenine ring system of SAM ‘anchors’ the molecule in the active site, hydrogen-bonding to the 
backbone amides of Ile133, Gly134, Tyr136 and Leu138 with the ring system ‘sandwiched’ between Pro85 
and the side chains of Leu138 and Ala144, in a volume that can be defined as the ‘adenine binding region’ 
(Figure 31). All 27 fragment hits were shown in their X-ray crystal structures with Mab TrmD to occupy 
the adenine binding region to an extent, with most recreating at least some of the hydrogen-bonding 
interactions of the adenine moiety of SAM in this region. 50 
 
Figure 31: X-ray crystal structure of Mab TrmD bound to SAM (PDB code 6NW6, 1.67 Å, subunit A = white, subunit B = green, SAM 
= lilac), illustrating the binding of the adenine motif in one of the active sites. 50 
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The ribose moiety of SAM is enclosed by three loops of the trefoil knot, oriented above residues Gly140 
and Gly141, interacting on either side with the backbone amides of residues Pro83 and Gly109 
respectively and behind with an ordered water molecule in the ‘ribose binding region’ (Figure 32a). 50 
 
 
Figure 32: X-ray crystal structure of Mab TrmD bound to SAM (PDB code 6NW6, 1.67 Å, subunit A = white, subunit B = green, SAM 
= lilac), illustrating (a) the binding of the ribose motif in one of the active sites, and (b) the binding of the methionine motif in one 
of the active sites. 50 
Finally, despite only interacting directly with the backbone carbonyl of Glu112, the methionine portion of 
SAM occupies a large volume in the active site. This ‘methionine binding region’ encompasses the volume 
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bordered by Thr84 to Pro85, Tyr111 to Gly113, the side chains of Val137 and Arg154, Glu180 to Gly181, 
and a portion of the interdomain linker that is not visible in the X-ray crystal structure (Figure 32b). Most 
of the fragment hits were shown to extend at least partially into the ribose binding region in their X-ray 
crystal structures, however only a few were shown to venture into the methionine binding region. 50 
The fragment hits were prioritised for elaboration by consideration of both synthetic tractability and 
binding pose in X-ray crystal structures with Mab TrmD, including the available unoccupied volume in the 
active site and the suitability of vectors from positions on the scaffold for future elaboration. Fragment 
hits of interest were subjected to further screening by ITC to obtain Kd values, in addition to SAR by 
catalogue studies with structurally-related compounds.  
 
3.1.1: Fragment-growth Approach with Hit 50 
Fragment hit 50 (Kd 89 µM, LE 0.55), which primarily binds in the adenine binding region with its pyrazole 
ring and ester carbonyl, was initially selected for elaboration due to its high LE and the volume remaining 
for elaboration in the active site (Figure 33). Further, the ester functional group provided a vector for 
growth that was judged to be desirable, in addition to offering attractive synthetic tractability. 50 
 
Figure 33: X-ray crystal structure of Mab TrmD bound to 50 (PDB code 6QOS, 2.05 Å, subunit A = white, subunit B = green, 50 = 
lilac), illustrating one of the active sites. 50 
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This fragment hit was used as a starting point for the design of a number of analogues, that were 
elaborated into the ribose and methionine binding regions using a benzyl ester motif (Figure 34). 123 
 
 
 
Figure 34: (a) Highlights of fragment-growth strategy applied to fragment hit 50; 123 (b) X-ray crystal structure of Mab TrmD 
bound to 52 (PDB code 6QQQ, 1.85 Å, subunit A = white, subunit B = green, 52 = lilac), illustrating one of the active sites. 123 
The application of a fragment-growth approach with 50 was carried out in conjunction with Alexander 
Fanourakis (Part III student, Department of Chemistry, University of Cambridge), who carried out ~70% of 
the published synthetic chemistry under the supervision of the author. Unfortunately, attempts to 
improve the affinity of 50 in a ligand-efficient manner proved challenging, with the best compound in this 
lead series 52 (Kd 6.7 µM, LE 0.31) only affording a 13-fold improvement in affinity with a significantly 
attenuated LE (Figure 34) . 123  As a result, an alternative fragment elaboration strategy focused on 
fragment hits 53 and 59 was prioritised. 
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3.1.2: Fragment-merging Approach with Hits 53 and 59 
The fragment hit 53 (Kd 170 µM, LE 0.37) was shown in its X-ray crystal structure to span the active site, 
with its 3-aminopyrazole ring system anchoring the molecule in place through hydrogen bonds in the 
adenine binding region to the backbone amides of Gly134, Tyr136 and Leu138, in addition to the side 
chain of Ser132 (Figure 35). 
 
 
 
Compound R Tma (°C) Kd (µM) LEb 
53 4-OMe +3.0 170 ± 14 0.37 
54 H +1.5 ND - 
55 4-Me +1.4 ND - 
56 3-OMe -0.5 ND - 
  
 
a 5 mM ligand and 10 μM Mab TrmD, measured by Dr Sherine Thomas (Department of Biochemistry, University of Cambridge) for 53-55. 
b kcal mol-1 HA-1. 
Figure 35: (a) The change in the melting temperatures (Tm), affinities (Kd) and ligand efficiencies of fragment hit 53 and its 
structural analogues; (b) X-ray crystal structure of Mab TrmD bound to 53 (PDB code 6QOT, 1.62 Å, subunit A = white, subunit B 
= green, 53 = lilac), illustrating one of the active sites. 50 
Extending from the 5-position of the pyrazole ring, the 4-methoxyphenyl ring system of 53 occupies the 
ribose binding region where it makes no further hydrogen-bonding interactions. However, this portion of 
the fragment hit was shown to be sensitive to modification, with the phenyl 54 and 4-tolyl 55 derivatives 
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in the fragment library affording smaller Tm values of +1.5 and +1.4 °C respectively in comparison to 53 
(Tm +3.0 °C) (Figure 35). 
Further SAR on the 4-methoxyphenyl ring system of 53 was provided by the synthesis of the 3-
methoxyphenyl analogue 56 (Scheme 7). This was achieved through the conversion of methyl ester 57 to 
the corresponding β-ketonitrile 58 through treatment with n-butyllithium and acetonitrile (99% yield). 
Compound 58 was then heated under reflux with hydrazine in ethanol to afford 56 (73% yield). 124 The 
screening of 56 afforded a Tm of -0.5 °C, suggesting a preference for 4-substitution on the phenyl ring of 
53 (Figure 35a). 
 
Reagents and Conditions: (a) n-butyllithium (1.6 M in hexanes), acetonitrile, THF, -78 °C, 30 min; (b) N2H4·H2O, EtOH, reflux, 6 h. 
Scheme 7: Synthesis of 56 in two steps from 57.  
With fragment hit 59 (Kd 260 µM, LE 0.41) the ribose binding region is occupied by an indole ring, oriented 
with its nitrogen atom facing the opening of the active site and forming a water-mediated interaction with 
the backbone carbonyl of Leu138 (Figure 36a and b). This fragment is held in the active site through its 6-
substituted boronic acid, which extends into the adenine binding region and hydrogen bonds to the 
backbone amides of Tyr136 and Leu138 in addition to two water molecules, not present in the X-ray 
crystal structure with 53, through which it interacts with residues Val131, Ser132, Ile133 and Gly134. The 
indole ring was demonstrated to possess a preference for presentation of the nitrogen atom towards 
Leu138 through screening of the 5-substituted isomer 61. The X-ray crystal structure of 61 in complex 
with Mab TrmD showed the indole ring ‘flipping’ to present the boronic acid anchor in an identical position 
as 53 in the adenine binding region with the same direct and water-mediated interactions (Figure 36c). 
To achieve this, the indole ring is oriented to present its nitrogen atom towards the rear of the ribose 
binding region, where it hydrogen bonds to an ordered water network, however the screening of 61 by 
DSF gave a lower Tm of +1.3 °C in comparison to 53 (Tm +3.0 °C) (Figure 36a).  
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Compound R Tma (°C) Kd (µM) LEb 
59 6-B(OH)2 +4.0 260 ± 15 0.41 
60 6-CO2H -0.6 ND - 
61 5-B(OH)2 +1.3 ND - 
  
 
 
a 5 mM ligand and 10 μM Mab TrmD, measured by Dr Sherine Thomas (Department of Biochemistry, University of Cambridge) for 59 and 60.  
b kcal mol-1 HA-1. 
Figure 36: (a) The change in the melting temperatures (Tm), affinities (Kd) and ligand efficiencies of fragment hit 59 and its 
structural analogues; X-ray crystal structures of Mab TrmD (subunit A = white, subunit B = green, ligand = lilac) bound to (b) 59 
(PDB code 6QOU, 1.56 Å), 50 and 61 (PDB code 6QQR, 1.56 Å), 123 illustrating one of the active sites.  
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Further, through comparison with the corresponding carboxylic acid fragment 60, which afforded a 
negative Tm in the initial fragment screen, it appeared that such a replacement of the boronic acid of 59 
was not a good way to proceed (Figure 36a). 
An overlay of the X-ray crystal structures of 53 and 59 in complex with Mab TrmD revealed significant 
overlap of their respective 4-methoxyphenyl and indole ring systems (Figure 37a). This suggested that a 
fragment-merging strategy could be used (Figure 37b). The replacement of the 4-methoxyphenyl ring 
system of 53, which had shown sensitivity to alternative substitution profiles in 54-56, with an indole in 
62 was believed to provide improved vectors for future elaboration into the methionine binding region. 
Similarly, the 3-aminopyrazole ring system in 62 offered more promise for elaboration in comparison to 
the boronic acid of 59, specifically from the 4-position of the ring system. 
 
 
 
Figure 37: (a) Overlay of X-ray crystal structures of Mab TrmD bound to 53 or 59 (overlay of PDB code 6QOT and PDB code 6QOU, 
subunit A = white, subunit B = green, 53 = lilac, 59 = pink), illustrating one of the active sites; 50 (b) proposed fragment-merging 
strategy with 53 and 59. 
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3.1.3: Synthesis and Screening of 62 and 66a 
The initial route explored for the synthesis of 62 was based around the protection of the indole nitrogen 
with a p-methoxybenzyl protecting group (Scheme 8a). The installation of this group on 63 was achieved 
by heating under reflux with 4-methoxybenzyl chloride and Cs2CO3 in acetonitrile (88% yield), with 64a 
converted to the corresponding β-ketonitrile 65a through treatment with n-butyllithium and acetonitrile 
(88% yield). 
 
 
 
 
Reagents and Conditions: (a) 4-methoxybenzyl chloride, Cs2CO3, acetonitrile, reflux, 1 h; (b) n-butyllithium (1.6 M in hexanes), acetonitrile, THF, -
78 °C, 15 min; (c) N2H4·H2O, EtOH, reflux, 5 h; (d) TFA, anisole, 60 °C; (e) NaH, TBDMSCl, THF, 0 °C to rt, 10 h; (f) (i) n-butyllithium (1.6 M in 
hexanes), acetonitrile, toluene, -78 °C, 1 h (ii) TBAF (1 M in THF), THF, 20 min; (g) N2H4·H2O, EtOH, reflux, 12 h. 
Scheme 8: Synthesis of (a) 66a in three steps from 63, with attempted deprotection to 62, and (b) 62 in three steps from 63. 
(b) 
(a) 
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Compound 65a was then heated under reflux with hydrazine in ethanol to afford p-methoxybenzyl-
protected 62, 66a (62% yield) (Scheme 8a). However, TFA-mediated deprotection of 66a in the presence 
of anisole predominantly afforded byproducts with only trace amounts of the desired product 62 by LCMS 
analysis. 125  Therefore, an alternative route was initiated with the protection of 63 using a TBDMS group 
(59% yield) (Scheme 8b). Ester 67 was then converted to the corresponding β-ketonitrile, with the silyl 
protecting group removed by TBAF following aqueous work up (99% yield overall). Compound 68 was 
then heated under reflux with hydrazine in ethanol to afford 62 (59% yield). 
Compound Tma (°C) Tmb (°C) Kd (µM) LEc 
53 
     
+3.0 +0.2 170 ± 14 0.37 
59 
 
+4.0 -0.1 260 ± 15 0.41 
62 
 
+4.8 +1.1 110 ± 11 0.36 
66a 
 
+4.3 +3.4 59 ± 17 0.24 
   
a 5 mM ligand and 10 μM Mab TrmD, measured by Dr Sherine Thomas for 53 and 59. 
b 100 µM ligand and 10 μM Mab TrmD. 
c kcal mol-1 HA-1. 
Table 5: The change in the melting temperatures (Tm), affinities (Kd) and ligand efficiencies of fragment hits 53 and 59, and 
compounds 62 and 66a. 
Screening of 62 (Kd 110 µM, LE 0.36) by ITC revealed an improved binding affinity relative to 53 (Kd 170 µM, 
LE 0.37) and 59 (Kd 260 µM, LE 0.41), with a comparable LE (Table 5). The X-ray crystal structure of 62 in 
complex with Mab TrmD showed its 3-aminopyrazole and indole ring systems adopting the same binding 
poses as the respective moieties in 53 and 59 (Figure 38a). Further, 62 replicates the hydrogen bond 
interactions of 53 and 59, with its 3-aminopyrazole ring system interacting with Ser132, Gly134, Tyr136 
and Leu138, and the indole nitrogen interacting with the backbone carbonyl of Leu138 through a water 
molecule. 
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Figure 38: X-ray crystal structures of Mab TrmD (subunit A = white, subunit B = green, ligand = lilac) bound to (a) 62 (PDB code 
6QQS, 1.76 Å), and (b) 66a (PDB code 6QQT, 1.67 Å), illustrating one of the active sites. 123 
Intermediate 66a (Kd 59 µM, LE 0.24), the analogue of 62 with a p-methoxybenzyl group attached to the 
indole nitrogen from the first attempted synthetic route, was also screened to reveal a smaller Kd than 62 
(Kd 110 µM, LE 0.36) (Table 5). The X-ray crystal structure of 66a in complex with Mab TrmD showed no 
significant shift in the aminopyrazole-indole portion of the molecule relative to 62, with the same 
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hydrogen-bonding interactions visible between the 3-aminopyrazole ring system and residues Ser132, 
Gly134, Tyr136 and Leu138 (Figure 38b). The methylene linker in the p-methoxybenzyl group allows the 
phenyl ring of 66a to reach up the active site to the methionine binding region, where it is surrounded by 
Pro85, Glu112, Val137 and Arg154, with its methoxy group lying 3.2 Å below the carboxylate side chain of 
Glu180. 
The improvement in binding affinity from 62 to the synthetic intermediate was encouraging, however the 
LE of 66a (0.24) was significantly below the recommended threshold of 0.3 kcal mol-1 HA-1 . 109 
Consequently, further work based on 66a would have to focus on improvement of binding affinity without 
a corresponding increase in molecular weight. 
 
3.2: Development of the 3-Aminopyrazole Lead Series 
Based on the successful screening of compounds 62 and 66a, the 3-aminopyrazole lead series derived 
from the application of a fragment-merging strategy to fragment hits 53 and 59 was continued, with the 
synthesis and screening of further analogues. Throughout the development of this lead series, DSF was 
generally used as a first-line screen followed by ITC. This biophysical screening cascade was supported by 
comparison of ΔTm values and binding affinities from the lead series against Mab TrmD, which revealed a 
good correlation between ΔTm and the order of magnitude of the Kd (Figure 39). 
 
Figure 39: Comparison of melting temperatures (Tm), measured at 100 µM ligand and 10 µM Mab TrmD, and the logarithm of 
the affinities (Kd) for synthesised compounds in the 3-aminopyrazole lead series. 
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3.2.1: Optimisation of the Phenyl Ring of 66a 
Preliminary SAR with 66a was focused on the phenyl ring and methoxy group (Figure 40). Due to the 
proximity of its methoxy group to Glu180 (Figure 38b), the impact of its removal or movement to an 
adjacent position on the phenyl ring to binding affinity was explored, in addition to the use of alternate 
substituents on the phenyl ring (Figure 40). With the second position of the phenyl ring of 66a lying 4.1 Å 
from the side chain of the catalytic residue Arg154 (Figure 38b), the investigation of alternate substituents 
was focused on its engagement from this position. Finally, investigation of the tolerance of the scaffold of 
66a to replacement of the phenyl ring with alternate heterocycles was sought (Figure 40). 
 
Figure 40: Areas of focus for the SAR study on 66a, the phenyl ring and methoxy group, with initial ideas for modification. 
Derivatives of 66a with either alternately-substituted phenyl rings or a pyridyl ring attached through a 
methylene linker to the indole in place of the p-methoxybenzyl group were synthesised. The first step 
involved the heating under reflux of 63 with benzyl or picolyl halides and Cs2CO3 in acetonitrile (80-93% 
yield) (Scheme 9). Esters 64b-c and 64f were converted to the corresponding β-ketonitriles 65b-c and 65f 
through treatment with n-butyllithium and acetonitrile (84-99% yield), which were then heated under 
reflux with hydrazine in ethanol (31-41% yield). Due to challenges in the purification of the corresponding 
β-ketonitrile of 64d, the material was taken forwards crude for the reaction with hydrazine (18% yield 
overall). The nitrile group of the resultant compound 66d was hydrolysed to an amide through heating 
under reflux in aqueous sodium hydroxide (28% yield). 
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Reagents and Conditions: (a) RCH2X (.HX), Cs2CO3, acetonitrile, reflux, 1 to 15 h; (b) n-butyllithium (1.6 M in hexanes), acetonitrile, toluene/THF, 
-78 °C, 30 min to 1 h; (c) N2H4·H2O, EtOH, reflux, 5 to 13 h; (d) n-butyllithium (1.6 M in hexanes), acetonitrile, toluene, -78 °C, 1 h; (e) N2H4·H2O, 
EtOH, reflux, 5 h; (f) NaOH, H2O, 100 °C, 7 h. 
Scheme 9: Synthesis of 66b-d and 66f in three steps from 63, and 66e in one step from 66d. 
Screening of the 3-methoxyphenyl analogue of 66a, 66b (Kd 13 µM, LE 0.28), revealed a greater than four-
fold improvement in binding affinity (Table 6). The X-ray crystal structure of 66b in complex with Mab 
TrmD showed the phenyl ring of 66b oriented with the methoxy group facing the interior of the active 
site, away from Glu112 and Arg154 (Figure 41a). Removal of the methoxy group in 66c (Kd 19 µM, LE 0.29) 
afforded a similar 3-fold improvement in binding affinity relative to 66a (Table 6 and Figure 41b). From 
the 2-substituted phenyl compounds, 66d (Kd 12 µM, LE 0.28) did not give a significant improvement in Kd 
over 66b and 66c, whilst 66e afforded a ΔTm of +1.4 °C but was not screened by ITC (Table 6). The X-ray 
crystal structure of 66d in complex with Mab TrmD showed a similar binding mode to 66b, with the nitrile 
group oriented towards the interior of the active site above the indole ring (Figure 42a). 
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Compound R Tma (°C) Kd (µM) LEb GEb (R) 
66a 
     
+3.4 59 ± 17 0.24 0.04 
66b 
       
+4.6 13 ± 2 0.28 0.14 
66c 
      
+3.4 19 ± 1 0.29 0.15 
66d 
      
+4.4 12 ± 2 0.28 0.15 
66e 
      
+1.4 ND - - 
66f 
      
+3.1 12 ± 1 0.30 0.18 
 
 
a 100 µM ligand and 10 μM Mab TrmD. 
b kcal mol-1 HA-1. 
Table 6: The change in the melting temperatures (Tm), affinities (Kd) and efficiency metrics of compounds 66a-f. 
Out of the screened 66a analogues, the pyridyl compound 66f (Kd 12 µM, LE 0.30) possessed the highest 
LE (Table 6), despite its X-ray crystal structure not demonstrating any additional hydrogen-bonding 
interactions by the ring nitrogen (Figure 42b). The improved LE of 66f was represented in the GE of 0.18 
from its pyridyl ring and methylene linker, in comparison the low value of 0.04 from the p-methoxybenzyl 
group of 66a. 
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Figure 41: X-ray crystal structures of Mab TrmD (subunit A = white, subunit B = green, ligand = lilac) bound to (a) 66b (PDB code 
6QRC, 1.73 Å), and (b) 66c (PDB code 6QQW, 1.80 Å), illustrating one of the active sites. 123 
(b) 
Arg154 
Tyr136 
Asp135 
Gly134 Ile133 
Ser132 
Pro85 
Thr84 
Pro83 
Val137 Leu138 
133 
Asn139 
Gly140 
Glu180 
Tyr111 
Glu112 
Gly113 
Ile114 
(a) 
Arg154 
Tyr136 
Asp135 
Gly134 Ile133 
Ser132 
Pro85 
Thr84 
Pro83 
Val137 Leu138 
133 
Asn139 
Gly140 
Glu180 
Tyr111 
Glu112 
Gly113 
Ile114 
72 
 
 
 
Figure 42: X-ray crystal structures of Mab TrmD (subunit A = white, subunit B = green, ligand = lilac) bound to (a) 66d (PDB code 
6QQV, 1.71 Å), 123 and (b) 66f (PDB code 6QQX, 2.69 Å), 50 illustrating one of the active sites. 
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3.2.2: Exploration of Substitution from the Pyrazole 4-Position 
In addition to the SAR study on the phenyl ring of 66a, elaboration was also performed on the 3-
aminopyrazole ring system of the lead series. The 4-position of this ring system was shown in the X-ray 
crystal structure of 62 in complex with Mab TrmD to face an elongated narrow pocket, bordered by 
residues Pro83, Thr84, Val131, Ser132, Ile133 and Ala144 (Figure 43). Hence, the substitution from this 
position of the pyrazole ring into the pocket was proposed.  
 
Figure 43: X-ray crystal structure of Mab TrmD bound to 62 (PDB code 6QQS, 1.76 Å, subunit A = white, subunit B = green, 62 = 
lilac), illustrating the 3-aminopyrazole ring system in one of the active sites. 50 
From consideration of the shape of the pocket, the addition of a nitrile group was selected. The synthesis 
of an analogue of 62 with a nitrile group attached to the 4-position of its 3-aminopyrazole ring system was 
carried out using β-ketonitrile 68 (Scheme 10), taken from the synthetic route for 62 (Scheme 8b). The 
methylene group of 68 was reacted with trichloroacetonitrile and sodium acetate to form enone 69 (87% 
yield) (Scheme 10), using a literature procedure previously utilised with another β-ketonitrile. 126  Enone 
69 was then heated under reflux with hydrazine in ethanol to afford 70 (24% yield). This route was also 
adapted for the synthesis of nitrile analogues of compounds from the SAR study with 66a, compounds 
66c and 66f (Scheme 10), using β-ketonitriles 65c and 65f from their respective synthetic routes (Scheme 
9). However, the enones produced from these β-ketonitriles were taken forwards without purification, 
after an aqueous workup, for heating under reflux with hydrazine in ethanol (45-62% yield overall) 
(Scheme 10).  
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Reagents and Conditions: (a) CCl3CN, NaOAc, EtOH, 90 min; (b) N2H4·H2O, EtOH, reflux, 22 h; (c) (i) CCl3CN, NaOAc, EtOH, 90 min to 9 h (ii) N2H4·H2O, 
EtOH, reflux, 5 to 15 h. 
Scheme 10: Synthesis of (a) 70 in two steps from 68 and (b) 71c and 71f in one step from 65c or 65f. 
The screening of the nitrile analogue 70 by ITC (Kd 5.0 µM, LE 0.43) revealed a greater than 20-fold 
improvement in binding affinity relative to 62 (Kd 110 µM, LE 0.36), with the nitrile group possessing a GE 
of 0.91 (Table 7).  
 
 
Compound R Tma (°C) Kd (µM) LEb GEb (R) GEb (CN) 
70 H +4.4 5.0 ± 2.1 0.43 - 0.91 
71c 
 
+10.1 NDc - - - 
71f 
 
+8.3 0.50 ± 0.14 0.36 0.20 0.95 
 
 
a 100 µM ligand and 10 μM Mab TrmD. 
b kcal mol-1 HA-1. 
c Not determined due to aqueous solubility. 
Table 7: The change in the melting temperatures (Tm), affinities (Kd) and efficiency metrics of compounds 70, 71c and 71f. 
(a) 
(b) 
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Figure 44: X-ray crystal structures of Mab TrmD (subunit A = white, subunit B = green, ligand = lilac) bound to (a) 70 (PDB code 
6QQU, 1.59 Å), 123 illustrating the 4-nitrile 3-aminopyrazole ring system in one of the active sites, and (b) 71f (PDB code 6QQY, 
1.49 Å), 50 illustrating one of the active sites. 
The X-ray crystal structure of 70 in complex with Mab TrmD showed the nitrile group extending into the 
desired pocket, with rest of the scaffold not shifted significantly in the active site relative to 62 (Figure 
44a). A similar improvement in binding affinity and retention of binding mode was seen with 71f (Kd 0.50 
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µM, LE 0.36) in comparison to 66f (Kd 12 µM, LE 0.30) (Table 7 and Figure 44b). However, with 71c (Tm 
+10.1 °C) a Kd was not determined due to poor solubility in the ITC buffer. Whilst the Tm of 71c was large 
relative to 66c (Tm +3.4 °C), subsequent SAR study was focused on 71f due to its improved aqueous 
solubility. 
 
3.2.3: Structure-activity Relationship Study of 71f and Pyridyl Isomers 
Whilst the submicromolar Kd of 71f (Kd 0.50 µM, LE 0.36) represented a greater than 200-fold 
improvement relative to 62 (Kd 110 µM, LE 0.36), achieved with the maintenance of LE, further 
improvement was sought. This was initially attempted with the exploration of the other isomers of 71f 
with the pyridyl ring attached to the methylene linker from the 3- and 4-positions. 
The synthesis of the 3- and 4-pyridyl analogues of 71f was achieved by a route beginning with the 
deprotonation of indole 63 by NaH and treatment with the respective picolyl halides. Following 
consumption of starting material, methanol and sulfuric acid were added to the reaction mixture, which 
was heated under reflux to recover the carboxylic acid side-product and afford esters 64g-h (71-75% yield) 
(Scheme 11). These esters were then converted to the corresponding β-ketonitriles 65g-h (71-82% yield), 
which were used to synthesise the 4-cyanopyrazole compounds 71g-h in the same manner as 71c and 71f 
(54-57% yield overall) (Scheme 10b). 
 
Reagents and Conditions: (a) (i) RCH2X.HX, NaH, DMF, 0 °C to rt, 45 min (ii) MeOH, H2SO4, reflux, 16 h; (b) n-butyllithium (1.6 M in hexanes), 
acetonitrile, THF, -78 °C, 45 min; (c) (i) CCl3CN, NaOAc, EtOH, 13 h (ii) N2H4·H2O, EtOH, reflux, 21 h. 
Scheme 11: Synthesis of 71g and 71h in three steps from 63. 
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The screening of the 3- and 4-pyridyl isomers 71g (Kd 0.18 µM, LE 0.38) and 71h (Kd 0.12 µM, LE 0.39) 
demonstrated 3- and 4-fold improvements in binding affinity relative to 71f (Kd 0.50 µM, LE 0.36) (Figure 
45a).  
 
 
Compound R Tma (°C) Kd (µM) LEb GEb (R) 
71f 
 
+8.3 0.50 ± 0.14 0.36 0.20 
71g 
 
+10.5 0.18 ± 0.06 0.38 0.28 
71h 
 
+11.5 0.12 ± 0.02 0.39 0.31 
   
 
a 100 µM ligand and 10 μM Mab TrmD. 
b kcal mol-1 HA-1. 
Figure 45: (a) The change in the melting temperatures (Tm), affinities (Kd) and efficiency metrics of compounds 71f-h; X-ray crystal 
structure of Mab TrmD bound to 71g (PDB code 6QQZ, 1.70 Å, subunit A = white, subunit B = green, 71g = lilac), illustrating one 
of the active sites. 123 
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Figure 46: X-ray crystal structures of Mab TrmD (subunit A = white, subunit B = green, ligand = lilac) bound to (a) 71h (PDB code 
6QR0, 1.59 Å), illustrating one of the active sites, and (b) 71g (PDB code 6QQZ, 1.70 Å), illustrating the indole ring in one of the 
active sites. 123 
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The X-ray crystal structures of 71g and 71h in complex with Mab TrmD did not reveal significant 
differences in the binding poses or hydrogen-bonding interactions of these ligands in comparison to 71f, 
with the exception of the 2.9 Å distance between the pyridyl nitrogen of 71h and the carboxylate side 
chain of Glu180 that could represent an electrostatic interaction (Figure 45b and Figure 46a). 
With their improved binding affinities relative to 71f, 71g and 71h were then used as the starting point 
for three elaboration strategies to further explore the active site. Firstly, it was unknown whether the 3- 
or 4-positions of the indole ring in the lead series, which were shown in X-ray crystal structures to face a 
region lined by residues Pro83 to Thr84 and Cys108 to Gly109 to the side and Gly141 beneath, could 
tolerate substitution (Figure 46b). Hence, the synthesis of at least one analogue with a conservative 
substitution from one of these positions on the indole ring was sought. Secondly, further investigation on 
the engagement of the side chains of residues Arg154, Glu112 and Glu180 adjacent to the pyridyl ring was 
desired, building on the screening of 66d-e. An idea for the engagement of these residues was the 
screening of derivatives of 71g incorporating the heterocycle 2-pyridone, which exhibits keto/enol 
tautomerism in the presence of water, 127 with the intention of the 2-hydroxy isomer engaging Arg154 
and the 6-hydroxy isomer engaging Glu112 and Glu180 (Figure 45b). Finally, the further probing of the 
methionine binding region into the volume defined by Glu112 to Gly113 and Thr84 to Pro85, above the 
indole ring of the lead series and adjacent to the pyridyl rings of 71g and 71h was sought (Figure 45b and 
Figure 46a). Hence, the development of a larger quinolyl analogue that would extend into this volume was 
selected.  
The synthesis of an analogue with a substituent on the rear of the indole ring was achieved through late-
stage functionalisation of 71g with N-chlorosuccinimide in DMF, resulting in the installation of a chloride 
group from the indole 3-position in 72g (63% yield). Synthesis of the 2-pyridone and quinoline analogues 
required longer synthetic routes than 71g or 71h, all involving the synthesis of methyl esters 64i, 64k and 
64m from reaction of the corresponding electrophile with indole 63 and NaH, followed by heating under 
reflux with methanol and sulfuric acid in the same manner as 64g-h (Scheme 12b-d). In contrast to 64g-h 
however, the corresponding electrophiles required further synthesis. With methyl ester 64i, this began 
with the reduction of ester 73 by NaBH4 to alcohol 74 (67% yield), which was treated with p-
toluenesulfonyl chloride and DMAP before being taken forwards crude for reaction with indole 63 (31% 
yield overall) (Scheme 12b).  
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Reagents and Conditions: (a) NCS, DMF, 7 h 30 min; (b) NaBH4, EtOH, 0 °C to rt, 1 d; (c) (i) TsCl, DMAP, NEt3, DCM, 2 h (ii) 63, NaH, DMF, 0 °C to 
rt, 30 min (iii) MeOH, H2SO4, reflux, 90 min; (d) LiAlH4, THF, 0 °C, 1 h; (e) TsCl, DMAP, NEt3, DCM, 18 h; (f) (i) 63, NaH, DMF, 0 °C to rt, 1 h (ii) MeOH, 
H2SO4, reflux, 1 h; (g) NaBH4, MeOH, 0 °C, 90 min; (h) (i) aqueous HBr (48%), reflux, 90 min (ii) 63, NaH, DMF, 0 °C to rt, 15 min (iii) MeOH, H2SO4, 
reflux, 2 h. 
Scheme 12: Synthesis of (a) 72g in one step from 71g, (b) 64i in two steps from 73, including 63, (c) 64k in three steps from 75, 
including 63, and (d) 64m in two steps from 78, including 63. 
(c) 
(a) 
(b) 
(d) 
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A similar approach was taken with methyl ester 64k, with the reduction of ester 75 by LiAlH4 to alcohol 76 
(91% yield), however the resultant alkyl halide 77 from treatment with p-toluenesulfonyl chloride and 
DMAP was isolated (17% yield) before reaction with indole 63 (85% yield) (Scheme 12c). With methyl ester 
64m, aldehyde 78 was reduced by NaBH4 to alcohol 79 (79% yield), 128  which was heated under reflux in 
aqueous hydrobromic acid. Concentration of the reaction mixture in vacuo afforded a crude solid that was 
reacted with indole 63 (65% yield overall) (Scheme 12d).  
 
 
 
 
 
 
Reagents and Conditions: (a) n-butyllithium (1.6 M in hexanes), acetonitrile, THF (+ toluene for 64m), -78 °C, 30 min to 1 h; (b) (i) CCl3CN, NaOAc, 
EtOH, 15 to 36 h (ii) N2H4·H2O, EtOH, reflux, 6 to 18 h; (c) LiCl, TsOH·H2O, DMF, 120 °C, 25 min. 
Scheme 13: Synthesis of (a) 71i, 71k and 71m in two steps from 64i, 64k or 64m, (b) 71j in one step from 71i, and (c) 71l in one 
step from 71k. 
Methyl esters 64i, 64k and 64m were converted to the corresponding β-ketonitriles 65i, 65k and 65m (26-
76% yield), which were used to synthesise the 4-cyanopyrazole compounds 71i, 71k and 71m in the same 
(b) 
(c) 
(a) 
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manner as 71c and 71f (41-61% yield overall) (Scheme 13a). 2-Pyridone compounds 71j and 71l were 
synthesised from the methoxypyridyl analogues 71i and 71k respectively by heating at 125 °C with LiCl 
and p-toluenesulfonic acid in DMF (47-51% yield) (Scheme 13b and c), using a literature procedure 
previously utilised with other methoxypyridyl compounds. 129 
Screening of the 3-chloroindole analogue 72g (Kd 8.6 µM, LE 0.28) afforded an almost 50-fold attenuation 
of binding affinity in comparison to 71g (Table 8), suggesting that substitution from the rear of the indole 
into the adjacent region was not tolerated. Hence, further analogues with alternate substitution from the 
indole ring were not developed. Comparison of the X-ray crystal structure of 72g in complex with Mab 
TrmD to that from 71g did not show significant movement by the indole ring (Figure 46b and Figure 47a). 
The change in binding affinity could be related to disruption of a hydrogen-bonded water network visible 
in the X-ray crystal structure of 71g in complex with Mab TrmD (Figure 46b), with the closest water 
molecule to the indole 3-position bound to the backbone carbonyl of Pro83 not present in the X-ray crystal 
structure with 72g (Figure 47a).  
2-Pyridone analogues 71j (Kd 3.2 µM, LE 0.30) and 71l (Kd 1.3 µM, LE 0.32) both possessed worse binding 
affinities than 71g (Kd 0.18 µM, LE 0.38) (Table 8), despite the X-ray crystal structure of 71j in complex 
with Mab TrmD showing evidence of a water-mediated hydrogen-bonding interaction between the 2-
pyridone oxygen and both the guanidyl group of Arg154 and backbone carbonyl of Leu138 (Figure 47b). 
The Tm values for the methoxypyridyl intermediates 71i (Tm +5.6 °C) and 71k (Tm +9.9 °C) were also 
measured, which suggested similar behaviour to 71j (Tm +5.5 °C) and 71l (Tm +8.3 °C) respectively (Table 
8), however Kd values could not be obtained by ITC due to poor aqueous solubility in a similar manner to 
71c. Unfavourable aqueous solubility was also seen in the quinolyl analogue 71m (ΔTm +10.3 °C), 
precluding affinity determination by ITC. 
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Compound R1 R2 Tma (°C) Kd (µM) LEb GEb (R1) 
71g 
      
H +10.5 0.18 ± 0.06 0.38 0.28 
71h 
      
H +11.5 0.12 ± 0.02 0.39 0.31 
71i 
      
H +5.6 NDc - - 
71j 
      
H +5.5 3.2 ± 0.3 0.30 0.03 
71k 
      
H +9.9 NDc - - 
71l 
      
H +8.3 1.3 ± 0.1 0.32 0.10 
71m 
      
H +10.3 NDc - - 
72g 
      
Cl +5.8 8.6 ± 1.0 0.28 - 
 
 
a 100 µM ligand and 10 μM Mab TrmD. 
b kcal mol-1 HA-1. 
c Not determined due to aqueous solubility. 
Table 8: The change in the melting temperatures (Tm), affinities (Kd) and efficiency metrics of compounds 71g-m and 72g. 
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Figure 47: X-ray crystal structures of Mab TrmD (subunit A = white, subunit B = green, ligand = lilac) bound to (a) 72g (PDB code 
6QR1, 1.67 Å), illustrating the indole ring in one of the active sites, and (b) 71j (PDB code 6QR2, 1.55 Å), illustrating one of the 
active sites. 123 
(b) 
Arg154 
Tyr136 
Asp135 
Gly134 Ile133 
Ser132 
Pro85 
Thr84 
Pro83 
Val137 Leu138 
133 
Asn139 
Gly140 
Glu180 
Tyr111 
Glu112 
Gly113 
Ile114 
(a) 
Pro83 
Thr84 
Pro85 
Tyr111 
Glu112 
Gly113 Ile114 
Leu138 
133 
Asn139 
Cys108 
Ala107 
Arg110 
Gly109 
Gly141 
Gly140 
85 
 
3.2.4: Incorporation of Increased sp3-content in the Scaffold 
In light of the reduced aqueous solubility possessed by a number of analogues of 71g and 71h, focus was 
shifted to the screening of compounds with higher sp3 content due to its association with improved 
aqueous solubility . 130  Further, due to the presentation of a positively-charged sulfur atom by SAM 
adjacent to the volume occupied by the phenyl and pyridyl rings of recent analogues in the lead series 
(Figure 48), and the nearby presence of the carboxylate side chains of residues Glu112 and Glu180, it was 
believed that their replacement by a saturated amine, protonated under physiological conditions, would 
be tolerated. Hence, piperidinyl analogues were explored.  
 
Figure 48: Overlay of X-ray crystal structures of Mab TrmD bound to SAM or 71h (overlay of PDB code 6NW6 and PDB code 6QR0, 
subunit A = white, subunit B = green, SAM = lilac, 71h = pink), illustrating the overlap between 71h (representing the 3-
aminopyrazole lead series) and the methionine portion of SAM in one of the active sites. 50,   123 
The routes for the synthesis of the piperidinyl analogues involved the synthesis of methyl esters 64n-o 
from reaction of the corresponding electrophile with indole 63 and NaH in a similar manner to 64g-h (27-
45% yield) (Scheme 14a and b). However, to achieve conversion of starting material for 64n-o, the reaction 
mixture in DMF was heated to 60 °C, with NaI added as a catalyst in the case of 64o. As with 64i, 64k and 
64m, the corresponding electrophiles required further synthesis. This was achieved through the 
treatment of racemic alcohols 80 and 82 with thionyl chloride or a mixture of p-toluenesulfonyl chloride 
and DMAP respectively (36-58% yield). Methyl esters 64n-o were converted to the corresponding β-
ketonitriles 65n-o (32-67% yield), which were used to synthesise the 4-cyanopyrazole compounds 71n-o 
in the same manner as 71c and 71f (38-57% yield overall) (Scheme 14c). 
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Reagents and Conditions: (a) SOCl2, DCM, reflux, 7 h; (b) 63, NaH, DMF, 0 to 60 °C, 1 h (ii) MeOH, H2SO4, reflux, 1 h; (c) TsCl, DMAP, NEt3, DCM, 4 
h; (d) (i) 63, NaH, NaI, DMF, 0 to 60 °C, 1 h; (e) n-butyllithium (1.6 M in hexanes), acetonitrile, THF, -78 °C, 30 min to 1 h; (f) (i) CCl3CN, NaOAc, 
EtOH, 3 h 30 min to 18 h (ii) N2H4·H2O, EtOH, reflux, 15 h to 1 d. 
Scheme 14: Synthesis of (a) 64n in two steps from 80, including 63, (b) 64o in two steps from 82, including 63, and (c) 71n-o in two 
steps from 64n-o. 
Screening of the piperidinyl analogues 71n (Kd 0.59 µM, LE 0.34) and 71o (Kd 0.36 µM, LE 0.35) as racemic 
mixtures afforded sigmoidal ITC isotherms that suggest binding affinities at the level of 71f (Kd 0.50 µM, 
LE 0.36) (Figure 49a). Whilst these Kd values are not as low as 71g (Kd 0.18 µM, LE 0.38) and 71h (Kd 0.12 
µM, LE 0.39), they demonstrate a tolerance of the methionine binding site for three-dimensional moieties 
with a protonated group, as expected from the X-ray crystal structure of SAM in complex with Mab TrmD 
(Figure 48), and encouraged further exploration.  
(a) 
(b) 
(c) 
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Compound R Tma (°C) Kd (µM) LEb GEb (R) 
71n 
      
+8.8 0.59 ± 0.23 0.34 0.16 
71o 
      
+10.9 0.36 ± 0.05 0.35 0.20 
   
  
a 100 µM ligand and 10 μM Mab TrmD. 
b kcal mol-1 HA-1. 
Figure 49: (a) the change in the melting temperatures (Tm), affinities (Kd) and efficiency metrics of compounds 71n-o; ITC traces 
for 71o from (b) injection of ligand into sample cell (‘forward titration’), and (c) injection of protein into sample cell (‘reverse 
titration’). 
(a) 
(b) (c) 
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As compounds 71n and 71o were screened as racemic mixtures, care must be taken in the interpretation 
of the results. Mixtures of two compounds with equivalent enthalpies of binding but differing affinity 
values can afford deceptively simple isotherms by ITC, with curvatures that reflect the affinity of the 
weaker compound, masking the binding of the most potent compound. 131 Hence, a ‘reverse titration’ ITC 
experiment, with the injection of an excess of protein into the racemic mixture to separate out the binding 
of the two enantiomers, was performed with 71o (Figure 49c). The resultant isotherm could be fitted by 
a one-site binding model using similar parameters to the ‘forward titration’ (Figure 49b), suggesting that 
the two enantiomers are equipotent. 
X-ray crystal structures obtained by the soaking of racemic mixtures of 71n or 71o into Mab TrmD crystals 
were successfully refined using the individual enantiomers. For 71n, the piperidinyl rings of both 
enantiomers were shown to orient with their N-methyl group facing out of the active site, interacting with 
the backbone carbonyl of Tyr111 (Figure 50). 
 
Figure 50: Overlay of X-ray crystal structures of Mab TrmD soaked with racemic 71n solution and refined with individual 
enantiomers (1.52 Å, subunit A = white, subunit B = green, (R)-71n = lilac, (S)-71n = pink), illustrating one of the active sites. 132 
In contrast to 71n, the piperidinyl rings of both (R) and (S)-71o could be modelled in one site with the N-
methyl group oriented to form an electrostatic interaction with the carboxylate side chain of Glu112 
(Figure 51a). In the other site however, (S)-71o was shown to interact with Glu180 (Figure 51b). 
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Figure 51: Overlay of X-ray crystal structures of Mab TrmD soaked with racemic 71o solution and refined with individual 
enantiomers (1.61 Å, subunit A = white, subunit B = green, (R)-71o = lilac, (S)-71o = pink), illustrating active sites 1 (a) and 2 (b). 132 
The results from the screening of compounds 71n-o, with the presentation of piperidinyl ring systems in 
the methionine binding region affording comparable binding affinities to the pyridyl analogue 71f, 
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encouraged further targeting of the carboxylate side chains of Glu112 and Glu180 by electrostatic 
interactions with similar saturated motifs. However, whilst the chiral nature of 71o was addressed in ITC 
screening, challenges in the acquisition of pure enantiomers encouraged a return to the screening of 
achiral analogues. To improve affinity, the design of these analogues was focused on the presentation of 
a protonated amine closer to the side chains of Glu112 and Glu180.  
In the previous study on H. influenzae TrmD (Figure 11), the addition of basic motifs to a phenyl ring 
through a methylene linker was used, as represented by aminomethyl analogue 85 which afforded a 5-
fold improvement in IC50 relative to the unsubstituted compound 84 (0.56 vs 2.6 µM) (Figure 52). 63  
 
 
 
Figure 52: The addition of aminomethylene-based motifs to starting point 84 in the study against H. influenzae TrmD, with 
analogues 85 and 86 shown. 63 
Similarly to 71o (Figure 51a), the X-ray crystal structure of 85 with H. influenzae TrmD showed an 
electrostatic interaction between the aminomethyl group of 85 and the carboxylate side chain of Glu116 
(Figure 53a), corresponding to Glu112 in Mab TrmD. Due to the proximity of the phenyl ring of 85 and the 
phenyl and pyridyl rings of analogues 66a-f and 71f-m in X-ray crystal structures with TrmD from H. 
influenzae and Mab respectively as represented with 71f and 85, in addition to residues Glu112 and 
Glu116 (Figure 53b), it was believed that the strategy could be incorporated into the 3-aminopyrazole 
lead series. 
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Figure 53: (a) X-ray crystal structure of H. influenzae TrmD bound to 85 (PDB code 4MCC, 1.95 Å, subunit A = yellow, subunit B = 
cyan, 85 = pink), illustrating one of the active sites; 63 (b) overlay of X-ray crystal structures of H. influenzae TrmD (subunit A = 
yellow, subunit B = cyan) and Mab TrmD (subunit A = white, subunit B = green) bound to 85 and 71f respectively (overlay of PDB 
code 4MCC and PDB code 6QQY, 85 = pink, 71f = lilac), illustrating one of the active sites. 50,   63 
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From the compounds described in the H. influenzae study the pyrrolidinyl ring from 86 (Figure 52), which 
possessed a comparable IC50 to 85 (1.1 vs 0.56 µM), was selected for incorporation into the lead series 
due to its small steric profile relative to other screened moieties. 63 The scaffolds of both 71f and 66c were 
used for the design of analogues incorporating the pyrrolidinyl ring and methylene linker of 86 for GE 
analysis (Figure 54).  
 
 
Figure 54: Idea for incorporation of the pyrrolidinyl ring and methylene linker of 86 to the scaffolds of 71f and 66c. 
The eight-step route for the synthesis of the pyridyl analogue 87 began with the regioselective reduction 
of one of the ester groups of 89 by a mixture of NaBH4 and CaCl2 (84% yield), 133  with the resultant alcohol 
of 90 protected as a THP ether (77% yield) (Scheme 15). The remaining ester group of 91 was reduced by 
LiAlH4 (64% yield), with the resultant alcohol of 92 converted to the corresponding mesylate by treatment 
with methanesulfonyl chloride. The mesylate was taken forwards crude after aqueous workup and stirred 
with pyrrolidine and Cs2CO3 in DMF to afford 93 (66% yield overall). The THP protecting group of 93 was 
removed by heating at 50 °C with p-toluenesulfonic acid in ethanol (86% yield), with the resultant alcohol 
of 94 treated with methanesulfonyl chloride as with 92. Following aqueous workup, the crude material 
was reacted with indole 63 at 60 °C using NaH and NaI in DMF (7% yield overall). Methyl ester 95 was 
converted to the corresponding β-ketonitrile 96 (71% yield), which was used to synthesise the 4-
cyanopyrazole compound 87 in the same manner as 71c and 71f (6% yield overall). 
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Reagents and Conditions: (a) NaBH4, CaCl2, MeOH, THF, 0 °C, 90 min; (b) MeSO3H, 3,4-dihydro-2H-pyran, DCM, 150 min; (c) LiAlH4, THF, 0 °C, 45 
min; (d) (i) MeSO2Cl, NEt3, DCM, 0 °C to rt, 1 h (ii) pyrrolidine, Cs2CO3, DMF, 14 h; (e) TsOH·H2O, ethanol, 50 °C, 30 min; (f) (i) MeSO2Cl, NEt3, DCM, 
0 °C to rt, 150 min; (ii) 63, NaH, NaI, DMF, 0 to 60 °C, 75 min (iii) MeOH, H 2SO4, reflux, 14 h; (g) n-butyllithium (1.6 M in hexanes), acetonitrile, 
THF, -78 °C, 1 h; (h) (i) CCl3CN, NaOAc, EtOH, 36 h (ii) N2H4·H2O, EtOH, reflux, 1 d. 
Scheme 15: Synthesis of 87 in eight steps from 89. 
With the synthesis of the phenyl analogue 88a a convergent six-step route was utilised, beginning with 
the reduction of indole 63 to indoline 97 by sodium cyanoborohydride in acetic acid (66% yield) (Scheme 
16a) . 134  In parallel, 4-formylbenzonitrile 98 was reacted with pyrrolidine in a reductive amination 
reaction with sodium triacetoxyborohydride and acetic acid (85% yield), with the nitrile group of 99a 
reduced by DIBAL-H to afford aldehyde 100a (75% yield) (Scheme 16b). Compounds 97 and 100a were 
used to produce methyl ester 101a by microwave-assisted condensation with benzoic acid in toluene (53% 
yield) (Scheme 16c), using a literature procedure previously utilised with other indolines and aromatic 
aldehydes. 135  Methyl ester 101a was converted to the corresponding β-ketonitrile 102a (87% yield), 
which was used to synthesise the 3-aminopyrazole compound 88a in the same manner as 66b-d and 66f 
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(22% yield). β-ketonitrile 102a was also subsequently used to synthesise the 4-cyanopyrazole compound 
103a in the same manner as 71c and 71f (51% yield overall). 
 
 
 
 
 
 
Reagents and Conditions: (a) NaCNBH3, AcOH, 0 °C to rt, 7 h; (b) Na(OAc)3BH, pyrrolidine, AcOH, DCM, 15 h; (c) DIBAL-H, THF, 0 °C to rt, 1 h; (d) 
PhCO2H, toluene, 200 °C µW, 20 min; (e) n-butyllithium (1.6 M in hexanes), acetonitrile, THF, -78 °C, 1 h; (f) N2H4·H2O, EtOH, reflux, 12 h; (g) (i) 
CCl3CN, NaOAc, EtOH, 4 h (ii) N2H4·H2O, EtOH, reflux, 18 h. 
Scheme 16: Synthesis of (a) 97 in one step from 63, (b) 100a in two steps from 98, and (c) 88a and 103a in three steps from 97 
and 100a. 
(b) 
(a) 
(c) 
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The screening of 87 (Kd 92 nM, LE 0.32) revealed a greater than 5-fold improvement in binding affinity in 
comparison to 71f (Kd 0.50 µM, LE 0.36) (Table 9), supporting the adopted strategy. However, with 88a 
(Kd 0.49 µM, LE 0.31) the change in binding affinity from the parent compound 66c (Kd 19 µM, LE 0.29) 
was more beneficial with a 40-fold improvement. This is reflected in the differing GE values for the added 
pyrrolidin-1-ylmethyl moiety in 87 (GE 0.17) and 88a (GE 0.36), which could reflect intramolecular 
interactions between the pyrrolidinyl and pyridyl ring systems in 87. The high GE value for the added 
moiety in 88a was reflected in the nitrile analogue 103a (Kd 27 nM, LE 0.34), which did not exhibit the 
poor aqueous solubility of 71c that precluded screening. 
 
 
 
Compound X R Tma (°C) Kd (nM) LEb GEb 
87 N CN +12.0 92 ± 18 0.32 0.17 
88a CH H +7.0 490 ± 210 0.31 0.36 
103a CH CN +12.9 27 ± 4 0.34 - 
   
a 100 µM ligand and 10 μM Mab TrmD. 
b kcal mol-1 HA-1, determined for the pyrrolidin-1-ylmethyl moiety highlighted in red. 
Table 9: The change in the melting temperatures (Tm), affinities (Kd) and efficiency metrics of compounds 87, 88a and 103a. 
The X-ray crystal structure of 103a in complex with Mab TrmD showed the molecule adopting different 
conformations depending on the active site, with the pyrrolidinyl ring either oriented towards Pro57 and 
forming an electrostatic interaction with Glu112 (Figure 55a) or oriented towards Ser177 (Figure 55b), 
reflecting communication between the sites. 55 
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Figure 55: X-ray crystal structure of Mab TrmD bound to 103a (PDB code 6QR6, 1.71 Å, subunit A = white, subunit B = green, 103a 
= lilac), illustrating active sites 1 (a) and 2 (b). 50 
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3.2.5: Structure-activity Relationship Study of 103a 
Following the screening of 103a (Kd 27 nM, LE 0.34), an exploration of SAR was carried out around the 
nitrile group and pyrrolidinyl ring. In the lead series, analogues had previously only been synthesised with 
the 4-position of the pyrazole ring either unsubstituted or bearing a nitrile group. Therefore, the tolerance 
of this position to substitution with other functional groups was sought, with the 4-methylpyrazole 
analogue of 103a a focus for synthesis. In the study on H. influenzae TrmD, 15 analogues were reported 
in addition to 86 (IC50 1.1 µM) with alternatives to the pyrrolidinyl ring, which varied in IC50 from 0.33 to 
9.3 µM. 63 However, H. influenzae and Mab TrmD only share 42% sequence identity overall and 58% 
similarity. Further, whilst an X-ray crystal structure was provided for one analogue of 86 with H. influenzae 
TrmD, the lack of observable density for the interdomain linker in the X-ray crystal structure of 103a in 
complex with Mab TrmD (Figure 55b and c), which surrounds one side of the pyrrolidinyl ring of 103a, 
makes direct comparisons challenging. Hence, SAR with the pyrrolidinyl ring of 103a was sought. Three 
analogues of 103a were proposed, including replacement of the pyrrolidinyl ring with a piperidinyl ring to 
explore the tolerance of the binding pocket for larger ring sizes, and a morpholinyl ring to investigate the 
impact of reduced basicity on the pyrrolidinyl nitrogen atom and its interaction with the carboxylate side 
chain of Glu112. Finally, an analogue of 103a with a piperazinyl ring was desired, whose second nitrogen 
atom could later be used as a synthetic handle to further explore the active site towards Ser177. 
4-Methylpyrazole analogue 105a was synthesised in two steps from the previously made methyl ester 
101a (Scheme 16), which was treated with n-butyllithium and propionitrile to afford β-ketonitrile 104a 
(35% yield) (Scheme 17a). Compound 104a was then heated under reflux with hydrazine in ethanol to 
afford 105a (21% yield). Analogues of 103a with alternate heterocyclic rings in place of the pyrrolidinyl 
ring were synthesised by the same convergent route as 103a, using indoline 97 (Scheme 16). For each 
analogue the corresponding heterocycle was reacted with 98 using sodium triacetoxyborohydride and 
acetic acid (70-79% yield), with the nitrile group of 99b-d reduced by DIBAL-H to afford aldehydes 100b-d 
(46-58% yield) (Scheme 17b). Compounds 97 and 100b-d were then used to produce methyl esters 101b-
d in the same manner as 101a (55-67% yield). Methyl esters 101b-d were converted to the corresponding 
β-ketonitriles 102b-d (77-87% yield), which were used to synthesise the 4-cyanopyrazole compounds 
103b-d in the same manner as 71c and 71f (32-59% yield overall). 
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Reagents and Conditions: (a) n-butyllithium (1.6 M in hexanes), propionitrile, toluene, -78 to 0 °C, 2 h; (b) N2H4·H2O, EtOH, reflux, 1 d; (c) 
Na(OAc)3BH, RH, AcOH, DCM, 80 min to 5 h; (d) DIBAL-H, THF, 0 °C to rt, 90 min to 1 h; (e) 97, PhCO2H, toluene, 200 °C µW, 30 min; (f) n-
butyllithium (1.6 M in hexanes), acetonitrile, THF, -78 °C, 20 min to 1 h; (g) (i) CCl3CN, NaOAc, EtOH, 14 h to 2 d (ii) N2H4·H2O, EtOH, reflux, 22 h 
to 1 d. 
Scheme 17: Synthesis of (a) 105a in two steps from 101a, and (b) 103b-d in five steps from 98, including 97. 
(b) 
(a) 
99 
 
The 4-methylpyrazole analogue 105a (Kd 2.0 µM, LE 0.27) showed a significantly attenuated binding 
affinity on screening in comparison to the 4-cyanopyrazole derivative 103a (Kd 27 nM, LE 0.34), illustrating 
a preference for nitrile over methyl substitution from the 4-position of the pyrazole ring of the lead series 
(Table 10). Further, comparison of 105a (Kd 2.0 µM, LE 0.27) with the unsubstituted analogue 88a (Kd 
0.49 µM, LE 0.31) shows that 4-methyl substitution is less preferable than a lack of substitution from the 
3-aminopyrazole ring system of the lead series. It is possible that the greater steric bulk of the methyl 
group is not tolerated by the residues lining the binding pocket normally occupied by the nitrile group 
(Figure 43), however it could also be due to an impact on the dihedral angle between the indole and 
pyrazole rings that is detrimental to binding in the active site.  
 
 
 
Compound R1 R2 Tma (°C) Kd (nM) LEb 
88a 
     
H +7.0 490 ± 210 0.31 
103a 
     
CN +12.9 27 ± 4 0.34 
103b 
     
CN +12.6 70 ± 29 0.31 
103c 
     
CN +12.6 190 ± 23 0.30 
103d 
     
CN +12.0 73 ± 30 0.30 
105a 
     
Me +6.1 2000 ± 300 0.27 
 
 
a 100 µM ligand and 10 μM Mab TrmD. 
b kcal mol-1 HA-1. 
Table 10: The change in the melting temperatures (Tm), affinities (Kd) and efficiency metrics of compounds 88a, 103a-d and 105a. 
From the screening of the heterocyclic analogues of 103a (Kd 27 nM, LE 0.34), it was shown that expansion 
from a pyrrolidinyl to piperidinyl ring in 103b (Kd 70 nM, LE 0.31) resulted in an almost 3-fold weaker 
binding affinity (Table 10), suggesting constraints on ring size in this portion of the methionine binding 
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region. This was reflected in the X-ray crystal structure of 103b in complex with Mab TrmD, which did not 
show the orientation exhibited by the pyrrolidinyl ring of 103a towards Ser177, with the piperidinyl ring 
oriented towards Pro57 in both active sites (Figure 56).  
 
Figure 56: X-ray crystal structure of Mab TrmD bound to 103b (PDB code 6QR7, 2.03 Å, subunit A = white, subunit B = green, 103b 
= lilac), illustrating one of the active sites. 123 
A further almost 3-fold weakening of binding affinity was observed in the morpholinyl analogue 103c (Kd 
0.19 µM, LE 0.30) in comparison to 103b (Kd 70 nM, LE 0.31) (Table 10), which is likely due to the impact 
of the reduced basicity of the nitrogen atom in the ring and its electrostatic interaction with the 
carboxylate side chain of Glu112. The X-ray crystal structure of 103c in complex with Mab TrmD did not 
show the oxygen atom of the morpholinyl ring forming any hydrogen-bonding interactions in the active 
site, however the ring system was rotated significantly in comparison to the piperidinyl ring of 103b 
(Figure 57a). 
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Figure 57: X-ray crystal structures of Mab TrmD (subunit A = white, subunit B = green, ligand = lilac) bound to (a) 103c (PDB code 
6QR9, 2.42 Å), 123 and (b) 103d (PDB code 6QR8, 2.15 Å), 50 illustrating one of the active sites. 
In contrast to 103c (Kd 0.19 µM, LE 0.30), screening of the 4-methylpiperazinyl analogue 103d (Kd 73 nM, 
LE 0.30) afforded a comparable binding affinity to 103b (Kd 70 nM, LE 0.31), with the added N-methyl 
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group tolerated by the active site (Table 10). However, the N-methyl piperazinyl ring system showed 
different behaviour to the corresponding heterocyclic rings in analogues 103a-c in its X-ray crystal 
structure in complex with Mab TrmD, with both active sites showing the ring oriented towards Ser177 
(Figure 57b). As no additional hydrogen-bonding interactions were witnessed with the piperazinyl ring, it 
is likely that this is due to its larger steric bulk in comparison to the other heterocycles with its added 
methyl group. 
 
3.2.6: Screening against Mycobacteria and Optimisation for Activity 
Compounds from the lead series were sent to Dr Karen Brown (Department of Medicine, University of 
Cambridge) for testing against Mab in liquid culture up to a concentration of 400 µM. 50,   123 Whilst MIC 
values were determined for compounds, a lack of correlation between activity against Mab and target 
binding affinity was observed (Table 11). This could be attributed to a number of factors, including the 
impact of differential metabolism, retention or permeability on activity. Further experiments by Dr Karen 
Brown and fellow researchers in the Floto research group (Department of Medicine, University of 
Cambridge) to evaluate the effects of key compounds from the lead series on Mab are ongoing. 
Select compounds from the lead series were also sent to collaborators Dr Daben Libardo and Dr Helena 
Boshoff (Tuberculosis Research Section, National Institutes of Health) for testing against Mtb in liquid 
culture. 123 The compounds were tested against Mtb in the four growth media previously described (2.3.3: 
Screening against Mycobacterium tuberculosis). Promising results were observed for several compounds 
when applied to Mtb in 7H9 growth media in the absence of BSA, with compounds 88a and 103d affording 
MIC values of 12.5 and 6.3 µM with glucose or DPPC utilised as a carbon source respectively (Table 11). 
Similarly to the 2-based lead series (Table 4), the relatively poor activity afforded by compounds in the 
presence of BSA suggests that plasma protein binding could be an issue for this series (Table 11). 
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Compound     
 Mab 
TrmD Kd 
(nM) 
Mab 
MIC 
(µM) 
H37Rv Mtb MIC (µM) 
 GAST
-Fe 
7H9/ 
BSA 
7H9/ 
glucose 
7H9/ 
DPPC 
71h 
 
 
120 ± 15 50 50 >100 ND 
87 
 
 
92 ± 18 50 ND 
88a 
 
 
490 ± 210 50 25   100 12.5 6.3 
103a 
 
 
27 ± 4 50 50 >100 25 12.5 
103b 
 
 
70 ± 29 50 50   100 25 12.5 
103c 
 
 
190 ± 23 50 50 >100 100 50 
103d 
 
 
73 ± 30 50 25 50 12.5 6.3 
105a 
 
 
2000 ± 
300 
50 ND 
Table 11: MIC values afforded by compounds 71h, 87, 88a, 103a-d and 105a against Mab, performed by Dr Karen Brown, and 
H37Rv Mtb, performed by Dr. Daben Libardo. 
The promising results for key compounds against Mtb encouraged optimisation of activity through a 
consideration of physicochemical properties, in parallel with experiments by collaborators focused on 
Mab. Due to the low MIC values afforded by 103d against Mtb in comparison to other analogues (Table 
11), its scaffold was selected for the design of further compounds. An initial idea for modification of 103d 
was the replacement of its N-methyl group with an N-isopropyl group in 103e (Figure 58), which was 
104 
 
intended to increase lipophilicity (cLogP 4.06 to 4.90) without significantly impacting either aqueous 
solubility or the steric profile, avoiding disruption of ligand-target interactions. 
 
 
 
Figure 58: Idea for modification of 103d with replacement of the N-methyl group. 
The synthetic route used for compounds 103a-d (Scheme 16 and Scheme 17b) required five steps for the 
synthesis of each analogue, excluding the synthesis of indoline 97. With the N-isopropyl piperazinyl 
analogue 103e there was a desire to reduce the synthetic burden, facilitating the rapid synthesis of 
analogues in future physicochemical studies. This was achieved through the synthesis of methyl ester 109, 
which could then be used to produce 4-cyanopyrazole analogues with alternate heterocyclic rings 
attached in place of its alcohol in three steps. Methyl ester 109 was synthesised in three steps (Scheme 
18a), beginning with the protection of one of the alcohols of 1,4-benzenedimethanol 106 with a TBDPS 
group to afford 107 (38% yield). The remaining alcohol of 107 was reacted initially with methanesulfonyl 
chloride, then with indole 63 and NaH. The silyl protecting group of the resultant product 108, which was 
not purified, was removed following aqueous workup by the addition of TBAF (72% yield overall). The 
deprotected alcohol of methyl ester 109 was reacted initially with methanesulfonyl chloride as with 107, 
then stirred with 1-isopropylpiperazine and Cs2CO3 in DMF to afford 101e (43% yield overall) (Scheme 
18b). Methyl ester 101e was converted to the corresponding β-ketonitrile 102e (83% yield), which was 
used to synthesise the 4-cyanopyrazole compound 103e in the same manner as 71c and 71f (75% yield 
overall). 
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Reagents and Conditions: (a) TBDPSCl, imidazole, DMF, 21 h; (b) (i) MeSO2Cl, NEt3, DCM, 0 °C to rt, 1 h (ii) 63, NaH, DMF, 0 °C to rt, 45 min; (c) 
TBAF (1 M in THF), 30 min; (d) (i) MeSO2Cl, NEt3, DCM, 0 °C to rt, 90 min (ii) 1-isopropylpiperazine, Cs2CO3, DMF, 12 h; (e) n-butyllithium (1.6 M in 
hexanes), acetonitrile, THF, -78 °C, 30 min; (f) (i) CCl3CN, NaOAc, EtOH, 10 h (ii) N2H4·H2O, EtOH, reflux, 7 h. 
Scheme 18: Synthesis of (a) 109 in three steps from 106, and (b) 103e in three steps from 109. 
Compound 103e was sent to our collaborators as with previous compounds in the lead series for testing 
against both Mab and Mtb in liquid culture. 123  Whilst 103e did not afford an improved MIC value against 
Mab in comparison to 103a and 103d, lower values were observed with Mtb across all media types (Table 
12). Four-fold improvements in MIC were witnessed for 103e in contrast to 103d with Mtb in GAST-Fe and 
(a) 
(b) 
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7H9/DPPC media, whilst a greater than five-fold improvement was seen with Mtb in 7H9 media utilising 
glucose as a carbon source. Further, a four-fold improvement in comparison to 103d was demonstrated 
with Mtb in 7H9 media supplemented with BSA, implying a reduction of plasma protein binding. 
 
 
 
Compound R 
Mab TrmD Kd 
(nM) 
Mab MIC 
(µM) 
H37Rv Mtb MIC (µM) 
  
GAST-
Fe 
7H9/ 
BSA 
7H9/ 
glucose 
7H9/ 
DPPC 
103a 
     
27 ± 4 50 50 >100 25 12.5 
103d 
     
73 ± 30 50 25 50 12.5 6.3 
103e 
     
100 ± 24 50 6.3 12.5 2.3 1.6 
 
Table 12: MIC values afforded by compound 103e in contrast to 103a and 103d against Mab, performed by Dr Karen Brown, and 
H37Rv Mtb, performed by Dr. Daben Libardo. 
The activity of 103e against Mtb across multiple media types encouraged the synthesis of further 
derivatives (Table 12), utilising the newly developed shorter synthetic route starting from methyl ester 
109 (Scheme 18b). However, this was not possible due to time constraints. 
 
3.3: Investigation of Mycobacterium tuberculosis tRNA (m1G37) 
methyltransferase 
In addition to the synthesis and screening of 103e, following the screening of compounds 88a and 103a-
d against Mtb, the evaluation of the applicability of the lead series to the Mtb TrmD homolog was sought. 
Mab and Mtb TrmD share 77% sequence identity overall and 86% similarity. 
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3.3.1: Protein Expression and Screening by Isothermal Titration Calorimetry 
An E. coli colony on agar was kindly provided by the Gründling research group (MRC Centre for Molecular 
Bacteriology and Infection, Imperial College London). 136  This was grown and processed to afford the 
pET23b plasmid for Mtb TrmD. The isolated plasmid was used to transform E. coli BL21(DE3) strain, with 
the target protein expressed and purified to a yield of 5.0 mg L-1. The Mtb TrmD was used to screen several 
compounds by ITC, including its substrate SAM (Kd 40 µM, LE 0.22) whose binding affinity was equivalent 
to that determined for Mab TrmD (Kd 47 µM, LE 0.22) by Dr Sherine Thomas (Table 13).  
Compound     
Mab TrmD Mtb TrmD 
Kd (µM) LEa Kd (µM) LEa 
SAM 
 
40 ± 2b 0.22 47 ± 1 0.22 
88a 
 
0.49 ± 0.21 0.31 0.90 ± 0.10 0.29 
103d 
 
0.073 ± 0.030 0.30 0.33 ± 0.06 0.28 
 
 
a kcal mol-1 HA-1. 
b Measured by Dr Sherine Thomas. 
Table 13: The affinities (Kd) and efficiency metrics of SAM and compounds 88a and 103d with Mab and Mtb TrmD. 
Based on a consideration of activity against Mtb, compounds 88a (Kd 0.90 µM, LE 0.29) and 103d (Kd 0.33 
µM, LE 0.28) were selected for screening against Mtb TrmD by ITC (Table 13). The binding affinities 
afforded by these compounds against Mtb TrmD were of the same order of magnitude as the 
corresponding Kd values for Mab TrmD with less than a 2-fold difference for 88a, demonstrating the 
broader applicability of the lead series. 
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3.3.2: Screening by Differential Scanning Fluorimetry 
A larger selection of compounds from the lead series was also screened against Mtb TrmD by DSF. Under 
the same experimental conditions as used with Mab TrmD, an apo Tm of 57 °C was measured with ΔTm 
values varying from -0.3 to +4.3 °C for compounds in the lead series (Figure 59).  
Compound 
Tma (°C)   
Compound 
Tma (°C) 
Mab TrmD Mtb TrmD   Mab TrmD Mtb TrmD 
62 +1.1 0.0   71j +5.5 +1.5 
66a +3.4 0.0   71n +8.8 +1.0 
66b +4.6 +0.5   71o +10.9 +1.4 
66c +3.4 -0.3   72g +5.8 -0.3 
66d +4.4 +1.3   87 +12.0 +3.1 
66e +1.4 0.0   88a +7.0 +0.5 
66f +3.1 0.0   103a +12.9 +3.6 
70 +4.4 +0.5   103b +12.6 +4.0 
71f +8.3 +2.5   103c +12.6 +4.3 
71g +10.5 +3.5   103d +12.0 +3.9 
71h +11.5 +3.8   103e +11.9 +3.5 
 
 
 
a 100 µM ligand and 10 μM protein. 
Figure 59: The melting temperatures (Tm) of compounds in the 3-aminopyrazole lead series determined against both Mab and 
Mtb TrmD. 
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Whilst the range of ΔTm values against Mtb TrmD was smaller than for Mab TrmD, attributed to differing 
thermodynamics of protein unfolding as demonstrated by its higher apo Tm in contrast to Mab TrmD (40.5 
- 42.5 °C) under the screened conditions, 88 the results broadly correlated (Figure 59). Analogues of 103d 
with comparable ΔTm values (>10 °C) against Mab TrmD, associated with submicromolar Kd values, 
generally afforded the highest ΔTm values against Mtb TrmD (>3 °C). 
 
3.4: Summary and Future Work 
The screening of a fragment library provided a number of fragment hits with associated ΔTm values and 
structural information for elaboration. 50 Whilst the application of a structure-guided fragment-growth 
strategy to a highly ligand-efficient starting point did not afford the desired gains in binding affinity, 123 a 
fragment-merging strategy based on fragment hits with overlapping binding modes resulted in the 
development of a lead series based on the 3-aminopyrazole-indole scaffold of 62 (Kd 110 µM, LE 0.36) that 
proved amenable to elaboration. The optimisation of the phenyl ring of a p-methoxybenzyl-protected 
synthetic intermediate 66a led to a 10-fold improvement in binding affinity in 66f (Kd 12 µM, LE 0.30), with 
the addition of a nitrile group to a position on the pyrazole ring facing a narrow pocket affording a further 
25-fold improvement in 71f (Kd 0.50 µM, LE 0.36). Further gains were realised in the exploration of isomers 
and structurally-related analogues, with 71h (Kd 0.12 µM, LE 0.39) possessing a ligand efficiency higher 
than the original 3-aminopyrazole fragment hit 53 (Kd 170 µM, LE 0.37). Due to poorer aqueous solubility 
that precluded the screening of a number of analogues by ITC, moieties with greater sp3 content were 
incorporated into the lead series that, in combination with a consideration of findings from a prior study 
on the homolog to Mab TrmD in H. influenzae, 63 enabled the design of a low-nanomolar binding affinity 
compound 103a (Kd 27 nM, LE 0.34). Whilst 103a and its analogs did not perform as desired against Mab 
in vitro, promising results were found against Mtb that were improved in the more lipophilic derivative 
103e, which afforded low-micromolar activity against Mtb across different media types and carbon 
sources (MIC 1.6 – 12.5 µM).  
In light of these results, the homolog to Mab TrmD in Mtb was expressed and screened against the lead 
series to afford positive results illustrating the wider applicability of the compounds beyond the initial 
target of interest. This encourages further screening and development of the lead series. In a similar 
manner to 103e, the design and synthesis of further analogues would be based on a consideration of 
physicochemical properties and activity against mycobacteria, in addition to binding affinity for TrmD. The 
determination of the underlying causes behind the lack of correlation between binding affinity and activity 
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against Mab in vitro is important, and experiments are currently ongoing by collaborators focused on an 
analysis of target engagement, compound retention in the organism and the susceptibility of Mab TrmD 
as a target to inhibition. 
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4: Experimental Methods 
4.1: Synthetic Chemistry 
4.1.1: General Chemistry 
All reactions were carried out in oven-dried glassware under a positive pressure of dry nitrogen 
atmosphere. Temperatures of 0 and -78 °C were obtained by submerging the reaction vessel in a bath 
containing either ice or a mixture of solid CO2 pellets and acetone respectively. The solvents DCM, EtOAc, 
acetonitrile, methanol, PET and toluene were distilled over CaH2 under a dry nitrogen atmosphere prior 
to use, with THF distilled over a mixture of CaH2, LiAlH4 and triphenylphosphine. DMF was purchased as 
anhydrous from commercial suppliers, with ethanol and acetic acid obtained in the absolute and glacial 
forms respectively. All purchased chemicals were used as received. Solutions of Na2CO3, NaHCO3, NaCl 
(brine) and NH4Cl were aqueous and saturated. Solutions of LiCl were aqueous and 5% w/v. 
Flash chromatography was performed using automated Biotage® Isolera™ Spektra purification systems 
with appropriately sized Biotage® SNAP cartridges, containing either KP 50 µm silica (default) or HP-sphere 
25 µm C18 silica (‘reverse phase’). Analytical thin layer chromatography (TLC) was performed using Merck 
glass-backed silica plates, with visualization by 254 or 365 nm ultraviolet light. 
Liquid chromatography mass spectrometry (LCMS) was carried out using a Waters® Acquity UPLC® H-Class 
system, with samples run on a solvent gradient from 0 to 95% acetonitrile in water (+ 0.1% formic acid) 
over 4 minutes. Peaks corresponding to desired product are described, including the retention time (rt) 
and % purity by integration. High resolution mass spectrometry (HRMS) was mainly performed using 
ThermoFinnigan Orbitrap Classic, Waters® LCT PremierTM or Waters® VionTM IMS QTof systems. A Perkin-
Elmer® Spectrum One FT-IR spectrometer fitted with a universal attenuated total reflectance accessory 
was used to record infrared spectra, with wavelengths of maximum absorbance (νmax) quoted in 
wavenumbers (cm-1) for signals outside of the fingerprint region (br = broad). Only peaks corresponding 
to key functional groups were characterized. Nuclear magnetic resonance (NMR) spectra were recorded 
in the indicated deuterated solvents with AvanceTM III HD (400 MHz), QNP Cryoprobe (400 MHz) or DCH 
Cryoprobe (500 MHz) Bruker spectrometers. 1H NMR data are presented in the following order: chemical 
shift (in ppm on a δ scale relative to the residual solvent resonance peak), integration, multiplicity (s = 
singlet, d = doublet, t = triplet, q = quartet, quin = quintet, sep = septet, m = multiplet) and coupling 
constant (J, in Hz). 13C NMR spectra were proton-decoupled, with chemical shifts recorded and further 
description provided for certain peaks (br = broad). 
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A combination of TLC and LCMS analysis was used to monitor reactions. All tested compounds possessed 
a purity of at least 95% as determined by LCMS analysis. 
 
4.1.2: Methods and Characterisation Data for Screened Compounds 
N-(5-(Azepan-1-ylsulfonyl)-2-methoxyphenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide (2) 
 
T3P® (50 wt. % in DMF, 1.3 mL, 2.2 mmol) and DIPEA (0.64 mL, 3.7 mmol) were added to a solution of 2-
(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid 16 (0.150 g, 0.735 mmol) and 5-(azepan-1-ylsulfonyl)-2-
methoxyaniline 20 (0.209 g, 0.735 mmol) in DMF (2 mL). The reaction mixture was heated to 70 °C over 1 
hour. The reaction mixture was diluted with water (15 mL), adjusted to pH 1 and extracted into EtOAc (3 
x 20 mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo. Purification by 
flash chromatography (0 – 20% methanol in DCM) afforded 2 (0.206 g, 60% yield). 
LCMS (ESI+): m/z 471.3 [M + H]+, (ESI-): m/z 469.1 [M - H]-, rt 1.92 minutes, >99%; 1H NMR (400 MHz, 
(CD3)2SO) 12.62 (1H, s), 9.86 (1H, s), 8.45 (1H, d, J = 2.1 Hz), 8.27 (1H, d, J = 7.9 Hz), 7.99-7.91 (2H, m), 7.90-
7.82 (1H, m), 7.49 (1H, dd, J = 8.5, 2.2 Hz), 7.24 (1H, d, J = 8.8 Hz), 4.21 (2H, s), 3.96 (3H, s), 3.12 (4H, t, J = 
5.9 Hz), 1.64-1.51 (4H, m), 1.50-1.39 (4H, m); 13C NMR (125 MHz, (CD3)2SO) 168.4, 159.5, 152.0, 142.1, 
133.5, 131.6, 130.4, 129.8, 127.7, 127.6, 125.9, 125.5, 123.4, 119.1, 111.2, 56.3, 47.6, 28.5, 26.3 (1 peak 
missing); spectroscopic data consistent with literature. 41 
Ethyl 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetate (15)  41,  137 
 
Hydrazine monohydrate (0.47 mL, 9.0 mmol) was added dropwise to a solution of ethyl (E)-2-(3-
oxoisobenzofuran-1(3H)-ylidene)acetate 14 (1.97 g, 9.03 mmol) in ethanol (10 mL). The reaction mixture 
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was stirred at 50 °C over 2 hours. The reaction mixture was cooled to rt and left to stand for 12 hours. The 
resulting precipitate was obtained by vacuum filtration and washed with ethanol (10 mL) to afford 15 
(2.21 g, 99% yield). 
LCMS (ESI+): m/z 233.2 [M + H]+, rt 1.53 minutes, >99%; 1H NMR (400 MHz, (CD3)2SO) 12.63 (1H, s), 8.30-
8.24 (1H, m), 7.98-7.91 (1H, m), 7.90-7.83 (2H, m), 4.11 (2H, q, J = 7.1 Hz), 4.05 (2H, s), 1.17 (3H, t, J = 7.1 
Hz); 13C NMR (100 MHz, (CD3)2SO) 169.8, 159.4, 140.9, 133.6, 131.7, 129.4, 127.5, 125.9, 125.5, 60.7, 37.9, 
14.0; 1H NMR spectroscopic data consistent with literature. 137 
2-(4-Oxo-3,4-dihydrophthalazin-1-yl)acetic acid (16)  41 
 
Ethyl 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetate 15 (0.260 g, 1.12 mmol) was dissolved in a mixture of 
aqueous NaOH (10% w/v, 10 mL) and THF (10 mL). The reaction mixture was heated under reflux for 1 
hour. The reaction mixture was adjusted to pH 1 by the addition of aqueous HCl (2 M) at 0 °C, then 
extracted into diethyl ether (3 x 100 mL). The combined organic extracts were washed (brine), dried 
(MgSO4) and concentrated in vacuo. Purification by flash chromatography (0 – 10% methanol in DCM) 
afforded 16 (0.101 g, 44% yield). 
1H NMR (400 MHz, (CD3)2SO) 12.61 (1H, s), 8.26 (1H, d, J = 7.7 Hz), 7.94 (1H, ddd, J = 8.3, 6.9, 1.4 Hz), 7.90-
7.82 (2H, m), 3.95 (2H, s); 13C NMR (100 MHz, (CD3)2SO) 171.4, 159.5, 141.5, 133.5, 131.6, 129.6, 127.5, 
125.9, 125.6, 38.2; 1H NMR spectroscopic data consistent with literature. 137 
5-(Azepan-1-ylsulfonyl)-2-methoxyaniline (20)  41 
 
Hexamethyleneimine (0.212 mL, 1.89 mmol) was added dropwise at 0 °C to a suspension of NaH (60% in 
mineral oil, 0.189 g, 4.72 mmol) in DMF (2 mL). The reaction mixture was stirred at 0 °C over 30 minutes. 
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A solution of 4-methoxy-3-(2,2,2-trifluoroacetamido)benzenesulfonyl chloride 19 (0.500 g, 1.57 mmol) in 
DMF (3 mL) was added dropwise at 0 °C to the reaction mixture. The reaction mixture was warmed to rt 
and stirred over 3 hours. Ethanol (10 mL) was added dropwise at 0 °C to the reaction mixture, followed 
by water (10 mL) and aqueous HCl (37.5% w/v, 10 mL). The reaction mixture was heated under reflux for 
20 hours. The reaction mixture was concentrated in vacuo to remove ethanol, then adjusted to pH 9 by 
the dropwise addition of aqueous NaOH (10% w/v). The mixture was diluted with EtOAc (50 mL), and the 
resultant aqueous layer discarded. The organic layer was washed with water (3 x 50 mL) and brine (50 
mL), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (20 – 50% EtOAc in 
PET) afforded 20 (0.373 g, 83% yield). 
LCMS (ESI+): m/z 285.2 [M + H]+, rt 1.85 minutes, >99%; 1H NMR (400 MHz, CDCl3) 7.17 (1H, dd, J = 8.4, 
2.3 Hz), 7.09 (1H, d, J = 2.2 Hz), 6.81 (1H, d, J = 8.4 Hz), 3.98 (2H, br s), 3.90 (3H, s), 3.23 (4H, t, J = 5.9 Hz), 
1.75-1.64 (4H, m), 1.62-1.53 (4H, m); 13C NMR (100 MHz, CDCl3) 150.1, 136.7, 131.6, 118.1, 112.7, 109.7, 
55.8, 48.3, 29.3, 27.1; νmax/cm-1 3484 (N-H), 3379 (N-H), 2932, 2849, 1610, 1577, 1513; HRMS (ESI)+: m/z 
calculated for [C13H20N2O3S + K]+ = 323.0826, observed 323.0835. 
N-(2-Methoxyphenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide (21) 
 
T3P® (50 wt. % in DMF, 0.35 mL, 0.59 mmol) and DIPEA (0.10 mL, 0.59 mmol) were added to a solution of 
2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid 16 (40 mg, 0.20 mmol) and o-anisidine 17 (33 µL, 0.29 
mmol) in DMF (1 mL). The reaction mixture was heated to 40 °C over 2 hours. The reaction mixture was 
diluted with water (15 mL) and extracted into DCM (3 x 20 mL). The combined organic extracts were dried 
(MgSO4) and concentrated in vacuo. The residue was dissolved in toluene (10 mL) and concentrated in 
vacuo. Purification by flash chromatography (50 – 100% EtOAc in PET, 0 – 20% methanol in DCM) afforded 
21 (50 mg, 82% yield). 
LCMS (ESI+): m/z 332.1 [M + Na]+, rt 1.64 minutes, >99%; 1H NMR (500 MHz, (CD3)2SO) 12.61 (1H, s), 9.56 
(1H, s), 8.27 (1H, d, J = 7.9 Hz), 8.01-7.79 (4H, m), 7.11-7.00 (2H, m), 6.92-6.83 (1H, m), 4.16 (2H, s), 3.86 
(3H, s); 13C NMR (125 MHz, (CD3)2SO) 167.6, 159.5, 149.6, 142.3, 133.5, 131.5, 129.8, 127.6, 127.2, 125.8, 
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125.6, 124.6, 121.8, 120.2, 111.2, 55.7 (1 peak missing); νmax/cm-1 2905, 1665 (C=O), 1646, 1597, 1539; 
HRMS (ESI)+: m/z calculated for [C17H15N3O3 + H]+ = 310.1186, observed 310.1175. 
N-(5-(Azepan-1-ylsulfonyl)-2-methoxyphenyl)acetamide (22) 
 
Acetic anhydride (10 µL, 0.11 mmol) was added to a solution of 5-(azepan-1-ylsulfonyl)-2-methoxyaniline 
20 (15 mg, 0.053 mmol) and pyridine (8.5 µL, 0.11 mmol) in DCM (2 mL). The reaction mixture was stirred 
over 90 minutes. The reaction mixture was diluted with water (10 mL) and extracted into DCM (3 x 15 
mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo. Purification by flash 
chromatography (50 – 80% EtOAc in PET) afforded 22 (14 mg, 79% yield). 
LCMS (ESI+): m/z 327.3 [M + H]+, (ESI-): m/z 325.2 [M - H]-, rt 1.90 minutes, 96%; 1H NMR (400 MHz, CDCl3) 
8.78 (1H, d, J = 1.8 Hz), 7.76 (1H, br s), 7.53 (1H, dd, J = 8.5, 2.3 Hz), 6.91 (1H, d, J = 8.6 Hz), 3.94 (3H, s), 
3.30 (4H, t, J = 6.0 Hz), 2.22 (3H, s), 1.80-1.67 (4H, m), 1.65-1.53 (4H, m); 13C NMR (125 MHz, CDCl3) 168.4, 
150.4, 132.1, 128.2, 123.5, 118.0, 109.5, 56.2, 48.5, 29.3, 27.1, 25.0; νmax/cm-1 3349, 2930, 2855, 1673 
(C=O), 1592, 1518; HRMS (ESI)+: m/z calculated for [C15H22N2O4S + H]+ = 327.1373, observed 327.1375. 
1-((4-Methoxyphenyl)sulfonyl)azepane (23) 
 
Hexamethyleneimine (0.141 mL, 1.26 mmol) was added dropwise at 0 °C to a suspension of NaH (60% in 
mineral oil, 0.137 g, 3.43 mmol) in DMF (1 mL). The reaction mixture was stirred at 0 °C over 20 minutes. 
A solution of 4-methoxybenzenesulfonyl chloride 29 (0.236 g, 1.14 mmol) in DMF (2 mL) was added 
dropwise at 0 °C to the reaction mixture. The reaction mixture was warmed to rt and stirred over 1 hour. 
Water (15 mL) was added dropwise at 0 °C to the reaction mixture. The product was extracted into DCM 
(3 x 20 mL). The combined organic extracts were washed (brine), dried (MgSO4) and concentrated in 
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vacuo. The residue was dissolved in toluene (5 mL) and concentrated in vacuo. Purification by flash 
chromatography (0 – 35% EtOAc in PET) afforded 23 (0.243 g, 79% yield). 
LCMS (ESI+): m/z 270.2 [M + H]+, rt 2.15 minutes, >99%; 1H NMR (400 MHz, CDCl3) 7.75-7.70 (2H, m), 6.99-
6.93 (2H, m), 3.86 (3H, s), 3.25 (4H, t, J = 5.9 Hz), 1.75-1.66 (4H, m), 1.62-1.53 (4H, m); 13C NMR (100 MHz, 
CDCl3) 162.6, 131.5, 129.1, 114.2, 55.7, 48.3, 29.2, 27.1; νmax/cm-1 2929, 2848, 1595, 1579, 1501; HRMS 
(ESI)+: m/z calculated for [C13H19NO3S + H]+ = 270.1158, observed 270.1153. 
N-(2-Methoxy-5-(N-methylsulfamoyl)phenyl)acetamide (24) 
 
Acetic anhydride (18 µL, 0.19 mmol) was added to a solution of 3-amino-4-methoxy-N-
methylbenzenesulfonamide 33a (42 mg, 0.19 mmol) and pyridine (16 µL, 0.19 mmol) in DCM (2 mL). The 
reaction mixture was stirred over 2 days. The reaction mixture was diluted with water (15 mL) and 
extracted into DCM (3 x 20 mL). The combined organic extracts were dried (MgSO4) and concentrated in 
vacuo. Purification by flash chromatography (50 – 100% EtOAc in PET) afforded 24 (28 mg, 56% yield). 
LCMS (ESI+): m/z 259.2 [M + H]+, (ESI-): m/z 257.2 [M - H]-, rt 1.31 minutes, >99%; 1H NMR (400 MHz, 
CD3CN) 8.74 (1H, d, J = 2.0 Hz), 8.30 (1H, br s), 7.51 (1H, dd, J = 8.5, 2.2 Hz), 7.10 (1H, d, J = 8.6 Hz), 5.43-
5.27 (1H, m), 3.94 (3H, s), 2.47 (3H, d, J = 5.3 Hz), 2.14 (3H, s); 13C NMR (100 MHz, CD3CN) 170.0, 152.2, 
131.6, 129.5, 124.0, 118.7, 111.2, 56.9, 29.5, 24.7; νmax/cm-1 3422 (N-H), 3168, 1672 (C=O), 1594, 1530; 
HRMS (ESI)+: m/z calculated for [C10H14N2O4S + Na]+ = 281.0566, observed 281.0569. 
2-Amino-4-(azepan-1-ylsulfonyl)phenol (25) 
 
NaBH4 (28 mg, 0.75 mmol) was added portionwise at 0 °C to a suspension of NiCl2·6H2O (59 mg, 0.25 
mmol) in methanol (2 mL). The reaction mixture was warmed to rt and stirred over 20 minutes. A solution 
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of 4-(azepan-1-ylsulfonyl)-2-nitrophenol 32 (0.170 g, 0.498 mmol) in methanol (2 mL) was added at 0 °C 
to the reaction mixture, followed by further NaBH4 (94 mg, 2.5 mmol). The reaction mixture was warmed 
to rt and stirred over 2 hours. Water (15 mL) was added at 0 °C and the reaction mixture filtered through 
celite. The product was extracted into DCM (3 x 25 mL). The combined organic extracts were washed 
(brine), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (20 – 50% EtOAc 
in PET) afforded 25 (83 mg, 62% yield). 
LCMS (ESI+): m/z 271.2 [M + H]+, (ESI-): m/z 269.2 [M - H]-, rt 1.71 minutes, >99%; 1H NMR (400 MHz, 
CD3CN) 7.45 (1H, br s), 7.04 (1H, d, J = 2.3 Hz), 6.94 (1H, dd, J = 8.2, 2.2 Hz), 6.80 (1H, d, J = 8.3 Hz), 4.26 
(2H, br s), 3.18 (4H, t, J = 5.9 Hz), 1.74-1.60 (4H, m), 1.59-1.50 (4H, m); 13C NMR (100 MHz, CD3CN) 148.0, 
137.6, 131.9, 117.8, 114.8, 113.6, 48.9, 29.8, 27.6; νmax/cm-1 3397, 3350, 3320, 3285, 2927, 2855, 1593, 
1510; HRMS (ESI)-: m/z calculated for [C12H18N2O3S - H]- = 269.0965, observed 269.0965. 
3-(Azepan-1-ylsulfonyl)aniline (26) 
 
NaBH4 (51 mg, 1.4 mmol) was added portionwise at 0 °C to a suspension of NiCl2 (59 mg, 0.45 mmol) in 
methanol (2 mL). The reaction mixture was warmed to rt and stirred over 30 minutes. 1-((3-
Nitrophenyl)sulfonyl)azepane 35 (0.257 g, 0.904 mmol) was added at 0 °C to the reaction mixture, 
followed by further methanol (4 mL) and NaBH4 (0.171 g, 4.52 mmol). The reaction mixture was warmed 
to rt and stirred over 45 minutes. Water (10 mL) was added at 0 °C and the mixture filtered through celite, 
eluted with methanol (10 mL) and water (15 mL). The filtrate was concentrated in vacuo to remove 
methanol, then extracted into EtOAc (3 x 25 mL). The combined organic extracts were washed (brine), 
dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (20 – 50% EtOAc in PET) 
afforded 26 (0.188 g, 82% yield). 
LCMS (ESI+): m/z 255.2 [M + H]+, rt 1.77 minutes, >99%; 1H NMR (400 MHz, CDCl3) 7.24 (1H, t, J = 7.8 Hz), 
7.15-7.10 (1H, m), 7.08 (1H, t, J = 2.0 Hz), 6.81 (1H, ddd, J = 7.9, 2.3, 0.7 Hz), 3.89 (2H, br s), 3.26 (4H, t, J = 
5.9 Hz), 1.77-1.65 (4H, m), 1.63-1.54 (4H, m); 13C NMR (100 MHz, CDCl3) 147.2, 140.4, 130.0, 118.6, 116.7, 
113.0, 48.4, 29.3, 27.0; νmax/cm-1 3391 (N-H), 3326 (N-H), 2928, 2851, 1639, 1596; HRMS (ESI)+: m/z 
calculated for [C12H18N2O2S + H]+ = 255.1162, observed 255.1166. 
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N-(3-(Azepan-1-ylsulfonyl)phenyl)acetamide (27) 
 
Acetic anhydride (11 µL, 0.12 mmol) was added to a solution of 3-(azepan-1-ylsulfonyl)aniline 26 (15 mg, 
0.059 mmol) and pyridine (10 µL, 0.12 mmol) in DCM (2 mL). The reaction mixture was stirred over 5 
hours. The reaction mixture was diluted with water (10 mL) and extracted into DCM (3 x 15 mL). The 
combined organic extracts were dried (MgSO4) and concentrated in vacuo. Purification by flash 
chromatography (35 – 70% EtOAc in PET) afforded 27 (15 mg, 86% yield). 
LCMS (ESI+): m/z 297.2 [M + H]+, (ESI-): m/z 295.2 [M - H]-, rt 1.87 minutes, >99%; 1H NMR (500 MHz, 
CDCl3) 7.98 (1H, d, J = 7.9 Hz), 7.91 (1H, br s), 7.83-7.78 (1H, m), 7.52-7.47 (1H, m), 7.45 (1H, t, J = 7.9 Hz), 
3.27 (4H, t, J = 6.0 Hz), 2.21 (3H, s), 1.76-1.66 (4H, m), 1.65-1.53 (4H, m); 13C NMR (125 MHz, CDCl3) 169.0, 
139.9, 139.1, 130.0, 123.7, 122.2, 117.9, 48.5, 29.3, 27.0, 24.7; νmax/cm-1 3305, 3257, 3192, 3117, 2929, 
2851, 1670 (C=O), 1592, 1545; HRMS (ESI)+: m/z calculated for [C14H20N2O3S + H]+ = 297.1267, observed 
297.1268. 
N-(3-(Azepan-1-ylsulfonyl)phenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide (39) 
 
T3P® (50 wt. % in EtOAc, 0.35 mL, 0.59 mmol) and DIPEA (0.17 mL, 0.98 mmol) were added to a solution 
of 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid 16 (47 mg, 0.20 mmol) and 3-(azepan-1-
ylsulfonyl)aniline 26 (50 mg, 0.20 mmol) in DMF (2 mL). The reaction mixture was heated to 70 °C over 2 
hours. The reaction mixture was diluted with EtOAc (25 mL), washed with water (3 x 25 mL) and brine (25 
mL), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (50 – 90% EtOAc in 
PET) afforded 39 (40 mg, 45% yield). 
LCMS (ESI+): m/z 441.3 [M + H]+, (ESI-): m/z 439.2 [M - H]-, rt 1.82 minutes, 98%; 1H NMR (500 MHz, 
(CD3)2SO) 12.63 (1H, s), 10.67 (1H, s), 8.30-8.25 (1H, m), 8.13 (1H, t, J = 1.8 Hz), 7.98-7.92 (2H, m), 7.86 
(1H, ddd, J = 8.1, 5.7, 2.4 Hz), 7.78 (1H, dq, J = 8.2, 1.0 Hz), 7.54 (1H, t, J = 8.0 Hz), 7.44 (1H, dq, J = 7.8, 0.9 
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Hz), 4.10 (2H, s), 3.18 (4H, t, J = 5.9 Hz), 1.66-1.56 (4H, m), 1.53-1.44 (4H, m); 13C NMR (125 MHz, (CD3)2SO) 
168.1, 159.5, 141.8, 139.7, 139.5, 133.6, 131.6, 130.0, 129.8, 127.6, 125.8, 125.6, 122.6, 121.2, 116.7, 
47.7, 28.5, 26.3 (1 peak missing); νmax/cm-1 2929, 2852, 1644 (C=O), 1591, 1541; HRMS (ESI)+: m/z 
calculated for [C22H24N4O4S + H]+ = 441.1591, observed 441.1613. 
N-(5-(Azepan-1-ylsulfonyl)-2-methylphenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide (40) 
 
T3P® (50 wt. % in EtOAc, 0.33 mL, 0.56 mmol) and DIPEA (0.16 mL, 0.93 mmol) were added to a solution 
of 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid 16 (44 mg, 0.19 mmol) and 5-(azepan-1-ylsulfonyl)-2-
methylaniline 38 (50 mg, 0.19 mmol) in DMF (2 mL). The reaction mixture was heated to 70 °C over 2 
hours. The reaction mixture was diluted with EtOAc (25 mL), washed with water (3 x 25 mL) and brine (25 
mL), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (50 – 90% EtOAc in 
PET, 0 – 5% methanol in DCM) afforded 40 (42 mg, 50% yield). 
LCMS (ESI+): m/z 455.3 [M + H]+, (ESI-): m/z 453.2 [M - H]-, rt 1.82 minutes, >99%; 1H NMR (500 MHz, 
(CD3)2SO) 12.64 (1H, s), 9.84 (1H, s), 8.28 (1H, d, J = 7.7 Hz), 8.02-7.92 (3H, m), 7.87 (1H, ddd, J = 8.0, 6.7, 
1.5 Hz), 7.49-7.41 (2H, m), 4.15 (2H, s), 3.14 (4H, t, J = 6.0 Hz), 2.33 (3H, s), 1.65-1.53 (4H, m), 1.51-1.42 
(4H, m); 13C NMR (125 MHz, (CD3)2SO) 168.0, 159.5, 142.0, 136.8, 136.5, 135.8, 133.5, 131.6, 131.3, 129.8, 
127.6, 125.9, 125.5, 122.8, 122.1, 47.7, 28.5, 26.3, 18.0 (1 peak missing); νmax/cm-1 3177, 3045, 2915, 2853, 
1651 (C=O), 1612, 1600, 1582, 1553; HRMS (ESI)+: m/z calculated for [C23H26N4O4S + H]+ = 455.1748, 
observed 455.1769. 
N-(5-(Azepane-1-carbonyl)-2-methoxyphenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide (45) 
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T3P® (50 wt. % in EtOAc, 0.12 mL, 0.20 mmol) and DIPEA (58 µL, 0.33 mmol) were added to a solution of 
2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid 16 (14 mg, 0.067 mmol) and (3-amino-4-
methoxyphenyl)(azepan-1-yl)methanone 44 (17 mg, 0.067 mmol) in DMF (1 mL). The reaction mixture 
was heated to 70 °C over 2 hours. The reaction mixture was diluted with EtOAc (25 mL), washed with 
water (3 x 10 mL) and brine (25 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash 
chromatography (50 – 100% EtOAc in PET, 0 – 10% methanol in DCM) afforded 45 (13 mg, 45% yield). 
LCMS (ESI+): m/z 435.3 [M + H]+, (ESI-): m/z 433.3 [M - H]-, rt 1.68 minutes, >99%; 1H NMR (400 MHz, 
(CD3)2CO) 11.69 (1H, br s), 9.01 (1H, br s), 8.39-8.32 (2H, m), 8.04 (1H, d, J = 8.1 Hz), 7.94 (1H, td, J = 7.7, 
1.5 Hz), 7.89-7.82 (1H, m), 7.09 (1H, dd, J = 8.4, 2.0 Hz), 7.04 (1H, d, J = 8.4 Hz), 4.21 (2H, s), 3.91 (3H, s), 
3.56 (2H, br s), 3.40 (2H, br s), 1.81-1.47 (8H, m); 13C NMR (125 MHz, (CD3)2SO) 169.9, 167.9, 159.5, 149.7, 
142.2, 133.5, 131.5, 129.8, 129.1, 127.6, 126.8, 125.8, 125.5, 122.9, 119.9, 110.8, 55.9, 49.2, 45.5, 28.9, 
27.2, 26.8, 25.8 (1 peak missing); νmax/cm-1 3191, 2929, 2856, 1674, 1648, 1618, 1548; HRMS (ESI)+: m/z 
calculated for [C24H26N4O4 + H]+ = 435.2027, observed 435.2025. 
N-(5-(Azepan-1-ylsulfonyl)-2-methoxyphenyl)-2-(1H-indol-3-yl)acetamide (46a) 
 
T3P® (50 wt. % in EtOAc, 0.15 mL, 0.26 mmol) and DIPEA (75 µL, 0.43 mmol) were added to a solution of 
3-indoleacetic acid (15 mg, 0.086 mmol) and 5-(azepan-1-ylsulfonyl)-2-methoxyaniline 20 (24 mg, 0.086 
mmol) in DMF (1 mL). The reaction mixture was heated to 70 °C over 4 hours. The reaction mixture was 
diluted with EtOAc (25 mL), washed with water (3 x 10 mL) and brine (25 mL), dried (MgSO4) and 
concentrated in vacuo. Purification by flash chromatography (40 – 80% EtOAc in PET) afforded 46a (8 mg, 
21% yield). 
LCMS (ESI+): m/z 442.3 [M + H]+, (ESI-): m/z 440.2 [M - H]-, rt 2.13 minutes, 97%; 1H NMR (400 MHz, 
(CD3)2SO) 10.98 (1H, s), 9.34 (1H, s), 8.50 (1H, d, J = 2.2 Hz), 7.61 (1H, d, J = 7.9 Hz), 7.45 (1H, dd, J = 8.6, 
2.4 Hz), 7.37 (1H, d, J = 8.1 Hz), 7.30 (1H, d, J = 2.3 Hz), 7.18 (1H, d, J = 8.8 Hz), 7.09 (1H, ddd, J = 8.1, 7.0, 
1.1 Hz), 6.99 (1H, ddd, J = 7.9, 7.0, 1.0 Hz), 3.87 (2H, s), 3.85 (3H, s), 3.12 (4H, t, J = 5.9 Hz), 1.65-1.52 (4H, 
m), 1.51-1.38 (4H, m); 13C NMR (100 MHz, (CD3)2SO) 170.4, 151.7, 136.2, 130.4, 127.9, 127.2, 124.3, 123.1, 
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121.2, 118.7, 118.6, 118.5, 111.5, 111.1, 108.2, 56.3, 47.7, 33.5, 28.5, 26.4; νmax/cm-1 3345 (br, N-H), 2928, 
2856, 1673 (C=O), 1594, 1524; HRMS (ESI)+: m/z calculated for [C23H27N3O4S + Na]+ = 464.1614, observed 
464.1615. 
N-(5-(Azepan-1-ylsulfonyl)-2-methoxyphenyl)-2-(5-methoxy-1H-indol-3-yl)acetamide (46b) 
 
T3P® (50 wt. % in EtOAc, 0.31 mL, 0.53 mmol) and DIPEA (0.15 mL, 0.88 mmol) were added to a solution 
of 5-methoxy-3-indoleacetic acid (36 mg, 0.18 mmol) and 5-(azepan-1-ylsulfonyl)-2-methoxyaniline 20 (50 
mg, 0.18 mmol) in DMF (2 mL). The reaction mixture was heated to 70 °C over 2 hours. The reaction 
mixture was diluted with EtOAc (100 mL), washed with water (3 x 100 mL) and brine (100 mL), dried 
(MgSO4) and concentrated in vacuo. Purification by flash chromatography (30 – 70% EtOAc in PET) 
afforded 46b (32 mg, 38% yield). 
LCMS (ESI+): m/z 472.3 [M + H]+, (ESI-): m/z 470.2 [M - H]-, rt 2.09 minutes, 98%; 1H NMR (500 MHz, 
(CD3)2SO) 10.81 (1H, d, J = 1.6 Hz), 9.29 (1H, s), 8.51 (1H, d, J = 2.1 Hz), 7.45 (1H, dd, J = 8.7, 2.3 Hz), 7.29-
7.24 (2H, m), 7.17 (1H, d, J = 8.8 Hz), 7.13 (1H, d, J = 2.4 Hz), 6.74 (1H, dd, J = 8.7, 2.4 Hz), 3.84 (3H, s), 3.83 
(2H, s), 3.74 (3H, s), 3.13 (4H, t, J = 6.0 Hz), 1.64-1.54 (4H, m), 1.51-1.42 (4H, m); 13C NMR (125 MHz, 
(CD3)2SO) 170.4, 153.2, 151.6, 131.3, 130.4, 127.8, 127.4, 124.9, 123.0, 118.5, 112.1, 111.2, 111.0, 107.9, 
100.5, 56.2, 55.3, 47.7, 33.6, 28.4, 26.3; νmax/cm-1 3350 (br, N-H), 2933, 1719, 1675 (C=O), 1593, 1522; 
HRMS (ESI)+: m/z calculated for [C24H29N3O5S + H]+ = 472.1901, observed 472.1890. 
N-(5-(Azepan-1-ylsulfonyl)-2-methoxyphenyl)-3-(1H-indol-3-yl)propanamide (46c) 
 
T3P® (50 wt. % in EtOAc, 0.25 mL, 0.42 mmol) and DIPEA (0.12 mL, 0.70 mmol) were added to a solution 
of 3-indolepropionic acid (27 mg, 0.14 mmol) and 5-(azepan-1-ylsulfonyl)-2-methoxyaniline 20 (40 mg, 
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0.14 mmol) in DMF (2 mL). The reaction mixture was heated to 70 °C over 1 hour. The reaction mixture 
was diluted with EtOAc (25 mL), washed with water (3 x 25 mL) and brine (25 mL), dried (MgSO4) and 
concentrated in vacuo. Purification by flash chromatography (30 – 70% EtOAc in PET) afforded 46c (26 
mg, 41% yield). 
LCMS (ESI+): m/z 456.3 [M + H]+, (ESI-): m/z 454.3 [M - H]-, rt 2.17 minutes, >99%; 1H NMR (400 MHz, 
(CD3)2SO) 10.78 (1H, s), 9.37 (1H, s), 8.51 (1H, d, J = 1.9 Hz), 7.57 (1H, d, J = 7.8 Hz), 7.47 (1H, dd, J = 8.7, 
2.4 Hz), 7.33 (1H, d, J = 8.0 Hz), 7.19 (1H, d, J = 8.7 Hz), 7.14 (1H, d, J = 2.0 Hz), 7.06 (1H, t, J = 7.5 Hz), 6.97 
(1H, t, J = 7.4 Hz), 3.89 (3H, s), 3.16 (4H, t, J = 5.9 Hz), 3.01 (2H, t, J = 7.5 Hz), 2.82 (2H, t, J = 7.5 Hz), 1.70-
1.56 (4H, m), 1.55-1.41 (4H, m); 13C NMR (100 MHz, (CD3)2SO) 171.8, 152.0, 136.2, 130.3, 127.8, 127.0, 
123.1, 122.3, 120.9, 119.4, 118.5, 118.2, 113.6, 111.3, 111.0, 56.2, 47.7, 36.8, 28.5, 26.4, 20.7; νmax/cm-1 
3360 (br, N-H), 2927, 2856, 1674 (C=O), 1594, 1524; HRMS (ESI)+: m/z calculated for [C24H29N3O4S + H]+ = 
456.1952, observed 456.1970. 
N-(5-(Azepan-1-ylsulfonyl)-2-methoxyphenyl)-2-(benzofuran-3-yl)acetamide (46d) 
 
T3P® (50 wt. % in EtOAc, 0.31 mL, 0.53 mmol) and DIPEA (0.15 mL, 0.88 mmol) were added to a solution 
of benzo[b]furan-3-ylacetic acid (31 mg, 0.18 mmol) and 5-(azepan-1-ylsulfonyl)-2-methoxyaniline 20 (50 
mg, 0.18 mmol) in DMF (2 mL). The reaction mixture was heated to 70 °C over 90 minutes. The reaction 
mixture was diluted with EtOAc (25 mL), washed with water (3 x 25 mL) and brine (25 mL), dried (MgSO4) 
and concentrated in vacuo. Purification by flash chromatography (30 – 60% EtOAc in PET) afforded 46d 
(50 mg, 64% yield). 
LCMS (ESI+): m/z 443.3 [M + H]+, (ESI-): m/z 441.3 [M - H]-, rt 2.24 minutes, >99%; 1H NMR (500 MHz, 
(CD3)2SO) 9.70 (1H, s), 8.46 (1H, d, J = 2.0 Hz), 7.92 (1H, s), 7.69 (1H, d, J = 7.6 Hz), 7.57 (1H, d, J = 8.2 Hz), 
7.49 (1H, dd, J = 8.5, 2.3 Hz), 7.32 (1H, td, J = 7.7, 1.1 Hz), 7.27 (1H, t, J = 7.5 Hz), 7.22 (1H, d, J = 8.7 Hz), 
3.94 (3H, s), 3.92 (2H, s), 3.13 (4H, t, J = 5.9 Hz), 1.64-1.53 (4H, m), 1.51-1.42 (4H, m); 13C NMR (125 MHz, 
(CD3)2SO) 169.0, 154.5, 152.1, 143.5, 130.4, 127.8, 127.6, 124.4, 123.4, 122.6, 120.2, 119.3, 114.6, 111.3, 
111.2, 56.3, 47.6, 31.2, 28.4, 26.3; νmax/cm-1 3353, 2929, 2855, 1680 (C=O), 1593, 1523; HRMS (ESI)+: m/z 
calculated for [C23H26N2O5S + H]+ = 443.1635, observed 443.1652. 
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N-(5-(Azepan-1-ylsulfonyl)-2-methoxyphenyl)-2-(benzo[d]isoxazol-3-yl)acetamide (46e) 
 
T3P® (50 wt. % in EtOAc, 81 µL, 0.14 mmol) and DIPEA (39 µL, 0.23 mmol) were added to a solution of 2-
(1,2-benzisoxazol-3-yl)acetic acid (8 mg, 0.05 mmol) and 5-(azepan-1-ylsulfonyl)-2-methoxyaniline 20 (13 
mg, 0.045 mmol) in DMF (1 mL). The reaction mixture was heated to 70 °C over 3 hours. The reaction 
mixture was diluted with EtOAc (25 mL), washed with water (3 x 15 mL) and brine (25 mL), dried (MgSO4) 
and concentrated in vacuo. Purification by flash chromatography (30 – 70% EtOAc in PET) followed by 
reverse phase flash chromatography (0 – 100% acetonitrile in water (+ 0.1% NH3)) afforded 46e (11 mg, 
55% yield). 
LCMS (ESI+): m/z 444.3 [M + H]+, (ESI-): m/z 442.2 [M - H]-, rt 2.15 minutes, >99%; 1H NMR (400 MHz, 
(CD3)2SO) 10.03 (1H, s), 8.44 (1H, d, J = 1.9 Hz), 7.91 (1H, d, J = 8.0 Hz), 7.75 (1H, d, J = 8.5 Hz), 7.66 (1H, t, 
J = 7.7 Hz), 7.52 (1H, dd, J = 8.6, 2.2 Hz), 7.41 (1H, t, J = 7.4 Hz), 7.25 (1H, d, J = 8.7 Hz), 4.34 (2H, s), 3.97 
(3H, s), 3.13 (4H, t, J = 5.9 Hz), 1.67-1.52 (4H, m), 1.51-1.39 (4H, m); 13C NMR (100 MHz, (CD3)2SO) 166.8, 
162.4, 154.2, 152.2, 130.4, 127.4, 123.7, 122.6, 121.5, 119.5, 111.3, 109.7, 56.3, 47.6, 32.8, 28.5, 26.3 (2 
peaks missing); νmax/cm-1 2923, 2856, 1689 (C=O), 1595, 1527; HRMS (ESI)+: m/z calculated for 
[C22H25N3O5S + H]+ = 444.1588, observed 444.1592. 
N-(5-(Azepan-1-ylsulfonyl)-2-methoxyphenyl)-2-(1H-benzo[d]imidazol-1-yl)acetamide (46f) 
 
T3P® (50 wt. % in EtOAc, 0.25 mL, 0.42 mmol) and DIPEA (0.12 mL, 0.70 mmol) were added to a solution 
of 2-(1H-benzimidazol-1-yl)acetic acid (25 mg, 0.14 mmol) and 5-(azepan-1-ylsulfonyl)-2-methoxyaniline 
20 (40 mg, 0.14 mmol) in DMF (2 mL). The reaction mixture was heated to 70 °C over 1 hour. The reaction 
mixture was diluted with EtOAc (25 mL), washed with water (3 x 25 mL) and brine (25 mL), dried (MgSO4) 
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and concentrated in vacuo. Purification by flash chromatography (50 – 100% EtOAc in PET, 0 – 5% 
methanol in DCM) afforded 46f (33 mg, 53% yield). 
LCMS (ESI+): m/z 443.3 [M + H]+, (ESI-): m/z 441.2 [M - H]-, rt 1.62 minutes, >99%; 1H NMR (500 MHz, 
(CD3)2SO) 10.00 (1H, s), 8.45 (1H, d, J = 2.2 Hz), 8.23 (1H, s), 7.70-7.65 (1H, m), 7.54 (1H, d, J = 7.8 Hz), 7.51 
(1H, dd, J = 8.7, 2.3 Hz), 7.29-7.19 (3H, m), 5.31 (2H, s), 3.98 (3H, s), 3.11 (4H, t, J = 5.9 Hz), 1.62-1.51 (4H, 
m), 1.49-1.40 (4H, m); 13C NMR (125 MHz, (CD3)2SO) 166.5, 152.0, 145.0, 143.2, 134.4, 130.4, 127.3, 123.7, 
122.4, 121.6, 119.4, 119.1, 111.3, 110.3, 56.4, 47.6, 47.3, 28.4, 26.3; νmax/cm-1 2930, 2853, 1694 (C=O), 
1596, 1533; HRMS (ESI)+: m/z calculated for [C22H26N4O4S + H]+ = 443.1748, observed 443.1769. 
N-(5-(Azepan-1-ylsulfonyl)-2-methoxyphenyl)-2-(quinolin-4-yl)acetamide (46g) 
 
Lithium diisopropylamide (2 M in THF/heptane/ethylbenzene, 1.5 mL, 3.0 mmol) was added dropwise 
over 30 minutes at -78 °C to a mixture of 4-methylquinoline 47 (0.33 mL, 2.5 mmol) and THF (5 mL). The 
reaction mixture was stirred at -78 °C over 1 hour, then solid CO2 pellets (1 g) were added. The reaction 
mixture was stirred at -78 °C over 10 minutes, then warmed to rt and stirred over 1 hour. Water (20 mL) 
was added dropwise at 0 °C, followed by aqueous NaOH (10% w/v, 5 mL). The mixture was washed with 
DCM (3 x 25 mL), then adjusted to pH 6 and washed with DCM/methanol (9:1, 3 x 50 mL). The aqueous 
phase was concentrated in vacuo to afford a crude residue. 5-(azepan-1-ylsulfonyl)-2-methoxyaniline 20 
(0.140 g, 0.492 mmol) and DMF (10 mL) were added to the crude residue, followed by T3P® (50 wt. % in 
EtOAc, 3.5 mL, 5.9 mmol) and DIPEA (1.7 mL, 9.9 mmol). The reaction mixture was heated to 70 °C over 
40 minutes. The reaction mixture was diluted with EtOAc (100 mL), washed with water (3 x 100 mL) and 
brine (100 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (50 – 100% 
EtOAc in PET, 0 – 10% methanol in DCM) followed by reverse phase flash chromatography (0 – 50% 
acetonitrile in water (+ 0.1% NH3)) afforded 46g (11 mg, 5% yield). 
LCMS (ESI+): m/z 454.3 [M + H]+, (ESI-): m/z 452.3 [M - H]-, rt 1.70 minutes, >99%; 1H NMR (400 MHz, 
(CD3)2SO) 9.90 (1H, s), 8.85 (1H, d, J = 4.3 Hz), 8.42 (1H, d, J = 2.2 Hz), 8.19 (1H, d, J = 8.4 Hz), 8.05 (1H, dd, 
J = 8.4, 0.7 Hz), 7.77 (1H, ddd, J = 8.4, 6.9, 1.4 Hz), 7.65 (1H, ddd, J = 8.4, 6.9, 1.3 Hz), 7.53-7.46 (2H, m), 
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7.24 (1H, d, J = 8.8 Hz), 4.39 (2H, s), 3.97 (3H, s), 3.11 (4H, t, J = 5.9 Hz), 1.63-1.51 (4H, m), 1.50-1.39 (4H, 
m); 13C NMR (125 MHz, CDCl3) 167.1, 150.6, 150.5, 148.8, 140.2, 132.2, 130.6, 130.0, 127.63, 127.58, 
127.4, 124.0, 123.7, 122.8, 118.1, 109.6, 56.2, 48.5, 42.1, 29.3, 27.0; νmax/cm-1 3295, 2923, 1663 (C=O), 
1593, 1537; HRMS (ESI)+: m/z calculated for [C24H27N3O4S + H]+ = 454.1795, observed  454.1781. 
N-(5-(Azepan-1-ylsulfonyl)-2-methoxyphenyl)-2-(naphthalen-1-yl)acetamide (46h) 
 
T3P® (50 wt. % in EtOAc, 0.31 mL, 0.53 mmol) and DIPEA (0.15 mL, 0.88 mmol) were added to a solution 
of 1-naphthaleneacetic acid (33 mg, 0.18 mmol) and 5-(azepan-1-ylsulfonyl)-2-methoxyaniline 20 (50 mg, 
0.18 mmol) in DMF (2 mL). The reaction mixture was heated to 70 °C over 2 hours. The reaction mixture 
was diluted with EtOAc (25 mL), washed with water (3 x 25 mL) and brine (25 mL), dried (MgSO4) and 
concentrated in vacuo. Purification by flash chromatography (0 – 50% EtOAc in PET) afforded 46h (53 mg, 
67% yield). 
LCMS (ESI+): m/z 453.3 [M + H]+, (ESI-): m/z 451.3 [M - H]-, rt 2.37 minutes, >99%; 1H NMR (400 MHz, 
(CD3)2SO) 9.69 (1H, s), 8.44 (1H, d, J = 2.3 Hz), 8.12 (1H, d, J = 7.9 Hz), 7.98-7.91 (1H, m), 7.86 (1H, dd, J = 
7.2, 2.2 Hz), 7.59-7.44 (5H, m), 7.22 (1H, d, J = 8.8 Hz), 4.30 (2H, s), 3.94 (3H, s), 3.11 (4H, t, J = 5.9 Hz), 
1.62-1.51 (4H, m), 1.49-1.40 (4H, m); 13C NMR (125 MHz, CDCl3) 169.0, 150.6, 134.2, 132.2, 132.1, 130.6, 
129.0, 128.9, 128.6, 127.9, 127.1, 126.4, 125.8, 123.9, 123.6, 117.9, 109.4, 56.0, 48.5, 43.1, 29.4, 27.0; 
νmax/cm-1 3360, 2925, 2862, 1675 (C=O), 1592, 1519; HRMS (ESI)+: m/z calculated for [C25H28N2O4S + Na]+ 
= 475.1662, observed 475.1652. 
N-(5-(Azepan-1-ylsulfonyl)-2-methoxyphenyl)-2-(pyridin-4-yl)acetamide (46i) 
 
EDC.HCl (83 mg, 0.43 mmol), DIPEA (0.15 mL, 0.86 mmol) and DMAP (5 mg, 0.04 mmol) were added to a 
solution of 4-pyridylacetic acid hydrochloride (50 mg, 0.29 mmol) and 5-(azepan-1-ylsulfonyl)-2-
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methoxyaniline 20 (98 mg, 0.35 mmol) in DCM (2 mL). The reaction mixture was stirred over 90 minutes, 
then diluted with water (25 mL) and extracted into DCM (3 x 25 mL). The combined organic extracts were 
washed (brine), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (50 – 
100% EtOAc in PET, 0 – 5% methanol in DCM) afforded 46i (74 mg, 64% yield). 
LCMS (ESI+): m/z 404.3 [M + H]+, (ESI-): m/z 402.2 [M - H]-, rt 1.54 minutes, >99%; 1H NMR (400 MHz, 
(CD3)2SO) 9.73 (1H, s), 8.54-8.48 (2H, m), 8.45 (1H, d, J = 2.2 Hz), 7.49 (1H, dd, J = 8.6, 2.3 Hz), 7.38-7.31 
(2H, m), 7.23 (1H, d, J = 8.8 Hz), 3.94 (3H, s), 3.86 (2H, s), 3.14 (4H, t, J = 5.9 Hz), 1.66-1.54 (4H, m), 1.52-
1.41 (4H, m); 13C NMR (125 MHz, CDCl3) 167.2, 150.6, 150.5, 143.1, 132.3, 127.6, 124.7, 124.0, 118.2, 
109.6, 56.3, 48.5, 44.2, 29.3, 27.0; νmax/cm-1 3300, 2931, 2858, 1658 (C=O), 1596, 1536; HRMS (ESI)+: m/z 
calculated for [C20H25N3O4S + Na]+ = 426.1458, observed 426.1447. 
N-(2-Methoxy-5-(N-methylsulfamoyl)phenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide (49a) 
 
T3P® (50 wt. % in EtOAc, 93 µL, 0.16 mmol) and DIPEA (46 µL, 0.26 mmol) were added to a solution of 2-
(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid 16 (11 mg, 0.052 mmol) and 3-amino-4-methoxy-N-
methylbenzenesulfonamide 33a (11 mg, 0.052 mmol) in DMF (1 mL). The reaction mixture was heated to 
70 °C over 5 hours. The reaction mixture was diluted with EtOAc (25 mL), washed with water (3 x 15 mL) 
and brine (15 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (50 – 
100% EtOAc in PET, 0 – 10% methanol in DCM) afforded 49a (6 mg, 29% yield). 
LCMS (ESI+): m/z 403.2 [M + H]+, (ESI-): m/z 401.1 [M - H]-, rt 1.44 minutes, >99%; 1H NMR (500 MHz, 
(CD3)2SO) 12.61 (1H, s), 9.83 (1H, s), 8.47 (1H, d, J = 2.2 Hz), 8.27 (1H, d, J = 7.5 Hz), 8.00-7.92 (2H, m), 7.86 
(1H, ddd, J = 8.0, 6.3, 1.9 Hz), 7.50 (1H, dd, J = 8.7, 2.3 Hz), 7.31-7.22 (2H, m), 4.21 (2H, s), 3.96 (3H, s), 
2.35 (3H, d, J = 5.0 Hz); 13C NMR (125 MHz, (CD3)2SO) 168.2, 159.5, 152.0, 142.2, 133.5, 131.6, 130.7, 129.8, 
127.6, 127.5, 125.8, 125.6, 123.5, 119.5, 111.1, 56.3, 28.6 (1 peak missing); νmax/cm-1 3277, 3173, 3016, 
2904, 1660 (C=O), 1594, 1537; HRMS (ESI)+: m/z calculated for [C18H18N4O5S + H]+ = 403.1071, observed 
403.1064. 
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N-(5-(Azocan-1-ylsulfonyl)-2-methoxyphenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide (49b) 
 
T3P® (50 wt. % in EtOAc, 0.24 mL, 0.40 mmol) and DIPEA (0.12 mL, 0.67 mmol) were added to a solution 
of 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid 16 (32 mg, 0.13 mmol) and 5-(azocan-1-ylsulfonyl)-2-
methoxyaniline 33b (40 mg, 0.13 mmol) in DMF (2 mL). The reaction mixture was heated to 70 °C over 2 
hours. The reaction mixture was diluted with EtOAc (25 mL), washed with water (3 x 25 mL) and brine (25 
mL), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (50 – 100% EtOAc in 
PET, 0 – 5% methanol in DCM) afforded 49b (24 mg, 37% yield). 
LCMS (ESI+): m/z 485.3 [M + H]+, (ESI-): m/z 483.2 [M - H]-, rt 1.94 minutes, >99%; 1H NMR (500 MHz, 
(CD3)2SO) 12.62 (1H, s), 9.86 (1H, s), 8.45 (1H, d, J = 2.2 Hz), 8.30-8.25 (1H, m), 7.98-7.92 (2H, m), 7.89-
7.83 (1H, m), 7.48 (1H, dd, J = 8.6, 2.3 Hz), 7.24 (1H, d, J = 8.8 Hz), 4.21 (2H, s), 3.97 (3H, s), 3.01 (4H, t, J = 
5.8 Hz), 1.67-1.44 (10H, m); 13C NMR (125 MHz, (CD3)2SO) 168.4, 159.5, 152.1, 142.1, 133.5, 131.6, 129.8, 
129.5, 127.7, 127.6, 125.9, 125.5, 123.5, 119.2, 111.2, 56.3, 48.0, 27.2, 26.2, 24.6 (1 peak missing); νmax/cm-
1 3307, 2923, 1693, 1644 (C=O), 1596, 1530; HRMS (ESI)+: m/z calculated for [C24H28N4O5S + H]+ = 
485.1853, observed 485.1848. 
N-(2-Methoxy-5-(piperidin-1-ylsulfonyl)phenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide (49c) 
 
T3P® (50 wt. % in EtOAc, 0.14 mL, 0.23 mmol) and DIPEA (66 µL, 0.38 mmol) were added to a solution of 
2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid 16 (16 mg, 0.076 mmol) and 2-methoxy-5-(piperidin-1-
ylsulfonyl)aniline 33c (21 mg, 0.076 mmol) in DMF (1 mL). The reaction mixture was heated to 70 °C over 
2 hours. The reaction mixture was diluted with EtOAc (25 mL), washed with water (3 x 10 mL) and brine 
(25 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (50 – 100% EtOAc 
in PET, 0 – 10% methanol in DCM) afforded 49c (14 mg, 40% yield). 
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LCMS (ESI+): m/z 457.3 [M + H]+, (ESI-): m/z 455.2 [M - H]-, rt 1.76 minutes, 98%; 1H NMR (500 MHz, 
(CD3)2SO) 12.62 (1H, s), 9.88 (1H, s), 8.39 (1H, d, J = 2.2 Hz), 8.28 (1H, d, J = 7.9 Hz), 7.99-7.92 (2H, m), 7.86 
(1H, ddd, J = 8.0, 5.7, 2.5 Hz), 7.45 (1H, dd, J = 8.6, 2.3 Hz), 7.28 (1H, d, J = 8.7 Hz), 4.22 (2H, s), 3.98 (3H, 
s), 2.81 (4H, t, J = 5.2 Hz), 1.50 (4H, quin, J = 5.7 Hz), 1.39-1.28 (2H, m); 13C NMR (125 MHz, (CD3)2SO) 168.4, 
159.5, 152.4, 142.1, 133.5, 131.6, 129.8, 127.59, 127.56, 126.7, 125.9, 125.5, 124.3, 119.9, 111.2, 56.4, 
46.5, 24.6, 22.8 (1 peak missing); νmax/cm-1 3176, 3057, 2923, 1674, 1646 (C=O), 1594, 1542; HRMS (ESI)+: 
m/z calculated for [C22H24N4O5S + H]+ = 457.1540, observed 457.1537. 
N-(2-Methoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide 
(49d) 
 
T3P® (50 wt. % in EtOAc, 0.24 mL, 0.41 mmol) and DIPEA (0.12 mL, 0.68 mmol) were added to a solution 
of 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid 16 (32 mg, 0.14 mmol) and 2-methoxy-5-((4-
methylpiperazin-1-yl)sulfonyl)aniline 33d (40 mg, 0.14 mmol) in DMF (2 mL). The reaction mixture was 
heated to 70 °C over 2 hours. The reaction mixture was diluted with EtOAc (25 mL), washed with water (3 
x 25 mL) and brine (25 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash 
chromatography (50 – 100% EtOAc in PET, 0 - 10% methanol in DCM) followed by reverse phase flash 
chromatography (0 – 30% acetonitrile in water (+ 0.1% NH3)) afforded 49d (10 mg, 16% yield). 
LCMS (ESI+): m/z 472.3 [M + H]+, (ESI-): m/z 470.2 [M - H]-, rt 1.23 minutes, >99%; 1H NMR (500 MHz, 
(CD3)2SO) 12.62 (1H, s), 9.91 (1H, s), 8.40 (1H, d, J = 2.2 Hz), 8.30-8.25 (1H, m), 7.99-7.92 (2H, m), 7.86 (1H, 
ddd, J = 8.0, 5.8, 2.4 Hz), 7.46 (1H, dd, J = 8.6, 2.3 Hz), 7.30 (1H, d, J = 8.7 Hz), 4.22 (2H, s), 3.99 (3H, s), 2.81 
(4H, br s), 2.38-2.28 (4H, m), 2.10 (3H, s); 13C NMR (125 MHz, (CD3)2SO) 168.4, 159.4, 152.6, 142.1, 133.5, 
131.6, 129.8, 127.62, 127.56, 126.0, 125.8, 125.5, 124.5, 120.0, 111.3, 56.4, 53.5, 45.7, 45.2 (1 peak 
missing); νmax/cm-1 3376, 2922, 1684, 1655 (C=O), 1594, 1533; HRMS (ESI)+: m/z calculated for 
[C22H25N5O5S + H]+ = 472.1649, observed 472.1662. 
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N-(2-Methoxy-5-(morpholinosulfonyl)phenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide (49e) 
 
T3P® (50 wt. % in EtOAc, 0.26 mL, 0.44 mmol) and DIPEA (0.13 mL, 0.73 mmol) were added to a solution 
of 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid 16 (35 mg, 0.15 mmol) and 2-methoxy-5-
(morpholinosulfonyl)aniline 33e (40 mg, 0.15 mmol) in DMF (2 mL). The reaction mixture was heated to 
70 °C over 2 hours. The reaction mixture was diluted with EtOAc (25 mL), washed with water (3 x 25 mL) 
and brine (25 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (50 – 
100% EtOAc in PET, 0 - 10% methanol in DCM) followed by reverse phase flash chromatography (0 – 60% 
acetonitrile in water (+ 0.1% NH3)) afforded 49e (7 mg, 10% yield). 
LCMS (ESI+): m/z 459.3 [M + H]+, (ESI-): m/z 457.3 [M - H]-, rt 1.55 minutes, >99%; 1H NMR (400 MHz, 
(CD3)2SO) 12.62 (1H, s), 9.93 (1H, s), 8.41 (1H, d, J = 2.0 Hz), 8.27 (1H, d, J = 7.8 Hz), 8.01-7.91 (2H, m), 7.86 
(1H, ddd, J = 8.0, 5.7, 2.5 Hz), 7.47 (1H, dd, J = 8.7, 2.2 Hz), 7.31 (1H, d, J = 8.7 Hz), 4.23 (2H, s), 3.99 (3H, 
s), 3.59 (4H, t, J = 4.5 Hz), 2.79 (4H, t, J = 4.4 Hz); 13C NMR (100 MHz, (CD3)2SO) 168.5, 159.5, 152.7, 142.1, 
133.6, 131.6, 129.8, 127.7, 127.6, 125.9, 125.6, 125.5, 124.6, 120.1, 111.4, 65.2, 56.4, 45.9 (1 peak 
missing); νmax/cm-1 3175, 3027, 2924, 2854, 1672, 1646 (C=O), 1593, 1538; HRMS (ESI)+: m/z calculated 
for [C21H22N4O6S + Na]+ = 481.1152, observed 481.1143. 
N-(2-Methoxy-5-(thiomorpholinosulfonyl)phenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide (49f) 
 
T3P® (50 wt. % in EtOAc, 0.24 mL, 0.40 mmol) and DIPEA (0.12 mL, 0.67 mmol) were added to a solution 
of 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid 16 (32 mg, 0.13 mmol) and 2-methoxy-5-
(thiomorpholinosulfonyl)aniline 33f (40 mg, 0.13 mmol) in DMF (2 mL). The reaction mixture was heated 
to 70 °C over 2 hours. The reaction mixture was diluted with EtOAc (25 mL), washed with water (3 x 25 
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mL) and brine (25 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography 
(50 – 100% EtOAc in PET, 0 – 10% methanol in DCM) afforded 49f (23 mg, 36% yield). 
LCMS (ESI+): m/z 475.2 [M + H]+, (ESI-): m/z 473.2 [M - H]-, rt 1.72 minutes, >99%; 1H NMR (500 MHz, 
(CD3)2SO) 12.62 (1H, s), 9.92 (1H, s), 8.41 (1H, d, J = 2.3 Hz), 8.27 (1H, d, J = 7.9 Hz), 8.00-7.92 (2H, m), 7.86 
(1H, ddd, J = 8.0, 5.8, 2.3 Hz), 7.47 (1H, dd, J = 8.7, 2.3 Hz), 7.29 (1H, d, J = 8.7 Hz), 4.23 (2H, s), 3.99 (3H, 
s), 3.13 (4H, t, J = 4.7 Hz), 2.63 (4H, t, J = 5.1 Hz); 13C NMR (125 MHz, (CD3)2SO) 168.4, 159.5, 152.6, 142.1, 
133.6, 131.6, 129.8, 127.8, 127.6, 127.2, 125.9, 125.6, 124.2, 119.6, 111.4, 56.4, 47.8, 26.3 (1 peak 
missing); νmax/cm-1 3391, 2929, 2849, 1674, 1645, 1607, 1516; HRMS (ESI)+: m/z calculated for 
[C21H22N4O5S2 + H]+ = 475.1104, observed 475.1104. 
N-(5-((1,1-Dioxidothiomorpholino)sulfonyl)-2-methoxyphenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-
yl)acetamide (49g) 
 
T3P® (50 wt. % in EtOAc, 0.67 mL, 1.1 mmol) and DIPEA (0.33 mL, 1.9 mmol) were added to a solution of 
2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid 16 (89 mg, 0.38 mmol) and 4-((3-amino-4-
methoxyphenyl)sulfonyl)thiomorpholine 1,1-dioxide 33g (0.120 g, 0.375 mmol) in DMF (2 mL). The 
reaction mixture was heated to 70 °C over 1 hour. The reaction mixture was diluted with EtOAc (25 mL), 
washed with water (3 x 25 mL) and brine (25 mL), dried (MgSO4) and concentrated in vacuo. Purification 
by flash chromatography (50 – 100% EtOAc in PET, 0 – 20% methanol in DCM) followed by reverse phase 
flash chromatography (0 – 60% acetonitrile in water (+ 0.1% NH3)) afforded 49g (55 mg, 28% yield). 
LCMS (ESI+): m/z 507.2 [M + H]+, (ESI-): m/z 505.2 [M - H]-, rt 1.61 minutes, 97%; 1H NMR (500 MHz, 
(CD3)2SO) 12.62 (1H, s), 9.96 (1H, s), 8.47 (1H, s), 8.27 (1H, d, J = 7.8 Hz), 8.02-7.82 (3H, m), 7.55 (1H, d, J = 
8.8 Hz), 7.32 (1H, d, J = 8.7 Hz), 4.23 (2H, s), 4.00 (3H, s), 3.27-3.19 (4H, m) (1 peak suspected to be 
obscured by H2O signal); 13C NMR (125 MHz, (CD3)2SO) 168.6, 159.5, 152.9, 142.1, 133.6, 131.6, 129.8, 
128.0, 127.6, 126.8, 125.9, 125.6, 124.2, 119.5, 111.7, 56.5, 49.9, 45.1 (1 peak missing); νmax/cm-1 3403, 
3001, 2933, 1663 (C=O), 1597, 1525; HRMS (ESI)-: m/z calculated for [C21H22N4O7S2 - H]- = 505.0857, 
observed 505.0851. 
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N-(2-Methoxy-5-(N-phenylsulfamoyl)phenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide (49h) 
 
T3P® (50 wt. % in EtOAc, 0.16 mL, 0.27 mmol) and DIPEA (79 µL, 0.45 mmol) were added to a solution of 
2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid 16 (19 mg, 0.090 mmol) and 3-amino-4-methoxy-N-
phenylbenzenesulfonamide 33h (25 mg, 0.090 mmol) in DMF (1 mL). The reaction mixture was heated to 
70 °C over 2 hours. The reaction mixture was diluted with EtOAc (25 mL), washed with water (3 x 10 mL) 
and brine (25 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (50 – 
100% EtOAc in PET, 0 – 10% methanol in DCM) afforded 49h (14 mg, 33% yield). 
LCMS (ESI+): m/z 465.2 [M + H]+, (ESI-): m/z 463.2 [M - H]-, rt 1.71 minutes, 98%; 1H NMR (500 MHz, 
(CD3)2SO) 12.61 (1H, s), 10.17 (1H, s), 9.78 (1H, s), 8.55 (1H, d, J = 2.2 Hz), 8.31-8.25 (1H, m), 7.98-7.91 (2H, 
m), 7.90-7.84 (1H, m), 7.47 (1H, dd, J = 8.7, 2.4 Hz), 7.22-7.14 (3H, m), 7.07-7.03 (2H, m), 7.00-6.94 (1H, 
m), 4.20 (2H, s), 3.91 (3H, s); 13C NMR (125 MHz, (CD3)2SO) 168.2, 159.4, 152.2, 142.1, 137.9, 133.5, 131.6, 
131.0, 129.8, 129.1, 127.6, 127.5, 125.8, 125.6, 123.7, 123.6, 119.6, 119.3, 111.0, 56.3 (1 peak missing); 
νmax/cm-1 3175, 3016, 1674, 1647 (C=O), 1592, 1538; HRMS (ESI)+: m/z calculated for [C23H20N4O5S + H]+ = 
465.1227, observed 465.1223. 
N-(5-(N-Benzylsulfamoyl)-2-methoxyphenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide (49i) 
 
T3P® (50 wt. % in EtOAc, 0.26 mL, 0.43 mmol) and DIPEA (0.12 mL, 0.71 mmol) were added to a solution 
of 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid 16 (30 mg, 0.14 mmol) and 3-amino-N-benzyl-4-
methoxybenzenesulfonamide 33i (45 mg, 0.14 mmol) in DMF (2 mL). The reaction mixture was heated to 
70 °C over 2 hours. The reaction mixture was diluted with EtOAc (25 mL), washed with water (3 x 25 mL) 
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and brine (25 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (50 – 
100% EtOAc in PET, 0 – 8% methanol in DCM) afforded 49i (25 mg, 37% yield). 
LCMS (ESI+): m/z 479.3 [M + H]+, (ESI-): m/z 477.2 [M - H]-, rt 1.74 minutes, >99%; 1H NMR (500 MHz, 
(CD3)2SO) 12.62 (1H, s), 9.81 (1H, s), 8.51 (1H, d, J = 2.2 Hz), 8.27 (1H, d, J = 7.8 Hz), 8.03-7.92 (3H, m), 7.86 
(1H, ddd, J = 8.0, 6.6, 1.6 Hz), 7.53 (1H, dd, J = 8.6, 2.3 Hz), 7.28-7.17 (6H, m), 4.22 (2H, s), 3.96 (3H, s), 
3.89 (2H, d, J = 6.5 Hz); 13C NMR (125 MHz, (CD3)2SO) 168.1, 159.5, 152.0, 142.2, 137.7, 133.5, 132.1, 131.6, 
129.8, 128.2, 127.6, 127.53, 127.49, 127.1, 125.8, 125.6, 123.4, 119.4, 111.1, 56.3, 46.1 (1 peak missing); 
νmax/cm-1 3287, 3176, 3026, 1672, 1647 (C=O), 1593, 1538; HRMS (ESI)+: m/z calculated for [C24H22N4O5S 
+ H]+ = 479.1384, observed 479.1381. 
N-(5-((3,4-Dihydroisoquinolin-2(1H)-yl)sulfonyl)-2-methoxyphenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-
yl)acetamide (49j) 
 
T3P® (50 wt. % in EtOAc, 0.28 mL, 0.47 mmol) and DIPEA (0.14 mL, 0.79 mmol) were added to a solution 
of 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid 16 (37 mg, 0.16 mmol) and 5-((3,4-dihydroisoquinolin-
2(1H)-yl)sulfonyl)-2-methoxyaniline 33j (50 mg, 0.16 mmol) in DMF (2 mL). The reaction mixture was 
heated to 70 °C over 1 hour. The reaction mixture was diluted with EtOAc (25 mL), washed with water (3 
x 25 mL) and brine (25 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash 
chromatography (50 – 100% EtOAc in PET, 0 – 5% methanol in DCM) afforded 49j (35 mg, 43% yield). 
LCMS (ESI-): m/z 503.3 [M - H]-, rt 1.90 minutes, 98%; 1H NMR (500 MHz, (CD3)2SO) 12.62 (1H, s), 9.89 (1H, 
s), 8.50 (1H, d, J = 2.2 Hz), 8.28 (1H, d, J = 7.9 Hz), 7.99-7.92 (2H, m), 7.86 (1H, ddd, J = 8.0, 5.9, 2.3 Hz), 
7.56 (1H, dd, J = 8.6, 2.3 Hz), 7.28 (1H, d, J = 8.7 Hz), 7.17-7.05 (4H, m), 4.22 (2H, s), 4.11 (2H, s), 3.97 (3H, 
s), 3.22 (2H, t, J = 6.0 Hz), 2.83 (2H, t, J = 5.8 Hz); 13C NMR (125 MHz, (CD3)2SO) 168.4, 159.5, 152.5, 142.1, 
133.5, 133.0, 131.6, 131.5, 129.8, 128.6, 127.7, 127.6, 126.9, 126.6, 126.4, 126.1, 125.8, 125.6, 124.4, 
119.9, 111.4, 56.4, 47.2, 43.6, 28.0 (1 peak missing); νmax/cm-1 3354, 2929, 2853, 1679 (C=O), 1592, 1523; 
HRMS (ESI)+: m/z calculated for [C26H24N4O5S + H]+ = 505.1540, observed 505.1534. 
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N-(5-((6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)-2-methoxyphenyl)-2-(4-oxo-3,4-
dihydrophthalazin-1-yl)acetamide (49k) 
 
T3P® (50 wt. % in EtOAc, 0.38 mL, 0.63 mmol) and DIPEA (0.18 mL, 1.1 mmol) were added to a solution of 
2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid 16 (50 mg, 0.21 mmol) and 5-((6,7-dimethoxy-3,4-
dihydroisoquinolin-2(1H)-yl)sulfonyl)-2-methoxyaniline 33k (80 mg, 0.21 mmol) in DMF (2 mL). The 
reaction mixture was heated to 70 °C over 1 hour. The reaction mixture was diluted with EtOAc (25 mL), 
washed with water (3 x 25 mL) and brine (25 mL), dried (MgSO4) and concentrated in vacuo. Purification 
by flash chromatography (50 – 100% EtOAc in PET, 0 – 7% methanol in DCM) followed by reverse phase 
flash chromatography (0 – 50% acetonitrile in water (+ 0.1% NH3)) afforded 49k (48 mg, 40% yield). 
LCMS (ESI+): m/z 565.4 [M + H]+, (ESI-): m/z 563.2 [M - H]-, rt 1.78 minutes, >99%; 1H NMR (500 MHz, 
(CD3)2SO) 12.62 (1H, s), 9.89 (1H, s), 8.50 (1H, d, J = 2.2 Hz), 8.28 (1H, d, J = 7.7 Hz), 7.99-7.92 (2H, m), 7.86 
(1H, ddd, J = 8.0, 6.0, 2.1 Hz), 7.54 (1H, dd, J = 8.6, 2.3 Hz), 7.28 (1H, d, J = 8.9 Hz), 6.71 (1H, s), 6.65 (1H, 
s), 4.22 (2H, s), 4.01 (2H, s), 3.97 (3H, s), 3.67 (3H, s), 3.65 (3H, s), 3.18 (2H, t, J = 5.9 Hz), 2.74 (2H, t, J = 
5.8 Hz); 13C NMR (125 MHz, (CD3)2SO) 168.4, 159.5, 152.5, 147.5, 147.3, 142.1, 133.5, 131.6, 129.8, 127.7, 
127.6, 127.0, 125.8, 125.6, 124.7, 124.4, 123.1, 119.8, 111.7, 111.3, 109.8, 56.4, 55.5, 55.4, 46.9, 43.7, 
27.7 (1 peak missing); νmax/cm-1 3299, 3010, 2938, 2837, 1695, 1641 (C=O), 1596, 1520; HRMS (ESI)+: m/z 
calculated for [C28H28N4O7S + Na]+ = 587.1571, observed 587.1543. 
N-(2-Methoxy-5-((1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-yl)sulfonyl)phenyl)-2-(4-oxo-3,4-
dihydrophthalazin-1-yl)acetamide (49l) 
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T3P® (50 wt. % in EtOAc, 0.38 mL, 0.63 mmol) and DIPEA (0.18 mL, 1.1 mmol) were added to a solution of 
2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid 16 (50 mg, 0.21 mmol) and 2-methoxy-5-((1,2,4,5-
tetrahydro-3H-benzo[d]azepin-3-yl)sulfonyl)aniline 33l (70 mg, 0.21 mmol) in DMF (2 mL). The reaction 
mixture was heated to 70 °C over 2 hours. The reaction mixture was diluted with EtOAc (25 mL), washed 
with water (3 x 25 mL) and brine (25 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash 
chromatography (50 – 80% EtOAc in PET, 0 – 5% methanol in DCM) followed by reverse phase flash 
chromatography (0 – 100% acetonitrile in water (+ 0.1% NH3)) afforded 49l (20 mg, 18% yield). 
LCMS (ESI+): m/z 519.3 [M + H]+, (ESI-): m/z 517.2 [M - H]-, rt 2.06 minutes, >99%; 1H NMR (500 MHz, 
(CD3)2SO) 12.61 (1H, s), 9.85 (1H, s), 8.42 (1H, d, J = 2.1 Hz), 8.27 (1H, d, J = 7.8 Hz), 7.97-7.90 (2H, m), 7.89-
7.83 (1H, m), 7.48 (1H, dd, J = 8.7, 2.3 Hz), 7.23 (1H, d, J = 8.8 Hz), 7.12-7.04 (4H, m), 4.19 (2H, s), 3.94 (3H, 
s), 3.18-3.04 (4H, m), 2.96-2.83 (4H, m); 13C NMR (125 MHz, (CD3)2SO) 168.4, 159.4, 152.3, 142.1, 140.4, 
133.5, 131.6, 129.8, 129.1, 128.7, 127.7, 127.6, 126.5, 125.9, 125.5, 123.9, 119.3, 111.3, 56.3, 48.1, 35.5 
(1 peak missing); νmax/cm-1 3302, 3173, 3011, 2906, 1687, 1650 (C=O), 1595, 1530; HRMS (ESI)-: m/z 
calculated for [C27H26N4O5S - H]- = 517.1551, observed 517.1549. 
N-(2-Methoxy-5-((7-methoxy-1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-yl)sulfonyl)phenyl)-2-(4-oxo-3,4-
dihydrophthalazin-1-yl)acetamide (49m) 
 
T3P® (50 wt. % in EtOAc, 0.50 mL, 0.84 mmol) and DIPEA (0.24 mL, 1.4 mmol) were added to a solution of 
2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid 16 (66 mg, 0.28 mmol) and 2-methoxy-5-((7-methoxy-
1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-yl)sulfonyl)aniline 33m (0.101 g, 0.279 mmol) in DMF (2 mL). The 
reaction mixture was heated to 70 °C over 1 hour. The reaction mixture was diluted with EtOAc (25 mL), 
washed with water (3 x 25 mL) and brine (25 mL), dried (MgSO4) and concentrated in vacuo. Purification 
by flash chromatography (50 – 100% EtOAc in PET, 0 – 7% methanol in DCM) afforded 49m (48 mg, 30% 
yield). 
LCMS (ESI+): m/z 549.4 [M + H]+, (ESI-): m/z 547.3 [M - H]-, rt 1.96 minutes, 96%; 1H NMR (500 MHz, 
(CD3)2SO) 12.61 (1H, s), 9.85 (1H, s), 8.41 (1H, d, J = 2.1 Hz), 8.27 (1H, d, J = 7.9 Hz), 7.97-7.90 (2H, m), 7.89-
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7.83 (1H, m), 7.47 (1H, dd, J = 8.7, 2.3 Hz), 7.22 (1H, d, J = 8.8 Hz), 6.98 (1H, d, J = 8.2 Hz), 6.67 (1H, d, J = 
2.6 Hz), 6.62 (1H, dd, J = 8.2, 2.8 Hz), 4.20 (2H, s), 3.94 (3H, s), 3.66 (3H, s), 3.15-3.02 (4H, m), 2.91-2.76 
(4H, m); 13C NMR (125 MHz, (CD3)2SO) 168.4, 159.5, 157.8, 152.3, 142.1, 141.7, 133.6, 132.4, 131.6, 130.2, 
129.8, 128.7, 127.7, 127.6, 125.9, 125.5, 123.9, 119.3, 115.0, 111.3, 111.2, 56.3, 55.0, 48.6, 48.1, 35.7, 
34.7 (1 peak missing); νmax/cm-1 3308, 2913, 1691, 1642 (C=O), 1595, 1529; HRMS (ESI)+: m/z calculated 
for [C28H28N4O6S + Na]+ = 571.1622, observed 571.1615. 
N-(2-Methoxy-5-((1,2,4,5-tetrahydro-3H-1,5-methanobenzo[d]azepin-3-yl)sulfonyl)phenyl)-2-(4-oxo-3,4-
dihydrophthalazin-1-yl)acetamide (49n) 
 
T3P® (50 wt. % in EtOAc, 0.26 mL, 0.43 mmol) and DIPEA (0.13 mL, 0.72 mmol) were added to a solution 
of 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid 16 (34 mg, 0.14 mmol) and 2-methoxy-5-((1,2,4,5-
tetrahydro-3H-1,5-methanobenzo[d]azepin-3-yl)sulfonyl)aniline 33n (55 mg, 0.14 mmol) in DMF (2 mL). 
The reaction mixture was heated to 70 °C over 45 minutes. The reaction mixture was diluted with EtOAc 
(25 mL), washed with water (3 x 25 mL) and brine (25 mL), dried (MgSO4) and concentrated in vacuo. 
Purification by flash chromatography (50 – 80% EtOAc in PET, 0 – 5% methanol in DCM) followed by 
reverse phase flash chromatography (0 – 50% acetonitrile in water (+ 0.1% NH3)) afforded 49n (26 mg, 
33% yield). 
LCMS (ESI+): m/z 531.3 [M + H]+, (ESI-): m/z 529.3 [M - H]-, rt 1.98 minutes, 96%; 1H NMR (500 MHz, 
(CD3)2SO) 12.64 (1H, s), 9.82 (1H, s), 8.28 (1H, d, J = 7.9 Hz), 8.22 (1H, d, J = 1.6 Hz), 8.01-7.92 (2H, m), 7.87 
(1H, ddd, J = 8.0, 6.3, 1.9 Hz), 7.22-7.06 (6H, m), 4.23 (2H, s), 3.97 (3H, s), 3.40 (2H, d, J = 10.6 Hz), 3.18-
3.12 (2H, m), 2.80 (2H, d, J = 10.8 Hz), 2.11-2.01 (1H, m), 1.51 (1H, d, J = 10.9 Hz); 13C NMR (125 MHz, 
(CD3)2SO) 168.2, 159.5, 152.1, 144.3, 142.1, 133.5, 131.6, 129.8, 128.1, 127.6, 127.5, 126.9, 125.9, 125.6, 
123.6, 122.4, 119.6, 111.0, 56.3, 49.2, 41.2 (2 peaks missing); νmax/cm-1 3177, 3020, 2937, 2908, 2851, 
1673, 1646 (C=O), 1597, 1540; HRMS (ESI)+: m/z calculated for [C28H26N4O5S + Na]+ = 553.1516, observed 
553.1517. 
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5-(3-Methoxyphenyl)-1H-pyrazol-3-amine (56) 
 
Hydrazine monohydrate (1.1 mL, 23 mmol) was added to a suspension of 3-(3-methoxyphenyl)-3-
oxopropanenitrile 58 (0.400 g, 2.28 mmol) in ethanol (10 mL). The reaction mixture was heated under 
reflux for 6 hours, then quenched with excess acetone at rt and concentrated in vacuo. Purification by 
flash chromatography (0 – 50% EtOAc in PET, 0 – 6% methanol in DCM) afforded 56 (0.314 g, 73% yield). 
LCMS (ESI+): m/z 190.2 [M + H]+, rt 1.21 minutes, >99%; 1H NMR (500 MHz, CDCl3) 7.28 (1H, t, J = 8.0 Hz), 
7.13 (1H, dt, J = 7.7, 1.2 Hz), 7.09 (1H, t, J = 2.0 Hz), 6.86 (1H, ddd, J = 8.2, 2.6, 0.8 Hz), 5.89 (1H, s), 3.80 
(3H, s); 13C NMR (125 MHz, CDCl3) 160.1, 154.5, 145.7, 131.8, 130.1, 118.0, 114.0, 111.2, 90.7, 55.4; 
νmax/cm-1 3200 (br, N-H), 2837, 1612, 1589, 1567, 1506; HRMS (ESI)+: m/z calculated for [C10H11N3O + H]+ 
= 190.0975, observed 190.0972. 
5-(1H-Indol-6-yl)-1H-pyrazol-3-amine (62) 
 
Hydrazine monohydrate (0.101 mL, 0.814 mmol) was added to a solution of 3-(1H-indol-6-yl)-3-
oxopropanenitrile 68 (50 mg, 0.27 mmol) in ethanol (5 mL). The reaction mixture was heated under reflux 
for 11 hours. Further hydrazine monohydrate (0.101 mL, 0.814 mmol) was added to the reaction mixture. 
The reaction mixture was heated under reflux for 1 hour, then concentrated in vacuo. Purification by flash 
chromatography (0 – 10% methanol in DCM) afforded 62 (32 mg, 59% yield). 
LCMS (ESI+): m/z 199.1 [M + H]+, (ESI-): m/z 197.0 [M - H]-, rt 1.98 minutes, 100%; 1H NMR (400 MHz, 
CD3OD) 7.65 (1H, s), 7.56 (1H, d, J = 8.3 Hz), 7.30 (1H, dd, J = 8.3, 1.5 Hz), 7.26 (1H, d, J = 3.1 Hz), 6.44 (1H, 
dd, J = 3.1, 0.7 Hz), 5.93 (1H, s); 13C NMR (125 MHz, CD3CN) 155.2, 147.7, 137.1, 128.8, 126.9, 125.5, 121.4, 
108.8, 102.5, 89.3 (1 peak missing); νmax/cm-1 3389 (N-H), 3250 (br, N-H), 1616, 1584, 1561, 1516; HRMS 
(ESI+): m/z calculated for [C11H10N4 + H]+ = 199.0978, observed 199.0973. 
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5-(1-(4-Methoxybenzyl)-1H-indol-6-yl)-1H-pyrazol-3-amine (66a) 
 
Hydrazine monohydrate (42 µL, 0.67 mmol) was added to a solution of 3-(1-(4-methoxybenzyl)-1H-indol-
6-yl)-3-oxopropanenitrile 65a (0.200 g, 0.611 mmol) in ethanol (5 mL). The reaction mixture was heated 
under reflux for 30 minutes, then further hydrazine monohydrate (0.114 mL, 1.83 mmol) was added at rt. 
The reaction mixture was heated under reflux for 4 hours, then quenched with excess acetone at rt and 
concentrated in vacuo. Purification by flash chromatography (0 – 10% methanol in DCM) afforded 66a 
(0.120 g, 62% yield). 
LCMS (ESI+): m/z 319.3 [M + H]+, rt 1.65 minutes, >99%; 1H NMR (500 MHz, CDCl3) 7.63 (1H, d, J = 8.3 Hz), 
7.46 (1H, s), 7.30-7.25 (1H, m), 7.12 (1H, d, J = 3.1 Hz), 7.06-7.02 (2H, m), 6.83-6.78 (2H, m), 6.52 (1H, d, J 
= 3.0 Hz), 5.88 (1H, s), 5.22 (2H, s), 3.74 (3H, s); 13C NMR (125 MHz, CDCl3) 159.3, 155.0, 146.7, 136.5, 
129.5, 129.3, 129.1, 128.3, 123.8, 121.6, 117.7, 114.3, 106.8, 101.9, 90.5, 55.4, 49.7; νmax/cm-1 3150 (br, 
N-H), 2927, 1610, 1585, 1510; HRMS (ESI+): m/z calculated for [C19H18N4O + H]+ = 319.1553, observed 
319.1557. 
5-(1-(3-Methoxybenzyl)-1H-indol-6-yl)-1H-pyrazol-3-amine (66b) 
 
Hydrazine monohydrate (0.104 mL, 2.14 mmol) was added to a solution of 3-(1-(3-methoxybenzyl)-1H-
indol-6-yl)-3-oxopropanenitrile 65b (65 mg, 0.21 mmol) in ethanol (4 mL). The reaction mixture was 
heated under reflux for 5 hours, then concentrated in vacuo. Purification by flash chromatography (0 – 
100% EtOAc in PET, 0 – 10% methanol in DCM) was carried out, followed by reverse phase 
chromatography (0 – 40% acetonitrile in water (+ 0.1% formic acid)) with addition of NaHCO3 solution (10 
mL) to the combined fractions and extraction into DCM (3 x 25 mL). The combined organic extracts were 
washed (brine), dried (MgSO4) and concentrated in vacuo to afford 66b (27 mg, 40% yield). 
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LCMS (ESI+): m/z 319.2 [M + H]+, rt 1.65 minutes, >99%; 1H NMR (500 MHz, CDCl3) 7.66 (1H, d, J = 8.3 Hz), 
7.42 (1H, s), 7.29-7.25 (1H, m), 7.21 (1H, t, J = 7.9 Hz), 7.17 (1H, d, J = 3.2 Hz), 6.80 (1H, dd, J = 8.2, 2.4 Hz), 
6.69 (1H, d, J = 7.6 Hz), 6.66-6.63 (1H, m), 6.56 (1H, dd, J = 3.2, 0.7 Hz), 5.89 (1H, s), 5.30 (2H, s), 3.72 (3H, 
s); 13C NMR (125 MHz, CDCl3) 160.2, 155.2, 146.6, 138.9, 136.6, 130.1, 129.8, 129.2, 123.8, 121.7, 119.1, 
117.7, 113.0, 112.8, 106.8, 102.1, 90.7, 55.3, 50.2; νmax/cm-1 3150 (br, N-H), 1585, 1505; HRMS (ESI+): m/z 
calculated for [C19H18N4O + H]+ = 319.1553, observed 319.1542. 
5-(1-Benzyl-1H-indol-6-yl)-1H-pyrazol-3-amine (66c) 
 
Hydrazine monohydrate (0.271 mL, 5.58 mmol) was added to a solution of 3-(1-benzyl-1H-indol-6-yl)-3-
oxopropanenitrile 65c (0.170 g, 0.558 mmol) in ethanol (10 mL). The reaction mixture was heated under 
reflux for 8 hours, then quenched with excess acetone at rt and concentrated in vacuo. Purification by 
flash chromatography (0 – 10% methanol in DCM) afforded 66c (50 mg, 31% yield). 
LCMS (ESI+): m/z 289.3 [M + H]+, rt 1.65 minutes, >99%; 1H NMR (400 MHz, CD3OD) 7.63 (1H, s), 7.58 (1H, 
d, J = 8.3 Hz), 7.34 (1H, dd, J = 8.4, 1.5 Hz), 7.31-7.20 (4H, m), 7.16 (2H, d, J = 7.2 Hz), 6.50 (1H, d, J = 3.1 
Hz), 5.90 (1H, s), 5.42 (2H, s); 13C NMR (125 MHz, CD3OD) 155.6, 148.7, 139.5, 137.9, 130.7, 130.4, 129.7, 
128.5, 127.9, 125.5, 122.0, 118.5, 107.7, 102.6, 90.2, 50.7; νmax/cm-1 2920, 2849, 1583, 1503; HRMS (ESI+): 
m/z calculated for [C18H16N4 + H]+ = 289.1448, observed 289.1446. 
2-((6-(3-Amino-1H-pyrazol-5-yl)-1H-indol-1-yl)methyl)benzonitrile (66d) 
 
n-Butyllithium (1.6 M in hexanes, 4.09 mL, 6.54 mmol) was added dropwise at -78 °C to a mixture of 
acetonitrile (0.68 mL, 13 mmol) and toluene (5 mL). The reaction mixture was stirred at -78 °C over 30 
minutes. A solution of methyl 1-(2-cyanobenzyl)-1H-indole-6-carboxylate 64d (0.380 g, 1.31 mmol) in 
toluene (5 mL) was added dropwise at -78 °C over 30 minutes. The reaction mixture was stirred at -78 °C 
over 1 hour, then aqueous HCl (1 M, 15 mL) was added dropwise at 0 °C. The product was extracted into 
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EtOAc (3 x 25 mL). The combined organic extracts were washed (brine), dried (MgSO4) and concentrated 
in vacuo. Purification by flash chromatography (0 – 80% EtOAc in PET) was attempted. Ethanol (20 mL) 
was added to the crude residue, followed by hydrazine monohydrate (0.50 mL, 10 mmol). The reaction 
mixture was heated under reflux for 5 hours, then quenched with excess acetone at rt and concentrated 
in vacuo. Purification by flash chromatography (0 – 10% methanol in DCM) afforded 66d (73 mg, 18% 
yield), with 14 mg subjected to further purification by flash chromatography (0 – 100% EtOAc in PET, 0 – 
5% methanol in DCM). 
LCMS (ESI+): m/z 314.3 [M + H]+, rt 1.58 minutes, 96%; 1H NMR (400 MHz, CD3OD) 7.77 (1H, dd, J = 7.6, 
1.1 Hz), 7.63 (1H, s), 7.61 (1H, d, J = 8.4 Hz), 7.49 (1H, td, J = 7.7, 1.2 Hz), 7.44-7.35 (2H, m), 7.34 (1H, d, J 
= 3.2 Hz), 6.90 (1H, d, J = 7.9 Hz), 6.56 (1H, d, J = 3.2 Hz), 5.92 (1H, s), 5.64 (2H, s); 13C NMR (125 MHz, 
CD3OD) 155.5, 148.5, 142.9, 137.9, 134.6, 134.2, 130.8, 130.4, 129.4, 128.8, 126.0, 122.2, 118.8, 118.3, 
112.0, 107.5, 103.3, 90.2 (1 peak missing); νmax/cm-1 3200 (br, N-H), 2225 (C≡N), 1585, 1505; HRMS (ESI+): 
m/z calculated for [C19H15N5 + H]+ = 314.1400, observed 314.1402. 
2-((6-(3-Amino-1H-pyrazol-5-yl)-1H-indol-1-yl)methyl)benzamide (66e) 
 
A suspension of 2-((6-(3-amino-1H-pyrazol-5-yl)-1H-indol-1-yl)methyl)benzonitrile 66d (50 mg, 0.16 
mmol) in aqueous NaOH (10 M, 4 mL) was heated under reflux for 7 hours. The reaction mixture was 
adjusted to pH 3 and extracted into DCM/methanol (10:1, 3 x 75 mL). The combined organic extracts were 
washed (brine), dried (MgSO4) and concentrated in vacuo. Purification by reverse phase flash 
chromatography (0 – 35% acetonitrile in water) afforded 66e (15 mg, 28% yield). 
LCMS (ESI+): m/z 332.3 [M + H]+, (ESI-): m/z 330.1 [M - H]-, rt 1.47 minutes, >99%; 1H NMR (500 MHz, 
CD3OD) 7.62-7.52 (3H, m), 7.37-7.24 (4H, m), 6.82-6.75 (1H, m), 6.51 (1H, d, J = 3.0 Hz), 5.90 (1H, s), 5.64 
(2H, s); 13C NMR (125 MHz, CD3OD) 174.6, 138.0, 137.7, 135.9, 131.6, 131.2, 130.3, 128.7, 128.5, 125.3 
(br), 122.0, 118.5, 107.7, 102.7, 90.5 (br), 48.3 (3 peaks missing); νmax/cm-1 3200 (br), 1635 (C=O), 1505; 
HRMS (ESI)+: m/z calculated for [C19H17N5O + H]+ = 332.1506, observed 332.1504. 
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5-(1-(Pyridin-2-ylmethyl)-1H-indol-6-yl)-1H-pyrazol-3-amine (66f) 
 
Hydrazine monohydrate (0.300 mL, 6.17 mmol) was added to a solution of 3-oxo-3-(1-(pyridin-2-
ylmethyl)-1H-indol-6-yl)propanenitrile 65f (0.170 g, 0.617 mmol) in ethanol (15 mL). The reaction mixture 
was heated under reflux for 13 hours, then concentrated in vacuo. Purification by flash chromatography 
(0 – 20% methanol in DCM) afforded 66f (73 mg, 41% yield). 
LCMS (ESI+): m/z 290.3 [M + H]+, rt 1.43 minutes, 100%; 1H NMR (400 MHz, CD3OD) 8.56-8.50 (1H, m), 
7.68 (1H, td, J = 7.7, 1.8 Hz), 7.63-7.58 (2H, m), 7.38-7.33 (2H, m), 7.28 (1H, dd, J = 7.6, 5.0 Hz), 6.89 (1H, 
d, J = 7.9 Hz), 6.55 (1H, d, J = 3.1 Hz), 5.90 (1H, s), 5.52 (2H, s); 13C NMR (125 MHz, CD3OD) 158.8, 155.7 
(br), 150.0, 148.4 (br), 139.2, 137.9, 130.9, 130.4, 125.8, 124.1, 122.7, 122.2, 118.7, 107.5, 103.1, 90.2, 
52.2; νmax/cm-1 3150 (br, N-H), 2916, 1597, 1585, 1504; HRMS (ESI+): m/z calculated for [C17H15N5 + H]+ = 
290.1400, observed 290.1405. 
3-Amino-5-(1H-indol-6-yl)-1H-pyrazole-4-carbonitrile (70) 
 
Hydrazine monohydrate (0.163 mL, 3.36 mmol) was added to a suspension of 3-amino-4,4,4-trichloro-2-
(1H-indole-6-carbonyl)but-2-enenitrile 69 (0.690 g, 2.10 mmol) in ethanol (10 mL). The reaction mixture 
was heated under reflux for 22 hours, then quenched with excess acetone at rt and concentrated in vacuo. 
Purification by flash chromatography (0 – 100% EtOAc in PET) afforded 70 (0.113 g, 24% yield). 
LCMS (ESI+): m/z 224.2 [M + H]+, (ESI-): m/z 222.1 [M - H]-, rt 1.50 minutes, >99%; 1H NMR (400 MHz, 
CD3OD) 7.89 (1H, s), 7.63 (1H, d, J = 8.0 Hz), 7.45 (1H, d, J = 7.0 Hz), 7.33 (1H, d, J = 2.1 Hz), 6.50 (1H, d, J = 
2.7 Hz); 13C NMR (125 MHz, CD3OD) 137.5, 130.6, 127.8, 121.7, 118.5, 116.9, 110.6, 102.6 (4 peaks 
missing); νmax/cm-1 3411 (N-H), 3200 (br, N-H), 2221 (C≡N), 1634, 1584, 1527; HRMS (ESI+): m/z calculated 
for [C12H9N5 + H]+ = 224.0931, observed 224.0935. 
 
141 
 
3-Amino-5-(1-benzyl-1H-indol-6-yl)-1H-pyrazole-4-carbonitrile (71c) 
 
Trichloroacetonitrile (0.168 mL, 1.67 mmol) was added to a suspension of 3-(1-benzyl-1H-indol-6-yl)-3-
oxopropanenitrile 65c (0.170 g, 0.558 mmol) and sodium acetate (0.229 g, 2.79 mmol) in ethanol (5 mL). 
The reaction mixture was stirred over 9 hours, then concentrated in vacuo, diluted with water (20 mL) 
and extracted into DCM (3 x 25 mL). The combined organic extracts were washed (brine), dried (MgSO4) 
and concentrated in vacuo. The crude residue was dissolved in ethanol (10 mL) and hydrazine 
monohydrate (0.271 mL, 5.58 mmol) was added. The reaction mixture was heated under reflux for 5 
hours, then quenched with excess acetone at rt and concentrated in vacuo. Purification by flash 
chromatography (0 – 100% EtOAc in PET) afforded 71c (78 mg, 45% yield). 
LCMS (ESI+): m/z 314.2 [M + H]+, (ESI-): m/z 312.1 [M - H]-, rt 1.84 minutes, 100%; 1H NMR (500 MHz, 
CDCl3) 7.72 (1H, s), 7.67 (1H, d, J = 8.3 Hz), 7.41 (1H, dd, J = 8.2, 1.5 Hz), 7.29-7.19 (4H, m), 7.13-7.08 (2H, 
m), 6.57 (1H, dd, J = 3.1, 0.8 Hz), 5.26 (2H, s), 4.12 (2H, br s); 13C NMR (125 MHz, CDCl3) 157.0, 150.1, 136.9, 
136.2, 130.8, 130.4, 129.0, 128.0, 127.1, 122.0, 120.8, 117.6, 115.3, 108.2, 102.3, 76.1, 50.4; νmax/cm-1 
3200 (br, N-H), 2211 (C≡N), 1621, 1582, 1524, 1501; HRMS (ESI+): m/z calculated for [C19H15N5 + H]+ = 
314.1400, observed 314.1404. 
3-Amino-5-(1-(pyridin-2-ylmethyl)-1H-indol-6-yl)-1H-pyrazole-4-carbonitrile (71f) 
 
Trichloroacetonitrile (0.186 mL, 1.85 mmol) was added to a suspension of 3-oxo-3-(1-(pyridin-2-ylmethyl)-
1H-indol-6-yl) propanenitrile 65f (0.170 g, 0.617 mmol) and sodium acetate (0.253 g, 3.09 mmol) in 
ethanol (5 mL). The reaction mixture was stirred over 90 minutes. The reaction mixture was concentrated 
in vacuo, then water (20 mL) was added. The intermediate was extracted into DCM (3 x 25 mL). The 
combined organic extracts were washed (brine), dried (MgSO4) and concentrated in vacuo. The crude 
residue was dissolved in ethanol (10 mL) and hydrazine monohydrate (0.300 mL, 6.17 mmol) was added. 
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The reaction mixture was heated under reflux for 15 hours, then concentrated in vacuo. Purification by 
flash chromatography (0 - 100% EtOAc in PET, 0 – 10% methanol in DCM) afforded 71f (0.121 g, 62% yield). 
LCMS (ESI+): m/z 315.2 [M + H]+, (ESI-): m/z 313.1 [M - H]-, rt 1.53 minutes, 100%; 1H NMR (400 MHz, 
CDCl3) 8.46 (1H, d, J = 5.0 Hz), 7.70 (1H, s), 7.67 (1H, d, J = 8.3 Hz), 7.62-7.53 (2H, m), 7.31 (1H, d, J = 3.1 
Hz), 7.14 (1H, dd, J = 7.6, 4.9 Hz), 6.91 (1H, d, J = 7.8 Hz), 6.58 (1H, d, J = 3.2 Hz), 5.38 (2H, s); 13C NMR (125 
MHz, CDCl3) 157.8, 156.7, 149.2, 149.1, 137.8, 136.1, 130.9, 130.4, 123.3, 122.1, 121.8, 121.0, 118.1, 
115.6, 107.6, 102.7, 76.2, 52.3; νmax/cm-1 3200 (br, N-H), 2211 (C≡N), 1621, 1592, 1503; HRMS (ESI+): m/z 
calculated for [C18H14N6 + H]+ = 315.1353, observed 315.1338. 
3-Amino-5-(1-(pyridin-3-ylmethyl)-1H-indol-6-yl)-1H-pyrazole-4-carbonitrile (71g) 
 
Trichloroacetonitrile (0.647 mL, 6.45 mmol) was added to a suspension of 3-oxo-3-(1-(pyridin-3-ylmethyl)-
1H-indol-6-yl)propanenitrile 65g (0.592 g, 2.15 mmol) and sodium acetate (0.882 g, 10.8 mmol) in ethanol 
(20 mL). The reaction mixture was stirred over 13 hours, then concentrated in vacuo, diluted with water 
(20 mL) and extracted into DCM (3 x 25 mL). The combined organic extracts were washed (brine), dried 
(MgSO4) and concentrated in vacuo. The crude residue was dissolved in ethanol (20 mL) and hydrazine 
monohydrate (1.1 mL, 22 mmol) was added. The reaction mixture was heated under reflux for 21 hours, 
then quenched with excess acetone at rt and concentrated in vacuo. Purification by flash chromatography 
(0 – 100% EtOAc in DCM, 5% methanol in DCM) afforded 71g (0.367 g, 54% yield). 
LCMS (ESI+): m/z 315.2 [M + H]+, (ESI-): m/z 313.1 [M - H]-, rt 1.38 minutes, >99%; 1H NMR (400 MHz, 
(CD3)2SO) 12.09 (1H, br s), 8.56 (1H, s), 8.46 (1H, dd, J = 4.7, 1.3 Hz), 7.90 (1H, s), 7.74-7.56 (3H, m), 7.50 
(1H, d, J = 8.2 Hz), 7.32 (1H, dd, J = 7.7, 4.8 Hz), 6.55 (1H, d, J = 2.8 Hz), 6.26 (2H, br s), 5.49 (2H, s); 13C 
NMR (100 MHz, (CD3)2SO) 148.8, 148.5, 135.4, 135.0, 133.5, 130.6, 128.9, 123.7, 120.9, 117.5, 116.5, 
107.4, 101.6, 46.8 (4 peaks missing); νmax/cm-1 3345 (N-H), 3100 (br, N-H), 2215 (C≡N), 1662, 1600, 1502; 
HRMS (ESI-): m/z calculated for [C18H14N6 - H]- = 313.1207, observed 313.1195. 
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3-Amino-5-(1-(pyridin-4-ylmethyl)-1H-indol-6-yl)-1H-pyrazole-4-carbonitrile (71h) 
 
Trichloroacetonitrile (0.309 mL, 3.08 mmol) was added to a suspension of 3-oxo-3-(1-(pyridin-4-ylmethyl)-
1H-indol-6-yl)propanenitrile 65h (0.283 g, 1.03 mmol) and sodium acetate (0.422 g, 5.14 mmol) in ethanol 
(20 mL). The reaction mixture was stirred over 13 hours, then concentrated in vacuo, diluted with water 
(20 mL) and extracted into DCM (4 x 25 mL). The combined organic extracts were washed (brine), dried 
(MgSO4) and concentrated in vacuo. The crude residue was dissolved in ethanol (20 mL) and hydrazine 
monohydrate (0.500 mL, 10.3 mmol) was added. The reaction mixture was heated under reflux for 21 
hours, then quenched with excess acetone at rt and concentrated in vacuo. Purification by flash 
chromatography (0 – 100% EtOAc in DCM, 8% methanol in DCM) afforded 71h (0.183 g, 57% yield). 
LCMS (ESI+): m/z 315.2 [M + H]+, (ESI-): m/z 313.1 [M - H]-, rt 1.35 minutes, >99%; 1H NMR (500 MHz, 
CD3OD) 8.40-8.36 (2H, m), 7.73 (1H, s), 7.66 (1H, d, J = 8.3 Hz), 7.53 (1H, dd, J = 8.2, 1.1 Hz), 7.37 (1H, d, J 
= 3.2 Hz), 7.12-7.08 (2H, m), 6.58 (1H, dd, J = 3.2, 0.8 Hz), 5.43 (2H, s); 13C NMR (125 MHz, CD3OD) 157.8, 
152.5, 150.3, 149.7, 137.4, 131.7, 131.3, 124.6, 123.3, 122.4, 119.2, 116.9, 108.8, 103.3, 73.9, 49.7; 
νmax/cm-1 2204 (C≡N), 1605, 1554, 1500; HRMS (ESI+): m/z calculated for [C18H14N6 + H]+ = 315.1353, 
observed 315.1350. 
3-Amino-5-(1-((2-methoxypyridin-3-yl)methyl)-1H-indol-6-yl)-1H-pyrazole-4-carbonitrile (71i) 
 
Trichloroacetonitrile (0.122 mL, 1.22 mmol) was added to a suspension of 3-(1-((2-methoxypyridin-3-
yl)methyl)-1H-indol-6-yl)-3-oxopropanenitrile 65i (0.124 g, 0.406 mmol) and sodium acetate (0.167 g, 2.03 
mmol) in ethanol (5 mL). The reaction mixture was stirred over 15 hours, then concentrated in vacuo, 
diluted with NaHCO3 solution (25 mL) and extracted into DCM (3 x 25 mL). The combined organic extracts 
were washed (brine), dried (MgSO4) and concentrated in vacuo. The crude residue was dissolved in 
ethanol (10 mL) and hydrazine monohydrate (0.198 mL, 4.06 mmol) was added. The reaction mixture was 
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heated under reflux for 18 hours, then quenched with excess acetone at rt and concentrated in vacuo. 
Purification by flash chromatography (0 – 70% EtOAc in PET) afforded 71i (85 mg, 61% yield). 
LCMS (ESI+): m/z 345.2 [M + H]+, (ESI-): m/z 343.1 [M - H]-, rt 1.83 minutes, 97%; 1H NMR (400 MHz, 
(CD3)2SO) 12.00 (1H, br s), 8.07 (1H, dd, J = 5.0, 1.6 Hz), 7.93-7.79 (1H, m), 7.76-7.42 (3H, m), 7.15 (1H, dd, 
J = 7.3, 1.8 Hz), 6.88 (1H, dd, J = 7.2, 5.0 Hz), 6.62-6.48 (1H, m), 6.39 (1H, br s), 5.37 (2H, s), 3.95 (3H, s); 
13C NMR (100 MHz, (CD3)2SO) 160.7, 154.6, 151.2, 145.9, 136.8, 135.6, 130.8, 128.5, 125.6, 120.6, 120.1, 
117.5, 117.2, 116.7, 107.3, 101.2, 69.6, 53.4, 44.2; νmax/cm-1 3200 (br, N-H), 2918, 2210 (C≡N), 1622, 1599, 
1584, 1526, 1500; HRMS (ESI+): m/z calculated for [C19H16N6O + Na]+ = 367.1278, observed 367.1277. 
3-Amino-5-(1-((2-hydroxypyridin-3-yl)methyl)-1H-indol-6-yl)-1H-pyrazole-4-carbonitrile (71j) 
 
LiCl (12 mg, 0.29 mmol) and p-toluenesulfonic acid monohydrate (55 mg, 0.29 mmol) were added to a 
solution of 3-amino-5-(1-((2-methoxypyridin-3-yl)methyl)-1H-indol-6-yl)-1H-pyrazole-4-carbonitrile 71i 
(20 mg, 0.058 mmol) in DMF (1 mL). The reaction mixture was heated to 120 °C over 25 minutes, then 
diluted with EtOAc (100 mL), washed with water (3 x 100 mL) and brine (100 mL), dried (MgSO4) and 
concentrated in vacuo. Purification by flash chromatography (50 – 100% EtOAc in PET, 0 – 10% methanol 
in DCM) afforded 71j (10 mg, 51% yield). 
LCMS (ESI+): m/z 331.2 [M + H]+, (ESI-): m/z 329.1 [M - H]-, rt 1.55 minutes, 97%; 1H NMR (500 MHz, 
CD3OD) 7.82 (1H, s), 7.66 (1H, d, J = 8.1 Hz), 7.51 (1H, d, J = 7.5 Hz), 7.45 (1H, s), 7.32 (1H, dd, J = 6.5, 2.0 
Hz), 7.08 (1H, d, J = 4.8 Hz), 6.55 (1H, d, J = 2.8 Hz), 6.25 (1H, t, J = 6.7 Hz), 5.28 (2H, s); 13C NMR (125 MHz, 
CD3OD) 164.1, 140.1, 137.4, 135.0, 132.1, 131.4, 129.6, 122.3, 119.0, 116.9, 109.0, 108.0, 102.7, 46.2 (4 
peaks missing); νmax/cm-1 3150 (br, N-H/O-H), 2925, 2207 (C≡N), 1647, 1611, 1564, 1529, 1501; HRMS 
(ESI+): m/z calculated for [C18H14N6O + Na]+ = 353.1121, observed 353.1105. 
3-Amino-5-(1-((6-methoxypyridin-3-yl)methyl)-1H-indol-6-yl)-1H-pyrazole-4-carbonitrile (71k) 
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Trichloroacetonitrile (0.114 mL, 1.14 mmol) was added to a suspension of 3-(1-((6-methoxypyridin-3-
yl)methyl)-1H-indol-6-yl)-3-oxopropanenitrile 65k (0.121 g, 0.380 mmol) and sodium acetate (0.156 g, 
1.90 mmol) in ethanol (5 mL). The reaction mixture was stirred over 18 hours, then concentrated in vacuo, 
diluted with NaHCO3 solution (20 mL) and extracted into DCM (3 x 25 mL). The combined organic extracts 
were washed (brine), dried (MgSO4) and concentrated in vacuo. The crude residue was dissolved in 
ethanol (10 mL) and hydrazine monohydrate (0.185 mL, 3.80 mmol) was added. The reaction mixture was 
heated under reflux for 7 hours, then quenched with excess acetone at rt and concentrated in vacuo. 
Purification by flash chromatography (0 – 100% EtOAc in PET) afforded 71k (62 mg, 47% yield). 
LCMS (ESI+): m/z 345.2 [M + H]+, (ESI-): m/z 343.1 [M - H]-, rt 1.75 minutes, >99%; 1H NMR (500 MHz, 
CD3OD) 8.07 (1H, d, J = 2.5 Hz), 7.91-7.87 (1H, m), 7.64 (1H, dd, J = 8.3, 0.5 Hz), 7.55 (1H, dd, J = 8.8, 2.5 
Hz), 7.51 (1H, dd, J = 8.2, 1.5 Hz), 7.40 (1H, d, J = 3.2 Hz), 6.72 (1H, dd, J = 8.6, 0.5 Hz), 6.55 (1H, dd, J = 3.1, 
0.8 Hz), 5.36 (2H, s), 3.85 (3H, s); 13C NMR (125 MHz, CD3OD) 165.3, 157.9, 152.6, 146.4, 139.8, 137.3, 
131.4, 131.2, 127.9, 124.3, 122.3, 118.9, 117.0, 111.9, 108.9, 103.0, 74.0, 54.2, 47.9; νmax/cm-1 2942, 2211 
(C≡N), 1676, 1608, 1573; HRMS (ESI)+: m/z calculated for [C19H16N6O + Na]+ = 367.1278, observed 
367.1278. 
3-Amino-5-(1-((6-hydroxypyridin-3-yl)methyl)-1H-indol-6-yl)-1H-pyrazole-4-carbonitrile (71l) 
 
LiCl (26 mg, 0.61 mmol) and p-toluenesulfonic acid monohydrate (0.116 g, 0.610 mmol) were added to a 
solution of 3-amino-5-(1-((6-methoxypyridin-3-yl)methyl)-1H-indol-6-yl)-1H-pyrazole-4-carbonitrile 71k 
(42 mg, 0.12 mmol) in DMF (1 mL). The reaction mixture was heated to 120 °C over 25 minutes, then 
diluted with EtOAc (100 mL), washed with water (3 x 100 mL) and brine (100 mL), dried (MgSO4) and 
concentrated in vacuo. Purification by flash chromatography (50 – 100% EtOAc in PET, 0 – 12% methanol 
in DCM) afforded 71l (19 mg, 47% yield). 
LCMS (ESI+): m/z 331.2 [M + H]+, (ESI-): m/z 329.1 [M - H]-, rt 1.47 minutes, >99%; 1H NMR (500 MHz, 
(CD3)2SO) 12.01 (1H, br s), 11.54 (1H, br s), 7.94 (1H, s), 7.73-7.29 (5H, m), 6.51 (1H, d, J = 2.4 Hz), 6.39 
(1H, br s), 6.26 (1H, d, J = 9.3 Hz), 5.15 (2H, s); 13C NMR (125 MHz, (CD3)2SO) 161.9, 141.0, 135.3, 133.9, 
130.3, 128.8, 125.6, 120.8, 120.3, 117.4, 116.6, 114.6, 107.5, 101.4, 45.7 (3 peaks missing); νmax/cm-1 3436, 
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3340, 3231, 2941, 2211 (C≡N), 1661, 1614, 1533; HRMS (ESI)+: m/z calculated for [C18H14N6O + H]+ = 
331.1302, observed 331.1289. 
3-Amino-5-(1-(quinolin-4-ylmethyl)-1H-indol-6-yl)-1H-pyrazole-4-carbonitrile (71m) 
 
Trichloroacetonitrile (92 µL, 0.91 mmol) was added to a suspension of 3-oxo-3-(1-(quinolin-4-ylmethyl)-
1H-indol-6-yl)propanenitrile 65m (99 mg, 0.30 mmol) and sodium acetate (0.125 g, 1.52 mmol) in ethanol 
(10 mL). The reaction mixture was stirred over 36 hours, then diluted with water (50 mL) and extracted 
into DCM (3 x 50 mL). The combined organic extracts were washed (brine), dried (MgSO4) and 
concentrated in vacuo. The crude residue was dissolved in ethanol (10 mL) and hydrazine monohydrate 
(0.148 mL, 3.04 mmol) was added. The reaction mixture was heated under reflux for 6 hours, then 
concentrated in vacuo. Purification by flash chromatography (50 – 100% EtOAc in PET) afforded 71m (45 
mg, 41% yield). 
LCMS (ESI+): m/z 365.3 [M + H]+, (ESI-): m/z 363.2 [M - H]-, rt 1.55 minutes, >99%; 1H NMR (400 MHz, 
CD3OD) 8.61 (1H, d, J = 4.6 Hz), 8.23 (1H, d, J = 8.3 Hz), 8.07 (1H, d, J = 8.6 Hz), 7.81 (1H, t, J = 7.9 Hz), 7.76-
7.65 (3H, m), 7.57 (1H, d, J = 7.9 Hz), 7.41 (1H, s), 6.65 (1H, d, J = 2.9 Hz), 6.62 (1H, d, J = 4.6 Hz), 5.99 (2H, 
s); 13C NMR (125 MHz, CD3OD) 151.2, 148.5, 146.2, 137.8, 131.6, 131.2, 129.9, 128.6, 127.3, 124.3, 122.4, 
119.6, 119.5, 117.0, 108.8, 103.6, 47.7 (5 peaks missing); νmax/cm-1 3150 (br, N-H), 2210 (C≡N), 1621, 1595, 
1504; HRMS (ESI+): m/z calculated for [C22H16N6 + Na]+ = 387.1329, observed 387.1328. 
3-Amino-5-(1-((1-methylpiperidin-2-yl)methyl)-1H-indol-6-yl)-1H-pyrazole-4-carbonitrile (71n) 
 
Trichloroacetonitrile (42 µL, 0.42 mmol) was added to a suspension of 3-(1-((1-methylpiperidin-2-
yl)methyl)-1H-indol-6-yl)-3-oxopropanenitrile 65n (43 mg, 0.14 mmol) and sodium acetate (58 mg, 0.71 
mmol) in ethanol (5 mL). The reaction mixture was stirred over 18 hours, then diluted with NaHCO3 
solution (12.5 mL) and water (12.5 mL) and extracted into DCM (3 x 25 mL). The combined organic extracts 
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were washed (brine), dried (MgSO4) and concentrated in vacuo. The crude residue was dissolved in 
ethanol (5 mL) and hydrazine monohydrate (69 µL, 1.4 mmol) was added. The reaction mixture was 
heated under reflux for 24 hours, then concentrated in vacuo. Purification by flash chromatography (50 – 
100% EtOAc in PET, 0 – 16% methanol in DCM) afforded 71n (27 mg, 57% yield). 
LCMS (ESI+): m/z 335.3 [M + H]+, (ESI-): m/z 333.2 [M - H]-, rt 1.22 minutes, >99%; 1H NMR (500 MHz, 
CD3OD) 7.90 (1H, s), 7.64 (1H, d, J = 8.4 Hz), 7.50 (1H, dd, J = 8.4, 0.9 Hz), 7.31 (1H, d, J = 3.2 Hz), 6.52 (1H, 
dd, J = 3.2, 0.6 Hz), 4.74 (1H, dd, J = 14.3, 4.7 Hz), 4.07 (1H, dd, J = 14.4, 9.5 Hz), 3.11-3.03 (1H, m), 2.97-
2.87 (1H, m), 2.66 (3H, s), 2.51 (1H, td, J = 11.3, 3.4 Hz), 1.74-1.58 (3H, m), 1.41-1.18 (3H, m); 13C NMR 
(125 MHz, CD3OD) 157.9 (br), 152.8 (br), 137.5, 131.8, 131.3, 124.4 (br), 122.4, 119.0, 117.2, 109.1, 102.9, 
74.3 (br), 64.2, 57.7, 42.8, 29.5, 25.5, 23.7 (1 peak missing); νmax/cm-1 3150 (br, N-H), 2927, 2210 (C≡N), 
1623, 1589, 1525, 1503; HRMS (ESI+): m/z calculated for [C19H22N6 + H]+ = 335.1979, observed 335.1971. 
3-Amino-5-(1-((1-methylpiperidin-3-yl)methyl)-1H-indol-6-yl)-1H-pyrazole-4-carbonitrile (71o) 
 
Trichloroacetonitrile (0.143 mL, 1.42 mmol) was added to a suspension of 3-(1-((1-methylpiperidin-3-
yl)methyl)-1H-indol-6-yl)-3-oxopropanenitrile 65o (0.140 g, 0.474 mmol) and sodium acetate (0.194 g, 
2.37 mmol) in ethanol (3 mL). The reaction mixture was stirred over 3 hours 30 minutes, then diluted with 
NaHCO3 solution (10 mL) and extracted into DCM (3 x 25 mL). The combined organic extracts were washed 
(brine), dried (MgSO4) and concentrated in vacuo. The crude residue was dissolved in ethanol (5 mL) and 
hydrazine monohydrate (0.231 mL, 4.74 mmol) was added. The reaction mixture was heated under reflux 
for 15 hours, then concentrated in vacuo. Purification by flash chromatography (50 – 100% EtOAc in PET, 
0 – 20% methanol in DCM) was carried out, followed by reverse phase chromatography (0 – 8% 
acetonitrile in water (+ 0.1% formic acid)) with addition of NaHCO3 solution (40 mL) to the combined 
fractions and extraction into DCM/methanol (9:1, 4 x 50 mL). The combined organic extracts were washed 
(brine), dried (MgSO4) and concentrated in vacuo to afford 71o (61 mg, 38% yield). 
LCMS (ESI+): m/z 335.3 [M + H]+, (ESI-): m/z 333.2 [M - H]-, rt 1.23 minutes, >99%; 1H NMR (500 MHz, 
CDCl3) 7.78 (1H, s), 7.63 (1H, d, J = 8.3 Hz), 7.41 (1H, dd, J = 8.2, 1.4 Hz), 7.11 (1H, d, J = 3.2 Hz), 6.49 (1H, 
dd, J = 3.0, 0.6 Hz), 4.44 (2H, br s), 4.05-3.91 (2H, m), 2.68 (1H, d, J = 9.6 Hz), 2.61 (1H, d, J = 10.4 Hz), 2.32-
2.21 (1H, m), 2.17 (3H, s), 2.05-1.88 (1H, m), 1.77 (1H, t J = 10.2 Hz), 1.69-1.45 (3H, m), 1.06-0.92 (1H, m); 
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13C NMR (125 MHz, CDCl3) 157.1, 150.2, 136.2, 130.8, 130.1, 121.8, 121.1, 117.6, 115.7, 108.2, 101.7, 76.0, 
59.4, 56.1, 50.4, 46.4, 37.0, 28.0, 24.5; νmax/cm-1 3200 (br, N-H), 2932, 2788, 2209 (C≡N), 1622, 1590, 1524, 
1501; HRMS (ESI+): m/z calculated for [C19H22N6 + H]+ = 335.1979, observed 335.1983. 
3-Amino-5-(3-chloro-1-(pyridin-3-ylmethyl)-1H-indol-6-yl)-1H-pyrazole-4-carbonitrile (72g) 
 
N-Chlorosuccinimide (21 mg, 0.16 mmol) was added to a solution of 3-amino-5-(1-(pyridin-3-ylmethyl)-
1H-indol-6-yl)-1H-pyrazole-4-carbonitrile 71g (50 mg, 0.16 mmol) in DMF (1 mL). The reaction mixture 
was stirred over 6 hours, then further N-chlorosuccinimide (7 mg, 0.05 mmol) was added. The reaction 
mixture was stirred over 90 minutes, then diluted with EtOAc (100 mL), washed with NaHCO3 solution (2 
x 100 mL) and brine (100 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash 
chromatography (0 – 100% EtOAc in PET, 0 – 7% methanol in DCM), followed by reverse phase flash 
chromatography (0 – 50% acetonitrile in water), afforded 72g (35 mg, 63% yield). 
LCMS (ESI+): m/z 349.2 [M + H]+, (ESI-): m/z 347.1 [M - H]-, rt 1.57 minutes, >99%; 1H NMR (500 MHz, 
(CD3)2SO) 8.60 (1H, d, J = 1.8 Hz), 8.47 (1H, dd, J = 4.8, 1.6 Hz), 7.97 (1H, s), 7.88 (1H, s), 7.67 (1H, dt, J = 
7.9, 1.9 Hz), 7.61 (1H, dd, J = 8.4, 1.3 Hz), 7.58 (1H, d, J = 8.4 Hz), 7.33 (1H, ddd, J = 7.9, 4.7, 0.8 Hz), 6.22 
(2H, br s), 5.48 (2H, s); 13C NMR (125 MHz, (CD3)2SO) 155.7, 149.6, 149.0, 148.6, 135.1, 134.6, 133.0, 127.2, 
126.0, 125.4, 123.8, 118.4, 118.0, 116.5, 108.0, 103.5, 70.8, 47.0; νmax/cm-1 3344 (N-H), 2218 (C≡N), 1623, 
1586, 1525; HRMS (ESI)-: m/z calculated for [C18H13ClN6 - H]- = 347.0817, observed 347.0804. 
3-Amino-5-(1-((5-(pyrrolidin-1-ylmethyl)pyridin-2-yl)methyl)-1H-indol-6-yl)-1H-pyrazole-4-carbonitrile 
(87) 
 
Trichloroacetonitrile (45 µL, 0.45 mmol) was added to a suspension of 3-oxo-3-(1-((5-(pyrrolidin-1-
ylmethyl)pyridin-2-yl)methyl)-1H-indol-6-yl)propanenitrile 96 (66 mg, 0.15 mmol) and sodium acetate (61 
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mg, 0.75 mmol) in ethanol (4 mL). The reaction mixture was stirred over 36 hours, then Na2CO3 solution 
(12.5 mL) and water (12.5 mL) were added. The intermediate was extracted into DCM (2 x 25 mL) and 
methanol/DCM (9:1, 4 x 25 mL). The combined organic extracts were washed (brine), dried (MgSO4) and 
concentrated in vacuo. The crude residue was dissolved in ethanol (5 mL) and hydrazine monohydrate 
(73 µL, 1.5 mmol) was added. The reaction mixture was heated under reflux for 24 hours, then quenched 
with excess acetone at rt and concentrated in vacuo. Purification by flash chromatography (0 – 20% 
methanol (+ 0.1% NH3) in DCM) afforded 87 (3.6 mg, 6% yield). 
LCMS (ESI+): m/z 398.3 [M + H]+, (ESI-): m/z 396.2 [M - H]-, rt 1.32 minutes, 100%; 1H NMR (500 MHz, 
CD3OD) 8.41 (1H, d, J = 1.9 Hz), 7.83 (1H, s), 7.66 (1H, d, J = 8.4 Hz), 7.64 (1H, dd, J = 8.1, 2.3 Hz), 7.51 (1H, 
d, J = 7.9 Hz), 7.47 (1H, d, J = 3.2 Hz), 7.42 (1H, d, J = 8.2 Hz), 6.58 (1H, d, J = 3.1 Hz), 5.49 (2H, s), 3.79 (2H, 
s), 2.67-2.59 (4H, m), 1.83-1.76 (4H, m); 13C NMR (125 MHz, CD3OD) 158.3, 148.5, 137.5, 137.2, 134.2, 
131.5, 125.0, 122.4, 119.0, 117.0, 109.0, 103.2, 61.9, 55.1, 48.2, 24.2 (5 peaks missing); νmax/cm-1 3150 (br, 
N-H), 2918, 2209 (C≡N), 1602, 1501; HRMS (ESI)+: m/z calculated for [C23H23N7 + H]+ = 398.2088, observed 
398.2082. 
5-(1-(4-(Pyrrolidin-1-ylmethyl)benzyl)-1H-indol-6-yl)-1H-pyrazol-3-amine (88a) 
 
Hydrazine monohydrate (0.157 mL, 3.22 mmol) was added to a solution of 3-oxo-3-(1-(4-(pyrrolidin-1-
ylmethyl)benzyl)-1H-indol-6-yl)propanenitrile 102a (0.115 g, 0.322 mmol) in ethanol (15 mL). The reaction 
mixture was heated under reflux for 12 hours, then concentrated in vacuo. Purification by reverse phase 
flash chromatography (0 – 100% acetonitrile in water, 0 – 65% methanol in acetonitrile) afforded 88a (27 
mg, 22% yield). 
LCMS (ESI+): m/z 372.5 [M + H]+, rt 1.22 minutes, 96%; 1H NMR (500 MHz, CDCl3) 7.63 (1H, d, J = 8.2 Hz), 
7.43 (1H, s), 7.30-7.25 (1H, m), 7.24 (2H, d, J = 8.2 Hz), 7.13 (1H, d, J = 3.1 Hz), 7.03 (2H, d, J = 8.1 Hz), 6.53 
(1H, dd, J = 3.1, 0.5 Hz), 5.87 (1H, s), 5.26 (2H, s), 3.68 (2H, br s), 3.55 (2H, s), 2.53-2.38 (4H, m), 1.81-1.67 
(4H, m); 13C NMR (125 MHz, CDCl3) 155.0 (br), 146.7 (br), 139.1, 136.6, 135.9, 129.6, 129.5, 129.0, 126.9, 
124.0, 121.5, 117.7, 106.8, 102.0, 90.5, 60.4, 54.3, 50.0, 23.5; νmax/cm-1 3150 (br, N-H), 2963, 2789, 1587, 
1505; HRMS (ESI+): m/z calculated for [C23H25N5 + H]+ = 372.2183, observed 372.2173. 
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3-Amino-5-(1-(4-(pyrrolidin-1-ylmethyl)benzyl)-1H-indol-6-yl)-1H-pyrazole-4-carbonitrile (103a) 
 
Trichloroacetonitrile (0.201 mL, 2.01 mmol) was added to a suspension of 3-oxo-3-(1-(4-(pyrrolidin-1-
ylmethyl)benzyl)-1H-indol-6-yl)propanenitrile 102a (0.239 g, 0.669 mmol) and sodium acetate (0.274 g, 
3.34 mmol) in ethanol (5 mL). The reaction mixture was stirred over 4 hours, then NaHCO3 solution 
(7.5 mL) and water (7.5 mL) were added. The intermediate was extracted into DCM (3 x 25 mL). The 
combined organic extracts were washed (brine), dried (MgSO4) and concentrated in vacuo. The crude 
residue was dissolved in ethanol (4 mL) and hydrazine monohydrate (0.325 mL, 6.69 mmol) was added. 
The reaction mixture was heated under reflux for 18 hours, then quenched with excess acetone at rt and 
concentrated in vacuo. Purification by flash chromatography (100% EtOAc, 0 – 7% methanol (+ 0.1% NH3) 
in DCM) afforded 103a (0.135 g, 51% yield). 
LCMS (ESI+): m/z 397.3 [M + H]+, (ESI-): m/z 395.3 [M - H]-, rt 1.35 minutes, 100%; 1H NMR (500 MHz, 
CDCl3) 7.70 (1H, s), 7.62 (1H, d, J = 8.3 Hz), 7.42 (1H, dd, J = 8.2, 1.5 Hz), 7.21 (2H, d, J = 8.2 Hz), 7.17 (1H, 
d, J = 3.0 Hz), 7.04 (2H, d, J = 8.1 Hz), 6.53 (1H, dd, J = 3.1, 0.8 Hz), 5.18 (2H, s), 4.40 (2H, br s), 3.55 (2H, s), 
2.55-2.42 (4H, m), 1.75-1.64 (4H, m); 13C NMR (125 MHz, CDCl3) 156.7, 152.0, 150.4, 138.5, 136.2, 136.0, 
130.4, 130.1, 129.7, 127.2, 121.8, 117.9, 115.9, 108.0, 102.2, 75.4, 60.3, 54.2, 50.1, 23.4; νmax/cm-1 3100 
(br, N-H), 2928, 2799, 2208 (C≡N), 1620, 1589, 1501; HRMS (ESI+): m/z calculated for [C24H24N6 + H]+ = 
397.2135, observed  397.2132. 
3-Amino-5-(1-(4-(piperidin-1-ylmethyl)benzyl)-1H-indol-6-yl)-1H-pyrazole-4-carbonitrile (103b) 
 
Trichloroacetonitrile (0.138 mL, 1.37 mmol) was added to a suspension of 3-oxo-3-(1-(4-(piperidin-1-
ylmethyl)benzyl)-1H-indol-6-yl)propanenitrile 102b (0.170 g, 0.458 mmol) and sodium acetate (0.188 g, 
2.29 mmol) in ethanol (5 mL). The reaction mixture was stirred over 44 hours, then diluted with NaHCO3 
solution (10 mL) and water (10 mL) and extracted into DCM (3 x 20 mL). The combined organic extracts 
were washed (brine), dried (MgSO4) and concentrated in vacuo. The crude residue was dissolved in 
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ethanol (10 mL) and hydrazine monohydrate (0.223 mL, 4.58 mmol) was added. The reaction mixture was 
heated under reflux for 24 hours, then concentrated in vacuo. Purification by flash chromatography (0 – 
100% EtOAc in PET, 0 – 15% methanol in DCM) was carried out, followed by reverse phase 
chromatography (0 – 35% acetonitrile in water (+ 0.1% formic acid)) with adjustment of the combined 
fractions to pH 8 and extraction into DCM/methanol (10:1, 3 x 50 mL). The combined organic extracts 
were washed (brine), dried (MgSO4) and concentrated in vacuo to afford 103b (60 mg, 32% yield). 
LCMS (ESI+): m/z 411.3 [M + H]+, rt 1.44 minutes, >99%; 1H NMR (500 MHz, CDCl3) 7.70 (1H, s), 7.63 (1H, 
d, J = 8.2 Hz), 7.40 (1H, dd, J = 8.2, 1.4 Hz), 7.21 (2H, d, J = 8.1 Hz), 7.19 (1H, d, J = 3.1 Hz), 7.04 (2H, d, J = 
7.9 Hz), 6.54 (1H, dd, J = 3.2, 0.6 Hz), 5.20 (2H, s), 4.33 (2H, br s), 3.42 (2H, s), 2.36 (4H, br s), 1.50 (4H, 
quin, J = 5.6 Hz), 1.42-1.33 (2H, m); 13C NMR (125 MHz, CDCl3) 156.8, 150.2, 137.4, 136.2, 136.0, 130.6, 
130.21, 130.17, 127.1, 121.9, 121.4, 117.7, 115.7, 108.1, 102.2, 75.7, 63.3, 54.5, 50.1, 25.6, 24.2; νmax/cm-
1 3200 (br, N-H), 2931, 2211 (C≡N), 1621, 1584, 1502; HRMS (ESI+): m/z calculated for [C25H26N6 + H]+ = 
411.2292, observed 411.2287. 
3-Amino-5-(1-(4-(morpholinomethyl)benzyl)-1H-indol-6-yl)-1H-pyrazole-4-carbonitrile (103c) 
 
Trichloroacetonitrile (0.142 mL, 1.42 mmol) was added to a suspension of 3-(1-(4-
(morpholinomethyl)benzyl)-1H-indol-6-yl)-3-oxopropanenitrile 102c (0.190 g, 0.473 mmol) and sodium 
acetate (0.194 g, 2.37 mmol) in ethanol (5 mL). The reaction mixture was stirred over 14 hours, then 
diluted with NaHCO3 solution (15 mL) and extracted into DCM (3 x 25 mL). The combined organic extracts 
were washed (brine), dried (MgSO4) and concentrated in vacuo. The crude residue was dissolved in 
ethanol (5 mL) and hydrazine monohydrate (0.230 mL, 4.73 mmol) was added. The reaction mixture was 
heated under reflux for 22 hours, then concentrated in vacuo. Purification by flash chromatography (0 – 
100% EtOAc in PET, 0 – 10% methanol in DCM) was carried out, followed by reverse phase 
chromatography (100% water (+ 0.1% formic acid)) with adjustment of the combined fractions to pH 8 
and extraction into DCM/methanol (10:1, 3 x 50 mL). The combined organic extracts were washed (brine), 
dried (MgSO4) and concentrated in vacuo to afford 103c (81 mg, 42% yield). 
LCMS (ESI+): m/z 413.3 [M + H]+, rt 1.36 minutes, >99%; 1H NMR (500 MHz, CDCl3) 7.73 (1H, s), 7.66 (1H, 
d, J = 8.2 Hz), 7.39 (1H, dd, J = 8.3, 1.3 Hz), 7.25-7.20 (3H, m), 7.08 (2H, d, J = 8.1 Hz), 6.56 (1H, dd, J = 3.2, 
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0.6 Hz), 5.26 (2H, s), 4.20 (2H, s), 3.64 (4H, t, J = 4.6 Hz), 3.41 (2H, s), 2.47-2.31 (4H, m); 13C NMR (125 MHz, 
CDCl3) 157.0, 150.1, 137.6, 136.2, 135.9, 130.7, 130.4, 129.9, 127.1, 122.0, 121.0, 117.6, 115.4, 108.2, 
102.3, 76.1, 67.0, 63.1, 53.7, 50.2; νmax/cm-1 3200 (br, N-H), 2922, 2212 (C≡N), 1740, 1624, 1584, 1502; 
HRMS (ESI+): m/z calculated for [C24H24N6O + H]+ = 413.2084, observed 413.2079. 
3-Amino-5-(1-(4-((4-methylpiperazin-1-yl)methyl)benzyl)-1H-indol-6-yl)-1H-pyrazole-4-carbonitrile (103d) 
 
Trichloroacetonitrile (0.167 mL, 1.66 mmol) was added to a suspension of 3-(1-(4-((4-methylpiperazin-1-
yl)methyl)benzyl)-1H-indol-6-yl)-3-oxopropanenitrile 102d (0.241 g, 0.555 mmol) and sodium acetate 
(0.228 g, 2.77 mmol) in ethanol (5 mL). The reaction mixture was stirred over 17 hours, then NaHCO3 
solution (25 mL) was added. The intermediate was extracted into DCM (3 x 25 mL). The combined organic 
extracts were washed (brine), dried (MgSO4) and concentrated in vacuo. The crude residue was dissolved 
in ethanol (10 mL) and hydrazine monohydrate (0.270 mL, 5.55 mmol) was added. The reaction mixture 
was heated under reflux for 24 hours, then concentrated in vacuo. Purification by reverse phase flash 
chromatography (0 – 50% acetonitrile in water (+ 0.1% formic acid)) was attempted, with the resultant 
fractions combined, adjusted to pH 8, and extracted into DCM/methanol (9:1, 6 x 50 mL). The combined 
organic extracts were dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (0 
– 20% methanol (+ 0.1% NH3) in DCM) afforded 103d (0.140 g, 59% yield). 
LCMS (ESI+): m/z 426.4 [M + H]+, (ESI-): m/z 424.3 [M - H]-, rt 1.36 minutes, 100%; 1H NMR (500 MHz, 
CD3OD) 7.84-7.81 (1H, m), 7.64 (1H, d, J = 8.3 Hz), 7.49 (1H, dd, J = 8.2, 1.4 Hz), 7.39 (1H, d, J = 3.1 Hz), 
7.27-7.21 (2H, m), 7.21-7.16 (2H, m), 6.53 (1H, dd, J = 3.1, 0.7 Hz), 5.37 (2H, s), 3.46 (2H, s), 2.44 (8H, br 
s), 2.24 (3H, s); 13C NMR (125 MHz, CD3OD) 158.0 (br), 152.5 (br), 138.3, 137.7, 137.4, 131.6, 131.4, 131.1, 
128.2, 124.0 (br), 122.2, 118.7, 117.0, 109.1, 102.7, 74.0 (br), 63.3, 55.5, 53.3, 50.8, 45.8; νmax/cm-1 3150 
(br, N-H), 2919, 2808, 2207 (C≡N), 1612, 1581; HRMS (ESI+): m/z calculated for [C25H27N7 + H]+ = 426.2401, 
observed 426.2396. 
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3-Amino-5-(1-(4-((4-isopropylpiperazin-1-yl)methyl)benzyl)-1H-indol-6-yl)-1H-pyrazole-4-carbonitrile 
(103e) 
 
Trichloroacetonitrile (0.129 mL, 1.29 mmol) was added to a suspension of 3-(1-(4-((4-isopropylpiperazin-
1-yl)methyl)benzyl)-1H-indol-6-yl)-3-oxopropanenitrile 102e (0.178 g, 0.429 mmol) and sodium acetate 
(0.176 g, 2.15 mmol) in ethanol (5 mL). The reaction mixture was stirred over 10 hours, then diluted with 
NaHCO3 solution (7.5 mL) and water (7.5 mL) and extracted into DCM (3 x 25 mL). The combined organic 
extracts were washed (brine), dried (MgSO4) and concentrated in vacuo. The crude residue was dissolved 
in ethanol (3 mL) and hydrazine monohydrate (0.209 mL, 4.29 mmol) was added. The reaction mixture 
was heated under reflux for 7 hours, then quenched with excess acetone at rt and concentrated in vacuo. 
Purification by flash chromatography (50 – 100% EtOAc in PET, 0 - 20% methanol in DCM (+ 0.1% NH3)) 
afforded 103e (0.147 g, 75% yield). 
LCMS (ESI+): m/z 454.3 [M + H]+, (ESI-): m/z 452.3 [M - H]-, rt 1.40 minutes, >99%; 1H NMR (500 MHz, 
CD3OD) 7.81 (1H, s), 7.63 (1H, d, J = 8.3 Hz), 7.48 (1H, d, J = 8.1 Hz), 7.39 (1H, d, J = 2.6 Hz), 7.25 (2H, d, J = 
8.1 Hz), 7.21 (2H, d, J = 8.2 Hz), 6.53 (1H, d, J = 3.2 Hz), 5.36 (2H, s), 3.55 (2H, s), 3.36-3.29 (1H, m), 3.10 
(4H, br s), 2.69 (4H, br s), 1.27 (6H, d, J = 6.9 Hz); 13C NMR (125 MHz, CD3OD) 138.6, 137.3, 137.1, 131.6, 
131.4, 130.8, 128.5, 122.2, 118.7, 117.0, 109.2, 102.7, 62.3, 59.0, 51.0, 50.8, 49.4, 17.3 (4 peaks missing); 
νmax/cm-1 2210 (C≡N), 1623, 1587, 1501; HRMS (ESI)+: m/z calculated for [C27H31N7 + H]+ = 454.2714, 
observed 454.2715. 
4-Methyl-5-(1-(4-(pyrrolidin-1-ylmethyl)benzyl)-1H-indol-6-yl)-1H-pyrazol-3-amine (105a) 
 
Hydrazine monohydrate (0.147 mL, 3.01 mmol) was added to a solution of 2-methyl-3-oxo-3-(1-(4-
(pyrrolidin-1-ylmethyl)benzyl)-1H-indol-6-yl)propanenitrile 104a (0.140 g, 0.301 mmol) in ethanol (5 mL). 
The reaction mixture was heated under reflux for 28 hours, then quenched with excess acetone at rt and 
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concentrated in vacuo. Purification by flash chromatography (50 – 100% EtOAc in PET, 0 – 20% methanol 
(+ 0.1% NH3) in DCM) afforded 105a (24 mg, 21% yield). 
LCMS (ESI+): m/z 386.3 [M + H]+, rt 1.25 minutes, >99%; 1H NMR (500 MHz, CDCl3) 7.69 (1H, d, J = 8.2 Hz), 
7.30 (1H, s), 7.26 (2H, d, J = 8.1 Hz), 7.20 (1H, d, J = 3.2 Hz), 7.18 (1H, dd, J = 8.4, 1.5 Hz), 7.08 (2H, d, J = 
8.1 Hz), 6.57 (1H, dd, J = 3.1, 0.7 Hz), 5.31 (2H, s), 3.58 (2H, s), 2.53-2.43 (4H, m), 1.98 (3H, s), 1.81-1.71 
(4H, m); 13C NMR (125 MHz, CDCl3) 154.4, 142.7, 139.1, 136.4, 135.8, 129.7, 129.6, 128.8, 126.9, 124.3, 
121.5, 119.0, 108.8, 101.9, 99.3, 60.3, 54.2, 50.3, 23.5, 7.9; νmax/cm-1 3200 (br, N-H), 2916, 2788, 1606, 
1502; HRMS (ESI)+: m/z calculated for [C24H27N5 + H]+ = 386.2339, observed 386.2354. 
 
4.2: Protein Expression and Purification 
4.2.1: Mycobacterium tuberculosis fumarate hydratase 
A single freshly transformed E. coli strain BL21(DE3) colony was transferred to LB media (20 mL) with 
ampicillin (100 µg mL-1) and incubated overnight (37 °C, 200 rpm). The starter culture was used to 
inoculate 2 flasks, each containing TB media (1 L) with ampicillin (100 µg mL-1), with incubation (37 °C, 200 
rpm) until an optical density (A600nm) of 1.1 was reached. Protein expression was induced by the addition 
of IPTG (0.5 mM), followed by overnight incubation (15 °C, 200 rpm). Cells were harvested by 
centrifugation (4 °C, 4000 g, 20 minutes), then frozen. 
The cells were resuspended in 50 mL lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 20 mM imidazole) 
with a tablet of cOmplete™ Protease Inhibitor Cocktail (Roche). The suspension was sonicated (15 
minutes, 10 seconds on/ 20 seconds off) and centrifuged (4 °C, 30000 g, 20 minutes). The lysate was 
loaded onto a 7.5 mL nickel SepharoseTM fast flow column (GE Healthcare), pre-equilibrated with lysis 
buffer. The column was washed with 5 column volumes of lysis buffer and eluted with buffer B (50 mM 
Tris pH 8.0, 150 mM NaCl, 300 mM imidazole) in 8 x 5 mL aliquots. Protein-containing aliquots, as 
determined by SDS-PAGE, were combined and concentrated (30 kDa cutoff), then loaded onto a Superdex 
200 HiloadTM 26/60 column (GE Healthcare) pre-equilibrated with filtration buffer (10 mM Tris pH 8.0, 150 
mM NaCl, 0.5 mM TCEP). Chromatography was conducted using an ÄKTATM FPLC system (GE Healthcare), 
with protein-containing fractions, as determined by SDS-PAGE, combined and concentrated to 27.9 mg 
mL-1 (24.3 mg L-1 yield), then flash-frozen in liquid nitrogen and stored at -80 °C. The identity of the protein 
was confirmed by LCMS analysis. 
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4.2.2: Mycobacterium abscessus tRNA (m1G37) methyltransferase 
Mab TrmD protein was supplied by Dr Sherine Thomas. 50 
 
4.2.3: Mycobacterium tuberculosis tRNA (m1G37) methyltransferase 
A colony of E. coli strain ANG3685 (XL1 Blue pET23b-His6-trmDTB) kindly provided by the research group 
of Professor Angelika Gründling at Imperial College London, 136 was transferred to LB media (5 mL) with 
ampicillin (100 µg mL-1) and incubated overnight (37 °C, 160 rpm). The resultant material was processed 
with a GeneJETTM Plasmid Miniprep Kit (Thermo Scientific™) to obtain plasmid (30 ng µL-1, A260nm/A280nm 
1.87), with identity confirmed by Sanger sequencing (DNA Sequencing Facility, Department of 
Biochemistry, University of Cambridge). 
The isolated plasmid was used to transform E. coli strain BL21(DE3), with a colony transferred to LB media 
(20 mL) with ampicillin (100 µg mL-1) and incubated overnight (37 °C, 160 rpm). The starter culture was 
used to inoculate 2 flasks, each containing LB media (1 L) with ampicillin (100 µg mL-1), with incubation 
(37 °C, 200 rpm) until an optical density (A600nm) of 0.5 was reached. Protein expression was induced by 
the addition of IPTG (0.5 mM), followed by overnight incubation (20 °C, 200 rpm). Cells were harvested 
by centrifugation (4 °C, 4000 g, 20 minutes), then frozen. 
The cells were resuspended in 50 mL lysis buffer (50 mM HEPES pH 7.4, 1 M NaCl, 25 mM imidazole, 5 
mM mercaptoethanol) with a tablet of cOmplete™ Protease Inhibitor Cocktail (Roche). The suspension 
was sonicated (10 minutes: 10 seconds on/ 20 seconds off), centrifuged (4 °C, 30000 g, 20 minutes) and 
filtered (0.45 µm). The resultant lysate was loaded onto a 7.5 mL nickel SepharoseTM fast flow column (GE 
Healthcare), pre-equilibrated with lysis buffer. The column was washed with 5 column volumes of buffer 
A (25 mM HEPES pH 7.5, 500 mM NaCl, 20 mM imidazole, 5 mM mercaptoethanol) and eluted with buffer 
B (25 mM HEPES pH 7.5, 500 mM NaCl, 500 mM imidazole, 5 mM mercaptoethanol) in 7 x 5 mL aliquots. 
Protein-containing aliquots, as determined by SDS-PAGE, were combined and concentrated (10 kDa 
cutoff) to a volume of 7 mL, then loaded onto a Superdex 75 HiloadTM 16/60 column (GE Healthcare) pre-
equilibrated with filtration buffer (25 mM HEPES pH 7.5, 500 mM NaCl, 5 mM mercaptoethanol). 
Chromatography was conducted using an ÄKTATM FPLC system (GE Healthcare), with protein-containing 
fractions, as determined by SDS-PAGE, combined and concentrated (10 kDa cutoff) to 14.4 mg mL-1 (5.0 
mg L-1 yield), then flash-frozen in liquid nitrogen and stored at -80 °C. The identity of the protein was 
confirmed by LCMS analysis. 
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4.3: Biochemical Assay with Mycobacterium tuberculosis fumarate hydratase 
The enzymatic activity of Mtb fumarase was followed by a CLARIOstar® microplate spectrometer (BMG 
Labtech) in a 96-well UV plate (Greiner). 2 μL of DMSO (control) or a solution of the ligand in DMSO was 
pipetted per well. 150 μL of a solution containing acetyl coenzyme A sodium salt (267 µM), β-nicotinamide 
adenine dinucleotide hydrate (200 µM), malate dehydrogenase (13.3 units mL-1), citrate synthase (1.33 
units mL-1) and Mtb fumarase (33.3 nM) in buffer (250 mM Tris pH 8.0, 5 mM MgCl2) was pipetted per 
well. The plate was left to equilibrate for 5 minutes at 25 °C, then 48 μL of either buffer (negative control) 
or fumaric acid (1.67 mM) (positive control or ligand) was pipetted per well. After 2 minutes the plate was 
read at a wavelength of 340 nm at intervals of 24 seconds over 10 minutes.  
Inhibition values for each ligand at a particular concentration were calculated from the gradient of the 
assay read over the 10 minutes, with correction by the negative control and normalization by the positive 
control. Inhibition experiments at 50 µM ligand concentration were performed at least twice (n ≥ 2), with 
% inhibition and standard error of the mean reported. IC50 experiments (n = 6) were performed with 10 
ligand concentrations, obtained through serial dilution. Dose-response curves were calculated using 
Origin software (OriginLab, Northampton, MA, USA), with IC50 and standard error reported, and are 
presented in appendix A.2 (Figure 60 - Figure 66). 
 
4.4: Biophysical Techniques 
4.4.1: Differential Scanning Fluorimetry 
DSF was performed using a BioRad CFX Connect™ system, from 25 to 95 °C in 0.5 °C increments of 30 
seconds duration. Samples were run in 96-well clear-bottomed plates, with two wells per ligand (n ≥ 2). 
In experiments with Mtb fumarase each well contained a final volume of 50 μL, consisting of 100 mM Tris 
pH 7.5, 50 mM NaCl, 2.5x SyproOrange®, 2.5 μM Mtb fumarase and either 5% DMSO or 5% ligand stock 
solution in DMSO. In experiments with Mab TrmD each well contained a final volume of 25 μL, consisting 
of 50 mM HEPES pH 7.5, 500 mM NaCl, 5x SyproOrange®, 10 μM Mab TrmD and either 5% DMSO or 5% 
ligand stock solution in DMSO. Data was processed with Microsoft Excel. 
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4.4.2: Isothermal Titration Calorimetry 
ITC experiments to quantify binding to TrmD were performed using Malvern MicroCal iTC200 or Auto-
iTC200 systems at 25 °C. Titrations consisted of an initial injection (0.2 µL), discarded during data 
processing, followed by either 19 (2 µL) or 39 (1 µL) injections separated by intervals of 60 – 150 seconds 
duration. Protein was dialysed overnight at 4 °C in storage buffer (Mab TrmD: 50 mM HEPES pH 7.5, 500 
mM NaCl, 5% glycerol; Mtb TrmD: 25 mM HEPES pH 7.5, 500 mM NaCl). Sample cell and syringe solutions 
were prepared using the same storage buffer, with a final DMSO concentration of 2 – 10% according to 
ligand solubility in the buffer. TrmD concentrations of either 33 or 100 µM were used, with ligand to 
protein concentration ratios ranging from 10-20:1. Control titrations without protein were also performed 
and subtracted from ligand to protein titrations. Titrations were fitted with Origin software (OriginLab, 
Northampton, MA, USA), using a one-site binding model with N fixed to 1 only for weakly binding ligands. 
Titrations were typically performed once (n = 1), with multiple isotherms obtained (n > 1) for key 
compounds of interest. Kd values are reported to 2 significant figures. Error provided by Origin software 
due to model fit is reported when n = 1, whereas standard deviation is reported when n > 1. ITC traces 
are presented in appendix A.3 (Figure 67 - Figure 73), with the exception of 71o (Figure 49b and c). 
For the reverse ITC titration with 71o (Figure 49c), protein solution (420 µM Mab TrmD) was injected into 
the sample cell (35 µM ligand). Other aspects of experiment setup and analysis were identical to the 
forward titrations. 
 
4.5: X-ray Crystallography with Mycobacterium tuberculosis fumarate 
hydratase 
Crystals were grown in Intelli-Plate® 24-4 well sitting drop plates (Art Robbins Instruments), incubated at 
19 °C in a ROCK IMAGER® 1000 system (FORMULATRIX®) that was used for drop imaging. 
 
4.5.1: Seed Stock 
A sitting drop was set up with 2 µL protein solution (14 mg mL-1 Mtb fumarase, 0.15 M NaCl, 10 mM Tris 
pH 8.0 and 0.5 mM TCEP) and 1 µL reservoir solution (10% w/v PEG3350, 5% DMSO and 0.30 M 
magnesium formate), equilibrated against 400 μL reservoir solution. After 3 weeks the drop was diluted 
with 5 µL reservoir solution, and the crystals disturbed with a loop before transfer to a Beads-for-Seeds 
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microcentrifuge tube (Jena Bioscience). Further reservoir solution was added to the tube to a total volume 
of 50 µL prior to sonication (10 cycles: 30 seconds on/ 30 seconds off). The resultant suspension was 
diluted both 5,000x and 10,000x in buffer (17% w/v PEG3350, 5% DMSO and 0.30 M magnesium formate), 
then flash-frozen in liquid nitrogen and stored at -80 °C. 
 
4.5.2: Crystal Growth and Soaking 
The recreation of the X-ray crystal structure of 2 in complex with Mtb fumarase was achieved with the 
setting up of a sitting drop with 3 µL protein solution (14 mg mL-1 Mtb fumarase, 0.15 M NaCl, 10 mM Tris 
pH 8.0 and 0.5 mM TCEP), 1 µL reservoir solution (12.8% w/v PEG3350, 5% DMSO and 0.30 M magnesium 
formate) and 0.5 µL 5,000x seed stock, equilibrated against 400 μL reservoir solution. After 6 days, the 
drop was treated with 2 µL soaking solution (1 mM ligand, 7.5% DMSO, 26.25% w/v PEG3350 and 0.20 M 
magnesium formate) and incubated overnight. 
The determination of the X-ray crystal structure of 49j in complex with Mtb fumarase was achieved with 
the setting up of a sitting drop with 3 µL protein solution (14 mg mL-1 Mtb fumarase, 0.15 M NaCl, 10 mM 
Tris pH 8.0 and 0.5 mM TCEP), 1 µL reservoir solution (11.4% w/v PEG3350, 5% DMSO and 0.30 M 
magnesium formate) and 0.5 µL 10,000x seed stock, equilibrated against 400 μL reservoir solution. After 
6 days the drop was treated with 2 µL soaking solution (1 mM ligand, 7.5% DMSO, 26.25% w/v PEG3350 
and 0.2 M magnesium formate) and incubated overnight. 
The determination of X-ray crystal structures of 46a, 46g, 49a-b, 49h and 49l in complex with Mtb 
fumarase was achieved with the setting up of sitting drops with 3 µL protein solution (14 mg mL-1 Mtb 
fumarase, 0.15 M NaCl, 10 mM Tris pH 8.0 and 0.5 mM TCEP), 1 µL reservoir solution (10% w/v PEG3350, 
5% DMSO and 0.30 M magnesium formate) and 0.5 µL 10,000x seed stock, equilibrated against 400 μL 
reservoir solution. After 1 – 2 weeks a drop was treated with 2 µL soaking solution (0.5 – 3 mM ligand, 
7.5% DMSO, 26.25% w/v PEG3350 and 0.20 M magnesium formate) and incubated overnight. Ligand 
concentrations: 0.5 mM (49l), 1 mM (46g and 49b), 2 mM (46a and 49h) and 3 mM (49a). 
Crystals were mounted into loops and flash frozen in liquid nitrogen. 
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4.5.3: X-ray Data Collection and Processing 
X-ray data for 2, 46a, 46g, 49a-b, 49h and 49j-l in complex with Mtb fumarase were collected on beamlines 
i03 and i04 at the Diamond Light Source synchrotron (Oxfordshire, United Kingdom) at wavelengths of 
0.9762 – 0.9795 Å, with Ω start 0.0°, Ω oscillation 0.10 – 0.20°, 1500 – 3000 images and an exposure of 
0.050 seconds. Data was processed using autoPROC. 138 
 
4.5.4: Structure Solution and Refinement 
Molecular replacement for structures of Mtb fumarase in complex with 2 or 49b was carried out using 
PHASER, 118 accessed through the CCP4 software suite, 119 with the previously published 2-bound Mtb 
fumarase structure (PDB code 5F91) used as a search model. 41 For structures of Mtb fumarase in complex 
with 46a, 46g, 49a, 49h, 49j or 49l, the solved 49b-bound structure was used as a search model. Models 
were manually rebuilt using the COOT molecular graphics software package , 120  and refined with 
REFMAC5 , 121  accessed through CCP4 . 119  The statistics for the resultant models, compiled using 
PHENIX, 139  are presented in appendix A.4 (Table 14), with the exception of 2 whose model was not fully 
rebuilt.  
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Appendix: Supporting Data 
A.1: Methods and Characterisation Data for Non-key Compounds 
Ethyl-(E)-2-(3-oxoisobenzofuran-1(3H)-ylidene)acetate (14)  41,  137 
 
A solution of (carbethoxymethylene)triphenylphosphorane (4.70 g, 13.5 mmol) in chloroform (12.5 mL) 
was added dropwise to a solution of phthalic anhydride 13 (2.00 g, 13.5 mmol) in chloroform (12.5 mL). 
The reaction mixture was heated under reflux for 3 hours, then concentrated in vacuo. Purification by 
flash chromatography (5% EtOAc in PET) afforded 14 (1.97 g, 67% yield). 
1H NMR (500 MHz, CDCl3) 9.05 (1H, d, J = 8.0 Hz), 7.96 (1H, dt, J = 7.5, 1.0 Hz), 7.84-7.78 (1H, m), 7.70 (1H, 
td, J = 7.5, 0.9 Hz), 6.15 (1H, s), 4.30 (2H, q, J = 7.2 Hz), 1.36 (3H, t, J = 7.2 Hz); 13C NMR (125 MHz, CDCl3) 
165.9, 165.7, 158.0, 136.3, 135.4, 132.6, 128.4, 126.7, 125.5, 102.6, 61.1, 14.4; 1H NMR spectroscopic data 
consistent with literature. 137 
2,2,2-Trifluoro-N-(2-methoxyphenyl)acetamide (18)  140 
 
Trifluoroacetic anhydride (0.55 mL, 3.9 mmol) was added dropwise at 0 °C to a mixture of o-anisidine 17 
(0.37 mL, 3.3 mmol), pyridine (0.39 mL, 4.9 mmol) and DCM (4 mL). The reaction mixture was warmed to 
rt and stirred over 3 days. Water (20 mL) was added dropwise at 0 °C to the reaction mixture. The product 
was extracted into DCM (3 x 20 mL). The combined organic extracts were dried (MgSO4) and concentrated 
in vacuo. Purification by flash chromatography (0 – 20% EtOAc in PET) afforded 18 (0.713 g, 99% yield). 
LCMS (ESI-): m/z 218.1 [M - H]-, rt 2.14 minutes, >99%; 1H NMR (400 MHz, CDCl3) 8.57 (1H, br s), 8.32 (1H, 
d, J = 8.0 Hz), 7.17 (1H, t, J = 8.0 Hz), 7.01 (1H, t, J = 7.7 Hz), 6.94 (1H, d, J = 8.2 Hz), 3.93 (3H, s); 13C NMR 
(100 MHz, CDCl3) 154.5 (q, J = 37 Hz), 148.4, 126.1, 125.2, 121.4, 120.3, 115.8 (q, J = 288 Hz), 110.3, 56.0; 
1H NMR spectroscopic data consistent with literature. 140 
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4-Methoxy-3-(2,2,2-trifluoroacetamido)benzenesulfonyl chloride (19)  140 
 
Chlorosulfonic acid (0.41 mL, 6.2 mmol) was added dropwise at 0 °C to a solution of 2,2,2-trifluoro-N-(2-
methoxyphenyl)acetamide 18 (0.683 g, 3.12 mmol) in DCM (6 mL). The reaction mixture was warmed to 
rt and stirred over 16 hours. Water (20 mL) was added dropwise at 0 °C to the reaction mixture. The 
product was extracted into DCM (3 x 20 mL). The combined organic extracts were dried (MgSO4) and 
concentrated in vacuo to afford 19 (0.767 g, 77% yield). 
1H NMR (400 MHz, CDCl3) 9.05 (1H, s), 8.59 (1H, br s), 7.90 (1H, d, J = 8.8 Hz), 7.11 (1H, d, J = 8.9 Hz), 4.09 
(3H, s); 13C NMR (100 MHz, CDCl3) 154.9 (q, J = 38 Hz), 153.1, 137.1, 126.1, 125.9, 118.9, 115.5 (q, J = 289 
Hz), 110.5, 57.1; 1H NMR spectroscopic data consistent with literature. 140 
4-Methoxybenzenesulfonyl chloride (29) 
 
Chlorosulfonic acid (0.25 mL, 3.7 mmol) was added dropwise at 0 °C to a mixture of anisole 28 (0.201 mL, 
1.85 mmol) and chloroform (5 mL). The reaction mixture was warmed to rt and stirred over 30 minutes. 
Water (15 mL) was added dropwise at 0 °C to the reaction mixture. The product was extracted into DCM 
(3 x 20 mL). The combined organic extracts were washed (brine), dried (MgSO4) and concentrated in vacuo 
to afford 29 (0.246 g, 64% yield). 
1H NMR (400 MHz, CDCl3) 7.98 (2H, d, J = 9.0 Hz), 7.05 (2H, d, J = 8.9 Hz), 3.92 (3H, s); 13C NMR (100 MHz, 
CDCl3) 165.0, 136.3, 129.7, 114.9, 56.1; spectroscopic data consistent with literature. 141 
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4-Hydroxy-3-nitrobenzenesulfonyl chloride (31) 
 
Chlorosulfonic acid (0.96 mL, 14 mmol) was added dropwise at 0 °C to a solution of 2-nitrophenol 30 (1.00 
g, 7.19 mmol) in chloroform (5 mL). The reaction mixture was heated under reflux for 90 minutes. Water 
(15 mL) was added dropwise at 0 °C to the reaction mixture. The product was extracted into DCM (3 x 25 
mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo to afford 31 (1.33 g, 
78% yield). 
LCMS (ESI-): m/z 236.0 [M - H]-, rt 1.89 minutes, >99%; 1H NMR (400 MHz, CDCl3) 11.12 (1H, s), 8.84 (1H, 
d, J = 2.4 Hz), 8.21 (1H, dd, J = 9.0, 2.4 Hz), 7.42 (1H, d, J = 9.0 Hz); 13C NMR (100 MHz, CDCl3) 159.5, 136.2, 
134.9, 132.9, 126.0, 122.4; νmax/cm-1 3249 (br, O-H), 3088, 1615, 1578, 1539 (N=O), 1328 (N=O). 
4-(Azepan-1-ylsulfonyl)-2-nitrophenol (32) 
 
Hexamethyleneimine (0.108 mL, 0.963 mmol) and DIPEA (0.305 mL, 1.75 mmol) were added to a solution 
of 4-hydroxy-3-nitrobenzenesulfonyl chloride 31 (0.208 g, 0.875 mmol) in DCM (2 mL). The reaction 
mixture was stirred over 15 hours, then water (10 mL) and aqueous HCl (37.5% w/v, 5 mL) were added. 
The product was extracted into DCM (3 x 25 mL). The combined organic extracts were dried (MgSO4) and 
concentrated in vacuo. Purification by flash chromatography (0 – 40% EtOAc in PET) afforded 32 (0.190 g, 
64% yield). 
LCMS (ESI+): m/z 301.2 [M + H]+, (ESI-): m/z 299.1 [M - H]-, rt 2.11 minutes, 88%; 1H NMR (400 MHz, CDCl3) 
10.85 (1H, s), 8.56 (1H, d, J = 2.4 Hz), 7.96 (1H, dd, J = 8.9, 2.2 Hz), 7.29 (1H, d, J= 8.7 Hz), 3.29 (4H, t, J = 
5.9 Hz), 1.79-1.69 (4H, m), 1.65-1.58 (4H, m); 13C NMR (100 MHz, CDCl3) 157.5, 135.2, 133.1, 132.5, 124.8, 
121.4, 48.5, 29.3, 27.0; νmax/cm-1 2939, 1615, 1583, 1528 (N=O), 1330 (N=O); HRMS (ESI)+: m/z calculated 
for [C12H16N2O5S + Na]+ = 323.0672, observed 323.0661. 
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3-Amino-4-methoxy-N-methylbenzenesulfonamide (33a) 
 
Methylamine (2 M in THF, 0.33 mL, 0.67 mmol) was added at 0 °C to a solution of 4-methoxy-3-(2,2,2-
trifluoroacetamido)benzenesulfonyl chloride 19 (0.106 g, 0.334 mmol) in THF (2 mL). The reaction mixture 
was warmed to rt and stirred overnight. Further methylamine (2 M in THF, 2.0 mL, 4.0 mmol) was added, 
and the reaction mixture heated under reflux for 1 hour. Further methylamine (2 M in THF, 1.0 mL, 2.0 
mmol) was added at rt, and the reaction mixture heated under reflux for 30 minutes. The reaction mixture 
was concentrated in vacuo, then ethanol (5 mL), water (5 mL) and aqueous HCl (37.5% w/v, 5 mL) were 
added. The reaction mixture was heated under reflux for 3 hours 30 minutes. The reaction mixture was 
adjusted to pH 14 by the dropwise addition of aqueous NaOH (10% w/v) at rt, then concentrated in vacuo 
to remove ethanol. The product was extracted into EtOAc (3 x 25 mL). The combined organic extracts 
were dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (25 – 75% EtOAc in 
PET) afforded 33a (59 mg, 82% yield). 
LCMS (ESI+): m/z 217.2 [M + H]+, rt 1.23 minutes, >99%; 1H NMR (400 MHz, CD3CN) 7.12-7.06 (2H, m), 6.92 
(1H, d, J = 8.0 Hz), 5.28-5.07 (1H, m), 4.39 (2H, br s), 3.88 (3H, s), 2.46 (3H, d, J = 5.3 Hz); 13C NMR (100 
MHz, CD3CN) 150.8, 138.8, 131.8, 117.8, 112.5, 110.7, 56.5, 29.6; νmax/cm-1 3388 (N-H), 3306 (N-H), 3043, 
2919, 2840, 1590, 1509; HRMS (ESI)+: m/z calculated for [C8H12N2O3S + Na]+ = 239.0461, observed 
239.0463. 
5-(Azocan-1-ylsulfonyl)-2-methoxyaniline (33b) 
 
Heptamethyleneimine (95 µL, 0.76 mmol) was added dropwise at 0 °C to a suspension of NaH (60% in 
mineral oil, 76 mg, 1.9 mmol) in DMF (2 mL). The reaction mixture was stirred at 0 °C over 20 minutes. A 
solution of 4-methoxy-3-(2,2,2-trifluoroacetamido)benzenesulfonyl chloride 19 (0.200 g, 0.630 mmol) in 
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DMF (1 mL) was added dropwise at 0 °C to the reaction mixture. The reaction mixture was warmed to rt 
and stirred over 2 hours. Ethanol (5 mL) was added dropwise at 0 °C to the reaction mixture, followed by 
water (5 mL) and aqueous HCl (37.5% w/v, 5 mL). The reaction mixture was heated under reflux for 17 
hours. The reaction mixture was adjusted to pH 9 by the dropwise addition of aqueous NaOH (10% w/v) 
at rt, then concentrated in vacuo to remove ethanol. The mixture was diluted with EtOAc (25 mL), and the 
resultant aqueous layer discarded. The organic layer was washed with water (2 x 25 mL) and brine (25 
mL), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (0 – 50% EtOAc in 
PET) afforded 33b (0.130 g, 69% yield). 
LCMS (ESI+): m/z 299.2 [M + H]+, rt 1.96 minutes, >99%; 1H NMR (400 MHz, CDCl3) 7.16 (1H, dd, J = 8.4, 
2.2 Hz), 7.09 (1H, d, J = 2.2 Hz), 6.81 (1H, d, J = 8.3 Hz), 3.97 (2H, br s), 3.89 (3H, s), 3.11 (4H, t, J = 5.8 Hz), 
1.75-1.57 (10H, m); 13C NMR (100 MHz, CDCl3) 150.1, 136.7, 130.8, 118.2, 112.9, 109.7, 55.8, 48.8, 28.0, 
26.8, 25.3; νmax/cm-1 3488 (N-H), 3383 (N-H), 2914, 2851, 1729, 1611, 1577, 1512; HRMS (ESI)+: m/z 
calculated for [C14H22N2O3S + H]+ = 299.1424, observed 299.1429. 
2-Methoxy-5-(piperidin-1-ylsulfonyl)aniline (33c) 
 
Piperidine (62 µL, 0.63 mmol) was added dropwise at 0 °C to a suspension of NaH (60% in mineral oil, 76 
mg, 1.9 mmol) in DMF (1 mL). The reaction mixture was stirred at 0 °C over 20 minutes. A solution of 4-
methoxy-3-(2,2,2-trifluoroacetamido)benzenesulfonyl chloride 19 (0.200 g, 0.630 mmol) in DMF (2 mL) 
was added dropwise at 0 °C to the reaction mixture. The reaction mixture was warmed to rt and stirred 
over 20 hours. Ethanol (5 mL) was added dropwise at 0 °C to the reaction mixture, followed by water (5 
mL) and aqueous HCl (37.5% w/v, 5 mL). The reaction mixture was heated under reflux for 9 hours. The 
reaction mixture was adjusted to pH 7 by the dropwise addition of aqueous NaOH (10% w/v) at rt, then 
concentrated in vacuo. Water (15 mL) was added to the crude residue. The product was extracted into 
DCM (3 x 20 mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo. 
Purification by flash chromatography (20 – 50% EtOAc in PET) afforded 33c (0.104 g, 61% yield). 
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LCMS (ESI+): m/z 271.2 [M + H]+, rt 1.86 minutes, >99%; 1H NMR (500 MHz, CDCl3) 7.13 (1H, dd, J = 8.4, 
2.1 Hz), 7.05 (1H, d, J = 2.2 Hz), 6.83 (1H, d, J = 8.4 Hz), 3.97 (2H, br s), 3.91 (3H, s), 2.95 (4H, t, J = 5.4 Hz), 
1.63 (4H, quin, J = 5.7 Hz), 1.45-1.36 (2H, m); 13C NMR (125 MHz, CDCl3) 150.3, 136.6, 128.2, 118.9, 113.3, 
109.7, 55.9, 47.1, 25.3, 23.7; νmax/cm-1 3475 (N-H), 3372 (N-H), 2939, 2851, 1616, 1581, 1510; HRMS (ESI)+: 
m/z calculated for [C12H18N2O3S + Na]+ = 293.0930, observed 293.0935. 
2-Methoxy-5-((4-methylpiperazin-1-yl)sulfonyl)aniline (33d) 
 
1-Methylpiperazine (84 µL, 0.76 mmol) was added dropwise at 0 °C to a suspension of NaH (60% in mineral 
oil, 76 mg, 1.9 mmol) in DMF (2 mL). The reaction mixture was stirred at 0 °C over 20 minutes. A solution 
of 4-methoxy-3-(2,2,2-trifluoroacetamido)benzenesulfonyl chloride 19 (0.200 g, 0.630 mmol) in DMF (1 
mL) was added dropwise at 0 °C to the reaction mixture. The reaction mixture was warmed to rt and 
stirred over 2 hours. Ethanol (5 mL) was added dropwise at 0 °C to the reaction mixture, followed by water 
(5 mL) and aqueous HCl (37.5% w/v, 5 mL). The reaction mixture was heated under reflux for 18 hours. 
The reaction mixture was adjusted to pH 9 by the dropwise addition of aqueous NaOH (10% w/v) at rt, 
then concentrated in vacuo to remove ethanol. The mixture was diluted with EtOAc (25 mL), and the 
resultant aqueous layer discarded. The organic layer was washed with water (2 x 25 mL) and brine (25 
mL), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (0 – 10% methanol 
in DCM) afforded 33d (0.120 g, 65% yield). 
LCMS (ESI+): m/z 286.3 [M + H]+, rt 0.47 minutes, 97%; 1H NMR (500 MHz, (CD3)2SO) 6.99-6.95 (2H, m), 
6.88 (1H, dd, J = 8.5, 2.3 Hz), 5.23 (2H, s), 3.84 (3H, s), 2.82 (4H, br s), 2.34 (4H, t, J = 4.4 Hz), 2.13 (3H, s); 
13C NMR (125 MHz, (CD3)2SO) 149.5, 138.3, 126.3, 116.1, 111.5, 109.9, 55.6, 53.6, 45.7, 45.3; νmax/cm-1 
3481 (N-H), 3376 (N-H), 2919, 2842, 2795, 1609, 1576, 1516; HRMS (ESI)+: m/z calculated for [C12H19N3O3S 
+ H]+ = 286.1220, observed 286.1225. 
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2-Methoxy-5-(morpholinosulfonyl)aniline (33e) 
 
Morpholine (66 µL, 0.76 mmol) was added dropwise at 0 °C to a suspension of NaH (60% in mineral oil, 76 
mg, 1.9 mmol) in DMF (2 mL). The reaction mixture was stirred at 0 °C over 20 minutes. A solution of 4-
methoxy-3-(2,2,2-trifluoroacetamido)benzenesulfonyl chloride 19 (0.200 g, 0.630 mmol) in DMF (1 mL) 
was added dropwise at 0 °C to the reaction mixture. The reaction mixture was warmed to rt and stirred 
over 2 hours. Ethanol (5 mL) was added dropwise at 0 °C to the reaction mixture, followed by water (5 
mL) and aqueous HCl (37.5% w/v, 5 mL). The reaction mixture was heated under reflux for 18 hours. The 
reaction mixture was adjusted to pH 9 by the dropwise addition of aqueous NaOH (10% w/v) at rt, then 
concentrated in vacuo to remove ethanol. The mixture was diluted with EtOAc (25 mL), and the resultant 
aqueous layer discarded. The organic layer was washed with water (2 x 25 mL) and brine (25 mL), dried 
(MgSO4) and concentrated in vacuo. Purification by flash chromatography (20 – 60% EtOAc in PET) 
afforded 33e (0.117 g, 68% yield). 
LCMS (ESI+): m/z 273.2 [M + H]+, rt 1.40 minutes, >99%; 1H NMR (500 MHz, (CD3)2SO) 7.01-6.96 (2H, m), 
6.89 (1H, dd, J = 8.3, 2.3 Hz), 5.25 (2H, s), 3.85 (3H, s), 3.62 (4H, t, J = 4.8 Hz), 2.80 (4H, t, J = 4.7 Hz); 13C 
NMR (125 MHz, (CD3)2SO) 149.6, 138.4, 125.9, 116.2, 111.5, 109.9, 65.3, 55.6, 45.9; νmax/cm-1 3486 (N-H), 
3390 (N-H), 2924, 2864, 1691, 1611, 1507; HRMS (ESI)+: m/z calculated for [C11H16N2O4S + Na]+ = 295.0723, 
observed 295.0719. 
2-Methoxy-5-(thiomorpholinosulfonyl)aniline (33f) 
 
Thiomorpholine (76 µL, 0.76 mmol) was added dropwise at 0 °C to a suspension of NaH (60% in mineral 
oil, 76 mg, 1.9 mmol) in DMF (2 mL). The reaction mixture was stirred at 0 °C over 20 minutes. A solution 
of 4-methoxy-3-(2,2,2-trifluoroacetamido)benzenesulfonyl chloride 19 (0.200 g, 0.630 mmol) in DMF (1 
167 
 
mL) was added dropwise at 0 °C to the reaction mixture. The reaction mixture was warmed to rt and 
stirred over 2 hours. Ethanol (5 mL) was added dropwise at 0 °C to the reaction mixture, followed by water 
(5 mL) and aqueous HCl (37.5% w/v, 5 mL). The reaction mixture was heated under reflux for 17 hours. 
The reaction mixture was adjusted to pH 9 by the dropwise addition of aqueous NaOH (10% w/v) at rt, 
then concentrated in vacuo to remove ethanol. The mixture was diluted with EtOAc (50 mL), washed with 
water (3 x 25 mL) and brine (25 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash 
chromatography (0 – 50% EtOAc in PET) afforded 33f (0.126 g, 67% yield). 
LCMS (ESI+): m/z 289.2 [M + H]+, rt 1.66 minutes, 96%; 1H NMR (400 MHz, CDCl3) 7.11 (1H, dd, J = 8.4, 2.2 
Hz), 7.02 (1H, d, J = 2.2 Hz), 6.83 (1H, d, J = 8.4 Hz), 4.02 (2H, br s), 3.91 (3H, s), 3.31 (4H, t, J = 4.9 Hz), 2.69 
(4H, t, J = 5.2 Hz); 13C NMR (100 MHz, CDCl3) 150.5, 137.0, 128.6, 118.5, 112.8, 109.8, 55.9, 48.1, 27.5; 
νmax/cm-1 3489 (N-H), 3389 (N-H), 2970, 2914, 2852, 1730, 1611, 1577, 1512; HRMS (ESI)+: m/z calculated 
for [C11H16N2O3S2 + H]+ = 289.0675, observed 289.0688. 
4-((3-Amino-4-methoxyphenyl)sulfonyl)thiomorpholine 1,1-dioxide (33g) 
 
Triethylamine (0.66 mL, 4.7 mmol) and DCM (20 mL) were added to a mixture of thiomorpholine 1,1-
dioxide (0.153 g, 1.13 mmol), 4-methoxy-3-(2,2,2-trifluoroacetamido)benzenesulfonyl chloride 19 (0.300 
g, 0.944 mmol) and DMAP (35 mg, 0.28 mmol). The reaction mixture was stirred over 30 minutes, then 
concentrated in vacuo. Ethanol (30 mL), water (30 mL) and aqueous HCl (37.5% w/v, 30 mL) were added, 
and the reaction mixture heated under reflux for 3 hours. The reaction mixture was concentrated in vacuo 
to remove ethanol, then adjusted to pH 14 by the dropwise addition of aqueous NaOH (10% w/v). The 
product was extracted into DCM (3 x 100 mL). The combined organic extracts were washed (brine), dried 
(MgSO4) and concentrated in vacuo. Purification by flash chromatography (20 – 70% EtOAc in PET, 0 – 7% 
methanol in DCM) afforded 33g (0.250 g, 80% yield). 
LCMS (ESI+): m/z 321.2 [M + H]+, rt 1.44 minutes, 97%; 1H NMR (400 MHz, (CD3)2SO) 7.03-6.92 (3H, m), 
5.27 (2H, s), 3.85 (3H, s), 3.42-3.30 (4H, m), 3.22 (4H, t, J = 5.0 Hz); 13C NMR (100 MHz, (CD3)2SO) 150.1, 
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138.9, 127.4, 116.2, 111.0, 110.4, 55.9, 50.2, 45.3; νmax/cm-1 3458 (N-H), 3369 (N-H), 2907, 2849, 1616, 
1579, 1510; HRMS (ESI)+: m/z calculated for [C11H16N2O5S2 + Na]+ = 343.0393, observed 343.0394. 
3-Amino-4-methoxy-N-phenylbenzenesulfonamide (33h) 
 
Aniline (43 µL, 0.47 mmol) was added dropwise at 0 °C to a suspension of NaH (60% in mineral oil, 57 mg, 
1.4 mmol) in DMF (1 mL). The reaction mixture was stirred at 0 °C over 20 minutes. A solution of 4-
methoxy-3-(2,2,2-trifluoroacetamido)benzenesulfonyl chloride 19 (0.150 g, 0.472 mmol) in DMF (2 mL) 
was added dropwise at 0 °C to the reaction mixture. The reaction mixture was warmed to rt and stirred 
over 1 hour. Ethanol (5 mL) was added dropwise at 0 °C to the reaction mixture, followed by water (5 mL) 
and aqueous HCl (37.5% w/v, 5 mL). The reaction mixture was heated under reflux for 10 hours. The 
reaction mixture was adjusted to pH 9 by the dropwise addition of aqueous NaOH (10% w/v) at rt, then 
concentrated in vacuo to remove ethanol. The product was extracted into DCM (3 x 25 mL). The combined 
organic extracts were washed (brine), dried (MgSO4) and concentrated in vacuo. Purification by flash 
chromatography (0 – 75% EtOAc in PET) afforded 33h (50 mg, 37% yield). 
LCMS (ESI+): m/z 279.2 [M + H]+, (ESI-): m/z 277.1 [M - H]-, rt 1.77 minutes, 97%; 1H NMR (400 MHz, CDCl3) 
7.25-7.19 (2H, m), 7.16 (1H, dd, J = 8.4, 2.3 Hz), 7.12-7.04 (4H, m), 6.82 (1H, s), 6.72 (1H, d, J = 8.5 Hz), 3.85 
(3H, s), 3.54 (1H, br s); 13C NMR (100 MHz, CDCl3) 150.7, 136.9, 136.7, 131.0, 129.4, 125.2, 121.6, 118.7, 
112.7, 109.6, 55.8; νmax/cm-1 3380 (N-H), 3250 (N-H), 1615, 1598, 1508; HRMS (ESI)+: m/z calculated for 
[C13H14N2O3S + H]+ = 279.0798, observed 279.0796. 
3-Amino-N-benzyl-4-methoxybenzenesulfonamide (33i) 
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Benzylamine (52 µL, 0.47 mmol) was added dropwise at 0 °C to a suspension of NaH (60% in mineral oil, 
57 mg, 1.4 mmol) in DMF (1 mL). The reaction mixture was stirred at 0 °C over 20 minutes. A solution of 
4-methoxy-3-(2,2,2-trifluoroacetamido)benzenesulfonyl chloride 19 (0.150 g, 0.472 mmol) in DMF (2 mL) 
was added dropwise at 0 °C to the reaction mixture. The reaction mixture was warmed to rt and stirred 
over 1 hour. Ethanol (5 mL) was added dropwise at 0 °C to the reaction mixture, followed by water (5 mL) 
and aqueous HCl (37.5% w/v, 5 mL). The reaction mixture was heated under reflux for 10 hours. The 
reaction mixture was adjusted to pH 7 by the dropwise addition of aqueous NaOH (10% w/v) at rt, then 
concentrated in vacuo to remove ethanol. The product was extracted into DCM (3 x 25 mL). The combined 
organic extracts were washed (brine), dried (MgSO4) and concentrated in vacuo. Purification by flash 
chromatography (0 – 10% methanol in DCM) afforded 33i (89 mg, 59% yield). 
LCMS (ESI+): m/z 293.2 [M + H]+, (ESI-): m/z 291.1 [M - H]-, rt 1.80 minutes, 92%; 1H NMR (400 MHz, CDCl3) 
7.31-7.18 (6H, m), 7.16 (1H, d, J = 2.3 Hz), 6.82 (1H, d, J = 8.5 Hz), 4.59 (1H, t, J = 6.2 Hz), 4.08 (2H, d, J = 
6.3 Hz), 3.91 (3H, s); 13C NMR (100 MHz, CDCl3) 150.5, 137.0, 136.6, 131.6, 128.8, 128.1, 128.0, 118.4, 
112.6, 109.8, 55.9, 47.5; 1H NMR spectroscopic data consistent with literature. 142 
5-((3,4-Dihydroisoquinolin-2(1H)-yl)sulfonyl)-2-methoxyaniline (33j) 
 
1,2,3,4-Tetrahydroisoquinoline (95 µL, 0.76 mmol) was added dropwise at 0 °C to a suspension of NaH 
(60% in mineral oil, 76 mg, 1.9 mmol) in DMF (2 mL). The reaction mixture was stirred at 0 °C over 20 
minutes. A solution of 4-methoxy-3-(2,2,2-trifluoroacetamido)benzenesulfonyl chloride 19 (0.200 g, 0.630 
mmol) in DMF (1 mL) was added dropwise at 0 °C to the reaction mixture. The reaction mixture was 
warmed to rt and stirred over 1 hour. Ethanol (5 mL) was added dropwise at 0 °C to the reaction mixture, 
followed by water (5 mL) and aqueous HCl (37.5% w/v, 5 mL). The reaction mixture was heated under 
reflux for 24 hours, then further ethanol (10 mL), water (10 mL) and aqueous HCl (37.5% w/v, 10 mL) were 
added. The reaction mixture was heated under reflux for 24 hours. The reaction mixture was adjusted to 
pH 10 by the dropwise addition of aqueous NaOH (10% w/v) at rt, then concentrated in vacuo to remove 
ethanol. The mixture was diluted with EtOAc (50 mL), and the resultant aqueous layer discarded. The 
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organic layer was washed with water (2 x 50 mL) and brine (50 mL), dried (MgSO4) and concentrated in 
vacuo. Purification by flash chromatography (0 – 30% EtOAc in PET) afforded 33j (0.146 g, 73% yield). 
LCMS (ESI+): m/z 319.2 [M + H]+, rt 1.94 minutes, >99%; 1H NMR (400 MHz, (CD3)2SO) 7.18-7.09 (4H, m), 
7.07 (1H, d, J = 1.9 Hz), 7.02-6.94 (2H, m), 5.23 (2H, s), 4.10 (2H, s), 3.83 (3H, s), 3.20 (2H, t, J = 5.9 Hz), 
2.86 (2H, t, J = 5.9 Hz); 13C NMR (100 MHz, (CD3)2SO) 149.5, 138.4, 133.0, 131.7, 128.7, 127.1, 126.6, 126.4, 
126.1, 116.1, 111.4, 110.0, 55.6, 47.3, 43.6, 28.2; νmax/cm-1 3457 (N-H), 3363 (N-H), 1624, 1583, 1505; 
HRMS (ESI)+: m/z calculated for [C16H18N2O3S + H]+ = 319.1111, observed 319.1122. 
5-((6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)-2-methoxyaniline (33k) 
 
6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (0.174 g, 0.756 mmol) was added 
portionwise at 0 °C to a suspension of NaH (60% in mineral oil, 0.126 g, 3.15 mmol) in DMF (3 mL). The 
reaction mixture was stirred at 0 °C over 20 minutes. A solution of 4-methoxy-3-(2,2,2-
trifluoroacetamido)benzenesulfonyl chloride 19 (0.200 g, 0.630 mmol) in DMF (2 mL) was added dropwise 
at 0 °C to the reaction mixture. The reaction mixture was warmed to rt and stirred over 1 hour. Ethanol 
(15 mL) was added dropwise at 0 °C to the reaction mixture, followed by water (15 mL) and aqueous HCl 
(37.5% w/v, 15 mL). The reaction mixture was heated under reflux for 20 hours. The reaction mixture was 
concentrated in vacuo to remove ethanol, then adjusted to pH 14 by the dropwise addition of aqueous 
NaOH (10% w/v). The mixture was diluted with EtOAc (50 mL), and the resultant aqueous layer discarded. 
The organic layer was washed with water (2 x 50 mL) and brine (50 mL), dried (MgSO4) and concentrated 
in vacuo. Purification by flash chromatography (0 – 100% EtOAc in PET) afforded 33k (0.194 g, 81% yield). 
LCMS (ESI+): m/z 379.3 [M + H]+, rt 1.80 minutes, >99%; 1H NMR (400 MHz, CDCl3) 7.21 (1H, dd, J = 8.4, 
2.2 Hz), 7.13 (1H, d, J = 2.2 Hz), 6.84 (1H, d, J = 8.4 Hz), 6.55 (1H, s), 6.50 (1H, s), 4.15 (2H, s), 4.01 (2H, br 
s), 3.90 (3H, s), 3.82 (3H, s), 3.81 (3H, s), 3.31 (2H, t, J = 5.9 Hz), 2.84 (2H, t, J = 5.8 Hz); 13C NMR (100 MHz, 
CDCl3) 150.5, 147.9, 147.8, 136.8, 128.1, 125.2, 123.8, 118.9, 113.2, 111.4, 109.8, 109.2, 56.1, 56.0, 55.9, 
47.5, 44.0, 28.7; νmax/cm-1 3483 (N-H), 3365 (N-H), 2966, 2930, 2842, 1661, 1611, 1578, 1512; HRMS (ESI)+: 
m/z calculated for [C18H22N2O5S + Na]+ = 401.1142, observed 401.1124. 
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2-Methoxy-5-((1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-yl)sulfonyl)aniline (33l) 
 
A solution of 2,3,4,5-tetrahydro-1H-benzo[d]azepine (0.167 g, 1.13 mmol) in DMF (1 mL) was added 
dropwise at 0 °C to a suspension of NaH (60% in mineral oil, 0.113 g, 2.83 mmol) in DMF (2 mL). The 
reaction mixture was stirred at 0 °C over 20 minutes. A solution of 4-methoxy-3-(2,2,2-
trifluoroacetamido)benzenesulfonyl chloride 19 (0.300 g, 0.944 mmol) in DMF (2 mL) was added dropwise 
at 0 °C to the reaction mixture. The reaction mixture was warmed to rt and stirred over 30 minutes. 
Ethanol (30 mL) was added dropwise at 0 °C to the reaction mixture, followed by water (30 mL) and 
aqueous HCl (37.5% w/v, 30 mL). The reaction mixture was heated under reflux for 15 hours. The reaction 
mixture was concentrated in vacuo to remove ethanol, then adjusted to pH 8 by the dropwise addition of 
aqueous NaOH (10% w/v). The mixture was diluted with EtOAc (100 mL), and the resultant aqueous layer 
discarded. The organic layer was washed with water (2 x 100 mL) and brine (100 mL), dried (MgSO4) and 
concentrated in vacuo. Purification by flash chromatography (0 – 50% EtOAc in PET) afforded 33l (0.131 
g, 42% yield). 
LCMS (ESI+): m/z 333.2 [M + H]+, rt 2.07 minutes, >99%; 1H NMR (500 MHz, (CD3)2SO) 7.10 (4H, s), 7.00-
6.96 (1H, m), 6.93-6.88 (2H, m), 5.17 (2H, s), 3.80 (3H, s), 3.17-3.06 (4H, m), 2.96-2.87 (4H, m); 13C NMR 
(125 MHz, (CD3)2SO) 149.3, 140.5, 138.3, 129.1, 129.0, 126.5, 115.5, 110.9, 109.9, 55.5, 48.2, 35.6; νmax/cm-
1 3459 (N-H), 3367 (N-H), 2906, 2850, 1615, 1579, 1509; HRMS (ESI)+: m/z calculated for [C17H20N2O3S + 
Na]+ = 355.1087, observed 355.1085. 
2-Methoxy-5-((7-methoxy-1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-yl)sulfonyl)aniline (33m) 
 
Triethylamine (0.29 mL, 2.1 mmol) and DCM (10 mL) were added to a mixture of 7-methoxy-2,3,4,5-
tetrahydro-1H-benzo[d]azepine hydrochloride (96 mg, 0.45 mmol), 4-methoxy-3-(2,2,2-
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trifluoroacetamido)benzenesulfonyl chloride 19 (0.130 g, 0.409 mmol) and DMAP (10 mg, 0.082 mmol). 
The reaction mixture was stirred over 1 hour, then concentrated in vacuo. Ethanol (30 mL), water (30 mL) 
and aqueous HCl (37.5% w/v, 30 mL) were added, and the reaction mixture heated under reflux for 3 
hours. The reaction mixture was adjusted to pH 10 by the dropwise addition of Na2CO3 solution at 0 °C 
and extracted into DCM (3 x 100 mL). The combined organic extracts were washed (brine), dried (MgSO4) 
and concentrated in vacuo. Purification by flash chromatography (20 – 50% EtOAc in PET) afforded 33m 
(0.111 g, 75% yield). 
LCMS (ESI+): m/z 363.3 [M + H]+, rt 2.01 minutes, >99%; 1H NMR (500 MHz, (CD3)2SO) 7.00 (1H, d, J = 8.3 
Hz), 6.97 (1H, d, J = 1.9 Hz), 6.93-6.87 (2H, m), 6.69 (1H, d, J = 2.7 Hz), 6.64 (1H, dd, J = 8.3, 2.7 Hz), 5.17 
(2H, s), 3.80 (3H, s), 3.67 (3H, s), 3.16-3.02 (4H, m), 2.91-2.77 (4H, m); 13C NMR (125 MHz, (CD3)2SO) 157.8, 
149.3, 141.8, 138.4, 132.5, 130.2, 129.0, 115.6, 115.0, 111.2, 110.9, 109.9, 55.6, 55.0, 48.7, 48.2, 35.8, 
34.7; νmax/cm-1 3474 (N-H), 3443, 3367 (N-H), 2944, 2906, 2845, 1613, 1579, 1506; HRMS (ESI)+: m/z 
calculated for [C18H22N2O4S + Na]+ = 385.1192, observed 385.1192. 
2-Methoxy-5-((1,2,4,5-tetrahydro-3H-1,5-methanobenzo[d]azepin-3-yl)sulfonyl)aniline (33n) 
 
Triethylamine (0.33 mL, 2.4 mmol) and DCM (10 mL) were added to a mixture of 2,3,4,5-tetrahydro-1H-
1,5-methano-3-benzazepine hydrochloride (0.102 g, 0.519 mmol), 4-methoxy-3-(2,2,2-
trifluoroacetamido)benzenesulfonyl chloride 19 (0.150 g, 0.472 mmol) and DMAP (12 mg, 0.094 mmol). 
The reaction mixture was stirred over 1 hour, then concentrated in vacuo. Ethanol (30 mL), water (30 mL) 
and aqueous HCl (37.5% w/v, 30 mL) were added, and the reaction mixture heated under reflux for 16 
hours. The reaction mixture was adjusted to pH 10 by the dropwise addition of Na2CO3 solution at 0 °C 
and extracted into DCM (3 x 100 mL). The combined organic extracts were washed (brine), dried (MgSO4) 
and concentrated in vacuo. Purification by flash chromatography (0 – 50% EtOAc in PET) afforded 33n 
(0.118 g, 65% yield). 
LCMS (ESI+): m/z 345.2 [M + H]+, rt 2.05 minutes, >99%; 1H NMR (500 MHz, (CD3)2SO) 7.25-7.14 (4H, m), 
6.88 (1H, d, J = 8.5 Hz), 6.84 (1H, d, J = 2.3 Hz), 6.68 (1H, dd, J = 8.3, 2.3 Hz), 5.14 (2H, s), 3.83 (3H, s), 3.46-
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3.38 (2H, m), 3.23-3.16 (2H, m), 2.74 (2H, dd, J = 10.7, 1.3 Hz), 2.14-2.04 (1H, m), 1.50 (1H, d, J = 10.8 Hz); 
13C NMR (125 MHz, (CD3)2SO) 149.2, 144.4, 138.1, 128.0, 126.9, 122.4, 115.6, 111.2, 109.8, 55.6, 49.3, 41.5 
(1 peak missing); νmax/cm-1 3455 (N-H), 3364 (N-H), 2950, 2854, 1733, 1621, 1578, 1509; HRMS (ESI)+: m/z 
calculated for [C18H20N2O3S + Na]+ = 367.1087, observed 367.1092. 
1-((3-Nitrophenyl)sulfonyl)azepane (35) 
 
Hexamethyleneimine (0.303 mL, 2.71 mmol) was added dropwise at 0 °C to a suspension of NaH (60% in 
mineral oil, 0.271 g, 6.77 mmol) in DMF (3 mL). The reaction mixture was stirred at 0 °C over 20 minutes. 
A solution of 3-nitrobenzenesulfonyl chloride 34 (0.500 g, 2.26 mmol) in DMF (2 mL) was added dropwise 
at 0 °C to the reaction mixture. The reaction mixture was warmed to rt and stirred over 90 min. Water (25 
mL) was added dropwise at 0 °C to the reaction mixture, followed by EtOAc (25 mL) with the resultant 
aqueous layer discarded. The organic layer was washed with water (2 x 25 mL) and brine (25 mL), dried 
(MgSO4) and concentrated in vacuo. Purification by flash chromatography (0 – 20% EtOAc in PET) afforded 
35 (0.267 g, 42% yield). 
1H NMR (400 MHz, CDCl3) 8.61 (1H, t, J = 1.9 Hz), 8.40 (1H, ddd, J = 8.2, 2.2, 1.0 Hz), 8.12 (1H, ddd, J = 7.8, 
1.7, 1.1 Hz), 7.73 (1H, t, J = 8.0 Hz), 3.31 (4H, t, J = 5.9 Hz), 1.80-1.68 (4H, m), 1.65-1.55 (4H, m); 13C NMR 
(100 MHz, CDCl3) 148.5, 142.0, 132.5, 130.5, 126.8, 122.1, 48.6, 29.3, 26.9; νmax/cm-1 3101, 2937, 2858, 
1608, 1523 (N=O), 1338 (N=O); HRMS (ESI)+: m/z calculated for [C12H16N2O4S + H]+ = 285.0904, observed 
285.0897. 
1-((4-Methyl-3-nitrophenyl)sulfonyl)azepane (37) 
 
Hexamethyleneimine (0.285 mL, 2.55 mmol) was added dropwise at 0 °C to a suspension of NaH (60% in 
mineral oil, 0.110 g, 2.76 mmol) in DMF (3 mL). The reaction mixture was stirred at 0 °C over 20 minutes. 
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A solution of 4-methyl-3-nitrobenzenesulfonyl chloride 36 (0.500 g, 2.12 mmol) in DMF (2 mL) was added 
dropwise at 0 °C to the reaction mixture. The reaction mixture was warmed to rt and stirred over 1 hour. 
Water (25 mL) was added dropwise at 0 °C to the reaction mixture, followed by EtOAc (25 mL) with the 
resultant aqueous layer discarded. The organic layer was washed with water (2 x 25 mL) and brine (25 
mL), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (0 – 20% EtOAc in 
PET) afforded 37 (0.453 g, 72% yield). 
LCMS (ESI+): m/z 299.2 [M + H]+, rt 2.15 minutes, >99%; 1H NMR (400 MHz, CDCl3) 8.35 (1H, d, J = 1.9 Hz), 
7.89 (1H, dd, J = 8.0, 1.9 Hz), 7.50 (1H, d, J = 8.1 Hz), 3.30 (4H, t, J = 5.9 Hz), 2.67 (3H, s), 1.81-1.68 (4H, m), 
1.65-1.54 (4H, m); 13C NMR (100 MHz, CDCl3) 149.3, 139.3, 137.9, 133.9, 130.8, 123.4, 48.5, 29.3, 27.0, 
20.6; νmax/cm-1 2934, 2861, 1608, 1523 (N=O), 1338 (N=O); HRMS (ESI)+: m/z calculated for [C13H18N2O4S 
+ H]+ = 299.1060, observed 299.1065. 
5-(Azepan-1-ylsulfonyl)-2-methylaniline (38) 
 
NaBH4 (83 mg, 2.2 mmol) was added portionwise at 0 °C to a suspension of NiCl2 (95 mg, 0.74 mmol) in 
methanol (2 mL). The reaction mixture was warmed to rt and stirred over 30 minutes. 1-((4-Methyl-3-
nitrophenyl)sulfonyl)azepane 37 (0.439 g, 1.47 mmol) was added at 0 °C to the reaction mixture, followed 
by further methanol (8 mL) and NaBH4 (0.278 g, 7.36 mmol). The reaction mixture was warmed to rt and 
stirred over 45 minutes. Water (10 mL) was added at 0 °C and the mixture filtered through celite, eluted 
with methanol (10 mL) and water (15 mL). The filtrate was concentrated in vacuo to remove methanol, 
then extracted into EtOAc (3 x 25 mL). The combined organic extracts were washed (brine), dried (MgSO4) 
and concentrated in vacuo. Purification by flash chromatography (20 – 50% EtOAc in PET) afforded 38 
(0.347 g, 88% yield). 
LCMS (ESI+): m/z 269.2 [M + H]+, rt 1.90 minutes, >99%; 1H NMR (400 MHz, CDCl3) 7.13 (1H, d, J = 8.4 Hz), 
7.10-7.04 (2H, m), 3.80 (2H, br s), 3.24 (4H, t, J = 5.9 Hz), 2.19 (3H, s), 1.77-1.65 (4H, m), 1.63-1.53 (4H, m); 
13C NMR (100 MHz, CDCl3) 145.2, 137.9, 131.0, 126.7, 116.9, 112.8, 48.4, 29.3, 27.1, 17.6; νmax/cm-1 3490 
(N-H), 3377 (N-H), 2930, 2858, 1625, 1574; HRMS (ESI)+: m/z calculated for [C13H20N2O2S + H]+ = 269.1318, 
observed 269.1321. 
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Azepan-1-yl(4-hydroxy-3-nitrophenyl)methanone (42) 
 
T3P® (50 wt. % in DMF, 3.3 mL, 5.5 mmol) and DIPEA (0.95 mL, 5.5 mmol) were added to a solution of 4-
hydroxy-3-nitrobenzoic acid 41 (0.500 g, 2.73 mmol) and hexamethyleneimine (0.61 mL, 5.5 mmol) in 
DMF (2 mL). The reaction mixture was stirred over 1 day, then diluted with water (15 mL), adjusted to pH 
2 and extracted into DCM (3 x 20 mL). The combined organic extracts were dried (MgSO4) and 
concentrated in vacuo. Purification by flash chromatography (0 – 10% methanol in DCM) afforded 42 
(0.174 g, 24% yield). 
LCMS (ESI+): m/z 265.3 [M + H]+, (ESI-): m/z 263.2 [M - H]-, rt 1.84 minutes, >99%; 1H NMR (400 MHz, 
CD3CN) 10.34 (1H, br s), 8.10 (1H, d, J = 2.0 Hz), 7.65 (1H, dd, J = 8.7, 2.2 Hz), 7.20 (1H, d, J = 8.6 Hz), 3.58 
(2H, t, J = 5.7 Hz), 3.37 (2H, t, J = 5.4 Hz), 1.83-1.71 (2H, m), 1.68-1.51 (6H, m); 13C NMR (100 MHz, CD3CN) 
169.3, 155.8, 136.8, 134.5, 130.8, 124.4, 120.9, 50.5, 46.9, 30.0, 28.4, 28.0, 27.0; νmax/cm-1 2927, 2857, 
1623 (C=O), 1531 (N=O), 1350 (N=O); HRMS (ESI)+: m/z calculated for [C13H16N2O4 + H]+ = 265.1183, 
observed 265.1184. 
Azepan-1-yl(4-methoxy-3-nitrophenyl)methanone (43) 
 
Dimethyl sulfate (0.115 mL, 1.21 mmol) was added to a suspension of azepan-1-yl(4-hydroxy-3-
nitrophenyl)methanone 42 (0.160 g, 0.605 mmol) and K2CO3 (0.167 g, 1.21 mmol) in acetone (5 mL). The 
reaction mixture was heated under reflux for 2 hours. The reaction mixture was diluted with water (15 
mL) at 0 °C, then concentrated in vacuo to remove acetone. The product was extracted into DCM (3 x 20 
mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo. Purification by flash 
chromatography (40 – 100% EtOAc in PET) afforded 43 (0.129 g, 77% yield). 
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LCMS (ESI+): m/z 279.3 [M + H]+, rt 1.90 minutes, >99%; 1H NMR (400 MHz, CD3CN) 7.83 (1H, d, J = 2.1 Hz), 
7.62 (1H, dd, J = 8.6, 2.1 Hz), 7.27 (1H, d, J = 8.7 Hz), 3.96 (3H, s), 3.58 (2H, t, J = 5.7 Hz), 3.37 (2H, t, J = 5.5 
Hz), 1.83-1.71 (2H, m), 1.67-1.50 (6H, m); 13C NMR (100 MHz, CD3CN) 169.4, 153.9, 140.1, 133.6, 130.7, 
124.7, 114.9, 57.6, 50.5, 46.8, 30.0, 28.5, 28.0, 27.0; νmax/cm-1 2928, 2854, 1615 (C=O), 1530 (N=O), 1350 
(N=O); HRMS (ESI)+: m/z calculated for [C14H18N2O4 + H]+ = 279.1339, observed 279.1345. 
(3-Amino-4-methoxyphenyl)(azepan-1-yl)methanone (44) 
 
NaBH4 (22 mg, 0.59 mmol) was added portionwise at 0 °C to a suspension of NiCl2·6H2O (47 mg, 0.20 
mmol) in methanol (1 mL). The reaction mixture was warmed to rt and stirred over 20 minutes. A solution 
of azepan-1-yl(4-methoxy-3-nitrophenyl)methanone 43 (0.109 g, 0.392 mmol) in methanol (1 mL) was 
added at 0 °C to the reaction mixture, followed by NaBH4 (52 mg, 1.4 mmol). The reaction mixture was 
warmed to rt and stirred over 1 hour, then further NaBH4 (30 mg, 0.78 mmol) was added at 0 °C. The 
reaction mixture was warmed to rt and stirred over 30 minutes. Water (15 mL) was added at 0 °C, and the 
reaction mixture filtered through celite. The filtrate was extracted into DCM (3 x 20 mL). The combined 
organic extracts were dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (20 
– 100% EtOAc in PET) afforded 44 (62 mg, 64% yield). 
LCMS (ESI+): m/z 249.3 [M + H]+, rt 1.61 minutes, >99%; 1H NMR (500 MHz, CD3CN) 6.80 (1H, d, J = 8.1 Hz), 
6.65 (1H, d, J = 2.0 Hz), 6.62 (1H, dd, J = 8.1, 2.1 Hz), 4.16 (2H, br s), 3.83 (3H, s), 3.61-3.48 (2H, m), 3.44-
3.29 (2H, m), 1.82-1.67 (2H, m), 1.66-1.48 (6H, m); 13C NMR (125 MHz, CD3CN) 172.2, 148.3, 138.0, 131.5, 
116.6, 113.3, 110.8, 56.2, 50.4, 46.6, 30.2, 28.5, 28.1, 27.0; νmax/cm-1 3466 (N-H), 3330 (N-H), 2922, 2853, 
1608 (C=O), 1584, 1516; HRMS (ESI)+: m/z calculated for [C14H20N2O2 + H]+ = 249.1598, observed 249.1600. 
3-(3-Methoxyphenyl)-3-oxopropanenitrile (58) 
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n-Butyllithium (1.6 M in hexanes, 5.2 mL, 8.3 mmol) was added dropwise at -78 °C to a mixture of 
acetonitrile (0.87 mL, 17 mmol) and THF (10 mL). The reaction mixture was stirred at -78 °C over 30 
minutes. Ethyl 3-methoxybenzoate 57 (0.600 g, 3.33 mmol) was added dropwise at -78 °C, and the 
reaction mixture stirred at -78 °C over 30 minutes. Water (10 mL) and aqueous HCl (1 M, 20 mL) were 
added dropwise at 0 °C. The product was extracted into DCM (3 x 25 mL). The combined organic extracts 
were washed (brine), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (0 
– 50% EtOAc in PET) afforded 58 (0.599 g, 99% yield). 
LCMS (ESI-): m/z 174.1 [M - H]-, rt 1.56 minutes, >99%; 1H NMR (400 MHz, CDCl3) 7.49-7.39 (3H, m), 7.23-
7.17 (1H, m), 4.07 (2H, s), 3.87 (3H, s); 13C NMR (100 MHz, CDCl3) 187.1, 160.3, 135.7, 130.3, 121.4, 121.1, 
113.9, 112.8, 55.7, 29.6; spectroscopic data consistent with literature. 143 
Methyl 1-(4-methoxybenzyl)-1H-indole-6-carboxylate (64a) 
 
4-Methoxybenzyl chloride (0.255 mL, 1.88 mmol) was added to a suspension of methyl 1H-indole-6-
carboxylate 63 (0.300 g, 1.71 mmol) and Cs2CO3 (1.12 g, 3.42 mmol) in acetonitrile (10 mL). The reaction 
mixture was heated under reflux for 1 hour, then concentrated in vacuo. Water (25 mL) was added to the 
resultant residue and the product extracted into DCM (3 x 25 mL). The combined organic extracts were 
washed (brine), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (0 – 30% 
EtOAc in PET) afforded 64a (0.445 g, 88% yield). 
LCMS (ESI+): m/z 296.2 [M + H]+, rt 2.16 minutes, >99%; 1H NMR (400 MHz, CDCl3) 8.12 (1H, s), 7.81 (1H, 
dd, J = 8.3, 1.3 Hz), 7.65 (1H, d, J = 8.4 Hz), 7.24 (1H, d, J = 3.1 Hz), 7.12-7.04 (2H, m), 6.87-6.81 (2H, m), 
6.57 (1H, dd, J = 3.1, 0.6 Hz), 5.31 (2H, s), 3.92 (3H, s), 3.77 (3H, s); 13C NMR (100 MHz, CDCl3) 168.3, 159.4, 
135.8, 132.5, 131.3, 129.1, 128.5, 123.5, 120.7, 120.6, 114.4, 112.1, 102.1, 55.4, 52.1, 49.7; νmax/cm-1 2951, 
2835, 1697 (C=O), 1614, 1585, 1511; HRMS (ESI)+: m/z calculated for [C18H17NO3 + Na]+ = 318.1101, 
observed 318.1107. 
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Methyl 1-(3-methoxybenzyl)-1H-indole-6-carboxylate (64b) 
 
3-Methoxybenzyl chloride (0.299 mL, 2.05 mmol) was added to a suspension of methyl 1H-indole-6-
carboxylate 63 (0.300 g, 1.71 mmol) and Cs2CO3 (1.12 g, 3.42 mmol) in acetonitrile (10 mL). The reaction 
mixture was heated under reflux for 1 hour, then concentrated in vacuo. Water (20 mL) was added to the 
resultant residue and the product extracted into DCM (3 x 25 mL). The combined organic extracts were 
washed (brine), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (0 – 25% 
EtOAc in PET) afforded 64b (0.471 g, 93% yield). 
LCMS (ESI+): m/z 296.2 [M + H]+, rt 2.18 minutes, 98%; 1H NMR (500 MHz, CDCl3) 8.10 (1H, s), 7.81 (1H, 
dd, J = 8.3, 1.4 Hz), 7.66 (1H, dd, J = 8.4, 0.6 Hz), 7.27 (1H, d, J = 3.2 Hz), 7.22 (1H, t, J = 7.9 Hz), 6.81 (1H, 
dd, J = 8.1, 2.4 Hz), 6.72-6.68 (1H, m), 6.65-6.62 (1H, m), 6.59 (1H, dd, J = 3.1, 0.9 Hz), 5.35 (2H, s), 3.91 
(3H, s), 3.73 (3H, s); 13C NMR (125 MHz, CDCl3) 168.3, 160.2, 138.8, 135.9, 132.4, 131.6, 130.1, 123.6, 
120.8, 120.7, 119.2, 113.1, 112.8, 112.1, 102.4, 55.3, 52.1, 50.1; νmax/cm-1 2913, 1703 (C=O), 1602, 1505; 
HRMS (ESI)+: m/z calculated for [C18H17NO3 + H]+ = 296.1281, observed 296.1277. 
Methyl 1-benzyl-1H-indole-6-carboxylate (64c) 
 
Benzyl bromide (0.244 mL, 2.05 mmol) was added to a suspension of methyl 1H-indole-6-carboxylate 63 
(0.300 g, 1.71 mmol) and Cs2CO3 (1.12 g, 3.42 mmol) in acetonitrile (15 mL). The reaction mixture was 
heated under reflux for 2 hours, then concentrated in vacuo. Water (15 mL) was added to the resultant 
residue and the product extracted into DCM (3 x 25 mL). The combined organic extracts were washed 
(brine), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (0 – 25% EtOAc in 
PET) afforded 64c (0.436 g, 91% yield). 
LCMS (ESI+): m/z 266.2 [M + H]+, rt 2.16 minutes, 95%; 1H NMR (400 MHz, CDCl3) 8.09 (1H, s), 7.80 (1H, 
dd, J = 8.3, 1.4 Hz), 7.65 (1H, d, J = 8.3 Hz), 7.34-7.23 (4H, m), 7.13-7.07 (2H, m), 6.58 (1H, dd, J = 3.1, 0.7 
Hz), 5.38 (2H, s), 3.90 (3H, s); 13C NMR (100 MHz, CDCl3) 168.3, 137.2, 135.9, 132.4, 131.5, 129.0, 128.0, 
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126.9, 123.6, 120.8, 120.7, 112.1, 102.3, 52.1, 50.2; νmax/cm-1 2949, 1704 (C=O), 1613; HRMS (ESI)+: m/z 
calculated for [C17H15NO2 + H]+ = 266.1176, observed 266.1182. 
Methyl 1-(2-cyanobenzyl)-1H-indole-6-carboxylate (64d) 
 
2-(Bromomethyl)benzonitrile (0.403 g, 2.05 mmol) was added to a suspension of methyl 1H-indole-6-
carboxylate 63 (0.300 g, 1.71 mmol) and Cs2CO3 (1.12 g, 3.42 mmol) in acetonitrile (10 mL). The reaction 
mixture was heated under reflux for 4 hours, then concentrated in vacuo. Water (20 mL) was added to 
the resultant residue and the product extracted into DCM (3 x 25 mL). The combined organic extracts 
were washed (brine), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (0 
– 25% EtOAc in PET) afforded 64d (0.399 g, 80% yield). 
1H NMR (400 MHz, CDCl3) 8.04 (1H, s), 7.84 (1H, dd, J = 8.4, 1.4 Hz), 7.73 (1H, dd, J = 7.5, 1.4 Hz), 7.69 (1H, 
d, J = 8.3 Hz), 7.44 (1H, td, J = 7.7, 1.4 Hz), 7.38 (1H, td, J = 7.6, 1.2 Hz), 7.33 (1H, d, J = 3.2 Hz), 6.78 (1H, 
dd, J = 7.7, 0.7 Hz), 6.65 (1H, dd, J = 3.2, 0.8 Hz), 5.62 (2H, s), 3.91 (3H, s); 13C NMR (100 MHz, CDCl3) 168.1, 
140.9, 135.8, 133.6, 133.3, 132.5, 131.6, 128.5, 127.4, 124.1, 121.2, 121.0, 117.2, 111.8, 110.9, 103.2, 
52.2, 48.3; νmax/cm-1 2227 (C≡N), 1703 (C=O), 1616, 1601, 1502; HRMS (ESI)+: m/z calculated for 
[C18H14N2O2 + H]+ = 291.1128, observed 291.1134. 
Methyl 1-(pyridin-2-ylmethyl)-1H-indole-6-carboxylate (64f) 
 
2-(Bromomethyl)pyridine hydrobromide (0.476 mg, 1.88 mmol) was added to a suspension of methyl 1H-
indole-6-carboxylate 63 (0.300 g, 1.71 mmol) and Cs2CO3 (1.39 g, 4.28 mmol) in acetonitrile (15 mL). The 
reaction mixture was heated under reflux for 15 hours, then concentrated in vacuo. Water (20 mL) was 
added and the product extracted into DCM (3 x 25 mL). The combined organic extracts were washed 
(brine), dried (MgSO4) and concentrated in vacuo.  Purification by flash chromatography (0 – 50% EtOAc 
in PET) afforded 64f (0.386 g, 85% yield). 
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LCMS (ESI+): m/z 267.3 [M + H]+, rt 1.82 minutes, 100%; 1H NMR (400 MHz, CDCl3) 8.60 (1H, dq, J = 4.9, 
0.8 Hz), 8.09-8.05 (1H, m), 7.82 (1H, dd, J = 8.3, 1.4 Hz), 7.67 (1H, dd, J = 8.3, 0.5 Hz), 7.54 (1H, td, J = 7.7, 
1.8 Hz), 7.37 (1H, d, J = 3.2 Hz), 7.21-7.14 (1H, m), 6.70 (1H, d, J = 7.8 Hz), 6.63 (1H, dd, J = 3.1, 0.8 Hz), 
5.52 (2H, s), 3.90 (3H, s); 13C NMR (100 MHz, CDCl3) 168.2, 157.1, 149.7, 137.3, 135.8, 132.5, 131.8, 123.8, 
122.8, 120.9, 120.8, 112.1, 102.7, 52.10, 52.08 (1 peak missing); νmax/cm-1 1717 (C=O), 1593, 1505; HRMS 
(ESI)+: m/z calculated for [C16H14N2O2 + H]+ = 267.1128, observed 267.1136. 
Methyl 1-(pyridin-3-ylmethyl)-1H-indole-6-carboxylate (64g) 
 
Methyl 1H-indole-6-carboxylate 63 (0.600 g, 3.42 mmol) was added portionwise at 0 °C to a suspension 
of NaH (60% in mineral oil, 0.685 g, 17.1 mmol) in DMF (5 mL). The reaction mixture was warmed to rt 
and stirred over 1 hour. 3-(Chloromethyl)pyridine hydrochloride (0.674 g, 4.11 mmol) was added 
portionwise at 0 °C to the reaction mixture. The reaction mixture was warmed to rt and stirred over 45 
minutes. Methanol (150 mL) was added dropwise at 0 °C, and the reaction mixture adjusted to pH 1 using 
sulfuric acid dropwise at 0 °C. The reaction mixture was heated under reflux for 14 hours, then further 
sulfuric acid (10 mL) was added dropwise at 0 °C. The reaction mixture was heated under reflux for 2 
hours, then concentrated in vacuo. NaHCO3 solution (200 mL) was added dropwise at 0 °C. The product 
was extracted into DCM (3 x 150 mL). The combined organic extracts were washed with NaHCO3 solution 
(100 mL) and brine (100 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash 
chromatography (70% EtOAc in PET) afforded 64g (0.732 g, 75% yield). 
LCMS (ESI+): m/z 267.2 [M + H]+, rt 1.61 minutes, 96%; 1H NMR (400 MHz, CDCl3) 8.54 (1H, dd, J = 4.8, 1.4 
Hz), 8.51 (1H, d, J = 1.9 Hz), 8.06 (1H, s), 7.82 (1H, dd, J = 8.3, 1.4 Hz), 7.67 (1H, d, J = 8.3 Hz), 7.33 (1H, dt, 
J = 7.8, 1.9 Hz), 7.27 (1H, d, J = 3.2 Hz), 7.22 (1H, dd, J = 7.8, 4.9 Hz), 6.62 (1H, dd, J = 3.2, 0.8 Hz), 5.41 (2H, 
s), 3.91 (3H, s); 13C NMR (100 MHz, CDCl3) 168.1, 149.4, 148.3, 135.7, 134.7, 132.9, 132.5, 131.2, 124.0, 
123.9, 121.1, 120.9, 111.8, 103.0, 52.1, 47.8; νmax/cm-1 3093, 2941, 1696 (C=O), 1613, 1577, 1506; HRMS 
(ESI)+: m/z calculated for [C16H14N2O2 + H]+ = 267.1128, observed 267.1122. 
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Methyl 1-(pyridin-4-ylmethyl)-1H-indole-6-carboxylate (64h) 
 
Methyl 1H-indole-6-carboxylate 63 (0.400 g, 2.28 mmol) was added portionwise at 0 °C to a suspension 
of NaH (60% in mineral oil, 0.457 g, 11.4 mmol) in DMF (5 mL). The reaction mixture was warmed to rt 
and stirred over 1 hour. 4-(Bromomethyl)pyridine hydrobromide (0.635 g, 2.51 mmol) was added 
portionwise at 0 °C to the reaction mixture. The reaction mixture was warmed to rt and stirred over 45 
minutes. Methanol (150 mL) was added dropwise at 0 °C, and the reaction mixture adjusted to pH 1 using 
sulfuric acid dropwise at 0 °C. The reaction mixture was heated under reflux for 14 hours, then further 
sulfuric acid (10 mL) was added dropwise at 0 °C. The reaction mixture was heated under reflux for 2 
hours, then concentrated in vacuo. NaHCO3 solution (200 mL) was added dropwise at 0 °C. The product 
was extracted into DCM (3 x 150 mL). The combined organic extracts were washed with NaHCO3 solution 
(100 mL) and brine (100 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash 
chromatography (20 – 80% EtOAc in PET) afforded 64h (0.474 g, 71% yield). 
LCMS (ESI+): m/z 267.2 [M + H]+, rt 1.53 minutes, 96%; 1H NMR (400 MHz, CDCl3) 8.56-8.49 (2H, m), 7.97 
(1H, s), 7.83 (1H, dd, J = 8.4, 1.4 Hz), 7.69 (1H, dd, J = 8.3, 0.5 Hz), 7.28 (1H, d, J = 3.1 Hz), 6.96-6.91 (2H, 
m), 6.65 (1H, dd, J = 3.2, 0.8 Hz), 5.41 (2H, s), 3.90 (3H, s); 13C NMR (100 MHz, CDCl3) 168.0, 150.3, 146.5, 
135.7, 132.4, 131.5, 124.1, 121.4, 121.2, 121.0, 111.7, 103.1, 52.1, 49.1; νmax/cm-1 2948, 1699 (C=O), 1602, 
1562, 1504; HRMS (ESI)+: m/z calculated for [C16H14N2O2 + Na]+ = 289.0947, observed 289.0940. 
Methyl 1-((2-methoxypyridin-3-yl)methyl)-1H-indole-6-carboxylate (64i) 
 
p-Toluenesulfonyl chloride (1.11 g, 5.80 mmol) and DMAP (6 mg, 0.05 mmol) were added to a solution of 
(2-methoxypyridin-3-yl)methanol 74 (0.673 g, 4.84 mmol) and triethylamine (1.35 mL, 9.67 mmol) in DCM 
(7 mL). The reaction mixture was stirred over 2 hours, then diluted with NaHCO3 solution (25 mL) and 
extracted into DCM (3 x 25 mL). The combined organic extracts were washed (brine), dried (MgSO4) and 
concentrated in vacuo. Purification by flash chromatography (0 – 15% EtOAc in PET) was attempted, 
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affording a crude residue. A solution of methyl 1H-indole-6-carboxylate 63 (0.710 g, 4.05 mmol) in DMF 
(2 mL) was added dropwise at 0 °C to a suspension of NaH (60% in mineral oil, 0.405 g, 10.1 mmol) in DMF 
(2 mL). The reaction mixture was warmed to rt and stirred over 30 minutes. A solution of the crude residue 
in DMF (1 mL) was added dropwise at 0 °C to the reaction mixture. The reaction mixture was warmed to 
rt and stirred over 30 minutes. Methanol (200 mL) was added dropwise at 0 °C to the reaction mixture 
followed by sulfuric acid (15 mL). The reaction mixture was heated under reflux for 90 minutes, then 
concentrated in vacuo. The reaction mixture was diluted with EtOAc (200 mL), washed with NaHCO3 
solution (2 x 200 mL) and brine (200 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash 
chromatography (10% EtOAc in PET) afforded 64i (0.455 g, 31% yield). 
LCMS (ESI+): m/z 297.2 [M + H]+, rt 2.14 minutes, 97%; 1H NMR (400 MHz, CDCl3) 8.10-8.05 (2H, m), 7.81 
(1H, dd, J = 8.3, 1.4 Hz), 7.66 (1H, dd, J = 8.4, 0.6 Hz), 7.31 (1H, d, J = 3.2 Hz), 6.89-6.84 (1H, m), 6.73 (1H, 
dd, J = 7.3, 5.1 Hz), 6.60 (1H, dd, J = 3.1, 0.9 Hz), 5.34 (2H, s), 4.06 (3H, s), 3.91 (3H, s); 13C NMR (100 MHz, 
CDCl3) 168.3, 161.1, 146.1, 136.1, 135.8, 132.4, 131.8, 123.7, 120.8, 120.7, 120.1, 117.1, 112.1, 102.4, 
53.7, 52.1, 45.1; νmax/cm-1 2948, 1711 (C=O), 1617, 1595, 1584, 1501; HRMS (ESI)+: m/z calculated for 
[C17H16N2O3 + Na]+ = 319.1053, observed 319.1056. 
1-((6-Methoxypyridin-3-yl)methyl)-1H-indole-6-carboxylate (64k) 
 
A solution of methyl 1H-indole-6-carboxylate 63 (0.237 g, 1.36 mmol) in DMF (1 mL) was added dropwise 
at 0 °C to a suspension of NaH (60% in mineral oil, 0.108 g, 2.71 mmol) in DMF (1 mL). The reaction mixture 
was warmed to rt and stirred over 30 minutes. A solution of 5-(chloromethyl)-2-methoxypyridine 77 
(0.160 g, 0.904 mmol) in DMF (1 mL) was added dropwise at 0 °C to the reaction mixture. The reaction 
mixture was warmed to rt and stirred over 1 hour. Methanol (150 mL) was added dropwise at 0 °C to the 
reaction mixture followed by sulfuric acid (5 mL). The reaction mixture was heated under reflux for 1 hour, 
then concentrated in vacuo. The reaction mixture was diluted with EtOAc (100 mL), washed with NaHCO3 
solution (2 x 100 mL) and brine (100 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash 
chromatography (0 – 15% EtOAc in PET) afforded 64k (0.227 g, 85% yield). 
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LCMS (ESI+): m/z 297.2 [M + H]+, rt 2.09 minutes, >99%; 1H NMR (400 MHz, CDCl3) 8.13-8.10 (1H, m), 8.05 
(1H, dd, J = 2.5, 0.6 Hz), 7.81 (1H, dd, J = 8.4, 1.4 Hz), 7.65 (1H, dd, J = 8.3, 0.6 Hz), 7.31 (1H, dd, J = 8.5, 2.5 
Hz), 7.23 (1H, d, J = 3.2 Hz), 6.67 (1H, d, J = 8.5 Hz), 6.58 (1H, dd, J = 3.2, 0.8 Hz), 5.29 (2H, s), 3.92 (3H, s), 
3.91 (3H, s); 13C NMR (100 MHz, CDCl3) 168.2, 164.1, 145.6, 137.8, 135.6, 132.5, 131.0, 125.4, 123.7, 120.9, 
120.8, 111.9, 111.5, 102.6, 53.7, 52.1, 47.3; νmax/cm-1 2948, 1704 (C=O), 1610, 1572; HRMS (ESI)+: m/z 
calculated for [C17H16N2O3 + H]+ = 297.1234, observed 297.1235. 
Methyl 1-(quinolin-4-ylmethyl)-1H-indole-6-carboxylate (64m) 
 
A suspension of quinolin-4-ylmethanol 79 (0.378 g, 2.37 mmol) in aqueous HBr (48%, 5 mL) was heated 
under reflux for 90 minutes, then concentrated in vacuo to afford a crude residue. A solution of methyl 
1H-indole-6-carboxylate 63 (0.400 g, 2.28 mmol) in DMF (2 mL) was added dropwise at 0 °C to a 
suspension of NaH (60% in mineral oil, 0.457 g, 11.4 mmol) in DMF (5 mL). The reaction mixture was 
warmed to rt and stirred over 30 minutes. The crude residue was added portionwise at 0 °C to the reaction 
mixture. The reaction mixture was warmed to rt and stirred over 15 minutes. Methanol (150 mL) was 
added dropwise at 0 °C to the reaction mixture followed by sulfuric acid (10 mL). The reaction mixture 
was heated under reflux for 2 hours, then concentrated in vacuo. The reaction mixture was diluted with 
EtOAc (200 mL), washed with NaHCO3 solution (2 x 100 mL), water (2 x 200 mL) and brine (100 mL), dried 
(MgSO4) and concentrated in vacuo. Purification by flash chromatography (0 – 30% EtOAc in PET) afforded 
64m (0.497 g, 65% yield). 
LCMS (ESI+): m/z 317.2 [M + H]+, rt 1.83 minutes, 94%; 1H NMR (400 MHz, (CD3)2SO) 8.69 (1H, d, J = 4.4 
Hz), 8.30 (1H, d, J = 8.4 Hz), 8.12-8.04 (2H, m), 7.85 (1H, ddd, J = 8.3, 7.0, 1.2 Hz), 7.79-7.67 (4H, m), 6.72 
(1H, dd, J = 3.1, 0.7 Hz), 6.34 (1H, d, J = 4.4 Hz), 6.20 (2H, s), 3.77 (3H, s); 13C NMR (100 MHz, (CD3)2SO) 
167.0, 150.5, 147.5, 144.0, 135.5, 133.4, 132.0, 129.7, 129.6, 126.9, 125.4, 123.7, 122.7, 120.7, 120.2, 
117.4, 112.0, 102.2, 51.8, 46.3; νmax/cm-1 3112, 3095, 1700 (C=O), 1618, 1599, 1570, 1508; HRMS (ESI)+: 
m/z calculated for [C20H16N2O2 + Na]+ = 339.1104, observed 339.1100. 
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Methyl 1-((1-methylpiperidin-2-yl)methyl)-1H-indole-6-carboxylate (64n) 
 
A solution of methyl 1H-indole-6-carboxylate 63 (0.392 g, 2.24 mmol) in DMF (2 mL) was added dropwise 
at 0 °C to a suspension of NaH (60% in mineral oil, 0.122 g, 3.05 mmol) in DMF (2 mL). The reaction mixture 
was warmed to rt and stirred over 30 minutes. A solution of 2-(chloromethyl)-1-methylpiperidine 81 
(0.300 g, 2.03 mmol) in DMF (2 mL) was added at 0 °C to the reaction mixture. The reaction mixture was 
heated to 60 °C over 1 hour. Methanol (150 mL) was added dropwise at 0 °C to the reaction mixture 
followed by sulfuric acid (10 mL). The reaction mixture was heated under reflux for 1 hour, then 
concentrated in vacuo. The reaction mixture was diluted with EtOAc (200 mL), washed with NaHCO3 
solution (2 x 200 mL) and brine (200 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash 
chromatography (0 – 100% EtOAc in PET, 0 – 10% methanol in DCM) afforded 64n (0.172 g, 27% yield). 
LCMS (ESI+): m/z 287.3 [M + H]+, rt 1.32 minutes, 90%; 1H NMR (400 MHz, CDCl3) 8.11 (1H, s), 7.78 (1H, 
dd, J = 8.3, 1.4 Hz), 7.61 (1H, d, J = 8.3 Hz), 7.24 (1H, d, J = 3.1 Hz), 6.52 (1H, dd, J = 3.0, 0.8 Hz), 4.56 (1H, 
dd, J = 14.2, 4.4 Hz), 4.01-3.90 (4H, m), 2.95-2.83 (1H, m), 2.47 (3H, s), 2.44-2.34 (1H, m), 2.14 (1H, td, J = 
11.3, 3.6 Hz), 1.67-1.46 (3H, m), 1.28-1.02 (3H, m); 13C NMR (100 MHz, CDCl3) 168.3, 135.9, 132.2, 132.0, 
123.3, 120.5, 120.4, 112.1, 101.8, 63.4, 57.3, 52.0, 49.4, 43.6, 29.5, 25.7, 23.6; νmax/cm-1 2938, 2855, 2784, 
1707 (C=O), 1614, 1505; HRMS (ESI)+: m/z calculated for [C17H22N2O2 + H]+ = 287.1754, observed 287.1751. 
Methyl 1-((1-methylpiperidin-3-yl)methyl)-1H-indole-6-carboxylate (64o) 
 
A solution of methyl 1H-indole-6-carboxylate 63 (0.568 g, 3.24 mmol) in DMF (2 mL) was added dropwise 
at 0 °C to a suspension of NaH (60% in mineral oil, 0.151 g, 3.78 mmol) in DMF (2 mL). The reaction mixture 
was warmed to rt and stirred over 30 minutes. A solution of (1-methylpiperidin-3-yl)methyl 4-
methylbenzenesulfonate 83 (0.797 g, 2.70 mmol) in DMF (2 mL) was added at 0 °C to the reaction mixture, 
followed by NaI (81 mg, 0.54 mmol). The reaction mixture was heated to 60 °C over 1 hour, then diluted 
with EtOAc (200 mL), washed with NaHCO3 solution (2 x 200 mL) and brine (200 mL), dried (MgSO4) and 
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concentrated in vacuo. Purification by flash chromatography (0 – 8% methanol in DCM), followed by 
reverse phase chromatography (40 – 60% acetonitrile in water (+ 0.1% NH3)), afforded 64o (0.348 g, 45% 
yield). 
LCMS (ESI+): m/z 287.3 [M + H]+, rt 1.49 minutes, >99%; 1H NMR (400 MHz, CDCl3) 8.10 (1H, s), 7.78 (1H, 
d, J = 8.3 Hz), 7.62 (1H, d, J = 8.4 Hz), 7.22 (1H, d, J = 3.0 Hz), 6.52 (1H, d, J = 2.9 Hz), 4.12 (1H, dd, J = 14.3, 
7.9 Hz), 4.04 (1H, dd, J = 14.2, 7.2 Hz), 3.94 (3H, s), 2.73-2.61 (1H, m), 2.56 (1H, d, J = 10.2 Hz), 2.30-2.16 
(4H, m), 2.06-1.93 (1H, m), 1.78 (1H, t, J = 10.1 Hz), 1.74-1.47 (3H, m), 1.12-0.97 (1H, m); 13C NMR (100 
MHz, CDCl3) 168.4, 135.8, 132.2, 131.6, 123.3, 120.6, 120.5, 112.1, 101.7, 59.6, 56.3, 52.1, 50.3, 46.8, 37.5, 
28.1, 24.7; νmax/cm-1 2934, 2780, 1707 (C=O), 1615, 1504; HRMS (ESI)+: m/z calculated for [C17H22N2O2 + 
H]+ = 287.1754, observed 287.1748. 
3-(1-(4-Methoxybenzyl)-1H-indol-6-yl)-3-oxopropanenitrile (65a) 
 
n-Butyllithium (1.6 M in hexanes, 1.8 mL, 2.9 mmol) was added dropwise at -78 °C to a mixture of 
acetonitrile (0.23 mL, 4.3 mmol) and THF (4 mL). The reaction mixture was stirred at -78 °C over 30 
minutes. A solution of methyl 1-(4-methoxybenzyl)-1H-indole-6-carboxylate 64a (0.425 g, 1.44 mmol) in 
THF (2 mL) was added dropwise at -78 °C over 30 minutes. The reaction mixture was stirred at -78 °C over 
15 minutes. Aqueous HCl (1 M, 25 mL) was added dropwise at 0 °C. The product was extracted into DCM 
(3 x 25 mL). The combined organic extracts were washed (brine), dried (MgSO4) and concentrated in 
vacuo. Purification by flash chromatography (0 – 50% EtOAc in PET) afforded 65a (0.387 g, 88% yield). 
LCMS (ESI+): m/z 327.2 [M + Na]+, (ESI-): m/z 303.1 [M - H]-, rt 2.01 minutes, >99%; (400 MHz, (CD3)2SO) 
8.22 (1H, s), 7.79 (1H, d, J = 3.0 Hz), 7.67 (1H, d, J = 8.3 Hz), 7.60 (1H, dd, J = 8.3, 1.5 Hz), 7.25-7.19 (2H, 
m), 6.91-6.84 (2H, m), 6.59 (1H, d, J = 3.1 Hz), 5.45 (2H, s), 4.77 (2H, s), 3.69 (3H, s); 13C NMR (100 MHz, 
(CD3)2SO) 189.2, 158.7, 135.0, 133.8, 132.7, 129.8, 128.7, 128.0, 120.5, 119.1, 116.3, 114.0, 111.9, 101.8, 
55.1, 48.6, 29.9; νmax/cm-1 2943, 1679 (C=O), 1607, 1511; HRMS (ESI)+: m/z calculated for [C19H16N2O2 + 
Na]+ = 327.1104, observed 327.1096. 
 
 
186 
 
3-(1-(3-Methoxybenzyl)-1H-indol-6-yl)-3-oxopropanenitrile (65b) 
 
n-Butyllithium (1.6 M in hexanes, 2.9 mL, 4.6 mmol) was added dropwise at -78 °C to a mixture of 
acetonitrile (0.40 mL, 7.6 mmol) and THF (5 mL). The reaction mixture was stirred at -78 °C over 45 
minutes. A solution of methyl 1-(3-methoxybenzyl)-1H-indole-6-carboxylate 64b (0.450 g, 1.52 mmol) in 
THF (5 mL) was added dropwise at -78 °C over 30 minutes. The reaction mixture was stirred at -78 °C over 
1 hour. Aqueous HCl (1 M, 15 mL) was added dropwise at 0 °C. The product was extracted into DCM (3 x 
25 mL). The combined organic extracts were washed (brine), dried (MgSO4) and concentrated in vacuo. 
Purification by flash chromatography (0 – 50% EtOAc in PET) afforded 65b (0.465 g, 99% yield). 
LCMS (ESI-): m/z 303.2 [M - H]-, rt 2.01 minutes, >99%; 1H NMR (400 MHz, CDCl3) 7.97 (1H, s), 7.70 (1H, d, 
J = 8.4 Hz), 7.59 (1H, dd, J = 8.4, 1.6 Hz), 7.37 (1H, d, J = 3.1 Hz), 7.24 (1H, t, J = 7.9 Hz), 6.81 (1H, dd, J = 
8.3, 2.5 Hz), 6.73-6.67 (1H, m), 6.64-6.60 (2H, m), 5.37 (2H, s), 4.09 (2H, s), 3.74 (3H, s); 13C NMR (100 MHz, 
CDCl3) 187.1, 160.2, 138.2, 136.0, 133.8, 133.4, 130.2, 128.1, 121.3, 119.7, 119.2, 114.5, 113.2, 112.9, 
111.3, 102.7, 55.4, 50.4, 29.6; νmax/cm-1 2942, 1677 (C=O), 1606, 1585; HRMS (ESI)+: m/z calculated for 
[C19H16N2O2 + Na]+ = 327.1104, observed 327.1089. 
3-(1-Benzyl-1H-indol-6-yl)-3-oxopropanenitrile (65c) 
 
n-Butyllithium (1.6 M in hexanes, 4.7 mL, 7.5 mmol) was added dropwise at -78 °C to a mixture of 
acetonitrile (0.78 mL, 15 mmol) and toluene (7 mL). The reaction mixture was stirred at -78 °C over 30 
minutes. A solution of methyl 1-benzyl-1H-indole-6-carboxylate 64c (0.418 g, 1.50 mmol) in toluene (5 
mL) was added dropwise at -78 °C over 30 minutes. The reaction mixture was stirred at -78 °C over 1 hour, 
then warmed to 0 °C and stirred over 20 minutes. Aqueous HCl (3 M, 15 mL) was added dropwise at 0 °C. 
The product was extracted into EtOAc (3 x 25 mL). The combined organic extracts were washed (brine), 
dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (0 – 30% EtOAc in PET, 0 
– 20% methanol in DCM) afforded 65c (0.384 g, 84% yield). 
187 
 
LCMS (ESI-): m/z 273.2 [M - H]-, rt 1.99 minutes, >99%; 1H NMR (400 MHz, (CD3)2SO) 8.21 (1H, s), 7.81 (1H, 
d, J = 3.0 Hz), 7.69 (1H, d, J = 8.3 Hz), 7.61 (1H, dd, J = 8.4, 1.2 Hz), 7.39-7.18 (5H, m), 6.63 (1H, d, J = 2.9 
Hz), 5.55 (2H, s), 4.76 (2H, s); 13C NMR (100 MHz, (CD3)2SO) 189.2, 138.0, 135.1, 134.0, 132.7, 128.7, 128.1, 
127.5, 127.1, 120.6, 119.2, 116.3, 111.8, 101.9, 49.1, 29.9; νmax/cm-1 1679, 1663, 1606, 1504; HRMS (ESI)+: 
m/z calculated for [C18H14N2O + H]+ = 275.1179, observed 275.1179. 
3-Oxo-3-(1-(pyridin-2-ylmethyl)-1H-indol-6-yl)propanenitrile (65f) 
 
n-Butyllithium (1.6 M in hexanes, 2.6 mL, 4.2 mmol) was added dropwise at -78 °C to a mixture of 
acetonitrile (0.369 mL, 7.06 mmol) and THF (5 mL). The reaction mixture was stirred at -78 °C over 30 
minutes. A solution of methyl 1-(pyridin-2-ylmethyl)-1H-indole-6-carboxylate 64f (0.376 g, 1.41 mmol) in 
THF (5 mL) was added dropwise at -78 °C over 30 minutes. The reaction mixture was stirred at -78 °C over 
30 minutes. Aqueous HCl (1 M, 15 mL) was added dropwise at 0 °C. The product was extracted into DCM 
(3 x 50 mL). The combined organic extracts were washed (brine), dried (MgSO4) and concentrated in vacuo 
to afford 65f (0.363 g, 93% yield). 
LCMS (ESI+): m/z 276.2 [M + H]+, (ESI-): m/z 274.2 [M - H]-, rt 1.65 minutes, 100%; 1H NMR (400 MHz, 
(CD3)2SO) 8.55 (1H, d, J = 4.8 Hz), 8.19 (1H, s), 7.81 (1H, d, J = 3.1 Hz), 7.76 (1H, td, J = 7.6, 1.7 Hz), 7.70 
(1H, d, J = 8.4 Hz), 7.61 (1H, dd, J = 8.4, 1.4 Hz), 7.31 (1H, dd, J = 7.5, 4.9 Hz), 7.06 (1H, d, J = 7.8 Hz), 6.64 
(1H, d, J = 3.1 Hz), 5.66 (2H, s), 4.74 (2H, s); 13C NMR (100 MHz, (CD3)2SO) 189.2, 156.8, 149.1, 137.6, 135.3, 
134.3, 132.7, 128.1, 122.9, 121.3, 120.5, 119.3, 116.3, 111.8, 102.0, 50.8, 29.9; νmax/cm-1 1673 (C=O), 1606, 
1590, 1502; HRMS (ESI)+: m/z calculated for [C17H13N3O + H]+ = 276.1131, observed 276.1126. 
3-Oxo-3-(1-(pyridin-3-ylmethyl)-1H-indol-6-yl)propanenitrile (65g) 
 
n-Butyllithium (1.6 M in hexanes, 5.1 mL, 8.1 mmol) was added dropwise at -78 °C to a mixture of 
acetonitrile (0.71 mL, 14 mmol) and THF (6 mL). The reaction mixture was stirred at -78 °C over 30 minutes. 
A solution of methyl 1-(pyridin-3-ylmethyl)-1H-indole-6-carboxylate 64g (0.721 g, 2.71 mmol) in THF (4 
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mL) was added dropwise at -78 °C over 30 minutes. The reaction mixture was stirred at -78 °C over 45 
minutes. Water (20 mL) was added dropwise at 0 °C, and the reaction mixture adjusted to pH 7. The 
product was extracted into DCM (3 x 25 mL). The combined organic extracts were washed (brine), dried 
(MgSO4) and concentrated in vacuo. Purification by flash chromatography (0 – 4% methanol in DCM) 
afforded 65g (0.612 g, 82% yield). 
LCMS (ESI+): m/z 276.2 [M + H]+, (ESI-): m/z 274.1 [M - H]-, rt 1.41 minutes, >99%; 1H NMR (500 MHz, 
(CD3)2SO) 8.55 (1H, d, J = 1.9 Hz), 8.47 (1H, dd, J = 4.8, 1.6 Hz), 8.25 (1H, s), 7.85 (1H, d, J = 3.1 Hz), 7.69 
(1H, d, J = 8.2 Hz), 7.64-7.59 (2H, m), 7.34 (1H, ddd, J = 7.8, 4.8, 0.8 Hz), 6.64 (1H, d, J = 3.0 Hz), 5.60 (2H, 
s), 4.76 (2H, s); 13C NMR (125 MHz, (CD3)2SO) 189.2, 148.9, 148.5, 135.0, 134.9, 133.8, 133.5, 132.7, 128.2, 
123.8, 120.7, 119.3, 116.3, 111.8, 102.3, 46.6, 29.9; νmax/cm-1 3089, 2952, 2926, 2267 (C≡N), 1677 (C=O), 
1611, 1577, 1561, 1502; HRMS (ESI-): m/z calculated for [C17H13N3O - H]- = 274.0986, observed 274.0976. 
3-Oxo-3-(1-(pyridin-4-ylmethyl)-1H-indol-6-yl)propanenitrile (65h) 
 
n-Butyllithium (1.6 M in hexanes, 2.9 mL, 4.7 mmol) was added dropwise at -78 °C to a mixture of 
acetonitrile (0.41 mL, 7.8 mmol) and THF (6 mL). The reaction mixture was stirred at -78 °C over 30 
minutes. A solution of methyl 1-(pyridin-4-ylmethyl)-1H-indole-6-carboxylate 64h (0.454 g, 1.55 mmol) in 
THF (4 mL) was added dropwise at -78 °C over 30 minutes. The reaction mixture was stirred at -78 °C over 
45 minutes. Water (20 mL) was added dropwise at 0 °C, and the reaction mixture adjusted to pH 7. The 
product was extracted into DCM (3 x 25 mL). The combined organic extracts were washed (brine), dried 
(MgSO4) and concentrated in vacuo. Purification by flash chromatography (0 – 4% methanol in DCM) 
afforded 65h (0.303 g, 71% yield). 
LCMS (ESI+): m/z 276.2 [M + H]+, (ESI-): m/z 274.2 [M - H]-, rt 1.37 minutes, >99%; 1H NMR (500 MHz, 
(CD3)2SO) 8.51-8.47 (2H, m), 8.15 (1H, s), 7.83 (1H, d, J = 3.1 Hz), 7.72 (1H, d, J = 8.4 Hz), 7.63 (1H, dd, J = 
8.4, 1.4 Hz), 7.11-7.06 (2H, m), 6.68 (1H, d, J = 2.9 Hz), 5.63 (2H, s), 4.74 (2H, s); 13C NMR (125 MHz, 
(CD3)2SO) 189.2, 149.9, 146.9, 135.2, 134.1, 132.6, 128.3, 121.7, 120.7, 119.4, 116.2, 111.7, 102.3, 47.9, 
29.8; νmax/cm-1 3076, 2918, 2258 (C≡N), 1664 (C=O), 1599, 1560; HRMS (ESI-): m/z calculated for 
[C17H13N3O - H]- = 274.0986, observed 274.0976. 
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3-(1-((2-Methoxypyridin-3-yl)methyl)-1H-indol-6-yl)-3-oxopropanenitrile (65i) 
 
n-Butyllithium (1.6 M in hexanes, 1.1 mL, 1.7 mmol) was added dropwise at -78 °C to a mixture of 
acetonitrile (0.15 mL, 2.9 mmol) and THF (4 mL). The reaction mixture was stirred at -78 °C over 30 
minutes. A solution of methyl 1-((2-methoxypyridin-3-yl)methyl)-1H-indole-6-carboxylate 64i (0.177 g, 
0.579 mmol) in THF (1 mL) was added dropwise at -78 °C. The reaction mixture was stirred at -78 °C over 
1 hour, then NH4Cl solution (25 mL) was added dropwise at 0 °C. The product was extracted into DCM (3 
x 25 mL). The combined organic extracts were washed (brine), dried (MgSO4) and concentrated in vacuo. 
Purification by flash chromatography (0 – 50% EtOAc in PET) afforded 65i (0.134 g, 76% yield). 
LCMS (ESI+): m/z 306.2 [M + H]+, (ESI-): m/z 304.1 [M - H]-, rt 1.94 minutes, >99%; 1H NMR (400 MHz, 
CDCl3) 8.09 (1H, dd, J = 5.0, 1.8 Hz), 8.02 (1H, s), 7.70 (1H, d, J = 8.3 Hz), 7.59 (1H, dd, J = 8.5, 1.5 Hz), 7.41 
(1H, d, J = 3.1 Hz), 6.97-6.92 (1H, m), 6.76 (1H, dd, J = 7.3, 5.0 Hz), 6.63 (1H, dd, J = 3.1, 0.6 Hz), 5.35 (2H, 
s), 4.12 (2H, s), 4.04 (3H, s); 13C NMR (100 MHz, CDCl3) 187.1, 161.2, 146.5, 136.3, 135.9, 133.7, 133.6, 
128.2, 121.4, 119.8, 119.5, 117.1, 114.4, 111.2, 102.7, 53.8, 45.3, 29.6; νmax/cm-1 2953, 2261 (C≡N), 1683 
(C=O), 1589; HRMS (ESI)+: m/z calculated for [C18H15N3O2 + H]+ = 306.1237, observed 306.1237. 
3-(1-((6-Methoxypyridin-3-yl)methyl)-1H-indol-6-yl)-3-oxopropanenitrile (65k) 
 
n-Butyllithium (1.6 M in hexanes, 1.3 mL, 2.1 mmol) was added dropwise at -78 °C to a mixture of 
acetonitrile (0.18 mL, 3.5 mmol) and THF (4 mL). The reaction mixture was stirred at -78 °C over 20 
minutes. A solution of methyl 1-((6-methoxypyridin-3-yl)methyl)-1H-indole-6-carboxylate 64k (0.206 g, 
0.695 mmol) in THF (2 mL) was added dropwise at -78 °C over 20 minutes. The reaction mixture was stirred 
at -78 °C over 30 minutes. NH4Cl solution (25 mL) was added dropwise at 0 °C. The product was extracted 
into DCM (3 x 25 mL). The combined organic extracts were washed (brine), dried (MgSO4) and 
concentrated in vacuo. Purification by flash chromatography (0 – 50% EtOAc in PET) afforded 65k (0.137 
g, 62% yield). 
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LCMS (ESI+): m/z 306.2 [M + H]+, (ESI-): m/z 304.1 [M - H]-, rt 1.86 minutes, 96%; 1H NMR (400 MHz, CDCl3) 
8.06-8.00 (2H, m), 7.69 (1H, d, J = 8.4 Hz), 7.58 (1H, dd, J = 8.3, 1.0 Hz), 7.36-7.30 (2H, m), 6.69 (1H, d, J = 
8.6 Hz), 6.61 (1H, d, J = 3.0 Hz), 5.32 (2H, s), 4.11 (2H, s), 3.90 (3H, s); 13C NMR (100 MHz, CDCl3) 187.1, 
164.3, 145.7, 137.8, 135.8, 133.9, 132.9, 128.2, 124.8, 121.4, 119.9, 114.5, 111.6, 111.0, 103.0, 53.7, 47.5, 
29.6; νmax/cm-1 2940, 2249 (C≡N), 1676 (C=O), 1607, 1572; HRMS (ESI)+: m/z calculated for [C18H15N3O2 + 
H]+ = 306.1237, observed 306.1234. 
3-Oxo-3-(1-(quinolin-4-ylmethyl)-1H-indol-6-yl)propanenitrile (65m) 
 
n-Butyllithium (1.6 M in hexanes, 1.7 mL, 2.8 mmol) was added dropwise at -78 °C to a mixture of 
acetonitrile (0.22 mL, 4.2 mmol) and toluene (3 mL). The reaction mixture was stirred at -78 °C over 30 
minutes. A suspension of methyl 1-(quinolin-4-ylmethyl)-1H-indole-6-carboxylate 64m (0.467 g, 1.39 
mmol) in toluene/THF (3:1, 12 mL) was added dropwise at -78 °C. The reaction mixture was stirred at -78 
°C over 30 minutes. Water (50 mL) was added dropwise at 0 °C, and the reaction mixture adjusted to pH 
8. The product was extracted into EtOAc (50 mL) and DCM/methanol (9:1, 3 x 50 mL). The combined 
organic extracts were dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (0 
– 60% EtOAc in PET) afforded 65m (0.119 g, 26% yield). 
LCMS (ESI+): m/z 326.2 [M + H]+, (ESI-): m/z 324.1 [M - H]-, rt 1.65 minutes, >99%; 1H NMR (400 MHz, 
(CD3)2SO) 8.70 (1H, d, J = 4.4 Hz), 8.31 (1H, d, J = 8.2 Hz), 8.20 (1H, s), 8.09 (1H, d, J = 8.2 Hz), 7.90-7.71 
(4H, m), 7.67 (1H, d, J = 8.3 Hz), 6.75 (1H, d, J = 2.7 Hz), 6.36 (1H, d, J = 4.4 Hz), 6.21 (2H, s), 4.70 (2H, s); 
13C NMR (100 MHz, (CD3)2SO) 189.2, 150.5, 147.5, 144.0, 135.6, 134.3, 132.6, 129.66, 129.64, 128.4, 126.9, 
125.4, 123.6, 120.8, 119.4, 117.4, 116.2, 111.9, 102.5, 46.3, 29.8; νmax/cm-1 2948, 2845, 2252 (C≡N), 1673 
(C=O), 1610, 1597, 1570, 1560, 1504; HRMS (ESI)+: m/z calculated for [C21H15N3O + Na]+ = 348.1107, 
observed 348.1106. 
3-(1-((1-Methylpiperidin-2-yl)methyl)-1H-indol-6-yl)-3-oxopropanenitrile (65n) 
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n-Butyllithium (1.6 M in hexanes, 0.62 mL, 0.99 mmol) was added dropwise at -78 °C to a mixture of 
acetonitrile (78 µL, 1.5 mmol) and THF (3 mL). The reaction mixture was stirred at -78 °C over 30 minutes. 
A solution of methyl 1-((1-methylpiperidin-2-yl)methyl)-1H-indole-6-carboxylate 64n (0.158 g, 0.497 
mmol) in THF (3 mL) was added dropwise at -78 °C over 30 minutes. The reaction mixture was stirred at -
78 °C over 1 hour. Water (50 mL) was added dropwise at 0 °C, and the reaction mixture adjusted to pH 
10. The product was extracted into DCM/methanol (10:1, 4 x 50 mL). The combined organic extracts were 
washed (brine), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (50 – 
100% EtOAc in PET, 0 – 5% methanol in DCM), followed by reverse phase chromatography (0 – 50% 
acetonitrile in water (+ 0.1% NH3)), afforded 65n (48 mg, 32% yield). 
LCMS (ESI+): m/z 296.3 [M + H]+, (ESI-): m/z 294.2 [M - H]-, rt 1.21 minutes, 97%; 1H NMR (400 MHz, CDCl3) 
8.02 (1H, s), 7.65 (1H, d, J = 8.5 Hz), 7.55 (1H, dd, J = 8.4, 1.1 Hz), 7.35 (1H, d, J = 3.1 Hz), 6.55 (1H, d, J = 
2.7 Hz), 4.55 (1H, dd, J = 14.2, 4.3 Hz), 4.12 (2H, br s), 3.99 (1H, dd, J = 14.3, 8.7 Hz), 2.88 (1H, d, J = 11.6 
Hz), 2.46 (3H, s), 2.42-2.32 (1H, m), 2.15 (1H, td, J = 11.5, 3.2 Hz), 1.72-1.42 (3H, m), 1.31-1.01 (3H, m); 13C 
NMR (100 MHz, CDCl3) 187.1, 136.1, 133.8, 133.4, 127.9, 121.1, 119.4, 114.6, 111.2, 102.2, 63.3, 57.2, 
49.3, 43.6, 29.6, 29.4, 25.5, 23.5; νmax/cm-1 2939, 2855, 2787, 2168 (C≡N), 1676 (C=O), 1606, 1500; HRMS 
(ESI)+: m/z calculated for [C18H21N3O + H]+ = 296.1757, observed 296.1747. 
3-(1-((1-Methylpiperidin-3-yl)methyl)-1H-indol-6-yl)-3-oxopropanenitrile (65o) 
 
n-Butyllithium (1.6 M in hexanes, 1.4 mL, 2.2 mmol) was added dropwise at -78 °C to a mixture of 
acetonitrile (0.17 mL, 3.3 mmol) and THF (3 mL). The reaction mixture was stirred at -78 °C over 30 
minutes. A suspension of methyl 1-((1-methylpiperidin-3-yl)methyl)-1H-indole-6-carboxylate 64o (0.318 
g, 1.11 mmol) in THF (10 mL) was added dropwise at -78 °C. The reaction mixture was stirred at -78 °C 
over 30 minutes. Water (50 mL) was added dropwise at 0 °C, and the reaction mixture adjusted to pH 8. 
The product was extracted into DCM/methanol (10:1, 4 x 50 mL). The combined organic extracts were 
washed (brine), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (50 – 
100% EtOAc in PET, 0 – 10% methanol in DCM) afforded 65o (0.221 g, 67% yield). 
LCMS (ESI+): m/z 296.3 [M + H]+, (ESI-): m/z 294.2 [M - H]-, rt 1.37 minutes, >99%; 1H NMR (400 MHz, 
CDCl3) 8.03 (1H, s), 7.66 (1H, d, J = 8.4 Hz), 7.57 (1H, d, J = 8.4 Hz), 7.31 (1H, d, J = 3.1 Hz), 6.56 (1H, d, J = 
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2.8 Hz), 4.34-3.96 (4H, m), 2.74-2.61 (1H, m), 2.55 (1H, d, J = 10.5 Hz), 2.31-2.14 (4H, m), 2.13-1.99 (1H, 
m), 1.83 (1H, t, J = 10.1 Hz), 1.78-1.68 (1H, m), 1.67-1.50 (2H, m), 1.15-1.01 (1H, m); 13C NMR (100 MHz, 
CDCl3) 187.2, 136.0, 133.5, 133.4, 127.9, 121.2, 119.5, 114.6, 111.2, 102.2, 59.3, 56.1, 50.1, 46.6, 37.3, 
29.7, 27.8, 24.4; νmax/cm-1 2936, 2782, 2166 (C≡N), 1675 (C=O), 1607, 1564; HRMS (ESI)+: m/z calculated 
for [C18H21N3O + H]+ = 296.1757, observed 296.1753. 
Methyl 1-(tert-butyldimethylsilyl)-1H-indole-6-carboxylate (67) 
 
A solution of methyl 1H-indole-6-carboxylate 63 (0.500 g, 2.71 mmol) in THF (10 mL) was added dropwise 
at 0 °C to a stirred suspension of NaH (60% in mineral oil, 0.141 g, 3.52 mmol) in THF (10 mL). The reaction 
mixture was warmed to rt and stirred over 30 minutes. tert-Butyldimethylsilyl chloride (1 M in DCM, 4.1 
mL, 4.1 mmol) was added dropwise at 0 °C to the reaction mixture. The reaction mixture was warmed to 
rt and stirred over 10 hours. NH4Cl solution (20 mL) was added dropwise at 0 °C. The product was extracted 
into diethyl ether (2 x 50 mL). The combined organic extracts were washed (brine), dried (MgSO4) and 
concentrated in vacuo. Purification by flash chromatography (0 – 20% EtOAc in PET) afforded 67 (0.462 g, 
59% yield). 
LCMS (ESI+): m/z 290.2 [M + H]+, rt 3.05 minutes, 100%; 1H NMR (500 MHz, CDCl3) 8.29-8.27 (1H, m), 7.80 
(1H, dd, J = 8.3, 1.4 Hz), 7.63 (1H, d, J = 8.4 Hz), 7.34 (1H, d, J = 3.2 Hz), 6.65 (1H, dd, J = 3.1, 0.9 Hz), 3.93 
(3H, s), 0.93 (9H, s), 0.65 (6H, s); 13C NMR (125 MHz, CDCl3) 168.5, 140.5, 135.3, 134.6, 123.2, 121.0, 120.2, 
116.2, 105.2, 52.1, 26.4, 19.5, -3.8; spectroscopic data consistent with literature. 144 
3-(1H-Indol-6-yl)-3-oxopropanenitrile (68) 
 
n-Butyllithium (1.6 M in hexanes, 3.0 mL, 4.8 mmol) was added dropwise at -78 °C to a mixture of 
acetonitrile (0.180 mL, 3.45 mmol) and toluene (3 mL). The reaction mixture was stirred at -78 °C over 30 
minutes. A solution of methyl 1-(tert-butyldimethylsilyl)-1H-indole-6-carboxylate 67 (0.200 g, 0.691 
mmol) in toluene (2 mL) was added dropwise at -78 °C over 30 minutes. The reaction mixture was stirred 
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at -78 °C over 1 hour, then warmed to rt over 1 hour. Aqueous HCl (3 M, 20 mL) was added dropwise at 0 
°C. The intermediate was extracted into EtOAc (2 x 25 mL). The combined organic extracts were washed 
(brine), dried (MgSO4) and concentrated in vacuo. The crude residue was dissolved in THF (2 mL) and TBAF 
(1 M in THF, 0.760 mL, 0.760 mmol) was added dropwise. The reaction mixture was stirred over 20 
minutes, then NaHCO3 solution (30 mL) was added dropwise. The product was extracted into DCM (3 x 25 
mL). The combined organic extracts were washed (brine), dried (MgSO4) and concentrated in vacuo. 
Purification by flash chromatography (0 – 20% methanol in DCM) afforded 68 (0.131 g, 99% yield). 
LCMS (ESI-): m/z 183.1 [M - H]-, rt 1.91 minutes, 100%; 1H NMR (500 MHz, CD3CN) 9.74 (1H, br s), 8.07 
(1H, s), 7.69 (1H, d, J = 8.4 Hz), 7.62 (1H, dd, J = 8.4, 1.5 Hz), 7.53 (1H, t, J = 2.8 Hz), 6.61-6.57 (1H, m), 4.36 
(2H, s); 13C NMR (125 MHz, CD3CN) 189.5, 136.2, 133.6, 131.0, 129.3, 121.3, 120.1, 116.4, 113.9, 103.2, 
30.6; νmax/cm-1 3326 (N-H), 1675 (C=O), 1611, 1501; HRMS (ESI)+: m/z calculated for [C11H8N2O + H]+ = 
185.0709, observed 185.0708. 
3-Amino-4,4,4-trichloro-2-(1H-indole-6-carbonyl)but-2-enenitrile (69) 
 
Trichloroacetonitrile (0.738 mL, 7.36 mmol) was added to a suspension of 3-(1H-indol-6-yl)-3-
oxopropanenitrile 68 (0.491 g, 2.45 mmol) and sodium acetate (1.01 g, 12.3 mmol) in ethanol (15 mL). 
The reaction mixture was stirred over 90 minutes. The reaction mixture was concentrated in vacuo, then 
NaHCO3 solution (20 mL) was added. The product was extracted into DCM/methanol (10:1, 3 x 50 mL). 
The combined organic extracts were washed (brine), dried (MgSO4) and concentrated in vacuo. 
Purification by flash chromatography (0 – 8% methanol in DCM) afforded 69 (0.717 g, 87% yield). 
1H NMR (500 MHz, (CD3)2SO) 11.88 (1H, br s), 11.49 (1H, s), 9.72 (1H, br s), 7.92-7.88 (1H, m), 7.62 (1H, d, 
J = 8.3 Hz), 7.58 (1H, t, J = 2.8 Hz), 7.38 (1H, dd, J = 8.3, 1.6 Hz), 6.55-6.51 (1H, m); 13C NMR (125 MHz, 
(CD3)2SO) 193.6, 167.9, 134.5, 131.1, 130.4, 129.0, 119.5, 119.0, 118.8, 112.5, 101.5, 91.3, 77.2; νmax/cm-1 
3389 (N-H), 3280 (N-H), 2205 (C≡N), 1597 (C=O), 1508; HRMS (ESI)+: m/z calculated for [C13H8Cl3N3O + H]+ 
= 327.9806, observed 327.9812. 
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(2-Methoxypyridin-3-yl)methanol (74) 
 
NaBH4 (1.02 g, 26.9 mmol) was added portionwise at 0 °C to a solution of methyl 2-methoxynicotinate 73 
(1.50 g, 8.97 mmol) in ethanol (24 mL). The reaction mixture was warmed to rt and stirred over 24 hours, 
then diluted with NaHCO3 solution (50 mL) and extracted into DCM (4 x 50 mL). The combined organic 
extracts were washed (brine), dried (MgSO4) and concentrated in vacuo. Purification by flash 
chromatography (0 – 10% methanol in DCM) afforded 74 (0.840 g, 67% yield). 
1H NMR (400 MHz, CDCl3) 8.09 (1H, dd, J = 5.1, 2.0 Hz), 7.62-7.55 (1H, m), 6.88 (1H, dd, J = 7.2, 5.1 Hz), 
4.64 (2H, s), 3.99 (3H, s), 2.41 (1H, br s); 13C NMR (100 MHz, CDCl3) 161.7, 145.8, 136.7, 123.5, 117.0, 61.1, 
53.6; spectroscopic data consistent with literature. 145 
(6-Methoxypyridin-3-yl)methanol (76) 
 
LiAlH4 (2.4 M in THF, 1.25 mL, 2.99 mmol) was added dropwise at 0 °C to a solution of methyl 6-
methoxynicotinate 75 (1.00 g, 5.98 mmol) in THF (10 mL). The reaction mixture was stirred at 0 °C over 1 
hour. Aqueous potassium sodium tartrate (1 M, 25 mL) was added dropwise at 0 °C to the reaction 
mixture. The product was extracted into EtOAc (3 x 25 mL). The combined organic extracts were washed 
(brine), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (0 – 5% methanol 
in DCM) afforded 76 (0.759 g, 91% yield). 
1H NMR (400 MHz, CDCl3) 8.07 (1H, d, J = 2.3 Hz), 7.60 (1H, dd, J = 8.5, 2.3 Hz), 6.73 (1H, d, J = 8.5 Hz), 4.59 
(2H, s), 3.91 (3H, s), 2.38 (1H, s); 13C NMR (100 MHz, CDCl3) 164.0, 145.7, 138.7, 129.2, 111.1, 62.5, 53.7; 
spectroscopic data consistent with literature. 146  
5-(Chloromethyl)-2-methoxypyridine (77) 
 
195 
 
p-Toluenesulfonyl chloride (1.21 g, 6.37 mmol) and DMAP (6 mg, 0.05 mmol) were added to a solution of 
(6-methoxypyridin-3-yl)methanol 76 (0.739 g, 5.31 mmol) and triethylamine (1.48 mL, 10.6 mmol) in DCM 
(10 mL). The reaction mixture was stirred over 18 hours, then diluted with water (20 mL). The product 
was extracted into DCM (3 x 25 mL). The combined organic extracts were washed (brine), dried (MgSO4) 
and concentrated in vacuo. Purification by flash chromatography (0 – 30% EtOAc in PET) afforded 77 
(0.160 g, 17% yield). 
LCMS (ESI+): m/z 158.2 [M + H]+, rt 1.71 minutes, 89%; 1H NMR (400 MHz, CDCl3) 8.15 (1H, d, J = 2.4 Hz), 
7.62 (1H, dd, J = 8.6, 2.5 Hz), 6.75 (1H, d, J = 8.5 Hz), 4.55 (2H, s), 3.94 (3H, s); spectroscopic data consistent 
with literature. 146 
Quinolin-4-ylmethanol (79)  128 
 
NaBH4 (0.144 g, 3.82 mmol) was added at 0 °C to a solution of 4-quinolinecarboxaldehyde 78 (0.500 g, 
3.18 mmol) in methanol (10 mL). The reaction mixture was stirred at 0 °C over 90 minutes, then diluted 
with water (50 mL) and extracted into DCM (3 x 50 mL). The combined organic extracts were washed 
(brine), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (0 – 7% methanol 
in DCM) afforded 79 (0.398 g, 79% yield). 
1H NMR (400 MHz, CD3OD) 8.82 (1H, d, J = 4.4 Hz), 8.11-7.99 (2H, m), 7.77 (1H, ddd, J = 8.4, 7.0, 1.4 Hz), 
7.69-7.59 (2H, m), 5.17 (2H, s); 13C NMR (100 MHz, CD3OD) 151.2, 150.0, 148.3, 130.8, 129.6, 128.0, 127.3, 
124.4, 119.3, 61.5; spectroscopic data consistent with literature. 128 
2-(Chloromethyl)-1-methylpiperidine (81) 
 
Thionyl chloride (3 mL) was added dropwise to a solution of (1-methylpiperidin-2-yl)methanol 80 (1.02 
mL, 7.74 mmol) in DCM (15 mL). The reaction mixture was heated under reflux for 7 hours, then diluted 
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with NaHCO3 solution (100 mL) and extracted into DCM (3 x 100 mL). The combined organic extracts were 
washed (brine), dried (MgSO4) and concentrated in vacuo to afford 81 (0.658 g, 58% yield). 
1H NMR (400 MHz, CDCl3) 3.63 (1H, dd, J = 11.5, 5.2 Hz), 3.50 (1H, dd, J = 11.5, 2.6 Hz), 2.84 (1H, dtd, J = 
11.5, 3.5, 1.5 Hz), 2.27 (3H, s), 2.14-2.02 (2H, m), 1.78-1.48 (5H, m), 1.34-1.18 (1H, m); 13C NMR (100 MHz, 
CDCl3) 64.2, 57.0, 46.9, 43.0, 29.6, 25.8, 24.0; νmax/cm-1 2936, 2855, 2780, 2712. 
(1-Methylpiperidin-3-yl)methyl 4-methylbenzenesulfonate (83) 
 
DMAP (47 mg, 0.39 mmol), triethylamine (2.2 mL, 16 mmol) and p-toluenesulfonyl chloride (1.62 g, 8.51 
mmol) were added to a solution of (1-methylpiperidin-3-yl)methanol 82 (0.987 mL, 7.74 mmol) in DCM 
(15 mL). The reaction mixture was stirred over 4 hours, then diluted with water (25 mL) and extracted into 
DCM (3 x 25 mL). The combined organic extracts were washed (brine), dried (MgSO4) and concentrated in 
vacuo. Purification by flash chromatography (0 – 20% methanol in DCM) afforded 83 (0.815 g, 36% yield). 
LCMS (ESI+): m/z 284.2 [M + H]+, rt 1.36 minutes, 96%; 1H NMR (500 MHz, CDCl3) 7.80-7.75 (2H, m), 7.36-
7.31 (2H, m), 3.91 (1H, dd, J = 9.7, 5.8 Hz), 3.86 (1H, dd, J = 9.6, 7.1 Hz), 2.74 (1H, d, J = 10.2 Hz), 2.68 (1H, 
d, J = 10.8 Hz), 2.44 (3H, s), 2.22 (3H, s), 2.02-1.93 (1H, m), 1.90 (1H, t, J = 11.3 Hz), 1.72 (1H, t, J = 10.5 Hz), 
1.67-1.48 (3H, m), 1.03-0.90 (1H, m); 13C NMR (125 MHz, CDCl3) 144.9, 133.1, 130.0, 128.0, 73.0, 58.3, 
56.0, 46.6, 35.9, 26.1, 24.4, 21.8; νmax/cm-1 2938, 2783, 1598; HRMS (ESI)+: m/z calculated for [C14H21NO3S 
+ H]+ = 284.1315, observed 284.1315. 
Methyl 6-(hydroxymethyl)nicotinate (90)  133 
 
NaBH4 (0.727 g, 19.2 mmol) was added portionwise at 0 °C to a suspension of dimethyl pyridine-2,5-
dicarboxylate 89 (2.50 g, 12.8 mmol) and CaCl2 (5.69 g, 51.2 mmol) in methanol/THF (2:1, 90 mL). The 
reaction mixture was stirred at 0 °C over 90 minutes, then diluted with water (50 mL) dropwise at 0 °C. 
The product was extracted into chloroform (3 x 50 mL). The combined organic extracts were washed 
(brine), dried (MgSO4) and concentrated in vacuo to afford 90 (1.80 g, 84% yield). 
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1H NMR (400 MHz, CDCl3) 9.15 (1H, d, J = 1.4 Hz), 8.29 (1H, dd, J = 8.2, 2.1 Hz), 7.36 (1H, d, J = 8.2 Hz), 4.83 
(2H, d, J = 3.6 Hz), 3.95 (3H, s), 3.75-3.65 (1H, m); 13C NMR (100 MHz, CDCl3) 165.8, 163.7, 150.1, 137.9, 
125.1, 120.1, 64.4, 52.6; spectroscopic data consistent with literature. 133 
Methyl 6-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)nicotinate (91) 
 
Methanesulfonic acid (0.763 mL, 11.8 mmol) was added to a solution of methyl 6-
(hydroxymethyl)nicotinate 90 (1.79 g, 10.7 mmol) and 3,4-dihydro-2H-pyran (1.95 mL, 21.4 mmol) in DCM 
(20 mL). The reaction mixture was stirred over 150 minutes, then washed with NaHCO3 solution (2 x 15 
mL) and brine (15 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (0 
– 20% EtOAc in PET) afforded 91 (2.07 g, 77% yield). 
1H NMR (400 MHz, CDCl3) 9.14 (1H, d, J = 2.1 Hz), 8.29 (1H, dd, J = 8.1, 2.2 Hz), 7.58 (1H, dd, J = 8.2, 0.7 
Hz), 4.95 (1H, d, J = 14.6 Hz), 4.78 (1H, t, J = 3.5 Hz), 4.70 (1H, d, J = 14.5 Hz), 3.94 (3H, s), 3.93-3.84 (1H, 
m), 3.60-3.52 (1H, m), 1.97-1.47 (6H, m); 13C NMR (100 MHz, CDCl3) 166.0, 163.5, 150.5, 137.8, 124.7, 
120.7, 98.8, 69.7, 62.5, 52.5, 30.6, 25.5, 19.5; νmax/cm-1 2946, 2926, 2876, 2848, 1714 (C=O), 1596; HRMS 
(ESI)+: m/z calculated for [C13H17NO4 + Na]+ = 274.1050, observed 274.1045. 
(6-(((Tetrahydro-2H-pyran-2-yl)oxy)methyl)pyridin-3-yl)methanol (92) 
 
LiAlH4 (2.4 M in THF, 5.1 mL, 12 mmol) was added dropwise at 0 °C to a solution of methyl 6-(((tetrahydro-
2H-pyran-2-yl)oxy)methyl)nicotinate 91 (2.06 g, 8.20 mmol) in THF (20 mL). The reaction mixture was 
stirred at 0 °C for 45 minutes. Isopropanol (5 mL) was added dropwise at 0 °C to the reaction mixture, 
followed by water (50 mL). The product was extracted into DCM/methanol (9:1, 3 x 100 mL). The 
combined organic extracts were washed (brine), dried (MgSO4) and concentrated in vacuo. Purification by 
flash chromatography (60 – 90% EtOAc in PET) afforded 92 (1.16 g, 64% yield). 
1H NMR (400 MHz, CDCl3) 8.50 (1H, d, J = 1.7 Hz), 7.74 (1H, dd, J = 7.9, 2.2 Hz), 7.48 (1H, d, J = 8.1 Hz), 4.90 
(1H, d, J = 13.3 Hz), 4.78 (1H, t, J = 3.6 Hz), 4.73 (2H, s), 4.65 (1H, d, J = 13.3 Hz), 3.97-3.88 (1H, m), 3.61-
3.53 (1H, m), 2.60 (1H, br s), 1.91-1.49 (6H, m); 13C NMR (100 MHz, CDCl3) 158.0, 148.0, 135.7, 135.0, 
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121.5, 98.7, 69.8, 62.7, 62.4, 30.7, 25.5, 19.5; νmax/cm-1 3300 (br, O-H), 2939, 2869, 1604, 1574; HRMS 
(ESI)+: m/z calculated for [C12H17NO3 + H]+ = 224.1281, observed 224.1284. 
5-(Pyrrolidin-1-ylmethyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)pyridine (93) 
 
Methanesulfonyl chloride (0.478 mL, 6.18 mmol) was added dropwise at 0 °C to a solution of (6-
(((tetrahydro-2H-pyran-2-yl)oxy)methyl)pyridin-3-yl)methanol 92 (1.15 g, 5.15 mmol) and triethylamine 
(0.933 mL, 6.70 mmol) in DCM (10 mL). The reaction mixture was warmed to rt and stirred over 1 hour. 
The reaction was diluted with NaHCO3 solution (25 mL) and extracted into DCM (3 x 50 mL). The combined 
organic extracts were washed (brine), dried (MgSO4) and concentrated in vacuo. The crude residue was 
dissolved in DMF (10 mL), then pyrrolidine (0.516 mL, 6.18 mmol) and Cs2CO3 (2.18 g, 6.70 mmol) were 
added. The reaction mixture was stirred over 14 hours, then diluted with EtOAc (100 mL), washed with 
Na2CO3 solution (2 x 100 mL) and brine (100 mL), dried (MgSO4) and concentrated in vacuo. Purification 
by flash chromatography (0 – 8% methanol in DCM) afforded 93 (0.970 g, 66% yield). 
LCMS (ESI+): m/z 277.3 [M + H]+, rt 0.65 minutes, 97%; 1H NMR (400 MHz, CDCl3) 8.48 (1H, s), 7.68 (1H, 
dd, J = 7.9, 1.7 Hz), 7.42 (1H, d, J = 7.9 Hz), 4.88 (1H, d, J = 13.2 Hz), 4.77 (1H, t, J = 3.4 Hz), 4.62 (1H, d, J = 
13.3 Hz), 3.96-3.85 (1H, m), 3.61 (2H, s), 3.58-3.51 (1H, m), 2.55-2.43 (4H, m), 1.95-1.48 (10H, m); 13C NMR 
(100 MHz, CDCl3) 157.3, 149.6, 137.3, 133.4, 121.3, 98.6, 69.9, 62.3, 57.8, 54.2, 30.7, 25.5, 23.5, 19.5; 
νmax/cm-1 2939, 2783, 1602, 1572; HRMS (ESI)+: m/z calculated for [C16H24N2O2 + H]+ = 277.1911, observed 
277.1906. 
(5-(Pyrrolidin-1-ylmethyl)pyridin-2-yl)methanol (94) 
 
p-Toluenesulfonic acid monohydrate (1.28 g, 6.74 mmol) was added to a solution of 5-(pyrrolidin-1-
ylmethyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)pyridine 93 (0.960 g, 3.37 mmol) in ethanol (10 mL). 
The reaction mixture was heated to 50 °C over 30 minutes, then diluted with water (15 mL), adjusted to 
pH 14 using aqueous NaOH (10% w/v) and extracted into DCM (6 x 25 mL). The combined organic extracts 
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were washed (brine), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (0 
– 15% methanol (+ 0.1% NH3) in DCM) afforded 94 (0.560 g, 86% yield). 
1H NMR (400 MHz, CDCl3) 8.48 (1H, d, J = 1.5 Hz), 7.69 (1H, dd, J = 7.9, 2.0 Hz), 7.21 (1H, d, J = 8.1 Hz), 4.74 
(2H, s), 3.62 (2H, s), 2.57-2.44 (4H, m), 1.85-1.73 (4H, m); 13C NMR (100 MHz, CDCl3) 158.0, 148.9, 137.5, 
133.6, 120.3, 64.2, 57.7, 54.2, 23.6; νmax/cm-1 3200 (br, O-H), 2963, 2794, 1603, 1572; HRMS (ESI)+: m/z 
calculated for [C11H16N2O + H]+ = 193.1335, observed 193.1335. 
Methyl 1-((5-(pyrrolidin-1-ylmethyl)pyridin-2-yl)methyl)-1H-indole-6-carboxylate (95) 
 
Methanesulfonyl chloride (0.242 mL, 3.12 mmol) was added dropwise at 0 °C to a solution of (5-
(pyrrolidin-1-ylmethyl)pyridin-2-yl)methanol 94 (0.500 g, 2.60 mmol) and triethylamine (0.471 mL, 3.38 
mmol) in DCM (10 mL). The reaction mixture was warmed to rt and stirred over 150 minutes. Na2CO3 
solution (15 mL) was added dropwise at 0 °C to the reaction mixture. The intermediate was extracted into 
DCM (4 x 25 mL). The combined organic extracts were washed (brine), dried (MgSO4) and concentrated in 
vacuo to afford the intermediate as a crude residue. A solution of methyl 1H-indole-6-carboxylate 63 
(0.547 g, 3.12 mmol) in DMF (3 mL) was added dropwise at 0 °C to a suspension of NaH (60% in mineral 
oil, 0.520 g, 13.0 mmol) in DMF (2 mL). The reaction mixture was warmed to rt over 30 minutes. The crude 
residue was dissolved in DMF (5 mL) and added dropwise at 0 °C to the reaction mixture. The reaction 
mixture was warmed to rt and stirred over 45 minutes. NaI (39 mg, 0.26 mmol) was added to the reaction 
mixture, and it was heated to 60 °C over 30 minutes. Methanol (150 mL) was added dropwise at 0 °C to 
the reaction mixture followed by sulfuric acid (10 mL). The reaction mixture was heated under reflux for 
14 hours, then concentrated in vacuo. Na2CO3 solution (200 mL) was added dropwise to the reaction 
mixture, followed by water (50 mL). The product was extracted into EtOAc (2 x 200 mL), followed by 
DCM/methanol (9:1, 3 x 200 mL). The combined organic extracts were washed (brine), dried (MgSO4) and 
concentrated in vacuo. Purification by flash chromatography (0 – 100% EtOAc in PET, 0 – 10% methanol 
in DCM) afforded 95 (95 mg, 7% yield). 
LCMS (ESI+): m/z 350.3 [M + H]+, rt 1.39 minutes, 84%; 1H NMR (400 MHz, CDCl3) 8.46 (1H, d, J = 1.6 Hz), 
8.07 (1H, s), 7.82 (1H, dd, J = 8.4, 1.4 Hz), 7.66 (1H, d, J = 8.4 Hz), 7.36 (1H, d, J = 7.9 Hz), 7.31 (1H, dd, J = 
8.0, 2.2 Hz), 7.27-7.24 (1H, m), 6.61 (1H, dd, J = 3.1, 0.8 Hz), 5.39 (2H, s), 3.92 (3H, s), 3.79 (2H, s), 2.61 
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(4H, br s), 1.87-1.75 (4H, m); 13C NMR (100 MHz, CDCl3) 168.0, 158.4, 147.6, 135.5, 135.1, 132.4, 131.10, 
131.08, 123.6, 123.4, 120.9, 120.7, 111.7, 102.7, 61.5, 54.1, 52.0, 47.4, 23.5; νmax/cm-1 2951, 2799, 1705 
(C=O), 1615, 1602, 1569, 1505; HRMS (ESI)+: m/z calculated for [C21H23N3O2 + H]+ = 350.1863, observed 
350.1863. 
3-Oxo-3-(1-((5-(pyrrolidin-1-ylmethyl)pyridin-2-yl)methyl)-1H-indol-6-yl)propanenitrile (96) 
 
n-Butyllithium (1.6 M in hexanes, 0.42 mL, 0.67 mmol) was added dropwise at -78 °C to a mixture of 
acetonitrile (58 µL, 1.1 mmol) and THF (2 mL). The reaction mixture was stirred at -78 °C over 30 minutes. 
A solution of methyl 1-((5-(pyrrolidin-1-ylmethyl)pyridin-2-yl)methyl)-1H-indole-6-carboxylate 95 (92 mg, 
0.22 mmol) in THF (3 mL) was added dropwise at -78 °C over 30 minutes. The reaction mixture was stirred 
at -78 °C over 1 hour. Water (15 mL) was added dropwise at 0 °C, and the reaction mixture adjusted to pH 
8. The product was extracted into DCM (3 x 25 mL), followed by DCM/methanol (9:1, 3 x 25 mL). The 
combined organic extracts were washed (brine), dried (MgSO4) and concentrated in vacuo. Purification by 
flash chromatography (0 – 20% methanol in DCM) afforded 96 (69 mg, 71% yield). 
LCMS (ESI+): m/z 359.2 [M + H]+, (ESI-): m/z 357.1 [M - H]-, rt 1.30 minutes, 81%; 1H NMR (400 MHz, CDCl3) 
8.38 (1H, s), 7.96 (1H, s), 7.66 (1H, d, J = 8.4 Hz), 7.56 (1H, d, J = 8.3 Hz), 7.42-7.29 (3H, m), 6.60 (1H, d, J = 
2.8 Hz), 5.37 (2H, s), 4.13 (2H, br s), 3.79 (2H, s), 2.70-2.55 (4H, m), 1.85-1.70 (4H, m); 13C NMR (100 MHz, 
CDCl3) 187.1, 158.3, 147.8, 135.7, 135.2, 133.7, 132.9, 130.8, 128.3, 123.5, 121.4, 119.8, 114.6, 110.9, 
103.1, 61.4, 54.2, 47.7, 29.8, 23.5; νmax/cm-1 2919, 2799, 2168 (C≡N), 1675 (C=O), 1605; HRMS (ESI)+: m/z 
calculated for [C22H22N4O + H]+ = 359.1866, observed 359.1866. 
Methyl indoline-6-carboxylate (97)  134 
 
Sodium cyanoborohydride (1.61 g, 25.7 mmol) was added portionwise at 0 °C to a solution of methyl 1H-
indole-6-carboxylate 63 (1.50 g, 8.56 mmol) in acetic acid (15 mL) over 30 minutes. The reaction mixture 
was warmed to rt and stirred over 7 hours. The reaction was diluted with EtOAc (100 mL), washed with 
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NaHCO3 solution (3 x 100 mL) and brine (100 mL), dried (MgSO4) and concentrated in vacuo. Purification 
by flash chromatography (0 – 30% EtOAc in PET) afforded 97 (1.11 g, 66% yield). 
LCMS (ESI+): m/z 178.2 [M + H]+, rt 1.00 minutes, 90%; 1H NMR (400 MHz, CDCl3) 7.40 (1H, dd, J = 7.6, 1.4 
Hz), 7.23 (1H, d, J = 1.4 Hz), 7.12 (1H, d, J = 7.6 Hz), 3.90 (1H, br s), 3.86 (3H, s), 3.57 (2H, t, J = 8.4 Hz), 3.04 
(2H, t, J = 8.4 Hz); 13C NMR (100 MHz, CDCl3) 167.6, 151.9, 135.0, 129.4, 124.3, 120.7, 109.6, 52.0, 47.5, 
29.9; 1H NMR spectroscopic data consistent with literature. 134 
4-(Pyrrolidin-1-ylmethyl)benzonitrile (99a) 
 
Sodium triacetoxyborohydride (1.29 g, 6.10 mmol) was added to a solution of 4-formylbenzonitrile 98 
(0.500 g, 3.81 mmol), pyrrolidine (0.318 mL, 3.81 mmol) and acetic acid (0.262 mL, 4.58 mmol) in DCM 
(10 mL). The reaction mixture was stirred over 15 hours. The reaction was diluted with water (25 mL), 
adjusted to pH 14 using aqueous NaOH (6 M) and extracted into DCM (3 x 25 mL). The combined organic 
extracts were dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (0 – 5% 
methanol in DCM) afforded 99a (0.645 g, 85% yield). 
1H NMR (400 MHz, CDCl3) 7.62-7.56 (2H, m), 7.47-7.41 (2H, m), 3.65 (2H, s), 2.55-2.44 (4H, m), 1.84-1.73 
(4H, m); 13C NMR (100 MHz, CDCl3) 145.4, 132.2, 129.4, 119.2, 110.8, 60.3, 54.4, 23.6; spectroscopic data 
consistent with literature. 147 
4-(Piperidin-1-ylmethyl)benzonitrile (99b) 
 
Sodium triacetoxyborohydride (2.59 g, 12.2 mmol) was added to a solution of 4-formylbenzonitrile 98 
(1.00 g, 7.63 mmol), piperidine (0.753 mL, 7.63 mmol) and acetic acid (0.524 mL, 9.15 mmol) in DCM (10 
mL). The reaction mixture was stirred over 5 hours, then diluted with water (10 mL), adjusted to pH 14 
and extracted into DCM (3 x 25 mL). The combined organic extracts were dried (MgSO4) and concentrated 
in vacuo. Purification by flash chromatography (0 – 25% EtOAc in PET) afforded 99b (1.21 g, 79% yield). 
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1H NMR (400 MHz, CDCl3) 7.62-7.55 (2H, m), 7.44 (2H, d, J = 8.3 Hz), 3.49 (2H, s), 2.43-2.27 (4H, m), 1.57 
(4H, quin, J = 5.6 Hz), 1.48-1.38 (2H, m); 13C NMR (100 MHz, CDCl3) 145.0, 132.1, 129.6, 119.2, 110.7, 63.4, 
54.7, 26.1, 24.3; spectroscopic data consistent with literature. 148  
4-(Morpholinomethyl)benzonitrile (99c) 
 
Sodium triacetoxyborohydride (1.42 g, 6.71 mmol) was added to a solution of 4-formylbenzonitrile 98 
(0.550 g, 4.19 mmol), morpholine (0.367 mL, 4.19 mmol) and acetic acid (0.288 mL, 5.03 mmol) in DCM (6 
mL). The reaction mixture was stirred over 90 minutes, then diluted with water (10 mL), adjusted to pH 
14 and extracted into DCM (3 x 25 mL). The combined organic extracts were dried (MgSO4) and 
concentrated in vacuo. Purification by flash chromatography (0 – 60% EtOAc in PET) afforded 99c (0.738 
g, 77% yield). 
1H NMR (400 MHz, CDCl3) 7.62-7.57 (2H, m), 7.45 (2H, d, J = 8.2 Hz), 3.70 (4H, t, J = 4.6 Hz), 3.53 (2H, s), 
2.43 (4H, t, J = 4.6 Hz); 13C NMR (100 MHz, CDCl3) 143.9, 132.3, 129.6, 119.0, 111.1, 67.0, 62.9, 53.7; 
spectroscopic data consistent with literature. 149  
4-((4-Methylpiperazin-1-yl)methyl)benzonitrile (99d) 
 
Sodium triacetoxyborohydride (2.59 g, 12.2 mmol) was added to a solution of 4-formylbenzonitrile 98 
(1.00 g, 7.63 mmol), 1-methylpiperazine (0.846 mL, 7.63 mmol) and acetic acid (0.524 mL, 9.15 mmol) in 
DCM (10 mL). The reaction mixture was stirred over 80 minutes. The reaction was diluted with water (10 
mL), adjusted to pH 14 using aqueous NaOH (10% w/v) and extracted into DCM (3 x 25 mL).  The combined 
organic extracts were dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (0 
– 4% methanol in DCM) afforded 99d (1.28 g, 70% yield). 
1H NMR (400 MHz, CDCl3) 7.61-7.56 (2H, m), 7.44 (2H, d, J = 8.2 Hz), 3.53 (2H, s), 2.45 (8H, br s), 2.27 (3H, 
s); 13C NMR (100 MHz, CDCl3) 144.4, 132.2, 129.6, 119.1, 111.0, 62.5, 55.2, 53.3, 46.1; spectroscopic data 
consistent with literature. 150 
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4-(Pyrrolidin-1-ylmethyl)benzaldehyde (100a) 
 
DIBAL-H (1 M in THF, 2.2 mL, 2.2 mmol) was added dropwise at 0 °C to a solution of 4-(pyrrolidin-1-
ylmethyl)benzonitrile 99a (0.408 g, 2.19 mmol) in THF (5 mL). The reaction mixture was warmed to rt and 
stirred over 45 minutes. Further DIBAL-H (2.2 mL, 2.2 mmol) was added dropwise at 0 °C to the reaction 
mixture. The reaction mixture was warmed to rt and stirred over 15 minutes, then NaHCO3 solution (50 
mL) was added dropwise at 0 °C. The product was extracted into DCM/methanol (10:1, 3 x 50 mL). The 
combined organic extracts were washed (brine), dried (MgSO4) and concentrated in vacuo. Purification by 
flash chromatography (0 – 4% methanol (+ 0.1% NH3) in DCM) afforded 100a (0.313 g, 75% yield). 
1H NMR (400 MHz, CDCl3) 9.99 (1H, s), 7.83 (2H, d, J = 8.2 Hz), 7.50 (2H, d, J = 8.0 Hz), 3.68 (2H, s), 2.56-
2.48 (4H, m), 1.84-1.75 (4H, m); 13C NMR (100 MHz, CDCl3) 192.2, 147.0, 135.5, 129.9, 129.4, 60.6, 54.4, 
23.7; spectroscopic data consistent with literature. 151 
4-(Piperidin-1-ylmethyl)benzaldehyde (100b) 
 
DIBAL-H (1 M in THF, 5.9 mL, 5.9 mmol) was added dropwise at 0 °C to a solution of 4-(piperidin-1-
ylmethyl)benzonitrile 99b (1.19 g, 5.94 mmol) in THF (10 mL). The reaction mixture was warmed to rt and 
stirred over 90 minutes, then NaHCO3 solution (50 mL) was added dropwise at 0 °C. The product was 
extracted into DCM/methanol (10:1, 3 x 50 mL). The combined organic extracts were washed (brine), 
dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (0 – 18% EtOAc in PET) 
afforded 100b (0.877 g, 58% yield). 
1H NMR (400 MHz, CDCl3) 9.97 (1H, s), 7.80 (2H, d, J = 8.1 Hz), 7.48 (2H, d, J = 8.1 Hz), 3.53 (2H, s), 2.48-
2.26 (4H, m), 1.64-1.51 (4H, m), 1.47-1.37 (2H, m); 13C NMR (100 MHz, CDCl3) 192.1, 146.3, 135.5, 129.8, 
129.6, 63.5, 54.6, 26.0, 24.3; spectroscopic data consistent with literature. 152 
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4-(Morpholinomethyl)benzaldehyde (100c) 
 
DIBAL-H (1 M in THF, 3.1 mL, 3.1 mmol) was added dropwise at 0 °C to a solution of 4-
(morpholinomethyl)benzonitrile 99c (0.717 g, 3.12 mmol) in THF (6 mL). The reaction mixture was warmed 
to rt and stirred over 30 minutes, then further DIBAL-H (1 M in THF, 3.1 mL, 3.1 mmol) was added dropwise 
at 0 °C. The reaction mixture was warmed to rt and stirred over 30 minutes, then NaHCO3 solution (50 
mL) was added dropwise at 0 °C. The product was extracted into DCM/methanol (10:1, 3 x 50 mL). The 
combined organic extracts were washed (brine), dried (MgSO4) and concentrated in vacuo. Purification by 
flash chromatography (0 – 50% EtOAc in PET) afforded 100c (0.297 g, 46% yield). 
1H NMR (400 MHz, CDCl3) 9.99 (1H, s), 7.87-7.81 (2H, m), 7.51 (2H, d, J = 8.1 Hz), 3.71 (4H, t, J = 4.6 Hz), 
3.57 (2H, s), 2.45 (4H, t, J = 4.5 Hz); 13C NMR (100 MHz, CDCl3) 192.1, 145.5, 135.7, 129.9, 129.6, 67.1, 63.2, 
53.8; spectroscopic data consistent with literature. 152 
4-((4-Methylpiperazin-1-yl)methyl)benzaldehyde (100d) 
 
DIBAL-H (1 M in THF, 5.3 mL, 5.3 mmol) was added dropwise at 0 °C to a solution of 4-((4-methylpiperazin-
1-yl)methyl)benzonitrile 99d (1.26 g, 5.27 mmol) in THF (10 mL). The reaction mixture was warmed to rt 
and stirred over 30 minutes. Further DIBAL-H (5.3 mL, 5.3 mmol) was added dropwise at 0 °C to the 
reaction mixture. The reaction mixture was warmed to rt and stirred over 30 minutes, then NaHCO3 
solution (50 mL) was added dropwise at 0 °C. The product was extracted into DCM/methanol (9:1, 3 x 50 
mL). The combined organic extracts were washed (brine), dried (MgSO4) and concentrated in vacuo. 
Purification by flash chromatography (0 – 4% methanol (+ 0.1% NH3) in DCM) afforded 100d (0.576 g, 50% 
yield). 
1H NMR (400 MHz, CDCl3) 9.98 (1H, s), 7.85-7.79 (2H, m), 7.50 (2H, d, J = 8.0 Hz), 3.57 (2H, s), 2.47 (8H, br 
s), 2.28 (3H, s); 13C NMR (100 MHz, CDCl3) 192.1, 146.0, 135.6, 129.9, 129.6, 62.8, 55.2, 53.3, 46.2; 
spectroscopic data consistent with literature. 152  
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Methyl 1-(4-(pyrrolidin-1-ylmethyl)benzyl)-1H-indole-6-carboxylate (101a) 
 
A solution of 4-(pyrrolidin-1-ylmethyl)benzaldehyde 100a (0.302 g, 1.60 mmol) in toluene (3 mL) was 
added to a mixture of methyl indoline-6-carboxylate 97 (0.377 g, 1.91 mmol) and benzoic acid (39 mg, 
0.32 mmol). The reaction mixture was heated to 200 °C by microwave for 20 minutes. The reaction was 
diluted with EtOAc (50 mL), washed with NaHCO3 solution (3 x 50 mL) and brine (50 mL), dried (MgSO4) 
and concentrated in vacuo. Purification by flash chromatography (40 – 80% EtOAc in PET) afforded 101a 
(0.297 g, 53% yield). 
LCMS (ESI+): m/z 349.3 [M + H]+, rt 1.51 minutes, 100%; 1H NMR (400 MHz, CDCl3) 8.11 (1H, s), 7.81 (1H, 
dd, J = 8.3, 1.3 Hz), 7.66 (1H, d, J = 8.4 Hz), 7.32-7.23 (3H, m), 7.07 (2H, d, J = 7.9 Hz), 6.59 (1H, dd, J = 3.1, 
0.5 Hz), 5.37 (2H, s), 3.92 (3H, s), 3.58 (2H, s), 2.52-2.44 (4H, m), 1.80-1.73 (4H, m); 13C NMR (100 MHz, 
CDCl3) 168.3, 139.3, 135.9, 135.6, 132.4, 131.5, 129.5, 126.9, 123.5, 120.72, 120.65, 112.1, 102.2, 60.4, 
54.3, 52.0, 50.0, 23.6; νmax/cm-1 2951, 2782, 1706 (C=O), 1615, 1505; HRMS (ESI)+: m/z calculated for 
[C22H24N2O2 + H]+ = 349.1911, observed 349.1913. 
Methyl 1-(4-(piperidin-1-ylmethyl)benzyl)-1H-indole-6-carboxylate (101b) 
 
A solution of 4-(piperidin-1-ylmethyl)benzaldehyde 100b (0.400 g, 1.57 mmol) in toluene (3 mL) was 
added to a mixture of methyl indoline-6-carboxylate 97 (0.360 g, 1.89 mmol) and benzoic acid (38 mg, 
0.32 mmol). The reaction mixture was heated to 200 °C by microwave for 30 minutes, then diluted with 
EtOAc (25 mL), washed with NaHCO3 solution (3 x 15 mL) and brine (15 mL), dried (MgSO4) and 
concentrated in vacuo. Purification by flash chromatography (20 – 41% EtOAc in PET) afforded 101b (0.393 
g, 67% yield). 
LCMS (ESI+): m/z 363.4 [M + H]+, rt 1.50 minutes, 97%; 1H NMR (400 MHz, CDCl3) 8.10 (1H, s), 7.83-7.77 
(1H, m), 7.65 (1H, d, J = 8.4 Hz), 7.29-7.22 (3H, m), 7.05 (2H, d, J = 7.6 Hz), 6.61-6.55 (1H, m), 5.36 (2H, s), 
3.91 (3H, s), 3.42 (2H, s), 2.34 (4H, br s), 1.62-1.50 (4H, m), 1.46-1.36 (2H, m); 13C NMR (100 MHz, CDCl3) 
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168.3, 138.6, 135.9, 135.6, 132.4, 131.5, 129.8, 126.8, 123.5, 120.72, 120.66, 112.2, 102.2, 63.6, 54.6, 
52.1, 50.0, 26.1, 24.5; νmax/cm-1 2933, 2851, 2793, 2754, 1707 (C=O), 1615, 1505; HRMS (ESI)+: m/z 
calculated for [C23H26N2O2 + H]+ = 363.2067, observed 363.2051. 
Methyl 1-(4-(morpholinomethyl)benzyl)-1H-indole-6-carboxylate (101c) 
 
Toluene (3 mL) was added to a mixture of 4-(morpholinomethyl)benzaldehyde 100c (0.282 g, 1.37 mmol), 
methyl indoline-6-carboxylate 97 (0.325 g, 1.65 mmol) and benzoic acid (34 mg, 0.28 mmol). The reaction 
mixture was heated to 200 °C by microwave for 30 minutes, then diluted with EtOAc (25 mL), washed with 
NaHCO3 solution (3 x 15 mL) and brine (15 mL), dried (MgSO4) and concentrated in vacuo. Purification by 
flash chromatography (0 – 55% EtOAc in PET) afforded 101c (0.330 g, 59% yield). 
LCMS (ESI+): m/z 365.3 [M + H]+, rt 1.45 minutes, >99%; 1H NMR (400 MHz, CDCl3) 8.10 (1H, s), 7.81 (1H, 
dd, J = 8.3, 1.4 Hz), 7.66 (1H, d, J = 8.3 Hz), 7.31-7.23 (3H, m), 7.06 (2H, d, J = 7.9 Hz), 6.59 (1H, dd, J = 3.1, 
0.7 Hz), 5.37 (2H, s), 3.91 (3H, s), 3.69 (4H, t, J = 4.7 Hz), 3.45 (2H, s), 2.41 (4H, t, J = 4.4 Hz); 13C NMR (100 
MHz, CDCl3) 168.3, 137.7, 136.0, 135.9, 132.4, 131.5, 129.8, 126.9, 123.6, 120.73, 120.68, 112.1, 102.3, 
67.1, 63.1, 53.7, 52.1, 50.0; νmax/cm-1 2950, 2854, 2808, 1706 (C=O), 1615, 1504; HRMS (ESI)+: m/z 
calculated for [C22H24N2O3 + H]+ = 365.1860, observed 365.1848. 
Methyl 1-(4-((4-methylpiperazin-1-yl)methyl)benzyl)-1H-indole-6-carboxylate (101d) 
 
Toluene (3 mL) was added to a mixture of 4-((4-methylpiperazin-1-yl)methyl)benzaldehyde 100d (0.300 
g, 1.37 mmol), methyl indoline-6-carboxylate 97 (0.314 g, 1.65 mmol) and benzoic acid (34 mg, 0.28 
mmol). The reaction mixture was heated to 200 °C by microwave for 30 minutes. The reaction was diluted 
with EtOAc (25 mL), washed with NaHCO3 solution (3 x 15 mL) and brine (15 mL), dried (MgSO4) and 
concentrated in vacuo. Purification by flash chromatography (0 – 10% methanol in DCM) afforded 101d 
(0.329 g, 55% yield). 
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LCMS (ESI+): m/z 378.3 [M + H]+, rt 1.46 minutes, 100%; 1H NMR (400 MHz, CDCl3) 8.12 (1H, s), 7.83 (1H, 
dd, J = 8.4, 1.4 Hz), 7.68 (1H, d, J = 8.4 Hz), 7.30-7.24 (3H, m), 7.08 (2H, d, J = 8.2 Hz), 6.61 (1H, dd, J = 3.1, 
0.7 Hz), 5.38 (2H, s), 3.93 (3H, s), 3.49 (2H, s), 2.49 (8H, br s), 2.31 (3H, s); 13C NMR (100 MHz, CDCl3) 168.1, 
137.9, 135.8, 135.7, 132.3, 131.3, 129.6, 126.7, 123.4, 120.6, 120.5, 112.0, 102.1, 62.5, 55.0, 52.8, 51.9, 
49.8, 45.8; νmax/cm-1 2937, 2794, 1706 (C=O), 1614, 1504; HRMS (ESI)+: m/z calculated for [C23H27N3O2 + 
H]+ = 378.2176, observed 378.2159. 
Methyl 1-(4-((4-isopropylpiperazin-1-yl)methyl)benzyl)-1H-indole-6-carboxylate (101e) 
 
Methanesulfonyl chloride (0.126 mL, 1.63 mmol) was added dropwise at 0 °C to a solution of methyl 1-(4-
(hydroxymethyl)benzyl)-1H-indole-6-carboxylate 109 (0.400 g, 1.35 mmol) and triethylamine (0.245 mL, 
1.76 mmol) in DCM (4 mL). The reaction mixture was warmed to rt and stirred over 90 minutes. Water (15 
mL) was added dropwise at 0 °C. The intermediate was extracted into DCM (3 x 25 mL). The combined 
organic extracts were washed (brine), dried (MgSO4) and concentrated in vacuo. The crude residue was 
dissolved in DMF (4 mL), then 1-isopropylpiperazine (0.233 mL, 1.63 mmol) and Cs2CO3 (0.574 g, 1.76 
mmol) were added. The reaction mixture was stirred over 11 hours, then further 1-isopropylpiperazine 
(0.233 mL, 1.63 mmol) and Cs2CO3 (0.574 g, 1.76 mmol) were added. The reaction mixture was stirred 
over 1 hour, then diluted with EtOAc (100 mL), washed with water (3 x 100 mL) and brine (100 mL), dried 
(MgSO4) and concentrated in vacuo. Purification by flash chromatography (50 – 100% EtOAc in PET) 
afforded 101e (0.254 g, 43% yield). 
LCMS (ESI+): m/z 406.3 [M + H]+, rt 1.54 minutes, 92%; 1H NMR (400 MHz, CDCl3) 8.10 (1H, s), 7.80 (1H, 
dd, J = 8.4, 1.4 Hz), 7.65 (1H, d, J = 8.4 Hz), 7.29-7.22 (3H, m), 7.06 (2H, d, J = 8.1 Hz), 6.58 (1H, dd, J = 3.2, 
0.8 Hz), 5.36 (2H, s), 3.91 (3H, s), 3.47 (2H, s), 2.62 (1H, sept, J = 6.5 Hz), 2.62-2.32 (8H, m), 1.03 (6H, d, J = 
6.5 Hz); 13C NMR (100 MHz, CDCl3) 168.3, 138.1, 135.9, 135.8, 132.4, 131.5, 129.8, 126.9, 123.6, 120.74, 
120.67, 112.1, 102.3, 62.8, 54.6, 53.6, 52.1, 50.0, 48.8, 18.8; νmax/cm-1 2964, 2929, 2875, 2808, 1709 (C=O), 
1618, 1571, 1505; HRMS (ESI)+: m/z calculated for [C25H31N3O2 + H]+ = 406.2489, observed 406.2481. 
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3-Oxo-3-(1-(4-(pyrrolidin-1-ylmethyl)benzyl)-1H-indol-6-yl)propanenitrile (102a) 
 
n-Butyllithium (1.6 M in hexanes, 2.7 mL, 4.3 mmol) was added dropwise at -78 °C to a mixture of 
acetonitrile (0.375 mL, 7.17 mmol) and THF (6 mL). The reaction mixture was stirred at -78 °C over 30 
minutes. A solution of methyl 1-(4-(pyrrolidin-1-ylmethyl)benzyl)-1H-indole-6-carboxylate 101a (0.500 g, 
1.43 mmol) in THF (4 mL) was added dropwise at -78 °C over 30 minutes. The reaction mixture was stirred 
at -78 °C over 1 hour. Water (15 mL) was added dropwise at 0 °C, and the reaction mixture adjusted to pH 
8. The product was extracted into DCM (3 x 25 mL). The combined organic extracts were washed (brine), 
dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (50 – 100% EtOAc in PET, 
0 – 10% methanol in DCM) afforded 102a (0.448 g, 87% yield). 
LCMS (ESI+): m/z 358.3 [M + H]+, (ESI-): m/z 356.2 [M - H]-, rt 1.38 minutes, 100%; 1H NMR (400 MHz, 
CDCl3) 7.98 (1H, s), 7.70 (1H, d, J = 8.3 Hz), 7.59 (1H, dd, J = 8.4, 1.3 Hz), 7.36 (1H, d, J = 3.1 Hz), 7.29 (2H, 
d, J = 8.1 Hz), 7.07 (2H, d, J = 7.9 Hz), 6.61 (1H, d, J = 3.1 Hz), 5.38 (2H, s), 4.09 (2H, br s), 3.59 (2H, s), 2.55-
2.44 (4H, m), 1.83-1.71 (4H, m); 13C NMR (100 MHz, CDCl3) 187.0, 139.4, 136.0, 135.2, 133.9, 133.4, 129.7, 
128.1, 127.0, 121.3, 119.7, 114.5, 111.3, 102.6, 60.3, 54.3, 50.3, 29.6, 23.5; νmax/cm-1 2960, 2786, 2165 
(C≡N), 1680 (C=O), 1607, 1503. 
3-Oxo-3-(1-(4-(piperidin-1-ylmethyl)benzyl)-1H-indol-6-yl)propanenitrile (102b) 
 
n-Butyllithium (1.6 M in hexanes, 1.3 mL, 2.0 mmol) was added dropwise at -78 °C to a mixture of 
acetonitrile (0.16 mL, 3.0 mmol) and THF (3 mL). The reaction mixture was stirred at -78 °C over 30 
minutes. A solution of methyl 1-(4-(piperidin-1-ylmethyl)benzyl)-1H-indole-6-carboxylate 101b (0.377 g, 
1.01 mmol) in THF (3 mL) was added dropwise at -78 °C over 30 minutes. The reaction mixture was stirred 
at -78 °C over 1 hour. Water (20 mL) was added dropwise at 0 °C, and the reaction mixture adjusted to pH 
8. The product was extracted into DCM (4 x 50 mL). The combined organic extracts were dried (MgSO4) 
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and concentrated in vacuo. Purification by flash chromatography (50 – 90% EtOAc in PET) afforded 102b 
(0.289 g, 77% yield). 
LCMS (ESI+): m/z 372.4 [M + H]+, rt 1.43 minutes, >99%; 1H NMR (400 MHz, CDCl3) 7.99 (1H, s), 7.70 (1H, 
d, J = 8.4 Hz), 7.60 (1H, dd, J = 8.3, 1.5 Hz), 7.37 (1H, d, J = 3.2 Hz), 7.27 (2H, d, J = 7.5 Hz), 7.06 (2H, d, J = 
8.2 Hz), 6.62 (1H, d, J = 3.1 Hz), 5.38 (2H, s), 4.09 (2H, s), 3.43 (2H, s), 2.34 (4H, br s), 1.55 (4H, quin, J = 5.6 
Hz), 1.47-1.36 (2H, m); 13C NMR (100 MHz, CDCl3) 187.0, 138.9, 136.0, 135.1, 133.8, 133.4, 129.9, 128.1, 
126.8, 121.3, 119.7, 114.5, 111.3, 102.6, 63.5, 54.6, 50.3, 29.6, 26.1, 24.5; νmax/cm-1 2914, 2805, 2252 
(C≡N), 1682 (C=O), 1608, 1503; HRMS (ESI)+: m/z calculated for [C24H25N3O + H]+ = 372.2070, observed 
372.2053. 
3-(1-(4-(Morpholinomethyl)benzyl)-1H-indol-6-yl)-3-oxopropanenitrile (102c) 
 
n-Butyllithium (1.6 M in hexanes, 1.5 mL, 2.3 mmol) was added dropwise at -78 °C to a mixture of 
acetonitrile (0.20 mL, 3.9 mmol) and THF (3 mL). The reaction mixture was stirred at -78 °C over 30 
minutes. A solution of methyl 1-(4-(morpholinomethyl)benzyl)-1H-indole-6-carboxylate 101c (0.315 g, 
0.778 mmol) in THF (3 mL) was added dropwise at -78 °C over 30 minutes. The reaction mixture was stirred 
at -78 °C over 20 minutes. Water (10 mL) was added dropwise at 0 °C, and the reaction mixture adjusted 
to pH 8. The product was extracted into DCM (3 x 25 mL). The combined organic extracts were washed 
(brine), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (20 – 80% EtOAc 
in PET) afforded 102c (0.272 g, 87% yield). 
LCMS (ESI+): m/z 374.2 [M + H]+, rt 1.36 minutes, 93%; 1H NMR (400 MHz, CDCl3) 7.99 (1H, s), 7.70 (1H, d, 
J = 8.3 Hz), 7.59 (1H, dd, J = 8.4, 1.5 Hz), 7.37 (1H, d, J = 3.2 Hz), 7.28 (2H, d, J = 8.1 Hz), 7.07 (2H, d, J = 7.9 
Hz), 6.62 (1H, d, J = 3.2 Hz), 5.38 (2H, s), 4.09 (2H, s), 3.68 (4H, t, J = 4.6 Hz), 3.45 (2H, s), 2.45-2.36 (4H, 
m); 13C NMR (100 MHz, CDCl3) 187.1, 138.0, 136.0, 135.5, 133.9, 133.4, 129.9, 128.1, 126.9, 121.3, 119.8, 
114.4, 111.3, 102.7, 67.1, 63.1, 53.7, 50.3, 29.6; νmax/cm-1 2940, 2846, 2251 (C≡N), 1681 (C=O), 1607, 1503; 
HRMS (ESI)-: m/z calculated for [C23H23N3O2 - H]- = 372.1718, observed 372.1723. 
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3-(1-(4-((4-Methylpiperazin-1-yl)methyl)benzyl)-1H-indol-6-yl)-3-oxopropanenitrile (102d) 
 
n-Butyllithium (1.6 M in hexanes, 1.4 mL, 2.2 mmol) was added dropwise at -78 °C to a mixture of 
acetonitrile (0.188 mL, 3.61 mmol) and THF (3 mL). The reaction mixture was stirred at -78 °C over 30 
minutes. A solution of methyl 1-(4-((4-methylpiperazin-1-yl)methyl)benzyl)-1H-indole-6-carboxylate 101d 
(0.313 g, 0.721 mmol) in THF (3 mL) was added dropwise at -78 °C over 30 minutes. The reaction mixture 
was stirred at -78 °C over 30 minutes. Water (20 mL) was added dropwise at 0 °C, and the reaction mixture 
adjusted to pH 8. The product was extracted into DCM (3 x 25 mL). The combined organic extracts were 
washed (brine), dried (MgSO4) and concentrated in vacuo. Purification by flash chromatography (50 – 
100% EtOAc in PET, 0 – 10% methanol in DCM) afforded 102d (0.258 g, 82% yield). 
LCMS (ESI+): m/z 387.2 [M + H]+, rt 1.38 minutes, 89%; 1H NMR (400 MHz, CDCl3) 7.98 (1H, s), 7.69 (1H, d, 
J = 8.3 Hz), 7.58 (1H, dd, J = 8.4, 1.6 Hz), 7.36 (1H, d, J = 3.2 Hz), 7.26 (2H, d, J = 8.1 Hz), 7.06 (2H, d, J = 8.2 
Hz), 6.61 (1H, dd, J = 3.1, 0.7 Hz), 5.37 (2H, s), 4.09 (2H, br s), 3.47 (2H, s), 2.44 (8H, br s), 2.27 (3H, s); 13C 
NMR (100 MHz, CDCl3) 187.0, 138.4, 136.0, 135.3, 133.8, 133.4, 129.9, 128.1, 126.9, 121.3, 119.7, 114.5, 
111.3, 102.6, 62.6, 55.2, 53.1, 50.3, 46.1, 29.7; νmax/cm-1 2934, 2790, 2165 (C≡N), 1680 (C=O), 1607, 1502; 
HRMS (ESI)-: m/z calculated for [C24H26N4O - H]- = 385.2034, observed 385.2029. 
3-(1-(4-((4-Isopropylpiperazin-1-yl)methyl)benzyl)-1H-indol-6-yl)-3-oxopropanenitrile (102e) 
 
n-Butyllithium (1.6 M in hexanes, 1.0 mL, 1.6 mmol) was added dropwise at -78 °C to a mixture of 
acetonitrile (0.14 mL, 2.7 mmol) and THF (2 mL). The reaction mixture was stirred at -78 °C over 30 
minutes. A solution of methyl 1-(4-((4-isopropylpiperazin-1-yl)methyl)benzyl)-1H-indole-6-carboxylate 
101e (0.241 g, 0.547 mmol) in THF (4 mL) was added dropwise at -78 °C over 30 minutes. The reaction 
mixture was stirred at -78 °C over 30 minutes. Water (15 mL) was added dropwise at 0 °C, and the reaction 
mixture adjusted to pH 8. The product was extracted into DCM/methanol (9:1, 3 x 25 mL). The combined 
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organic extracts were washed (brine), dried (MgSO4) and concentrated in vacuo. Purification by flash 
chromatography (50 – 100% EtOAc in PET, 0 – 8% methanol in DCM) afforded 102e (0.187 g, 83% yield). 
LCMS (ESI+): m/z 415.3 [M + H]+, (ESI-): m/z 413.2 [M - H]-, rt 1.45 minutes, >99%; 1H NMR (400 MHz, 
CDCl3) 7.98 (1H, s), 7.70 (1H, d, J = 8.4 Hz), 7.59 (1H, dd, J = 8.4, 1.5 Hz), 7.37 (1H, d, J = 3.2 Hz), 7.26 (2H, 
d, J = 8.2 Hz), 7.06 (2H, d, J = 8.1 Hz), 6.62 (1H, d, J = 3.2 Hz), 5.38 (2H, s), 4.10 (2H, s), 3.48 (2H, s), 2.76-
2.41 (9H, m), 1.06 (6H, d, J = 6.6 Hz); 13C NMR (100 MHz, CDCl3) 187.0, 138.2, 136.0, 135.4, 133.9, 133.4, 
130.0, 128.1, 126.9, 121.3, 119.7, 114.5, 111.3, 102.6, 62.6, 54.8, 53.1, 50.3, 48.7, 29.6, 18.6; νmax/cm-1 
2934, 2810, 2162 (C≡N), 1681 (C=O), 1607, 1502; HRMS (ESI)+: m/z calculated for [C26H30N4O + H]+ = 
415.2492, observed 415.2479. 
2-Methyl-3-oxo-3-(1-(4-(pyrrolidin-1-ylmethyl)benzyl)-1H-indol-6-yl)propanenitrile (104a) 
 
n-Butyllithium (1.6 M in hexanes, 1.1 mL, 1.7 mmol) was added dropwise at -78 °C to a mixture of 
propionitrile (0.123 mL, 1.72 mmol) and toluene (4 mL). The reaction mixture was stirred at -78 °C over 
30 minutes. A solution of methyl 1-(4-(pyrrolidin-1-ylmethyl)benzyl)-1H-indole-6-carboxylate 101a (0.300 
g, 0.861 mmol) in toluene (2 mL) was added dropwise at -78 °C over 30 minutes. The reaction mixture was 
stirred at -78 °C over 1 hour, then warmed to 0 °C and stirred over 1 hour. Water (15 mL) was added 
dropwise at 0 °C, and the reaction mixture adjusted to pH 8. The product was extracted into EtOAc (3 x 
25 mL). The combined organic extracts were washed (brine), dried (MgSO4) and concentrated in vacuo. 
Purification by flash chromatography (50 – 100% EtOAc in PET) afforded 104a (0.140 g, 35% yield). 
1H NMR (400 MHz, CDCl3) 8.03 (1H, s), 7.70 (2H, s), 7.36 (1H, d, J = 3.1 Hz), 7.29 (2H, d, J = 8.1 Hz), 7.09 
(2H, d, J = 7.9 Hz), 6.61 (1H, d, J = 2.9 Hz), 5.38 (2H, s), 4.42 (1H, q, J = 7.2 Hz), 3.58 (2H, s), 2.54-2.40 (4H, 
m), 1.80-1.70 (4H, m), 1.64 (3H, d, J = 7.2 Hz). 
 (4-(((Tert-butyldiphenylsilyl)oxy)methyl)phenyl)methanol (107) 
 
tert-Butyldiphenylchlorosilane (3.8 mL, 15 mmol) was added to a solution of 1,4-benzenedimethanol 106 
(4.02 g, 29.1 mmol) and imidazole (1.09 g, 16.0 mmol) in DMF (20 mL). The reaction mixture was stirred 
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over 21 hours. The reaction was diluted with EtOAc (100 mL), washed with water (3 x 100 mL) and brine 
(100 mL), dried (MgSO4) and concentrated in vacuo.  Purification by flash chromatography (0 – 20% EtOAc 
in PET) afforded 107 (4.14 g, 38% yield). 
1H NMR (400 MHz, CDCl3) 7.73-7.68 (4H, m), 7.47-7.32 (10H, m), 4.78 (2H, s), 4.70 (2H, d, J = 5.7 Hz), 1.66 
(1H, t, J = 5.9 Hz), 1.10 (9H, s); 13C NMR (100 MHz, CDCl3) 140.8, 139.6, 135.7, 133.6, 129.8, 127.9, 127.2, 
126.4, 65.5, 65.4, 27.0, 19.5; spectroscopic data consistent with literature. 153 
Methyl 1-(4-(hydroxymethyl)benzyl)-1H-indole-6-carboxylate (109) 
 
Methanesulfonyl chloride (1.0 mL, 13 mmol) was added dropwise at 0 °C to a solution of (4-(((tert-
butyldiphenylsilyl)oxy)methyl)phenyl)methanol 107 (4.12 g, 11.0 mmol) and triethylamine (2.0 mL, 14 
mmol) in DCM (20 mL). The reaction mixture was warmed to rt and stirred over 1 hour. Water (1 mL) was 
added dropwise at 0 °C. The mixture was diluted with DCM (30 mL), washed with water (3 x 50 mL) and 
brine (50 mL), dried (MgSO4) and concentrated in vacuo to afford a crude residue. A solution of methyl 
1H-indole-6-carboxylate 63 (1.88 g, 10.7 mmol) in DMF (6 mL) was added dropwise at 0 °C to a suspension 
of NaH (60% in mineral oil, 0.514 g, 12.8 mmol) in DMF (4 mL). The reaction mixture was warmed to rt 
over 30 minutes. A solution of the crude residue in DMF (10 mL) was added dropwise at 0 °C to the 
reaction mixture. The reaction mixture was warmed to rt and stirred over 45 minutes. Water (10 mL) was 
added dropwise at 0 °C. The mixture was diluted with EtOAc (200 mL), washed with water (3 x 200 mL) 
and brine (200 mL), dried (MgSO4) and concentrated in vacuo. TBAF (1 M in THF, 14 mL, 14 mmol) was 
added to the resultant residue. The mixture was stirred over 30 minutes, then water (50 mL) was added. 
The product was extracted into DCM (3 x 50 mL). The combined organic extracts were washed (brine), 
dried (MgSO4) and concentrated in vacuo.  Purification by flash chromatography (10 – 50% EtOAc in PET) 
afforded 109 (2.33 g, 72% yield). 
LCMS (ESI+): m/z 296.2 [M + H]+, rt 1.96 minutes, 100%; 1H NMR (400 MHz, CDCl3) 8.08 (1H, s), 7.80 (1H, 
dd, J = 8.4, 1.4 Hz), 7.66 (1H, d, J = 8.4 Hz), 7.30 (2H, d, J = 8.2 Hz), 7.26 (1H, d, J = 3.2 Hz), 7.10 (2H, d, J = 
8.2 Hz), 6.59 (1H, dd, J = 3.1, 0.8 Hz), 5.37 (2H, s), 4.65 (2H, d, J = 2.8 Hz), 3.90 (3H, s), 1.82-1.72 (1H, m); 
13C NMR (100 MHz, CDCl3) 168.3, 140.7, 136.5, 135.8, 132.5, 131.5, 127.6, 127.2, 123.6, 120.8, 120.7, 
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112.1, 102.4, 65.0, 52.1, 50.0; νmax/cm-1 3295 (br, O-H), 2949, 1705 (C=O), 1618, 1500; HRMS (ESI)+: m/z 
calculated for [C18H17NO3 + Na]+ = 318.1101, observed 318.1094.  
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A.2: Biochemical Assay Dose-response Curves 
 
 
Figure 60: Dose-response curves for 46g and 49a, with data points representing an average of replicates (n = 6) and error bars 
indicating standard errors of the mean. 
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Figure 61: Dose-response curves for 49b-c, with data points representing an average of replicates (n = 6) and error bars indicating 
standard errors of the mean. 
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Figure 62: Dose-response curves for 49d-e, with data points representing an average of replicates (n = 6) and error bars indicating 
standard errors of the mean. 
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Figure 63: Dose-response curves for 49f-g, with data points representing an average of replicates (n = 6) and error bars indicating 
standard errors of the mean. 
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Figure 64: Dose-response curves for 49h and 49j, with data points representing an average of replicates (n = 6) and error bars 
indicating standard errors of the mean. 
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Figure 65: Dose-response curves for 49k-l, with data points representing an average of replicates (n = 6) and error bars indicating 
standard errors of the mean. 
 
 
220 
 
 
Figure 66: Dose-response curves for 49m, with data points representing an average of replicates (n = 6) and error bars indicating 
standard errors of the mean. 
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A.3: Isothermal Titration Calorimetry Traces 
  
  
Figure 67: ITC traces with Mab TrmD for a) 53 (n = 1), b) 59 (n = 1), c) 62 (n = 2), and d) 66a (n = 1). 
b) a) 
c) d) 
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Figure 68: ITC traces with Mab TrmD (n = 1) for a) 66b, b) 66c, c) 66d, and d) 66f. 
 
b) a) 
c) d) 
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Figure 69: ITC traces with Mab TrmD for a) 70 (n = 2), b) 71f (n = 3), c) 71g (n = 3), and d) 71h (n = 3). 
 
b) a) 
c) d) 
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Figure 70: ITC traces with Mab TrmD for a) 71j (n = 1), b) 71l (n = 1), c) 71n (n = 2), and d) 72g (n = 1). 
 
b) a) 
c) d) 
225 
 
  
  
Figure 71: ITC traces with Mab TrmD for a) 87 (n = 1), b) 88a (n = 2), c) 103a (n = 3), and d) 103b (n = 3). 
 
b) a) 
c) d) 
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Figure 72: ITC traces with Mab TrmD for a) 103c (n = 1), b) 103d (n = 3), c) 103e (n = 3), and d) 105a (n = 1). 
 
a) 
c) d) 
b) 
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Figure 73: ITC traces with Mtb TrmD (n = 1) for a) SAM, b) 88a, and c) 103d. 
  
a) b) 
c) 
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A.4: X-ray Crystallography Statistics 
 
Table 14: Data collection and refinement statistics for X-ray crystal structures of Mtb fumarase in complex with 46a, 46g, 49a-b, 
49h, 49j and 49l. 
229 
 
References 
1. Fedrizzi, T.; Meehan, C. J.; Grottola, A.; Giacobazzi, E.; Serpini, G. F.; Tagliazucchi, S.; Fabio, A.; 
Bettua, C.; Bertorelli, R.; De Sanctis, V.; Rumpianesi, F.; Pecorari, M.; Jousson, O.; Tortoli, E.; Segata, 
N. Genomic characterization of nontuberculous mycobacteria. Sci. Rep. 2017, 7, 45258. 
2. Jankute, M.; Cox, J. A. G.; Harrison, J.; Besra, G.. Assembly of the mycobacterial cell wall. Annu. Rev. 
Microbiol. 2015, 69, 405-423. 
3. Bansal-Mutalik, R.; Nikaido, H. Mycobacterial outer membrane is a lipid bilayer and the inner 
membrane is unusually rich in diacyl phosphatidylinositol dimannosides. Proc. Natl. Acad. Sci. U. S. 
A. 2014, 111, 4958-4963. 
4. Chiaradia, L.; Lefebvre, C.; Parra, J.; Marcoux, J.; Burlet-Schiltz, O.; Etienne, G.; Tropis, M.; Daffé, M. 
Dissecting the mycobacterial cell envelope and defining the composition of the native 
mycomembrane. Sci. Rep. 2017, 7, 12807. 
5. da Silva, P. E. A.; Von Groll, A.; Martin, A.; Palomino, J. C. Efflux as a mechanism for drug resistance 
in Mycobacterium tuberculosis. FEMS Immunol. Med. Microbiol. 2011, 63, 1-9. 
6. Pule, C. M.; Sampson, S. L.; Warren, R. M.; Black, P. A.; van Helden, P. D.; Victor, T. C.; Louw, G. E. 
Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy. J. Antimicrob. 
Chemother. 2016, 71, 17-26. 
7. Global tuberculosis report 2018; World Health Organization: Geneva, 2018. 
8. Pai, M.; Behr, M. A.; Dowdy, D.; Dheda, K.; Divangahi, M.; Boehme, C. C.; Ginsberg, A.; Swaminathan, 
S.; Spigelman, M.; Getahun, H.; Menzies, D.; Raviglione, M. Tuberculosis. Nat. Rev. Dis. Primers 
2016, 2, Article Number 16076. 
9. Ramakrishnan, L. Revisiting the role of the granuloma in tuberculosis. Nat. Rev. Immunol. 2012, 12, 
352-366. 
10. Getahun, H.; Matteelli, A.; Chaisson, R. E.; Raviglione, M. Latent Mycobacterium tuberculosis 
infection. N. Engl. J. Med. 2015, 372, 2127-2135. 
11. Houben, R. M. G. J.; Dodd, P. J. The global burden of latent tuberculosis: A re-estimation using 
mathematical modelling. PLoS Med. 2016, 13, e1002152. 
12. Tiemersma, E. W.; van der Werf, M. J.; Borgdorff, M. W.; Williams, B. G.; Nagelkerke, N. J. D. Natural 
history of tuberculosis: Duration and fatality of untreated pulmonary tuberculosis in HIV negative 
patients: A systematic review. PLoS One 2011, 6, e17601. 
13. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update; World 
Health Organization: Geneva, 2017. 
230 
 
14. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update; World Health Organization: 
Geneva, 2016. 
15. Libardo, M. D. J.; Boshoff, H. I. M.; Barry, C. E. The present state of the tuberculosis drug 
development pipeline. Curr. Opin. Pharmacol. 2018, 42, 81-94. 
16. Moore, M.; Frerichs, J. B. An unusual acid-fast infection of the knee with subcutaneous, abscess-like 
lesions of the gluteal region; report of a case with a study of the organism, Mycobacterium 
abscessus, n. sp. J. Invest. Dermatol. 1953, 20, 133-169. 
17. Kusunoki, S.; Ezaki, T. Proposal of Mycobacterium peregrinum sp. nov., nom. rev., and elevation of 
Mycobacterium chelonae subsp. abscessus (Kubica et al.) to species status: Mycobacterium 
abscessus comb. nov. Int. J. Syst. Bacteriol. 1992, 42, 240-245. 
18. Macheras, E.; Roux, A.-L.; Bastian, S.; Leão, S. C.; Palaci, M.; Sivadon-Tardy, V.; Gutierrez, C.; Richter, 
E.; Rüsch-Gerdes, S.; Pfyffer, G.; Bodmer, T.; Cambau, E.; Gaillard, J.-L.; Heym, B. Multilocus 
sequence analysis and rpoB sequencing of Mycobacterium abscessus (sensu lato) strains. J. Clin. 
Microbiol. 2011, 49, 491-499. 
19. Koh, W.-J.; Jeon, K.; Lee, N. Y.; Kim, B.-J.; Kook, Y.-H.; Lee, S.-H.; Park, Y. K.; Kim, C. K.; Shin, S. J.; 
Huitt, G. A.; Daley, C. L.; Kwon, O. J. Clinical significance of differentiation of Mycobacterium 
massiliense from Mycobacterium abscessus. Am. J. Respir. Crit. Care Med. 2011, 183, 405-410. 
20. Ripoll, F.; Pasek, S.; Schenowitz, C.; Dossat, C.; Barbe, V.; Rottman, M.; Macheras, E.; Heym, B.; 
Herrmann, J.-L.; Daffé, M.; Brosch, R.; Risler, J.-L.; Gaillard, J.-L. Non mycobacterial virulence genes 
in the genome of the emerging pathogen Mycobacterium abscessus. PLoS One 2009, 4, e5660. 
21. Lee, M.-R.; Sheng, W.-H.; Hung, C.-C.; Yu, C.-J.; Lee, L.-N.; Hsueh, P.-R. Mycobacterium abscessus 
complex infections in humans. Emerging Infect. Dis. 2015, 21, 1638-1646. 
22. Griffith, D. E.; Aksamit, T.; Brown-Elliott, B. A.; Catanzaro, A.; Daley, C.; Gordin, F.; Holland, S. M.; 
Horsburgh, R.; Huitt, G.; Iademarco, M. F.; Iseman, M.; Olivier, K.; Ruoss, S.; Fordham von Reyn, C.; 
Wallace Jr, R. J.; Winthrop, K. An official ATS/IDSA statement: Diagnosis, treatment, and prevention 
of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 2007, 175, 367-416. 
23. Han, D.; Lee, K. S.; Koh, W.-J.; Yi, C. A.; Kim, T. S.; Kwon, O. J. Radiographic and CT findings of 
nontuberculous mycobacterial pulmonary infection caused by Mycobacterium abscessus. Am. J. 
Roentgenol. 2003, 181, 513-517. 
24. Esther Jr, C. R.; Esserman, D. A.; Gilligan, P.; Kerr, A.; Noone, P. G. Chronic Mycobacterium abscessus 
infection and lung function decline in cystic fibrosis. J. Cystic Fibrosis 2010, 9, 117-123. 
25. Qvist, T.; Taylor-Robinson, D.; Waldmann, E.; Olesen, H. V.; Hansen, C. R.; Mathiesen, I. H.; Høiby, 
N.; Katzenstein, T. L.; Smyth, R. L.; Diggle, P. J.; Pressler, T. Comparing the harmful effects of 
nontuberculous mycobacteria and gram negative bacteria on lung function in patients with cystic 
fibrosis. J. Cystic Fibrosis 2016, 15, 380-385. 
231 
 
26. Bryant, J. M.; Grogono, D. M.; Greaves, D.; Foweraker, J.; Roddick, I.; Inns, T.; Reacher, M.; Haworth, 
C. S.; Curran, M. D.; Harris, S. R.; Peacock, S. J.; Parkhill, J.; Floto, R. A. Whole-genome sequencing 
to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: A 
retrospective cohort study. Lancet 2013, 381, 1551-1560. 
27. Bryant, J. M.; Grogono, D. M.; Rodriguez-Rincon, D.; Everall, I.; Brown, K. P.; Moreno, P.; Verma, D.; 
Hill, E.; Drijkoningen, J.; Gilligan, P.; Esther, C. R.; Noone, P. G.; Giddings, O.; Bell, S. C.; Thomson, R.; 
Wainwright, C. E.; Coulter, C.; Pandey, S.; Wood, M. E.; Stockwell, R. E.; Ramsay, K. A.; Sherrard, L. 
J.; Kidd, T. J.; Jabbour, N.; Johnson, G. R.; Knibbs, L. D.; Morawska, L.; Sly, P. D.; Jones, A.; Bilton, D.; 
Laurenson, I.; Ruddy, M.; Bourke, S.; Bowler, I. C. J. W.; Chapman, S. J.; Clayton, A.; Cullen, M.; 
Dempsey, O.; Denton, M.; Desai, M.; Drew, R. J.; Edenborough, F.; Evans, J.; Folb, J.; Daniels, T.; 
Humphrey, H.; Isalska, B.; Jensen-Fangel, S.; Jönsson, B.; Jones, A. M.; Katzenstein, T. L.; Lillebaek, 
T.; MacGregor, G.; Mayell, S.; Millar, M.; Modha, D.; Nash, E. F.; O’Brien, C.; O’Brien, D.; Ohri, C.; 
Pao, C. S.; Peckham, D.; Perrin, F.; Perry, A.; Pressler, T.; Prtak, L.; Qvist, T.; Robb, A.; Rodgers, H.; 
Schaffer, K.; Shafi, N.; van Ingen, J.; Walshaw, M.; Watson, D.; West, N.; Whitehouse, J.; Haworth, 
C. S.; Harris, S. R.; Ordway, D.; Parkhill, J.; Floto, R. A. Emergence and spread of a human-
transmissible multidrug-resistant nontuberculous mycobacterium. Science 2016, 354, 751-757. 
28. Nessar, R.; Cambau, E.; Reyrat, J. M.; Murray, A.; Gicquel, B. Mycobacterium abscessus: A new 
antibiotic nightmare. J. Antimicrob. Chemother. 2012, 67, 810-818. 
29. Floto, R. A.; Olivier, K. N.; Saiman, L.; Daley, C. L.; Herrmann, J.-L.; Nick, J. A.; Noone, P. G.; Bilton, D.; 
Corris, P.; Gibson, R. L.; Hempstead, S. E.; Koetz, K.; Sabadosa, K. A.; Sermet-Gaudelus, I.; Smyth, A. 
R.; van Ingen, J.; Wallace, R. J.; Winthrop, K. L.; Marshall, B. C.; Haworth, C. S. US Cystic Fibrosis 
Foundation and European Cystic Fibrosis Society consensus recommendations for the management 
of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax 2016, 71, i1-i22. 
30. Novosad, S. A.; Beekmann, S. E.; Polgreen, P. M.; Mackey, K.; Winthrop, K. L.; M. abscessus Study 
Team. Treatment of Mycobacterium abscessus infection. Emerging Infect. Dis. 2016, 22, 511-514. 
31. Cole, S. T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, S. V.; Eiglmeier, K.; 
Gas, S.; Barry, C. E.; Tekaia, F.; Badcock, K.; Basham, D.; Brown, D.; Chillingworth, T.; Connor, R.; 
Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holroyd, S.; Hornsby, T.; Jagels, K.; Krogh, 
A.; McLean, J.; Moule, S.; Murphy, L.; Oliver, K.; Osborne, J.; Quail, M. A.; Rajandream, M. -A.; 
Rogers, J.; Rutter, S.; Seeger, K.; Skelton, J.; Squares, R.; Squares, S.; Sulston, J. E.; Taylor, K.; 
Whitehead, S.; Barrell, B. G. Deciphering the biology of Mycobacterium tuberculosis from the 
complete genome sequence. Nature 1998, 393, 537-544. 
32. Tian, J.; Bryk, R.; Itoh, M.; Suematsu, M.; Nathan, C. Variant tricarboxylic acid cycle in 
Mycobacterium tuberculosis: Identification of alpha-ketoglutarate decarboxylase. Proc. Natl. Acad. 
Sci. U. S. A. 2005, 102, 10670-10675. 
33. Watanabe, S.; Zimmermann, M.; Goodwin, M. B.; Sauer, U.; Barry, C. E.; Boshoff, H. I. Fumarate 
reductase activity maintains an energized membrane in anaerobic Mycobacterium tuberculosis. 
PLoS Pathog. 2011, 7, e1002287. 
232 
 
34. Eoh, H.; Rhee, K. Y. Multifunctional essentiality of succinate metabolism in adaptation to hypoxia in 
Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 6554-6559. 
35. Woods, S. A.; Schwartzbach, S. D.; Guest, J. R. Two biochemically distinct classes of fumarase in 
Escherichia coli. Biochim. Biophys. Acta, Protein Struct. Mol. Enzymol. 1988, 954, 14-26. 
36. Sassetti, C. M.; Boyd, D. H.; Rubin, E. J. Genes required for mycobacterial growth defined by high 
density mutagenesis. Mol. Microbiol. 2003, 48, 77-84. 
37. Ruecker, N.; Jansen, R.; Trujillo, C.; Puckett, S.; Jayachandran, P.; Piroli, G. G.; Frizzell, N.; Molina, H.; 
Rhee, K. Y.; Ehrt, S. Fumarase deficiency causes protein and metabolite succination and intoxicates 
Mycobacterium tuberculosis. Cell Chem. Biol. 2017, 24, 306-315. 
38. Mechaly, A. E.; Haouz, A.; Miras, I.; Barilone, N.; Weber, P.; Shepard, W.; Alzari, P. M.; Bellinzoni, M. 
Conformational changes upon ligand binding in the essential class II fumarase Rv1098c from 
Mycobacterium tuberculosis. FEBS Lett. 2012, 586, 1606-1611. 
39. Weaver, T. M.; Levitt, D. G.; Donnelly, M. I.; Wilkens Stevens, P. P.; Banaszak, L. J. The multisubunit 
active site of fumarase C from Escherichia coli. Nat. Struct. Biol. 1995, 2, 654-662. 
40. Weaver, T.; Banaszak, L. Crystallographic studies of the catalytic and a second site in fumarase C 
from Escherichia coli. Biochemistry 1996, 35, 13955-13965. 
41. Kasbekar, M.; Fischer, G.; Mott, B. T.; Yasgar, A.; Hyvönen, M.; Boshoff, H. I. M.; Abell, C.; Barry, C. 
E.; Thomas, C. J. Selective small molecule inhibitor of the Mycobacterium tuberculosis fumarate 
hydratase reveals an allosteric regulatory site. Proc. Natl. Acad. Sci. U. S. A. 2016, 113, 7503-7508. 
42. Fibriansah, G.; Veetil, V. P.; Poelarends, G. J.; Thunnissen, A.-M. W. H. Structural basis for the 
catalytic mechanism of aspartate ammonia lyase. Biochemistry 2011, 50, 6053-6062. 
43. Takeuchi, T.; Schumacker, P. T.; Kozmin, S. A. Identification of fumarate hydratase inhibitors with 
nutrient-dependent cytotoxicity. J. Am. Chem. Soc. 2015, 137, 564-567. 
44. de Pádua, R. A. P.; Nonato, M. C. Cloning, expression, purification, crystallization and preliminary X-
ray diffraction analysis of recombinant human fumarase. Acta Crystallogr., Sect. F: Struct. Biol. 
Commun. 2014, 70, 120-122. 
45. Anantharaman, V.; Koonin, E. V.; Aravind, L. SPOUT: A class of methyltransferases that includes spoU 
and trmD RNA methylase superfamilies, and novel superfamilies of predicted prokaryotic RNA 
methylases. J. Mol. Microbiol. Biotechnol. 2002, 4, 71-75. 
46. Holmes, W. M.; Andraos-Selim, C.; Roberts, I.; Wahab, S. Z. Structural requirements for tRNA 
methylation. Action of Escherichia coli tRNA(guanosine-1)methyltransferase on tRNA(1Leu) 
structural variants. J. Biol. Chem. 1992, 267, 13440-13445. 
47. Björk, G. R.; Wikström, P. M.; Byström, A. S. Prevention of translational frameshifting by the 
modified nucleoside 1-methylguanosine. Science 1989, 244, 986-989. 
233 
 
48. Gamper, H. B.; Masuda, I.; Frenkel-Morgenstern, M.; Hou, Y.-M. Maintenance of protein synthesis 
reading frame by EF-P and m1G37-tRNA. Nat. Commun. 2015, 6, 7226. 
49. Maehigashi, T.; Dunkle, J. A.; Miles, S. J.; Dunham, C. M. Structural insights into +1 frameshifting 
promoted by expanded or modification-deficient anticodon stem loops. Proc. Natl. Acad. Sci. U. S. 
A. 2014, 111, 12740-12745. 
50. Thomas, S. E.; Whitehouse, A. J.; Brown, K.; Belardinelli, J. M.; Lahiri, R.; Libardo, M. D. J.; Gupta, P.; 
Malhotra, S.; Boshoff, H. I. M.; Jackson, M.; Abell, C.; Coyne, A. G.; Blundell, T. L.; Floto, R. A.; 
Mendes, V. Fragment-based discovery of a new class of inhibitors targeting mycobacterial tRNA 
modification. 2019, doi: https://doi.org/10.1101/564013. bioRxiv. 
https://www.biorxiv.org/content/10.1101/564013v2 (accessed May 29, 2019). 
51. Tkaczuk, K. L.; Dunin-Horkawicz, S.; Purta, E.; Bujnicki, J. M. Structural and evolutionary 
bioinformatics of the SPOUT superfamily of methyltransferases. BMC Bioinf. 2007, 8, 73. 
52. Ahn, H. J.; Kim, H.-W.; Yoon, H.-J.; Lee, B. I.; Suh, S. W.; Yang, J. K. Crystal structure of 
tRNA(m1G37)methyltransferase: Insights into tRNA recognition. EMBO J. 2003, 22, 2593-2603. 
53. Elkins, P. A.; Watts, J. M.; Zalacain, M.; van Thiel, A.; Vitazka, P. R.; Redlak, M.; Andraos-Selim, C.; 
Rastinejad, F.; Holmes, W. M. Insights into catalysis by a knotted TrmD tRNA methyltransferase. J. 
Mol. Biol. 2003, 333, 931-949. 
54. Baugh, L.; Phan, I.; Begley, D. W.; Clifton, M. C.; Armour, B.; Dranow, D. M.; Taylor, B. M.; Muruthi, 
M. M.; Abendroth, J.; Fairman, J. W.; Fox III, D.; Dieterich, S. H.; Staker, B. L.; Gardberg, A. S.; Choi, 
R.; Hewitt, S. N.; Napuli, A. J.; Myers, J.; Barrett, L. K.; Zhang, Y.; Ferrell, M.; Mundt, E.; Thompkins, 
K.; Tran, N.; Lyons-Abbott, S.; Abramov, A.; Sekar, A.; Serbzhinskiy, D.; Lorimer, D.; Buchko, G. W.; 
Stacy, R.; Stewart, L. J.; Edwards, T. E.; Van Voorhis, W. C.; Myler, P. J. Increasing the structural 
coverage of tuberculosis drug targets. Tuberculosis (Oxford, U. K.) 2015, 95, 142-148. 
55. Christian, T.; Sakaguchi, R.; Perlinska, A. P.; Lahoud, G.; Ito, T.; Taylor, E. A.; Yokoyama, S.; Sulkowska, 
J. I.; Hou, Y.-M. Methyl transfer by substrate signaling from a knotted protein fold. Nat. Struct. Mol. 
Biol. 2016, 23, 941-948. 
56. Christian, T.; Lahoud, G.; Liu, C.; Hou, Y.-M. Control of catalytic cycle by a pair of analogous tRNA 
modification enzymes. J. Mol. Biol. 2010, 400, 204-217. 
57. Ito, T.; Masuda, I.; Yoshida, K.-i.; Goto-Ito, S.; Sekine, S.-i.; Suh, S. W.; Hou, Y.-M.; Yokoyama, S. 
Structural basis for methyl-donor–dependent and sequence-specific binding to tRNA substrates by 
knotted methyltransferase TrmD. Proc. Natl. Acad. Sci. U. S. A. 2015, 112, E4197-E4205. 
58. Sakaguchi, R.; Lahoud, G.; Christian, T.; Gamper, H.; Hou, Y.-M. A divalent metal ion-dependent N1 
transfer to G37-tRNA. Chem. Biol. (Oxford, U. K.) 2014, 21, 1351-1360. 
59. Björk, G. R.; Jacobsson, K.; Nilsson, K.; Johansson, M. J. O.; Byström, A. S.; Persson, O. P. A primordial 
tRNA modification required for the evolution of life? EMBO J. 2001, 20, 231-239. 
234 
 
60. Goto-Ito, S.; Ito, T.; Kuratani, M.; Bessho, Y.; Yokoyama, S. Tertiary structure checkpoint at anticodon 
loop modification in tRNA functional maturation. Nat. Struct. Mol. Biol. 2009, 16, 1109-1115. 
61. Christian, T.; Gamper, H.; Hou, Y.-M. Conservation of structure and mechanism by Trm5 enzymes. 
RNA 2013, 19, 1192-1199. 
62. Lahoud, G.; Goto-Ito, S.; Yoshida, K.-i.; Ito, T.; Yokoyama, S.; Hou, Y.-M. Differentiating analogous 
tRNA methyltransferases by fragments of the methyl donor. RNA 2011, 17, 1236-1246. 
63. Hill, P. J.; Abibi, A.; Albert, R.; Andrews, B.; Gagnon, M. M.; Gao, N.; Grebe, T.; Hajec, L. I.; Huang, J.; 
Livchak, S.; Lahiri, S. D.; McKinney, D. C.; Thresher, J.; Wang, H.; Olivier, N.; Buurman, E. T. Selective 
inhibitors of bacterial t-RNA-(N(1)G37) methyltransferase (TrmD) that demonstrate novel ordering 
of the lid domain. J. Med. Chem. 2013, 56, 7278-7288. 
64. Bohacek, R. S.; McMartin, C.; Guida, W. C. The art and practice of structure‐based drug design: A 
molecular modeling perspective. Med. Res. Rev. 1996, 16, 3-50. 
65. Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering high-affinity ligands for proteins: 
SAR by NMR. Science 1996, 274, 1531-1534. 
66. Erlanson, D. A.; Fesik, S. W.; Hubbard, R. E.; Jahnke, W.; Jhoti, H. Twenty years on: The impact of 
fragments on drug discovery. Nat. Rev. Drug Discovery 2016, 15, 605-619. 
67. Bollag, G.; Tsai, J.; Zhang, J.; Zhang, C.; Ibrahim, P.; Nolop, K.; Hirth, P. Vemurafenib: The first drug 
approved for BRAF-mutant cancer. Nat. Rev. Drug Discovery 2012, 11, 873-886. 
68. Mullard, A. Pioneering apoptosis-targeted cancer drug poised for FDA approval. Nat. Rev. Drug 
Discovery 2016, 15, 147-149. 
69. Peplow, M. Astex shapes CDK4/6 inhibitor for approval. Nat. Biotechnol. 2017, 35, 395-396. 
70. O’Leary, B.; Finn, R. S.; Turner, N. C. Treating cancer with selective CDK4/6 inhibitors. Nat. Rev. Clin. 
Oncol. 2016, 13, 417-430. 
71. Souers, A. J.; Leverson, J. D.; Boghaert, E. R.; Ackler, S. L.; Catron, N. D.; Chen, J.; Dayton, B. D.; Ding, 
H.; Enschede, S. H.; Fairbrother, W. J.; Huang, D. C. S.; Hymowitz, S. G.; Jin, S.; Khaw, S. L.; Kovar, P. 
J.; Lam, L. T.; Lee, J.; Maecker, H. L.; Marsh, K. C.; Mason, K. D.; Mitten, M. J.; Nimmer, P. M.; 
Oleksijew, A.; Park, C. H.; Park, C.-M.; Phillips, D. C.; Roberts, A. W.; Sampath, D.; Seymour, J. F.; 
Smith, M. L.; Sullivan, G. M.; Tahir, S. K.; Tse, C.; Wendt, M. D.; Xiao, Y.; Xue, J. C.; Zhang, H.; 
Humerickhouse, R. A.; Rosenberg, S. H.; Elmore, S. W. ABT-199, a potent and selective BCL-2 
inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. (N. Y., NY, U. S.) 2013, 19, 
202-208. 
72. Scott, D. E.; Coyne, A. G.; Hudson, S. A.; Abell, C. Fragment-based approaches in drug discovery and 
chemical biology. Biochemistry 2012, 51, 4990-5003. 
235 
 
73. Jhoti, H.; Williams, G.; Rees, D. C.; Murray, C. W. The ‘rule of three’ for fragment-based drug 
discovery: Where are we now? Nat. Rev. Drug Discovery 2013, 12, 644-645. 
74. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational 
approaches to estimate solubility and permeability in drug discovery and development settings. 
Adv. Drug Delivery Rev. 1997, 23, 3-25. 
75. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A 'rule of three' for fragment-based lead discovery? Drug 
Discovery Today 2003, 8, 876-877. 
76. Ruddigkeit, L.; van Deursen, R.; Blum, L. C.; Reymond, J.-L. Enumeration of 166 billion organic small 
molecules in the chemical universe database GDB-17. J. Chem. Inf. Model. 2012, 52, 2864-2875. 
77. Hall, R. J.; Mortenson, P. N.; Murray, C. W. Efficient exploration of chemical space by fragment-
based screening. Prog. Biophys. Mol. Biol. 2014, 116, 82-91. 
78. Keserű, G. M.; Erlanson, D. A.; Ferenczy, G. G.; Hann, M. M.; Murray, C. W.; Pickett, S. D. Design 
principles for fragment libraries: Maximizing the value of learnings from pharma fragment-based 
drug discovery (FBDD) programs for use in academia. J. Med. Chem. 2016, 59, 8189-8206. 
79. Hann, M. M.; Leach, A. R.; Harper, G. Molecular complexity and its impact on the probability of 
finding leads for drug discovery. J. Chem. Inf. Model. 2001, 41, 856-864. 
80. Murray, C. W.; Verdonk, M. L. The consequences of translational and rotational entropy lost by small 
molecules on binding to proteins. J. Comput.-Aided Mol. Des. 2002, 16, 741-753. 
81. Leeson, P. D.; St-Gallay, S. A. The influence of the ‘organizational factor’ on compound quality in 
drug discovery. Nat. Rev. Drug Discovery 2011, 10, 749-765. 
82. Renaud, J.-P.; Chung, C.-w.; Danielson, U. H.; Egner, U.; Hennig, M.; Hubbard, R. E.; Nar, H. 
Biophysics in drug discovery: Impact, challenges and opportunities. Nat. Rev. Drug Discovery 2016, 
15, 679-698. 
83. Schiebel, J.; Radeva, N.; Krimmer, S. G.; Wang, X.; Stieler, M.; Ehrmann, F. R.; Fu, K.; Metz, A.; 
Huschmann, F. U.; Weiss, M. S.; Mueller, U.; Heine, A.; Klebe, G. Six biophysical screening methods 
miss a large proportion of crystallographically discovered fragment hits: A case study. ACS Chem. 
Biol. 2016, 11, 1693-1701. 
84. Mashalidis, E. H.; Śledź, P.; Lang, S.; Abell, C. A three-stage biophysical screening cascade for 
fragment-based drug discovery. Nat. Protoc. 2013, 8, 2309-2324. 
85. Silvestre, H. L.; Blundell, T. L.; Abell, C.; Ciulli, A. Integrated biophysical approach to fragment 
screening and validation for fragment-based lead discovery. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 
12984-12989. 
86. Chilton, M.; Clennell, B.; Edfeldt, F.; Geschwindner, S. Hot-spotting with thermal scanning: A ligand- 
and structure- independent assessment of target ligandability. J. Med. Chem. 2017, 60, 4923-4931. 
236 
 
87. Niesen, F. H.; Berglund, H.; Vedadi, M. The use of differential scanning fluorimetry to detect ligand 
interactions that promote protein stability. Nat. Protoc. 2007, 2, 2212-2221. 
88. Scott, D. E.; Spry, C.; Abell, C. Fragment-based drug discovery lessons and outlook, Ch. 7.; Wiley-
VCH, 2016; Vol. 34, Methods and principles in medicinal chemistry, pp 139-170. 
89. Dai, R.; Wilson, D. J.; Geders, T. W.; Aldrich, C. C.; Finzel, B. C. Inhibition of Mycobacterium 
tuberculosis transaminase BioA by aryl hydrazines and hydrazides. ChemBioChem 2014, 15, 575-
586. 
90. Seetoh, W.-G.; Abell, C. Disrupting the constitutive, homodimeric protein−protein interface in CK2β 
using a biophysical fragment-based approach. J. Am. Chem. Soc. 2016, 138, 14303-14311. 
91. Śledź, P.; Abell, C.; Ciulli, A. NMR of biomolecules: Towards mechanistic systems biology, Ch. 15.; 
Wiley-VCH, 2012; pp 265-280. 
92. Mayer, M.; Meyer, B. Characterization of ligand binding by saturation transfer difference NMR 
spectroscopy. Angew. Chem., Int. Ed. 1999, 38, 1784-1788. 
93. Dalvit, C.; Pevarello, P.; Tatò, M.; Veronesi, M.; Vulpetti, A.; Sundström, M. Identification of 
compounds with binding affinity to proteins via magnetization transfer from bulk water. J. Biomol. 
NMR 2000, 18, 65-68. 
94. Hajduk, P. J.; Olejniczak, E. T.; Fesik, S. W. One-dimensional relaxation- and diffusion-edited NMR 
methods for screening compounds that bind to macromolecules. J. Am. Chem. Soc. 1997, 119, 
12257-12261. 
95. Davies, T. G.; Wixted, W. E.; Coyle, J. E.; Griffiths-Jones, C.; Hearn, K.; McMenamin, R.; Norton, D.; 
Rich, S. J.; Richardson, C.; Saxty, G.; Willems, H. M. G.; Woolford, A. J.-A.; Cottom, J. E.; Kou, J.-P.; 
Yonchuk, J. G.; Feldser, H. G.; Sanchez, Y.; Foley, J. P.; Bolognese, B. J.; Logan, G.; Podolin, P. L.; Yan, 
H.; Callahan, J. F.; Heightman, T. D.; Kerns, J. K. Monoacidic inhibitors of the Kelch-like ECH-
associated protein 1: Nuclear factor erythroid 2-related factor 2 (KEAP1:NRF2) protein-protein 
interaction with high cell potency identified by fragment-based discovery. J. Med. Chem. 2016, 59, 
3991-4006. 
96. Holdgate, G. A.; Ward, W. H. J. Measurements of binding thermodynamics in drug discovery. Drug 
Discovery Today 2005, 10, 1543-1550. 
97. Ladbury, J. E.; Klebe, G.; Freire, E. Adding calorimetric data to decision making in lead discovery: A 
hot tip. Nat. Rev. Drug Discovery 2010, 9, 23-27. 
98. Geschwindner, S.; Ulander, J.; Johansson, P. Ligand binding thermodynamics in drug discovery: Still 
a hot tip? J. Med. Chem. 2015, 58, 6321-6335. 
237 
 
99. Williams, G.; Ferenczy, G. G.; Ulander, J.; Keserű, G. M. Binding thermodynamics discriminates 
fragments from druglike compounds: A thermodynamic description of fragment-based drug 
discovery. Drug Discovery Today 2017, 22, 681-689. 
100. Trapero, A.; Pacitto, A.; Singh, V.; Sabbah, M.; Coyne, A. G.; Mizrahi, V.; Blundell, T. L.; Ascher, D. B.; 
Abell, C. Fragment-based approach to targeting inosine-5′-monophosphate dehydrogenase 
(IMPDH) from Mycobacterium tuberculosis. J. Med. Chem. 2018, 61, 2806-2822. 
101. Jencks, W. P. On the attribution and additivity of binding energies. Proc. Natl. Acad. Sci. U. S. A. 
1981, 78, 4046-4050. 
102. Hung, A. W.; Silvestre, H. L.; Wen, S.; Ciulli, A.; Blundell, T. L.; Abell, C. Application of fragment 
growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis 
pantothenate synthetase. Angew. Chem., Int. Ed. 2009, 48, 8452-8456. 
103. Woolford, A. J.-A.; Pero, J. E.; Aravapalli, S.; Berdini, V.; Coyle, J. E.; Day, P. J.; Dodson, A. M.; Grondin, 
P.; Holding, F. P.; Lee, L. Y. W.; Li, P.; Manas, E. S.; Marino, J.; Martin, A. C. L.; McCleland, B. W.; 
McMenamin, R. L.; Murray, C. W.; Neipp, C. E.; Page, L. W.; Patel, V. K.; Potvain, F.; Rich, S.; Rivero, 
R. A.; Smith, K.; Somers, D. O.; Trottet, L.; Velagaleti, R.; Williams, G.; Xie, R. Exploitation of a novel 
binding pocket in human lipoprotein-associated phospholipase A2 (Lp-PLA2) discovered through X-
ray fragment screening. J. Med. Chem. 2016, 59, 5356-5367. 
104. Hudson, S. A.; McLean, K. J.; Surade, S.; Yang, Y.-Q.; Leys, D.; Ciulli, A.; Munro, A. W.; Abell, C. 
Application of fragment screening and merging to the discovery of inhibitors of the Mycobacterium 
tuberculosis cytochrome P450 CYP121. Angew. Chem., Int. Ed. 2012, 51, 9311-9316. 
105. Hudson, S. A.; Surade, S.; Coyne, A. G.; McLean, K. J.; Leys, D.; Munro, A. W.; Abell, C. Overcoming 
the limitations of fragment merging: Rescuing a strained merged fragment series targeting 
Mycobacterium tuberculosis CYP121. ChemMedChem 2013, 8, 1451-1456. 
106. Drwal, M. N.; Bret, G.; Perez, C.; Jacquemard, C.; Desaphy, J.; Kellenberger, E. Structural insights on 
fragment binding mode conservation. J. Med. Chem. 2018, 61, 5963-5973. 
107. Mortenson, P. N.; Erlanson, D. A.; de Esch, I. J. P.; Jahnke, W.; Johnson, C. N. Fragment-to-lead 
medicinal chemistry publications in 2017. J. Med. Chem. 2019, 62, 3857-3872. 
108. Hopkins, A.; Keseru, G.; Leeson, P.; Rees, D.; Reynolds, C. The role of ligand efficiency metrics in drug 
discovery. Nat. Rev. Drug Discov. 2014, 13, 105-121. 
109. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: A useful metric for lead selection. Drug 
Discovery Today 2004, 9, 430-431. 
110. Verdonk, M. L.; Rees, D. C. Group efficiency: A guideline for hits-to-leads chemistry. ChemMedChem 
2008, 3, 1179-1180. 
238 
 
111. Hung, A. W.; Silvestre, H. L.; Wen, S.; George, G. P. C.; Boland, J.; Blundell, T. L.; Ciulli, A.; Abell, C. 
Optimization of inhibitors of Mycobacterium tuberculosis pantothenate synthetase based on group 
efficiency analysis. ChemMedChem 2016, 11, 38-42. 
112. Kavanagh, M. E.; Coyne, A. G.; McLean, K. J.; James, G. G.; Levy, C. W.; Marino, L. B.; de Carvalho, L. 
P. S.; Chan, D. S. H.; Hudson, S. A.; Surade, S.; Leys, D.; Munro, A. W.; Abell, C. Fragment-based 
approaches to the development of Mycobacterium tuberculosis CYP121 inhibitors. J. Med. Chem. 
2016, 59, 3272-3302. 
113. Chen, H.; Zhou, X.; Wang, A.; Zheng, Y.; Gao, Y.; Zhou, J. Evolutions in fragment-based drug design: 
The deconstruction–reconstruction approach. Drug Discovery Today 2015, 20, 105-113. 
114. Hoegenauer, K.; Soldermann, N.; Stauffer, F.; Furet, P.; Graveleau, N.; Smith, A. B.; Hebach, C.; 
Hollingworth, G. J.; Lewis, I.; Gutmann, S.; Rummel, G.; Knapp, M.; Wolf, R. M.; Blanz, J.; Feifel, R.; 
Burkhart, C.; Zécri, F. Discovery and pharmacological characterization of novel quinazoline-based 
PI3K delta-selective inhibitors. ACS Med. Chem. Lett. 2016, 7, 762-767. 
115. Babaoglu, K.; Shoichet, B. K. Deconstructing fragment-based inhibitor discovery. Nat. Chem. Biol. 
2006, 2, 720-723. 
116. Wissmann , H.; Kleiner, H. New peptide synthesis. Angew. Chem., Int. Ed. Engl. 1980, 19, 133-134. 
117. Kasbekar, M. Thesis; Department of Chemistry, University of Cambridge, 2016. 
118. McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser 
crystallographic software. J. Appl. Crystallogr. 2007, 40, 658-674. 
119. Winn, M. D.; Ballard, C. C.; Cowtan, K. D.; Dodson, E. J.; Emsley, P.; Evans, P. R.; Keegan, R. M.; 
Krissinel, E. B.; Leslie, A. G. W.; McCoy, A.; McNicholas, S. J.; Murshudov, G. N.; Pannu, N. S.; 
Potterton, E. A.; Powell, H. R.; Read, R. J.; Vagin, A.; Wilson, K. S. Overview of the CCP4 suite and 
current developments. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2011, 67, 235-242. 
120. Emsley, P.; Cowtan, K. Coot: Model-building tools for molecular graphics. Acta Crystallogr., Sect. D: 
Biol. Crystallogr. 2004, 60, 2126-2132. 
121. Murshudov, G. N.; Skubák, P.; Lebedev, A. A.; Pannu, N. S.; Steiner, R. A.; Nicholls, R. A.; Winn, M. 
D.; Long, F.; Vagin, A. A. REFMAC5 for the refinement of macromolecular crystal structures. Acta 
Crystallogr., Sect. D: Biol. Crystallogr. 2011, 67, 355-367. 
122. Ehrt, S.; Rhee, K. Mycobacterium tuberculosis metabolism and host interaction: Mysteries and 
paradoxes. Curr. Top. Microbiol. Immunol. 2013, 374, 163-188. 
123. Whitehouse, A. J.; Thomas, S. E.; Brown, K.; Fanourakis, A.; Chan, D. S. H.; Libardo, M. D. J.; Mendes, 
V.; Boshoff, H. I. M.; Floto, R. A.; Abell, C.; Blundell, T. L.; Coyne, A. G. Development of inhibitors 
against Mycobacterium abscessus tRNA (m1G37) methyltransferase (TrmD) using fragment-based 
approaches. J. Med. Chem. 2019, 62, 7210-7232. 
239 
 
124. Zanaletti, R.; Bettinetti, L.; Castaldo, C.; Cocconcelli, G.; Comery, T.; Dunlop, J.; Gaviraghi, G.; Ghiron, 
C.; Haydar, S. N.; Jow, F.; Maccari, L.; Micco, I.; Nencini, A.; Scali, C.; Turlizzi, E.; Valacchi, M. 
Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of 
the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-
(4-methoxyphenyl)-1H-pyrazol-3-yl] amide. J. Med. Chem. 2012, 55, 4806-4823. 
125. Wuts, P. G. M.; Greene, T. W. Greene's protective groups in organic synthesis, 4th ed.; John Wiley & 
Sons: Hoboken, New Jersey, 2007; p 882. 
126. Hassaneen, H. M. E. New approach to 4- and 5-aminopyrazole derivatives. Synth. Commun. 2007, 
37, 3579-3588. 
127. Mata, S.; Cortijo, V.; Caminati, W.; Alonso, J. L.; Sanz, M. E.; López, J. C.; Blanco, S. Tautomerism and 
microsolvation in 2-hydroxypyridine/2-pyridone. J. Phys. Chem. 2010, 114, 11393-11398. 
128. Wender, P. A.; Beckham, S.; O'Leary, J. G. A second generation photochemically activatable 
dynemicin analog: A concise synthesis and DNA cleavage studies. Synthesis 1994, 1278-1282. 
129. Soni, A.; Dutt, A.; Sattigeri, V.; Cliffe, I. A. Efficient and selective demethylation of heteroaryl methyl 
ethers in the presence of aryl methyl ethers. Synth. Commun. 2011, 41, 1852-1857. 
130. Lovering, F.; Bikker, J.; Humblet, C. Escape from flatland: Increasing saturation as an approach to 
improving clinical success. J. Med. Chem. 2009, 52, 6752-6756. 
131. Lundbäck, T.; O’Brien, R.; Williams, G. In The Mix: Simultaneous Affinity Determination for Isomers 
and Enantiomers; MicroCal: Northampton, MA, USA, 2006. 
132. Thomas, S. E. Unpublished work; Department of Biochemistry, University of Cambridge. 
133. Soler, M.; Figueras, E.; Serrano-Plana, J.; González-Bártulos, M.; Massaguer, A.; Company, A.; 
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